0001376339-20-000047.txt : 20200706 0001376339-20-000047.hdr.sgml : 20200706 20200706061555 ACCESSION NUMBER: 0001376339-20-000047 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 78 CONFORMED PERIOD OF REPORT: 20200331 FILED AS OF DATE: 20200706 DATE AS OF CHANGE: 20200706 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MIMEDX GROUP, INC. CENTRAL INDEX KEY: 0001376339 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 262792552 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35887 FILM NUMBER: 201012084 BUSINESS ADDRESS: STREET 1: 1775 W OAK COMMONS COURT, NE CITY: MARIETTA STATE: GA ZIP: 30062 BUSINESS PHONE: (770) 651-9100 MAIL ADDRESS: STREET 1: 1775 W OAK COMMONS COURT, NE CITY: MARIETTA STATE: GA ZIP: 30062 FORMER COMPANY: FORMER CONFORMED NAME: Alynx, Co. DATE OF NAME CHANGE: 20060922 10-Q 1 mdxg-2020331x10xq.htm 10-Q Document
false--12-31Q120201775 West Oak Commons Ct NEMariettaGA0001376339falseAccelerated Filerfalse0.0010.0011500000001500000001127039261127039261108186491105408600.0010.00150000005000000000018852772163066 0001376339 2020-01-01 2020-03-31 0001376339 2020-06-25 0001376339 2019-12-31 0001376339 2020-03-31 0001376339 2019-01-01 2019-03-31 0001376339 us-gaap:TreasuryStockMember 2019-01-01 2019-03-31 0001376339 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001376339 us-gaap:TreasuryStockMember 2018-12-31 0001376339 us-gaap:CommonStockMember 2019-03-31 0001376339 us-gaap:TreasuryStockMember 2019-03-31 0001376339 us-gaap:RetainedEarningsMember 2019-03-31 0001376339 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001376339 2019-03-31 0001376339 us-gaap:CommonStockMember 2018-12-31 0001376339 us-gaap:RetainedEarningsMember 2018-12-31 0001376339 2018-12-31 0001376339 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001376339 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001376339 us-gaap:TreasuryStockMember 2020-01-01 2020-03-31 0001376339 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001376339 us-gaap:TreasuryStockMember 2019-12-31 0001376339 us-gaap:CommonStockMember 2019-12-31 0001376339 us-gaap:TreasuryStockMember 2020-03-31 0001376339 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001376339 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001376339 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001376339 us-gaap:CommonStockMember 2020-03-31 0001376339 us-gaap:RetainedEarningsMember 2019-12-31 0001376339 us-gaap:RetainedEarningsMember 2020-03-31 0001376339 srt:MaximumMember 2020-01-01 2020-03-31 0001376339 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0001376339 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 2019-01-01 0001376339 srt:MinimumMember 2020-01-01 2020-03-31 0001376339 us-gaap:PatentsMember 2020-01-01 2020-03-31 0001376339 2019-07-01 2019-09-30 0001376339 us-gaap:PatentsMember 2019-01-01 2019-03-31 0001376339 srt:ScenarioForecastMember mdxg:HayfinLoanAgreementMember us-gaap:SeniorNotesMember 2021-01-01 2021-06-30 0001376339 srt:ScenarioForecastMember mdxg:HayfinLoanAgreementMember us-gaap:SeniorNotesMember 2021-07-01 2025-06-29 0001376339 mdxg:HayfinLoanAgreementMember us-gaap:SeniorNotesMember us-gaap:SubsequentEventMember 2020-07-02 2020-07-02 0001376339 srt:ScenarioForecastMember mdxg:HayfinLoanAgreementMember us-gaap:SeniorNotesMember 2020-07-02 2020-12-31 0001376339 mdxg:HayfinLoanAgreementTermLoanMember us-gaap:SeniorNotesMember us-gaap:SubsequentEventMember 2020-07-02 0001376339 mdxg:TermLoanAgreementMember us-gaap:NotesPayableOtherPayablesMember us-gaap:SubsequentEventMember 2020-07-02 2020-07-02 0001376339 srt:MaximumMember mdxg:HayfinLoanAgreementMember us-gaap:SeniorNotesMember us-gaap:SubsequentEventMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-07-02 2020-07-02 0001376339 mdxg:HayfinLoanAgreementMember us-gaap:SeniorNotesMember us-gaap:SubsequentEventMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-07-02 0001376339 mdxg:HayfinLoanAgreementDelayedDrawTermLoanMember us-gaap:NotesPayableOtherPayablesMember us-gaap:SubsequentEventMember 2020-07-02 2020-07-02 0001376339 us-gaap:SeriesBPreferredStockMember us-gaap:SubsequentEventMember 2020-07-02 0001376339 srt:MinimumMember mdxg:HayfinLoanAgreementMember us-gaap:SeniorNotesMember us-gaap:SubsequentEventMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-07-02 2020-07-02 0001376339 mdxg:HayfinLoanAgreementDelayedDrawTermLoanMember us-gaap:NotesPayableOtherPayablesMember us-gaap:SubsequentEventMember 2020-07-02 0001376339 us-gaap:SeriesBPreferredStockMember us-gaap:SubsequentEventMember 2020-07-02 2020-07-02 0001376339 mdxg:HayfinLoanAgreementMember us-gaap:SeniorNotesMember us-gaap:SubsequentEventMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-07-02 2020-07-02 0001376339 us-gaap:EquipmentMember 2020-03-31 0001376339 us-gaap:FurnitureAndFixturesMember 2019-12-31 0001376339 us-gaap:ConstructionInProgressMember 2020-03-31 0001376339 us-gaap:LeaseholdImprovementsMember 2019-12-31 0001376339 us-gaap:EquipmentMember 2019-12-31 0001376339 us-gaap:LeaseholdImprovementsMember 2020-03-31 0001376339 us-gaap:FurnitureAndFixturesMember 2020-03-31 0001376339 us-gaap:ConstructionInProgressMember 2019-12-31 0001376339 us-gaap:CustomerRelationshipsMember 2020-03-31 0001376339 us-gaap:NoncompeteAgreementsMember 2019-12-31 0001376339 us-gaap:NoncompeteAgreementsMember 2020-03-31 0001376339 mdxg:PatentsinProcessMember 2019-12-31 0001376339 us-gaap:TrademarksAndTradeNamesMember 2020-03-31 0001376339 us-gaap:TrademarksAndTradeNamesMember 2019-12-31 0001376339 us-gaap:CustomerRelationshipsMember 2019-12-31 0001376339 us-gaap:PatentsMember 2019-12-31 0001376339 mdxg:PatentsinProcessMember 2020-03-31 0001376339 us-gaap:LicensingAgreementsMember 2019-12-31 0001376339 us-gaap:LicensingAgreementsMember 2020-03-31 0001376339 us-gaap:PatentsMember 2020-03-31 0001376339 srt:ScenarioForecastMember mdxg:TermLoanAgreementMember us-gaap:NotesPayableOtherPayablesMember 2021-01-01 2022-06-20 0001376339 mdxg:TermLoanAgreementMember us-gaap:NotesPayableOtherPayablesMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-01-01 2020-03-31 0001376339 srt:ScenarioForecastMember mdxg:TermLoanAgreementMember us-gaap:NotesPayableOtherPayablesMember 2019-06-10 2020-05-31 0001376339 srt:ScenarioForecastMember mdxg:TermLoanAgreementMember us-gaap:NotesPayableOtherPayablesMember 2020-06-01 2020-12-30 0001376339 mdxg:TermLoanAgreementMember us-gaap:NotesPayableOtherPayablesMember 2020-03-31 0001376339 srt:ScenarioForecastMember mdxg:TermLoanAgreementMember us-gaap:NotesPayableOtherPayablesMember 2020-12-31 0001376339 mdxg:TermLoanAgreementMember us-gaap:NotesPayableOtherPayablesMember 2019-06-10 0001376339 srt:ScenarioForecastMember mdxg:TermLoanAgreementMember us-gaap:NotesPayableOtherPayablesMember 2020-06-11 2021-06-10 0001376339 mdxg:TermLoanAgreementMember us-gaap:NotesPayableOtherPayablesMember 2019-06-10 2019-06-10 0001376339 srt:ScenarioForecastMember mdxg:TermLoanAgreementMember us-gaap:NotesPayableOtherPayablesMember 2019-06-10 2020-06-10 0001376339 mdxg:TermLoanAgreementMember us-gaap:NotesPayableOtherPayablesMember 2020-01-01 2020-03-31 0001376339 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001376339 us-gaap:RestrictedStockMember 2019-01-01 2019-03-31 0001376339 us-gaap:RestrictedStockMember 2020-01-01 2020-03-31 0001376339 us-gaap:PerformanceSharesMember 2019-01-01 2019-03-31 0001376339 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-03-31 0001376339 us-gaap:PerformanceSharesMember 2020-01-01 2020-03-31 0001376339 srt:ScenarioForecastMember 2020-01-01 2020-12-31 0001376339 mdxg:DepartmentofVeteransAffairsOfficeoftheInspectorGeneralsInvestigationMember 2020-01-01 2020-03-31 0001376339 mdxg:DepartmentofVeteransAffairsOfficeoftheInspectorGeneralsInvestigationMember 2019-01-01 2019-01-31 0001376339 srt:MinimumMember 2020-03-31 0001376339 mdxg:SecuritiesClassActionMember 2019-01-16 2019-01-16 0001376339 srt:MaximumMember 2020-03-31 0001376339 mdxg:DepartmentofVeteransAffairsOfficeoftheInspectorGeneralsInvestigationMember 2018-05-01 2018-05-31 0001376339 srt:ChiefFinancialOfficerMember us-gaap:SubsequentEventMember 2020-01-01 2020-06-30 0001376339 mdxg:ShareholderDerivativeSuitsMember 2018-12-06 0001376339 mdxg:DirectCustomersMember 2020-01-01 2020-03-31 0001376339 mdxg:DistributorsMember 2020-01-01 2020-03-31 0001376339 mdxg:DistributorsMember 2019-01-01 2019-03-31 0001376339 mdxg:DirectCustomersMember 2019-01-01 2019-03-31 0001376339 srt:ScenarioForecastMember mdxg:TermLoanAgreementMember us-gaap:NotesPayableOtherPayablesMember 2020-04-01 2020-05-31 0001376339 mdxg:AmendedTermLoanAgreementMember us-gaap:NotesPayableOtherPayablesMember us-gaap:SubsequentEventMember 2020-04-22 0001376339 srt:ScenarioForecastMember mdxg:TermLoanAgreementMember us-gaap:NotesPayableOtherPayablesMember 2020-06-01 2020-11-30 0001376339 mdxg:AmendedTermLoanAgreementMember us-gaap:SubsequentEventMember 2020-04-22 0001376339 us-gaap:SubsequentEventMember 2020-04-01 2020-04-01 0001376339 mdxg:PaycheckProtectionProgramLoanMember 2020-03-27 0001376339 srt:ScenarioForecastMember mdxg:AmendedTermLoanAgreementMember us-gaap:NotesPayableOtherPayablesMember 2020-04-01 2020-05-31 0001376339 mdxg:TermLoanAgreementMember us-gaap:SubsequentEventMember 2020-04-22 0001376339 srt:ScenarioForecastMember mdxg:AmendedTermLoanAgreementMember us-gaap:NotesPayableOtherPayablesMember 2020-06-01 2020-11-30 0001376339 mdxg:AmendedTermLoanAgreementMember us-gaap:NotesPayableOtherPayablesMember us-gaap:SubsequentEventMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-04-22 2020-04-22 mdxg:former_employee iso4217:USD xbrli:shares xbrli:pure mdxg:segment iso4217:USD mdxg:lawsuit mdxg:distribution_channel xbrli:shares



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the
Quarterly Period Ended
March 31, 2020
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _____________________to______________________
Commission file number 001-35887
MIMEDX GROUP, INC.
(Exact name of registrant as specified in its charter)
Florida
 
26-2792552
(State or other jurisdiction of incorporation)
 
(I.R.S. Employer Identification Number)
1775 West Oak Commons Ct NE
Marietta, GA
 
30062
(Address of principal executive offices)
 
(Zip Code)
(770) 651-9100
(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes ¨ No x
 
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  
Yes ¨ No x

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer o
Accelerated filer x
Non-accelerated filer o
(Do not check if a smaller reporting company)
Smaller reporting company o
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(A) of the Exchange Act.
o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).




Yes No x
 
There were 110,328,875 shares of the registrant’s common stock, par value $0.001 per share, outstanding as of June 25, 2020.




Table of Contents
Part I     FINANCIAL INFORMATION
 
Item 1
Financial Statements (Unaudited)
 
 
Condensed Consolidated Balance Sheets
 
Condensed Consolidated Statements of Operations
 
Condensed Consolidated Statements of Stockholders’ Equity
 
Condensed Consolidated Statements of Cash Flows
 
Notes to the Unaudited Condensed Consolidated Financial Statements
Item 2
Management’s Discussion and Analysis of Financial Condition and Results of Operations
Item 3
Quantitative and Qualitative Disclosures About Market Risk
Item 4
Controls and Procedures
Part II   OTHER INFORMATION
Item 1
Legal Proceedings
Item 1A
Risk Factors
Item 2
Unregistered Sales of Equity Securities and Use of Proceeds
Item 3
Defaults upon Senior Securities
Item 4
Mine Safety Disclosures
Item 5
Other Information
Item 6
Exhibits
Signatures
 

3



As used herein, the terms “MiMedx,” “the Company,” “we,” “our” and “us” refer to MiMedx Group, Inc., a Florida corporation, and its consolidated subsidiaries as a combined entity, except where it is clear that the terms mean only MiMedx Group, Inc.
Explanatory Note
As previously disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 (the “2018 Form 10-K”), the Company filed no periodic reports after October 2017 until the filing of the 2018 Form 10-K. In June 2018, following an investigation (the “Audit Committee Investigation”), the Audit Committee of the Company’s Board of Directors, with the concurrence of management, concluded that the Company’s previously issued consolidated financial statements and financial information relating to each of the fiscal years ended December 31, 2016, 2015, 2014, 2013 and 2012 and each of the interim periods within such years, along with the unaudited condensed consolidated financial statements included in the Company’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2017, June 30, 2017 and September 30, 2017 (collectively, the “Non-Reliance Periods”), would need to be restated (the “Restatement”) and could no longer be relied upon due to accounting irregularities regarding the recognition of revenue under generally accepted accounting principles in the United States of America (“GAAP”). The 2018 Form 10-K contained our audited consolidated statements of operations, stockholders’ equity and cash flows for the years ended December 31, 2018 and 2017, which had not previously been filed, and for the year ended December 31, 2016, which were restated from the consolidated financial statements previously filed in our Annual Report on Form 10-K for the year ended December 31, 2016. The 2018 Form 10-K also included our audited consolidated balance sheets as of December 31, 2018 and 2017.

The Company, the Board, and the Audit Committee devoted considerable resources, including the time and attention of the Company’s financial and accounting staff and management, to completing the 2018 Form 10-K, which was not filed until March 17, 2020. This delayed the completion and filing of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 (the “2019 Form 10-K”) and Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, both of which were filed on July 6, 2020.
Forward-Looking Statements

This Form 10-Q contains forward-looking statements. All statements relating to events or results that may occur in the future are forward-looking statements, including, without limitation, statements regarding the following:
our strategic focus, as illustrated by our strategic priorities and our ability to implement these priorities;
our ability to access capital sufficient to implement our strategic priorities;
our expectations regarding our ability to fund our ongoing and future operating costs;
our expectations regarding future income tax liability;
the advantages of our products and development of new products;
market opportunities for our products;
the regulatory pathway for our products, including our existing and planned investigative new drug application and pre-market approval requirements, the design and success of our clinical trials and pursuit of biological license applications (“BLAs”) for certain products;
our expectations regarding our ability to manufacture certain of our products in compliance with current Good Manufacturing Practices (“cGMP”);
our expectations regarding costs relating to compliance with regulatory standards, including those arising from our clinical trials, pursuit of BLAs, and cGMP compliance;
our ability to continue marketing our micronized products and certain other products during and following the end of the period of enforcement discretion announced by the United States Food and Drug Administration (“FDA”);
expectations regarding government and other third-party coverage and reimbursement for our products;
expectations regarding future revenue growth;
the effects of the adoption of new accounting standards on the Company’s financial position or results of operations;
our ability to procure sufficient supplies of human tissue to manufacture and process our products;
the outcome of pending litigation and investigations;
our ability to relist our common stock, par value $0.001 per share (the “Common Stock”) on The Nasdaq Capital Market;
ongoing and future effects arising from the Audit Committee Investigation, the Restatement, and related litigation;
ongoing and future effects arising from the COVID-19 pandemic;
demographic and market trends;
our plans to remediate the identified material weaknesses in our internal control environment and to strengthen our internal control environment; and
our ability to compete effectively.


4




Forward-looking statements generally can be identified by words such as “expect,” “will,” “change,” “intend,” “seek,” “target,” “future,” “plan,” “continue,” “potential,” “possible,” “could,” “estimate,” “may,” “anticipate,” “to be” and similar expressions. These statements are based on numerous assumptions and involve known and unknown risks, uncertainties and other factors that could significantly affect the Company’s operations and may cause the Company’s actual actions, results, financial condition, performance or achievements to differ materially from any future actions, results, financial condition, performance or achievements expressed or implied by any such forward-looking statements. Factors that may cause such a difference include, without limitation, those discussed under the heading “Risk Factors” in the 2019 Form 10-K.
Unless required by law, the Company does not intend, and undertakes no obligation, to update or publicly release any revision to any forward-looking statements, whether as a result of the receipt of new information, the occurrence of subsequent events, a change in circumstances or otherwise. Each forward-looking statement contained in this Form 10-Q is specifically qualified in its entirety by the aforementioned factors. Readers are advised to carefully read this Form 10-Q in conjunction with the important disclaimers set forth above prior to reaching any conclusions or making any investment decisions and not to place undue reliance on forward-looking statements, which apply only as of the date of the filing of this Form 10-Q with the Securities and Exchange Commission (“SEC”).


5



PART I - FINANCIAL INFORMATION

Item 1. Financial Statements
MIMEDX GROUP, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)
 
March 31, 2020
(unaudited)
 
December 31, 2019
ASSETS
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
53,525

 
$
69,069

Accounts receivable, net
31,932

 
32,327

Inventory, net
9,247

 
9,104

Prepaid expenses
5,239

 
6,669

Income tax receivable
10,729

 
18

Other current assets
5,216

 
6,058

Total current assets
115,888

 
123,245

Property and equipment, net
11,833

 
12,328

Right of use asset
3,158

 
3,397

Goodwill
19,976

 
19,976

Intangible assets, net
7,581

 
7,777

Other assets
473

 
443

Total assets
$
158,909

 
$
167,166

LIABILITIES AND STOCKHOLDERS' EQUITY
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
9,756

 
$
8,710

Accrued compensation
17,116

 
21,302

Accrued expenses
30,661

 
32,161

Current portion of long term debt
3,750

 
3,750

Other current liabilities
2,416

 
1,399

Total current liabilities
63,699

 
67,322

Long term debt, net
61,637

 
61,906

Other liabilities
3,234

 
3,540

Total liabilities
$
128,570

 
$
132,768

Commitments and contingencies (Note 13)


 


Stockholders' equity:
 
 
 
Preferred stock; $.001 par value; 5,000,000 shares authorized; 0 issued and 0 outstanding at March 31, 2020 and 0 issued and 0 outstanding at December 31, 2019
$

 
$

Common stock; $.001 par value; 150,000,000 shares authorized; 112,703,926 issued and 110,540,860 outstanding at March 31, 2020 and 112,703,926 issued and 110,818,649 outstanding at December 31, 2019
113

 
113

Additional paid-in capital
149,765

 
147,231

Treasury stock at cost; 2,163,066 shares at March 31, 2020 and 1,885,277 shares at December 31, 2019
(12,578
)
 
(10,806
)
Accumulated deficit
(106,961
)
 
(102,140
)
Total stockholders' equity
30,339

 
34,398

Total liabilities and stockholders' equity
$
158,909

 
$
167,166

See notes to unaudited condensed consolidated financial statements

6



MIMEDX GROUP, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except share and per share data)
(unaudited)
 
Three Months Ended March 31,
 
2020
 
2019

 
 
 
Net sales
$
61,736

 
$
66,555

Cost of sales
10,025

 
7,418

Gross profit
51,711

 
59,137

 
 
 
 
Operating expenses:
 
 
 
Selling, general and administrative
46,942

 
50,862

Investigation, restatement and related
15,592

 
18,107

Research and development
2,650

 
2,902

Amortization of intangible assets
271

 
233

Impairment of intangible asset

 
446

Operating loss
$
(13,744
)
 
$
(13,413
)
 
 
 
 
Other income (expense), net
 
 
 
Interest (expense) income, net
(2,387
)
 
211

Other income (expense), net
6

 
(29
)
 
 
 
 
Loss before income tax provision
(16,125
)
 
(13,231
)
Income tax provision benefit (expense)
11,304

 
(42
)
 
 
 
 
Net loss
$
(4,821
)
 
$
(13,273
)
 
 
 
 
Net loss per common share - basic
$
(0.04
)
 
$
(0.12
)
 
 
 
 
Net loss per common share - diluted
$
(0.04
)
 
$
(0.12
)
 
 
 
 
Weighted average shares outstanding - basic
107,538,509

 
106,420,317

 
 
 
 
Weighted average shares outstanding - diluted
107,538,509

 
106,420,317

See notes to unaudited condensed consolidated financial statements

7




MIMEDX GROUP, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(in thousands, except share data)
(unaudited)
 
 
Common Stock Issued
Additional Paid - in
Treasury Stock
Accumulated
 
 
 
Shares
Amount
Capital
Shares
Amount
 Deficit
Total
Balance at December 31, 2019
 
112,703,926

$
113

$
147,231

1,885,277

$
(10,806
)
$
(102,140
)
$
34,398

Share-based compensation expense
 


1,915




1,915

Exercise of stock options
 


(1,214
)
(170,300
)
1,512


298

Restricted stock shares canceled/forfeited
 


1,746

242,998

(1,746
)


Shares repurchased for tax withholding
 


87

205,091

(1,538
)

(1,451
)
Net loss
 





(4,821
)
(4,821
)
Balance at March 31, 2020
 
112,703,926

$
113

$
149,765

2,163,066

$
(12,578
)
$
(106,961
)
$
30,339

 
 
Common Stock Issued
Additional Paid - in
Treasury Stock
Accumulated
 
 
 
Shares
Amount
Capital
Shares
Amount
Deficit
Total
Balance at December 31, 2018
 
112,703,926

$
113

$
164,744

3,605,263

$
(38,642
)
$
(76,560
)
$
49,655

Share-based compensation expense
 


3,014




3,014

Issuance of restricted stock
 


(3,025
)
(251,305
)
3,025



Restricted stock shares canceled/forfeited
 


1,563

141,381

(1,563
)


Shares repurchased for tax withholding
 



336,674

(1,044
)

(1,044
)
Net loss
 





(13,273
)
(13,273
)
Balance at March 31, 2019
 
112,703,926

$
113

$
166,296

3,832,013

$
(38,224
)
$
(89,833
)
$
38,352

See notes to unaudited condensed consolidated financial statements

8



MIMEDX GROUP, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)
 
Three Months Ended March 31,
 
2020
 
2019
Cash flows from operating activities:
 
 
 
Net loss
$
(4,821
)
 
$
(13,273
)
Adjustments to reconcile net income to net cash from operating activities:
 
 
 
Share-based compensation
3,349

 
3,014

Depreciation
1,506

 
1,695

Amortization of intangible assets
271

 
233

Amortization of deferred financing costs and debt discount
668

 

Non-cash lease expenses
239

 
269

Loss on fixed asset disposal

 
1

Impairment of intangible assets

 
1,258

Increase (decrease) in cash resulting from changes in:
 
 
 
Accounts receivable
395

 

Inventory
(143
)
 
(442
)
Prepaid expenses
1,430

 
2,053

Income tax receivable
(10,711
)
 
(12
)
Other assets
812

 
(1,612
)
Accounts payable
1,046

 
(4,173
)
Accrued compensation
(4,186
)
 
(7,501
)
Accrued expenses
(2,845
)
 
3,895

Income taxes

 

Other liabilities
709

 
(665
)
Cash flows used in operating activities
(12,281
)
 
(15,260
)
 
 
 
 
Cash flows from investing activities:
 
 
 
Purchases of equipment
(1,011
)
 
(648
)
Principal payments from note receivable

 
389

Patent application costs
(75
)
 
(174
)
Cash flows used in investing activities
(1,086
)
 
(433
)
 
 
 
 
Cash flows from financing activities:
 
 
 
Proceeds from exercise of stock options
298

 

Stock repurchased for tax withholdings on vesting of restricted stock
(1,538
)
 
(1,044
)
Repayment of term loan
(937
)
 

Cash flows used in financing activities
(2,177
)
 
(1,044
)
 
 
 
 
Net change in cash
(15,544
)
 
(16,737
)
 
 
 
 
Cash and cash equivalents, beginning of period
69,069

 
45,118

Cash and cash equivalents, end of period
$
53,525

 
$
28,381

See notes to unaudited condensed consolidated financial statements

9



MIMEDX GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE MONTHS ENDED MARCH 31, 2020 AND 2019
1.
Nature of Business
MiMedx Group, Inc. (together with its subsidiaries except where the context otherwise requires “MiMedx,” or the “Company”) is an advanced wound care and emerging therapeutic biologics company, developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. The Company derives its products from human placental tissues processed using proprietary processing methodologies. The Company’s mission is to offer physicians products and tissues to help the body heal itself. MiMedx provides products in the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic and dental sectors of healthcare. All of the Company’s products are regulated by the United States Food and Drug Administration (“FDA”).
MiMedx is the leading supplier of human placental allografts, which are human tissues that are transplanted from one person (a donor) to another person (a recipient). The Company operates in one business segment, Regenerative Biomaterials, which includes the design, manufacture, and marketing of products for the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic and dental sectors of healthcare. The Company’s allograft product families include: the dHACM family with AmnioFix® and EpiFix® brands; the Umbilical family with EpiCord® and AmnioCord® brands; and the Placental Collagen family with AmnioFill™ brands. AmnioFix and EpiFix are tissue allografts derived from amnion and chorion layers of human placental membrane; EpiCord and AmnioCord are tissue allografts derived from umbilical cord tissue. AmnioFill is a placental connective tissue matrix, derived from the placental disc and other placental tissue.
The Company’s business model is focused primarily on the United States of America but the Company is exploring potential future international expansion opportunities.
Effect of COVID-19 Pandemic
The COVID-19 pandemic and governmental and societal responses thereto have affected the Company’s business, results of operations and financial condition. The continuation or additional waves of the outbreak of COVID-19 or the outbreak of other health epidemics could harm the Company’s operations and increase the Company’s costs and expenses in numerous ways. The ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change. The Company does not yet know the full extent of delays or impacts on the business, clinical trials, healthcare systems or the global economy as a whole, or how long such effects will endure. The effects of the COVID-19 pandemic or other health epidemics could have an adverse impact on the Company’s business, results of operations and financial condition.
On March 27, 2020, the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”) was signed into law. The CARES Act includes provisions relating to refundable payroll tax credits, deferment of the employer portion of certain payroll taxes, loans and grants to certain business, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. As a result of the CARES Act, the Company expects a federal tax refund of approximately $11.3 million and has recognized an income tax benefit of the same amount.
2.
Significant Accounting Policies
Please see Note 3 to the Company’s Consolidated Financial Statements included in the Company’s Form 10-K for the fiscal year ended December 31, 2019 (the “2019 Form 10-K”), filed with the Securities and Exchange Commission (“SEC”) on July 6, 2020 for a description of all significant accounting policies. 
Basis of Presentation
The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) from interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.  Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of Accounting Standards Updates (“ASU’’) to the FASB’s Accounting Standards Codification (“ASC”).  In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the results of operations for the periods presented have been included.  Operating results for the three months ended March 31, 2020 and 2019, are not necessarily indicative of the results that may be expected for the fiscal year.  The balance sheet at December 31, 2019, has been derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements. 

10



You should read these condensed consolidated financial statements together with the historical consolidated financial statements of the Company for the year ended December 31, 2019, included in the 2019 Form 10-K.
Use of Estimates
The consolidated financial statements have been prepared in accordance with GAAP. Conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported consolidated statements of operations during the reporting period. Actual results could differ from those estimates. Significant estimates include estimated useful lives and potential impairment of property and equipment and intangible assets, estimates for contingent liabilities, management’s assessment of the Company’s ability to continue as a going concern, estimates of fair value of share-based payments and valuation of deferred tax assets.
Principles of Consolidation
The consolidated financial statements include the accounts of MiMedx Group, Inc. and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation.
Cash and Cash Equivalents
Cash and cash equivalents include cash and Federal Deposit Insurance Corporation (“FDIC”) insured certificates of deposit held at various banks with an original maturity of three months or less.
Accounts Receivable
Accounts receivable represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables.
The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing receivables. The Company determines the allowance based on factors such as historical collection experience, customers’ current creditworthiness, customer concentrations, age of accounts receivable and general economic conditions that may affect customers’ ability to pay.
Notes Receivable
Notes receivable represent formal payment agreements with customers which generally arise in situations where amounts shipped and billed have aged significantly as well as the promissory note issued by Stability Biologics, LLC (“Stability”) as part of the divestiture of Stability in 2017. The promissory note from Stability was paid in full in the three months ended September 30, 2019. The Company’s notes receivable are included in other current and long-term assets in the accompanying condensed consolidated balance sheets and were valued taking into consideration cost of the market participant inputs, market conditions, liquidity, operating results and other qualitative factors.
Inventories
Inventories are valued at the lower of cost or net realizable value, using the first-in, first-out (“FIFO”) method.  Inventory is tracked through raw material, work-in-process, and finished good stages as the product progresses through various production steps and stocking locations. Labor and overhead costs are absorbed through the various production processes until the work order closes. Historical yields and normal capacities are utilized in the calculation of production overhead rates. Reserves for inventory obsolescence are utilized to account for slow-moving inventory as well as inventory no longer needed due to diminished market demand.
Revenue Recognition
The Company sells its products primarily to individual customers and independent distributors (collectively referred to as “customers”). During the three months ended March 31, 2019, the Company’s control environment was such that it created uncertainty surrounding all of its customer arrangements, which required consideration related to the proper revenue recognition under the applicable literature. The control environment allowed for the existence of extra-contractual or undocumented terms or arrangements initiated by or agreed to by the Company and former members of Company management at the outset of the transactions (side agreements). Concessions were also agreed to subsequent to the initial sale (e.g. sales above established customer credit limits extended and unusually long payment terms, return or exchange rights, and contingent payment obligations) that called into question the ability to recognize revenue at the time that product was shipped to a customer. The applicable revenue

11



recognition guidance also changed beginning January 1, 2018, which further impacted the Company’s revenue recognition methodology.
As a result, the Company’s application of the applicable revenue recognition guidance varies for the three months ended March 31, 2020 and 2019. Additionally, the Company changed its pattern of revenue recognition effective October 1, 2019. The application of the relevant revenue recognition guidance and the pattern of revenue recognition are further discussed below for each period presented.
Three Months Ended March 31, 2019
The Company follows ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”) which establishes principles for reporting information about the nature, amount, timing and uncertainty of revenue and cash flows arising from the entity’s contracts to provide goods or services to customers. The core principle requires an entity to recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration that it expects to be entitled to receive in exchange for those goods or services recognized as performance obligations are satisfied.
ASC 606 establishes a five-step model for revenue recognition. The first of these steps requires the identification of the contract as described in ASC 606-10-25-1. The specific criteria (the “Step 1 Criteria”) to this determination are as follows:
The parties to the contract have approved the contract (in writing, orally, or in accordance with other customary business practices) and are committed to perform their respective obligations;
The entity can identify each party’s rights regarding the goods or services to be transferred; and
The entity can identify the payment terms for the goods or services to be transferred.
The contract has commercial substance.
It is probable that the entity will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.
For the three months ended March 31, 2019, the Company concluded that the first three of the above criteria were not met upon shipment of product to the customer, the fourth criterion had been met, and the Company acknowledges that there is a degree of uncertainty as to whether the last criterion above had been met. Although the parties to the contract may have approved the contract and purchase orders in writing, the Company concluded that upon shipment of products to the customer there is not sufficient evidence that its customers were committed to perform their obligations defined in the contract due to the existence of extra-contractual or undocumented terms or arrangements (e.g., regarding payment terms, right of return, etc.).
The Company’s inability to fulfill these criteria was due to uncertainties of contractual adjustments with customers created by a combination of an inappropriate tone at the top and extra-contractual arrangements. Consequently, the Company concluded that it did not meet the Step 1 Criteria upon shipment of the product. Subsequent to the shipment of product, uncertainties surrounding contractual adjustment were not resolved until either: (1) the customer returned the product prior to payment; or (2) the Company received payment from the customer. At that point, the Company determined that an accounting contract existed and the performance obligations of the Company to deliver product and the customer to pay for the product were satisfied. The Company determined the transaction price of its contracts to equal the amount of consideration received from customers less the amount expected to be refunded or credited to customers, which is recognized as a refund liability that is updated at the end of each reporting period for changes in circumstances. The refund liability is included within accrued expenses in the consolidated balance sheet.
Transition and the Three Months Ended March 31, 2020
The Company continued to assess contracts, new and existing, throughout 2019 to determine if the Step 1 Criteria noted above for the determination of a contract under ASC 606 were met for new contracts at the outset of a sales transaction (i.e., upon shipment of product) or for existing contracts at some point within 2019 when all the terms of the arrangement would have been known. Until the Step 1 Criteria had been met, revenue recognition continued to be deferred consistent with the assessment for the year ended December 31, 2018.
As further discussed above, the primary factors contributing to the determination in prior periods that the Step 1 Criteria had not been met were the inappropriate tone at the top and the existence of pervasive extra-contractual or undocumented terms or arrangements. These prior business practices and the lack of transparency surrounding them created a systemically implied right for customers to demand future, unknown performance by the Company. Although some of the former executives were employed by the Company only through June 2018, the Company determined that based on the impact of the prior tone at the top, the

12



continued internal sales force strategy and the existing customer base’s continued expectations (based on past practice), there would be flexibility with respect to arrangement terms even after delivery of the product so pervasive that all customer arrangements continued to be subject to uncertain modification of terms into 2019.
After identifying the primary factors contributing to the lack of knowledge regarding its customer contractual terms, the Company began implementing changes in mid-2018 to remediate the pervasive weaknesses in the control environment, followed by gradually implementing measures to empower its compliance, legal, and accounting departments, educating its sales force on appropriate business practices, and communicating its revised terms of sale to customers. The Company assessed its efforts throughout 2019 to determine when, if at any point, the factors contributing to the inability to satisfy the Step 1 Criteria were sufficiently addressed such that the Step 1 Criteria were met at the time of physical delivery to the customer. Determining when these conditions were effectively satisfied was a matter of judgment; however, the Company determined that adequate knowledge of the contractual arrangements with its customers did exist in 2019. Management did note that there is no single determinative change that overcame the pervasive challenges noted above, but rather an accumulation of efforts that taken together, resulted in sufficient knowledge of contractual relationships both internally within the Company and externally with its customers.
To address the tone at the top issues, the Company noted that proper remediation involved not only the removal of members of management that were setting an inappropriate tone but also the establishment of new management throughout the organization that emphasized a commitment to integrity, ethical values and transparency and have that reinforcement for a sustained period of time. The changes made to management positions throughout the organization and the resulting organization behavior changes were assessed to have been sufficiently addressed by mid-2019.
Therefore, beginning October 1, 2019, for all new customer arrangements, the Company determined adequate measures were in place to understand the terms of its contracts with customers. As such, beginning October 1, 2019, the Company concluded that the Step 1 Criteria would be met prior to shipment of product to the customer or implantation of the products on consignment.
For the remaining customer arrangements at September 30, 2019 (the “Remaining Contracts”), the Company concluded that due to the uncertainty that extracontractual arrangement may continue the Step 1 Criteria would not be satisfied until the Company receives payment from the customer. At that point, the Company determined that an accounting contract would exist and the performance obligations of the company to deliver product and the customer to pay for the product would be satisfied. As of March 31, 2020, upon reassessment, the Company concluded that the Step 1 Criteria continued to not be met due to the same circumstances described above. The amount related to these Remaining Contracts at March 31, 2020 was $4.5 million.
 
Amounts Invoiced and Not Collected

Deferred Cost of Sales
Amounts as of December 31, 2019
$
9,006

 
$
1,261

Revenue recognized related to amounts invoiced and not collected at September 30, 2019:
 
 
 
Cash collected during the three months ended March 31, 2020 related to the Remaining Contracts
(4,495
)
 
(629
)
Amounts as of March 31, 2020
$
4,511

 
$
632


As a result of the reassessment as of September 30, 2019, the Company also determined that, for approximately $10.3 million of existing contracts where payment had not been received, it was not probable that substantially all consideration would be collected. For these customer contracts, the Company continued to fail the Step 1 Criteria and, therefore, no revenue was recognized in 2019. Any collections during the three months ended March 31, 2020, as well as any future collections relating to these customer contracts, will be recorded as revenue at the time payment is received.
For all customer transactions concluded to meet the Step 1 Criteria, the Company then assessed the remaining criteria of ASC 606 to determine the proper timing of revenue recognition.
Under ASC 606, the Company recognizes revenue following the five-step model: (i) identify the contracts with a customer (the Step 1 Criteria); (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. As noted above, during the third quarter of 2019, the Company determined that they had met the Step 1 Criteria. The Company also determined that the performance obligation was met upon delivery of the product to the customer, or at the time the product is implanted for products on consignment, at which point the Company determined it will collect the consideration it is entitled to in exchange for the product transferred to the customer. As a result, the Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied, generally upon shipment of the product to the customer. The nature of the Company’s contracts gives rise

13



to certain types of variable consideration, including rebates and other discounts. The Company includes estimated amounts of variable consideration in the transaction price to the extent that it is probable there will not be a significant reversal of revenue. Estimates are based on historical or anticipated performance. The Company does have consignment agreements with several customers and distributors which allow the Company to better market its products by moving them closer to the end user. In these cases, the Company determined that it has fulfilled its performance obligation once control of the product has been delivered to the customer, which occurs simultaneously with the product being implanted.
The Company acts as the principal in all of its customer arrangements and therefore records revenue on a gross basis. Shipping is considered immaterial in the context of the overall customer arrangement, and damages or loss of goods in transit are rare. Therefore, shipping is not deemed a separately recognized performance obligation. The Company maintains a returns policy that allows its customers to return product that is consigned, damaged or non-conforming, ordered in error, or due to a recall. The estimate of the provision for returns is based upon historical experience with actual returns. The Company’s payment terms for customers are typically 30 to 60 days from receipt of title of the goods.
Subsequent to the Transition, the Company continued to defer the cost of sales for certain arrangements for which all revenue recognition criteria have not been met. These amounts were recorded within other current assets on the consolidated balance sheet in the amount of $0.6 million and $1.3 million as of March 31, 2020 and December 31, 2019, respectively.
GPO Fees
The Company sells to Group Purchasing Organization (“GPO”) members who transact directly with the Company at GPO-agreed pricing. GPOs are funded by administrative fees that are paid by the Company. These fees are set as a percentage of the purchase volume, which is typically 3% of sales made to the GPO members. The Company presents the administrative fees paid to GPOs as a reduction of revenues because the benefit received by the Company in exchange for the GPO fees is not sufficiently separable from the GPO member’s purchase of the Company’s products.
Cost of Sales
Cost of sales includes all costs directly related to bringing the Company’s products to their final selling destination. Amounts include direct and indirect costs to manufacture products including raw materials, personnel costs and direct overhead expenses necessary to convert collected tissues into finished goods, product testing costs, quality assurance costs, facility costs associated with the Company’s manufacturing and warehouse facilities, depreciation, freight charges, costs to operate equipment and other shipping and handling costs for products shipped to customers.
Leases
Effective January 1, 2019, the Company accounts for its leases under ASC 842, “Leases”. The Company determines if an arrangement is, or contains, a lease at inception. Right-of-use assets and the related liabilities result from operating leases were included in Right of use asset, Other current liabilities and Other liabilities, respectively, in the condensed consolidated balance sheets as of March 31, 2020 and December 31, 2019.
Operating lease assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. The lease term used in the calculation includes options to extend or terminate the lease when the exercise of such options are reasonably certain. The Company uses the estimated incremental borrowing rate in determining the present value of lease payments. Variable components of the lease payments such as fair market value adjustments, utilities, and maintenance costs are expensed as incurred and not included in determining the present value of lease liabilities. As an accounting policy election, the Company excludes short-term leases having initial terms of 12 months or fewer. Lease expense is recognized on a straight-line basis over the lease term. See Note 6, “Leases” for further information regarding lease obligations.
Patent Costs
The Company incurs certain legal and related costs in connection with patent applications for tissue-based products and processes. The Company capitalizes such costs as patents in progress until a patent is obtained. When a patent is issued, the costs are amortized over the expected life of the patent to the extent that an economic benefit is anticipated from the resulting patent or alternative future use is available to the Company. If a patent is not obtained, costs are expensed. Patents are included in Intangible assets in the condensed consolidated balance sheet. The Company capitalized approximately $0.1 million and $0.2 million of patent costs during the first three months of 2020 and 2019, respectively.
Treasury Stock

14



The Company accounts for the purchase of treasury stock under the cost method. Treasury stock which is reissued for the exercise of option grants and the issuance of restricted stock grants is accounted for on a FIFO basis.
Recently Issued Accounting Standards Adopted by the Company
In February 2016, FASB issued ASU No. 2016-02, “Leases (Topic 842)”, which amended the guidance on accounting for leases. The FASB issued this update to increase transparency and comparability among organizations. This update requires the recognition of lease assets and lease liabilities on the balance sheet and the disclosure of key information about leasing arrangements. The Company adopted the ASU effective January 1, 2019 using the additional (optional) approach, in accordance with ASU 2018-11, “Leases (Topic 842): Targeted Improvements.” Upon adoption, the Company recorded a right of use asset of $4.3 million and a right of use liability of $5.2 million. The right of use asset, in its entirety, is included in Right of use assets, net on the condensed consolidated balance sheet. Right of use liabilities are included in Other current liabilities to the extent that such liabilities are expected to be settled within one year and Other liabilities to the extent that such obligations are due more than one year from the balance sheet date. The difference between the right of use asset and liability relates to rent credits which existed as of January 1, 2019. There was no effect on opening retained earnings at adoption.
In adopting the new lease standard, the Company elected the permitted package of practical expedients permitted, which allowed the Company to account for existing leases under their current classification, as well as omit any new costs classified as initial direct costs, under the new standard. See Note 6 for additional information on leases.
In February 2018, the FASB issued ASU No. 2018-02, “Income Statement - Reporting Comprehensive Income (Topic 220),” to address certain income tax effects in Accumulated Other Comprehensive Income (“AOCI”) resulting from the tax reform enacted in 2017. The amended guidance provides an option to reclassify tax effects within AOCI to retained earnings in the period in which the effect of the tax reform is recorded. The amendments were effective for fiscal years beginning after December 15, 2018, including interim periods. The Company adopted this ASU on January 1, 2019, which did not have any impact on the Company’s results of operations or financial condition as there were no balances in AOCI that are tax effected.
In June 2018, the FASB issued ASU 2018-07, “Compensation-Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Payment Accounting” (“ASU 2018-07”), which simplifies the accounting for share-based payments to non-employees by aligning it with the accounting for share-based payments to employees, with certain exceptions. Under the new guidance, the measurement of equity-classified nonemployee awards will be fixed at the grant date. ASU 2018-07 is effective for interim and annual reporting periods beginning after December 15, 2018 and early adoption was permitted. The Company adopted the new standard on January 1, 2019. The adoption of ASU 2018-07 did not have a material impact on the Company’s consolidated financial statements and related disclosures.
In June 2016, the FASB issued ASU 2016-13, “Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,” that introduces a new model for recognizing credit losses on financial instruments based on an estimate of current expected credit losses. This includes accounts receivable, trade receivables, loans, held-to-maturity debt securities, net investments in leases and certain off-balance sheet credit exposures. The guidance also modifies the impairment model for available-for-sale debt securities. The ASU is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2019. The Company adopted this ASU on January 1, 2020 using a modified retrospective transition method which requires a cumulative-effect adjustment to the opening balance of retained earnings to be recognized on the date of adoption with no change to financial results reported in prior periods. The cumulative effect adjustment recorded on January 1, 2020 is not material. The adoption of this ASU did not have a significant impact on the Company’s consolidated financial statements and related disclosures.
All other ASUs issued and not yet effective for the three months ended March 31, 2020, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company’s financial position or results of operations.
3.
Liquidity and Capital Resources
Net Working Capital
As of March 31, 2020, the Company had approximately $53.5 million of cash and cash equivalents.  The Company reported total current assets of approximately $115.9 million and current liabilities of approximately $63.7 million as of March 31, 2020.  
Overall Liquidity and Capital Resources
The Company’s largest cash requirement for the three months ended March 31, 2020 was cash for general working capital needs and capital expenditures. The Company funded its cash requirements through its existing cash reserves, and the Term Loan that closed in June 2019. The Company believes that its anticipated cash from operating and financing activities and existing cash and

15



cash equivalents will enable the Company to meet its operational liquidity needs and fund its planned investing activities for the next year from the date these financial statements were available to be issued.
Issuance of $100 Million of Series B Convertible Preferred Stock
On July 2, 2020, the Company issued $100 million of the Company’s Series B Convertible Preferred Stock, par value $0.001 per share (the “Series B Preferred Stock”) to an affiliate of EW Healthcare Partners and to certain funds managed by Hayfin Capital Management LLP pursuant to a Securities Purchase Agreement with Falcon Fund 2 Holding Company, L.P., an affiliate of EW Healthcare Partners, and certain funds managed by Hayfin Capital Management LLP, dated as of June 30, 2020 (the “Securities Purchase Agreement”), for an aggregate purchase price of $100 million (the “Preferred Stock Transaction”).
$75 Million Loan Facility with Hayfin
On June 30, 2020, the Company entered into a Loan Agreement with, among others, Hayfin Services LLP, an affiliate of Hayfin Capital Management LLP (the “Hayfin Loan Agreement”), which funded on July 2, 2020 (the “Hayfin Loan Transaction”) and provided the Company with a senior secured term loan in an aggregate amount of $50 million (the “Hayfin Term Loan”) and an additional $25 million delayed draw term loan (the “DD TL”) in the form of a committed but undrawn facility. The Hayfin Term Loan and the DD TL mature on July 2, 2025 (the “Maturity Date”). The Hayfin Term Loan and the DD TL have no fixed amortization (i.e. interest only through the Maturity Date).
Borrowings under the Hayfin Loan Agreement bear interest at a rate equal to LIBOR (subject to a floor of 1.5%) plus a margin of 6.75%. The margin will be eligible to step down to 6.5% or 6.0% based on future Total Net Leverage levels, as defined in the Hayfin Loan Agreement. The Company paid an upfront commitment fee of 2% of the aggregate of the Hayfin Term Loan and the DD TL. The DD TL is subject to an additional commitment fee of 1% of the amount undrawn.
The Hayfin Loan Agreement also contains certain affirmative covenants that impose certain reporting and/or performance obligations on the Company and its subsidiaries, including (i) Maximum Total Net Leverage of 5.0x through December 31, 2020, stepping down to 4.5x through June 30, 2021, and to 4.0x thereafter until the Maturity Date; (ii) Cap on Cash Netting for the purposes of calculating Total Net Leverage set at $10,000,000; (iii) DD TL Incurrence Covenant of 3.5x Total Net leverage, tested prior to any drawings under the DD TL; and (iv) Minimum Liquidity of $10,000,000, an at-all-times covenant tested monthly.
Repayment and Termination of BT Loan Agreement
On July 2, 2020, the Company repaid the remaining $72.0 million of principal and accrued interest of $0.1 million under the loan agreement, dated as of June 10, 2019, by and among the Company, the subsidiaries of the Company as guarantors party thereto from time to time, the lenders party thereto from time to time, and Blue Torch Finance LLC (“Blue Torch”), as administrative agent and collateral agent, as amended by that certain First Amendment thereto, dated as of April 22, 2020 (the “BT Loan Agreement”), and terminated the BT Loan Agreement. As a result of the early termination of the BT Loan Agreement, the Company also incurred a prepayment premium of $1.4 million, which it paid with a portion of the proceeds from the Preferred Stock Transaction and the Hayfin Loan Transaction, as described above.
For more information regarding the Preferred Stock Transaction, the Hayfin Loan Transaction, and the repayment of the BT Term Loan (as defined below) refer to Item 9B of the 2019 Form 10-K.
4.
Inventory
Inventory consisted of the following (in thousands):
 
March 31, 2020
 
December 31, 2019
Raw materials
$
330

 
$
318

Work in process
3,913

 
4,299

Finished goods
5,587

 
5,206

 Inventory, gross
9,830

 
9,823

Reserve for obsolescence
(583
)
 
(719
)
 Inventory, net
$
9,247

 
$
9,104



16



5.
Property and Equipment 
Property and equipment consisted of the following (in thousands):
 
March 31, 2020
 
December 31, 2019
Leasehold improvements
$
5,321

 
$
5,321

Lab and clean room equipment
15,128

 
14,894

Furniture and office equipment
15,405

 
15,118

Construction in progress
1,463

 
972

   Property and equipment, gross
37,317

 
36,305

Less accumulated depreciation
(25,484
)
 
(23,977
)
   Property and equipment, net
$
11,833

 
$
12,328


Depreciation expense for the three months ended March 31, 2020 and 2019, was approximately $1.5 million and $1.7 million, respectively.
6.
Leases
As discussed in Note 2, on January 1, 2019, MiMedx adopted new guidance for the accounting and reporting of leases. The Company has operating leases primarily for corporate offices, vehicles, and certain equipment. Such leases do not require any contingent rental payments, impose any financial restrictions, or contain any residual value guarantees. The Company determines if an arrangement is or contains a lease at inception.
Under ASC 842 transition guidance, the Company has not elected the hindsight practical expedient to determine the lease term for existing leases, which permits companies to consider available information prior to the effective date of the new guidance as to the actual or likely exercise of options to extend or terminate the lease. Certain of the Company’s leases include renewal options and escalation clauses; renewal options have not been included in the calculation of the lease liabilities and right of use assets as the Company is not reasonably certain to exercise the options.
Lease expense for operating lease payments is recognized on a straight-line basis over the term of the lease. Operating lease assets and liabilities are recognized based on the present value of lease payments over the lease term. Since most of the Company’s leases do not have a readily determinable implicit discount rate, the Company uses its incremental borrowing rate to calculate the present value of lease payments. As a practical expedient, the Company has made an accounting policy election not to separate lease components from non-lease components in the event that the agreement contains both. The Company includes both the lease and non-lease components for purposes of calculating the right-of-use asset and related lease liability.
The Company does not act as a lessor or have any leases classified as financing leases.
Operating lease cost was $0.4 million for the three months ended March 31, 2020 and was recorded in Selling, general, and administrative expenses. Interest on lease obligations was $0.1 million for the three months ended March 31, 2019 and was recorded in Selling, general, and administrative expenses. Cash paid for amounts included in the measurement of operating lease liabilities was $0.4 million at March 31, 2020. The amortization of leased assets was $0.2 million and $0.3 million for the three months ended March 31, 2020 and 2019, respectively.

17



Supplemental balance sheet information related to operating leases is as follows (amounts in thousands, except lease term and discount rate):
 
 
March 31, 2020
 
December 31, 2019
Assets
 
 
 
 
Right of use asset
$
3,158

 
$
3,397

 
 
 
 
 
Liabilities
 
 
 
 
Short term lease liability
$
1,195

 
$
1,168

 
Long term lease liability
$
2,611

 
$
2,919

 
 
 
 
 
Weighted-average remaining lease term (years)
2.8

 
3.1

Weighted-average discount rate
11.5
%
 
11.5
%

Maturities of operating leases liabilities are as follows (amounts in thousands):
Year ended December 31,
Maturities
2020 (excluding the three months ended March 31, 2020)
$
1,170

2021
1,528

2022
1,552

2023
195

2024

Thereafter

Total lease payments
4,445

Less: imputed interest
(639
)
 
$
3,806


7.
Intangible Assets
Intangible assets are summarized as follows (in thousands):
 
 
March 31, 2020
 
December 31, 2019
 
 
Gross Carrying Amount
Accumulated Amortization
Net Carrying Amount
 
Gross Carrying Amount
Accumulated Amortization
Net Carrying Amount
Amortized intangible assets
 
 
 
 
 
 
 
 
Licenses
 
$
1,414

$
(1,234
)
$
180

 
$
1,414

$
(1,200
)
$
214

Patents and know how
 
9,108

(5,232
)
3,876

 
9,099

(5,070
)
4,029

Customer and supplier relationships
 
3,761

(2,485
)
1,276

 
3,761

(2,417
)
1,344

Non-compete agreements
 
120

(75
)
45

 
120

(68
)
52

Total amortized intangible assets
 
$
14,403

$
(9,026
)
$
5,377

 
$
14,394

$
(8,755
)
$
5,639

 
 
 
 
 
 
 
 
 
Unamortized intangible assets
 
 
 
 
 
 
 
 
Trade names and trademarks
 
$
1,008

 
$
1,008

 
$
1,008

 
$
1,008

Patents in process
 
1,196

 
1,196

 
1,130

 
1,130

Total intangible assets
 
$
16,607

 
$
7,581

 
$
16,532

 
$
7,777


Amortization expense for the three months ended March 31, 2020 and 2019, was approximately $0.3 million and $0.2 million, respectively.

18



Expected future amortization of intangible assets as of March 31, 2020, is as follows (in thousands):
Year ending December 31,
Estimated
Amortization
Expense
2020 (excluding the three months ended March 31, 2020)
$
739

2021
978

2022
955

2023
955

2024
955

Thereafter
795

 
$
5,377


8.
Accrued Expenses
Accrued expenses include the following (in thousands):
 
March 31, 2020
 
December 31, 2019
Legal costs
$
13,302

 
$
12,202

Settlement costs
5,931

 
5,931

Pricing adjustment settlement with Veterans Affairs
6,894

 
6,894

Estimated returns
1,567

 
2,581

External commissions
1,328

 
1,722

Accrued clinical trials
566

 
1,076

Other
1,073

 
1,755

    Total
$
30,661

 
$
32,161


9.
Long-Term Debt
On June 10, 2019, the Company entered into the BT Loan Agreement, pursuant to which the full amount was borrowed and funded (the “BT Term Loan”). The proceeds from the BT Term Loan were used (i) for working capital and general corporate purposes and (ii) to pay transaction fees, costs and expenses incurred in connection with the BT Term Loan and the related transactions. The BT Term Loan would have matured on June 20, 2022 and was repayable in quarterly installments of $0.9 million; the balance was due on June 20, 2022. Blue Torch maintained a first-priority security interest in substantially all the Company’s assets. The BT Term Loan was issued net of the original issue discount of $2.3 million. The Company also incurred $6.7 million of deferred financing costs.
As of March 31, 2020, interest applicable to any borrowings under the BT Term Loan accrued at a rate equal to LIBOR plus a margin of 8.00% per annum. The BT Term Loan had an interest rate equal to 10.46% at the time the BT Loan Agreement was executed and an interest rate as of March 31, 2020 was 9.95%.
The BT Loan Agreement originally contained financial covenants requiring the Company, on a consolidated basis, to maintain the following:
Maximum Total Leverage Ratio, defined as funded debt divided by consolidated adjusted EBITDA, of not more than 3.0 to 1.0 as of the last day of the previous four consecutive fiscal quarters.
Minimum Liquidity, defined as unrestricted cash and cash equivalents, of less than $40.0 million as of the last business day of each fiscal month following the BT Term Loan closing date through and including the fiscal month ending May 31, 2020. For fiscal months beginning June 30, 2020, the Company was not permitted to have liquidity of less than $30.0 million. Beginning with the fiscal month ending December 31, 2020, if the total leverage ratio is less than 2.50 to 1.0 as of the last business day of any fiscal month, the Company’s liquidity was not permitted to be less than $20.0 million.
The BT Term Loan was amended on April 22, 2020 to, among other things, modify the financial covenants. See Note 15, “Subsequent Events,” of the consolidated financial statements.

19



The BT Loan Agreement also specified that any prepayment of the loan, voluntary or mandatory, as defined in the BT Loan Agreement, subjected MiMedx to a prepayment penalty as of the date of the prepayment with respect to the BT Term Loan of:
During the period from June 10, 2019 through June 10, 2020, an amount equal to 3% of the principal amount of the BT Term Loan prepaid on such date; and
During the period from June 11, 2020 through June 10, 2021, an amount equal to 2% of the principal amount of the BT Term Loan prepaid on such date.
Principal prepayments after June 10, 2021 were not subject to a prepayment penalty.
The BT Loan Agreement also included events of default customary for facilities of this type, and upon the occurrence of such events of default, subject to customary cure rights, all outstanding loans under the BT Loan Agreement could have been accelerated and/or the lenders’ commitments terminated.
The balances of the BT Term Loan were as follows (amounts in thousands):
 
March 31, 2020
December 31, 2019
 
Current portion
 
Long-term
Current portion
 
Long-term
Liability component - principal
$
3,750

 
$
68,438

$
3,750

 
$
69,375

Original issue discount

 
(1,723
)

 
(1,890
)
Deferred financing cost

 
(5,078
)

 
(5,579
)
Liability component - net carrying value
$
3,750

 
$
61,637

$
3,750

 
$
61,906


Interest expense related to the BT Term Loan, included in Interest income (expense), net in the consolidated statements of operations, was as follows (amounts in thousands):
 
For the Three Months Ended
 
March 31, 2020
Interest expense - stated interest rate
$
1,840

Interest expense - amortization of original issue discount and costs
167

Interest expense - amortization of deferred financing costs
491

Total term loan interest expense
$
2,498


The future principal payments for the Company’s BT Term Loan as of March 31, 2020 were as follows (in thousands):
Year ending December 31,
Principal
2020 (excluding the three months ended March 31, 2020)
$
2,088

2021
3,750

2022
66,350

2023

2024

Thereafter

Total Long Term Debt
$
72,188


As of March 31, 2020, the fair value of the Company’s BT Term Loan was $62.7 million. This valuation was calculated based on a series of Level 2 and Level 3 inputs by calculating a discount rate based on the credit risk spread of debt instruments of a similar risk character in reference to U.S. Treasury instruments with identical securities, with an incremental risk premium for Company-specific risk factors. The remaining cash flows associated with the BT Term Loan were discounted to March 31, 2020 with this calculated discount rate to derive the fair value as of that date.
As described above in Note 3, “Liquidity and Capital Resources,” on July 2, 2020, a portion of the proceeds from the Preferred Stock Transaction and the Hayfin Loan Transaction were used to repay the outstanding balance of principal, accrued but unpaid

20



interest, and prepayment premium under the BT Loan Agreement. In connection with the repayment of the BT Term Loan, the Company terminated the BT Loan Agreement.
Additionally, on July 2, 2020, the Company borrowed an aggregate of $50 million pursuant to the Hayfin Loan Agreement, and obtained an additional committed but undrawn $25 million facility pursuant to the Hayfin Loan Agreement, as described above in Note 3, “Liquidity and Capital Resources.”
10.
Net Loss Per Share
Basic net loss per common share is computed using the weighted-average number of common shares outstanding during the period.  Diluted net loss per common share is computed using the weighted-average number of common and dilutive common equivalent shares from stock options, restricted stock and warrants using the treasury stock method. 
The following table sets forth the computation of basic and diluted net income per share (in thousands except share data):
 
Three Months Ended March 31,
 
2020
 
2019
Net loss
$
(4,821
)
 
$
(13,273
)
Denominator for basic earnings per share - weighted average shares
107,538,509

 
106,420,317

Effect of dilutive securities: Stock options, restricted stock, and warrants outstanding(a)
2,706,804

 
803,487

Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities
107,538,509

 
106,420,317

Loss per common share - basic
$
(0.04
)
 
$
(0.12
)
Loss per common share - diluted
$
(0.04
)
 
$
(0.12
)
(a) Securities outstanding that are included in the computation above, utilizing the treasury stock method are as follows:
 
Three Months Ended March 31,
 
2020
 
2019
Outstanding Stock Options
919,555

 
609,292

Performance Based Awards
17,402

 

Restricted Stock Awards
1,769,847

 
194,195

 
2,706,804

 
803,487


11.
Income Taxes 
The effective tax rates for the Company of 70.1% and 0.3% for the three months ended March 31, 2020 and March 31, 2019, respectively includes the impact of discrete items of approximately $11.4 million in 2020 and $0 in 2019. As of March 31, 2020, the projected annual effective tax rate for 2020 is (0.6)%. The discrete items recorded for the three months ended March 31, 2020 are primarily related to modifications to the tax rules for carryback of net operating losses as a result of the CARES Act which are expected to result in a federal tax refund of approximately $11.3 million and an income tax benefit of the same amount. No benefit had been recognized with respect to the net operating losses due to a valuation allowance previously recorded. 
12.
Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities
Selected cash payments, receipts, and noncash activities are as follows (in thousands):
 
Three Months Ended March 31,
 
2020
 
2019
Cash paid for interest
$
1,840

 
$
1

Income taxes paid
6

 
46



21



13.
Contractual Commitments and Contingencies
Contractual Commitments
In addition to the leases noted under Note 6 “Leases,” the Company has commitments for meeting space. These leases expire over 3 to 3.5 years following March 31, 2020, and generally contain renewal options. The Company anticipates that most of these leases will be renewed or replaced upon expiration.
Rent expense for the three months ended March 31, 2020 and 2019, was approximately $0.3 million and $0.4 million, respectively, and is allocated among cost of sales, research and development, and selling, general and administrative expenses.
Separation and Transition Services Agreement of Edward J. Borkowski
On November 18, 2019, the Company entered into a Separation and Transition Services Agreement (“Separation Agreement”) with Edward J. Borkowski, under which Mr. Borkowski resigned as Executive Vice President and Interim Chief Financial Officer of the Company, as well as from any and all officer, director or other positions that he held with the Company and its affiliates, effective November 15, 2019. Pursuant to the Separation Agreement, Mr. Borkowski agreed to perform the duties of the Interim Chief Financial Officer with respect to the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 (the “2018 Form 10-K”) and assist with the transition of his duties as described in the Separation Agreement from November 15, 2019 through the earlier of the first business day following the Company’s filing of its 2018 Form 10-K with the SEC or December 31, 2019 (the “Transition Period”). From the end of the Transition Period until March 31, 2020, Mr. Borkowski agreed to provide services as may be requested by the Company with respect to matters related to the 2018 Form 10-K and the 2019 Form 10-K. The Company has paid Mr. Borkowski the full amount of $4.0 million as of July 6, 2020.
Litigation and Regulatory Matters
In the ordinary course of business, the Company and its subsidiaries are parties to numerous civil claims and lawsuits and subject to regulatory examinations, investigations, and requests for information. Some of these matters involve claims for substantial amounts. The Company’s experience has shown that the damages alleged by plaintiffs or claimants are often overstated, based on unsubstantiated legal theories, unsupported by facts, and/or bear no relation to the ultimate award that a court might grant. Additionally, the outcome of litigation and regulatory matters and the timing of ultimate resolution are inherently difficult to predict. These factors make it difficult for the Company to provide a meaningful estimate of the range of reasonably possible outcomes of claims in the aggregate or by individual claim. However, on a case-by-case basis, reserves are established for those legal claims in which it is probable that a loss will be incurred and the amount of such loss can be reasonably estimated. The Company's financial statements at March 31, 2020 reflect the Company's current best estimate of probable losses associated with these matters, including costs to comply with various settlement agreements, where applicable. The actual costs of resolving these claims may be substantially higher or lower than the amounts reserved. For more information regarding the Company’s legal proceedings, refer to the disclosure under Item 3, “Legal Proceedings” and Note 16, “Commitments and Contingencies” in the Company’s 2019 Form 10-K, which disclosure is incorporated herein by reference.
The following is a description of certain litigation and regulatory matters:
Shareholder Derivative Suits
On December 6, 2018, the United States District Court for the Northern District of Georgia entered an order consolidating three shareholder derivative actions (Evans v. Petit, et al. filed September 25, 2018, Georgalas v. Petit, et al. filed September 27, 2018, and Roloson v. Petit, et al. filed October 22, 2018) that had been filed in the Northern District of Georgia. On January 22, 2019, plaintiffs filed a verified consolidated shareholder derivative complaint. The consolidated action sets forth claims of breach of fiduciary duty, corporate waste and unjust enrichment against certain former officers, and certain current and former directors, of the Company: Parker H. Petit, William C. Taylor, Michael J. Senken, John E. Cranston, Alexandra O. Haden, Joseph G. Bleser, J. Terry Dewberry, Charles R. Evans, Larry W. Papasan, Luis A. Aguilar, Bruce L. Hack, Charles E. Koob, Neil S. Yeston and Christopher M. Cashman. The allegations generally involve claims that the defendants breached their fiduciary duties by causing or allowing the Company to misrepresent its financial statements as a result of improper revenue recognition. The Company filed a motion to stay on February 18, 2019, pending the completion of the investigation by the Company’s Special Litigation Committee. The Special Litigation Committee completed its investigation relating to this action and filed an executive summary of its findings with the Court on July 1, 2019. The parties (together with parties from the Hialeah derivative lawsuit, the Nix and Demaio derivative lawsuit, and the Murphy derivative lawsuit, each described below) held a mediation on February 11, 2020. Following continued discussions, on May 1, 2020, the parties notified the Court that plaintiffs and the Company had reached an agreement in principle to settle this consolidated derivative action, which settlement also encompasses all claims asserted in the Hialeah derivative lawsuit, the Nix and Demaio derivative lawsuit, and the Murphy derivative lawsuit. As of the date of the filing of this Form 10-Q, the

22



parties are drafting, and intend to file, a stipulation of settlement and motion seeking preliminary approval of the settlement.
On February 10, 2020, Charles Pike filed a shareholder derivative complaint in the United States District Court for the Southern District of Florida (Pike v. Petit, et al.). The complaint alleges claims for breaches of fiduciary duty against certain former officers, and certain current and former directors, of the Company: Parker H. Petit, William C. Taylor, Michael J. Senken, John E. Cranston, Charles R. Evans, Luis A. Aguilar, Joseph G. Bleser, J. Terry Dewberry, Bruce L. Hack, Charles E. Koob, Larry W. Papasan and Neil S. Yeston. Similar to the prior-filed actions discussed above, the allegations generally involve claims that the defendants breached their fiduciary duties by causing or allowing the Company to misrepresent its financial statements as a result of improper revenue recognition. On May 12, 2020, prior to the Company’s time to respond to the complaint, the plaintiff filed a notice of voluntary dismissal of this action without prejudice.
On February 18, 2020, Bruce Cassamajor filed a shareholder derivative complaint in the United States District Court for the Northern District of Florida (Cassamajor v. Petit, et al.). The complaint alleges claims for breaches of fiduciary duty against certain former officers, and certain current and former directors, of the Company: Parker H. Petit, William C. Taylor, Michael J. Senken, John E. Cranston, Charles R. Evans, Luis A. Aguilar, Joseph G. Bleser, J. Terry Dewberry, Bruce L. Hack, Charles E. Koob, Larry W. Papasan and Neil S. Yeston. Similar to the prior-filed actions discussed above, the allegations generally involve claims that the defendants breached their fiduciary duties by causing or allowing the Company to misrepresent its financial statements as a result of improper revenue recognition. On May 22, 2020, prior to service of the complaint, the plaintiff filed a notice of voluntary dismissal of this action without prejudice. On May 26, 2020, the court ordered this case to be dismissed for failure to serve process.
Securities Class Action
On January 16, 2019, the United States District Court for the Northern District of Georgia entered an order consolidating two purported securities class actions (MacPhee v. MiMedx Group, Inc., et al. filed February 23, 2018 and Kline v. MiMedx Group, Inc., et al. filed February 26, 2018). The order also appointed Carpenters Pension Fund of Illinois as lead plaintiff. On May 1, 2019, the lead plaintiff filed a consolidated amended complaint, naming as defendants the Company, Michael J. Senken, Parker H. Petit, William C. Taylor, Christopher M. Cashman and Cherry Bekaert & Holland LLP. The amended complaint (the “Securities Class Action Complaint”) alleged violations of Section 10(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), Rule 10b-5 promulgated thereunder and Section 20(a) of the Exchange Act. It asserted a class period of March 7, 2013 through June 29, 2018. Following the filing of motions to dismiss by the various defendants, the lead plaintiff was granted leave to file an amended complaint. The lead plaintiff filed its amended complaint against the Company, Michael Senken, Pete Petit, William Taylor, and Cherry Bekaert & Holland (Christopher Cashman was dropped as a defendant) on March 30, 2020; defendants filed motions to dismiss on May 29, 2020.
Investigations
United States Attorney’s Office for the Southern District of New York (“USAO-SDNY”) Investigation
The USAO-SDNY is conducting an investigation into, among other things, the Company’s recognition of revenue and practices with certain distributors and customers. The USAO-SDNY requested that the Company provide it with copies of all information the Company furnished to the SEC staff and made additional requests for information. The USAO-SDNY conducted interviews of various individuals, including employees and former employees of the Company. In November 2019, former executives Messrs. Petit and Taylor were indicted for securities fraud and conspiracy to commit securities fraud, to make false filings with the SEC, and to influence improperly the conduct of audits relating to alleged misconduct that resulted in inflated revenue figures for fiscal 2015. The Company is cooperating with the USAO-SDNY.
Department of Veterans’ Affairs Office of Inspector General (“VA-OIG”) and Civil Division of the Department of Justice (“DOJ-Civil”) Subpoenas and/or Investigations
VA-OIG has issued subpoenas to the Company seeking, among other things, information concerning the Company’s financial relationships with VA clinicians. DOJ-Civil has requested similar information. The Company has cooperated fully and produced responsive information to VA-OIG and DOJ-Civil. Periodically, VA-OIG has requested additional documents and information regarding payments to individual VA clinicians. Most recently, on June 3, 2020, the Company received a subpoena from the VA-OIG requesting information regarding the Company’s financial relationships and interactions with two healthcare providers at the VA Long Beach Healthcare System. The Company has continued to cooperate and respond to these requests.

23



As part of its cooperation, the Company provided documents in response to subpoenas concerning its relationship with three now former VA employees in South Carolina, who were ultimately indicted in May 2018. Among other things, the indictment referenced speaker fees paid by the Company to the former VA employees and other interactions between now former Company employees and the former VA employees. In January 2019, prosecution was deferred for 18 months to allow the three former VA employees to enter and complete a Pretrial Diversion Program, the completion of which would result in the dismissal of the indictment. As far as the Company is aware, two of the former VA employees have completed the program early and the indictment has been dismissed with respect to them. To date, no actions have been taken against the Company with respect to this matter.
United States Attorney’s Office for the Middle District of North Carolina (“USAO-MDNC”) Investigation
On January 9, 2020, the USAO-MDNC informed the Company that it is investigating the Company’s financial relationships with two former clinicians at the Durham VA Medical Center. The Company is cooperating with the investigation.
Qui Tam Actions
On January 19, 2017, a former employee of the Company filed a qui tam False Claims Act complaint in the United States District Court for the District of South Carolina (United States of America, ex rel. Jon Vitale v. MiMedx Group, Inc.) alleging that the Company’s donations to the patient assistance program, Patient Access Network Foundation, violated the Anti-Kickback Statute and resulted in submission of false claims to the government. The government declined to intervene and the complaint was unsealed on August 10, 2018. The Company filed a motion to dismiss on October 1, 2018. The Company’s motion to dismiss was granted in part and denied in part on May 15, 2019. The case is in discovery.
Former Employee Litigation
On November 19, 2018, the Company’s former Chief Financial Officer filed a complaint in the Superior Court for Cobb County, Georgia (Michael J. Senken v. MiMedx Group, Inc.) in which he claims that the Company has breached its obligations under the Company’s charter and bylaws to advance to him, and indemnify him for, his legal fees and costs that he incurred in connection with certain Company internal investigations and litigation. The Company filed its answer denying the plaintiff’s claims on April 19, 2019. To date, no deadlines have been established by the court.
On January 21, 2019, a former employee filed a complaint in the Fifth Judicial Circuit, Richland County, South Carolina (Jon Michael Vitale v. MiMedx Group, Inc. et. al.) against the Company alleging retaliation, defamation and unjust enrichment and seeking monetary damages. The former employee claims he was retaliated against after raising concerns related to insurance fraud and later defamed by comments concerning the indictments of three South Carolina VA employees. On February 19, 2019, the case was removed to the U.S. District Court for the District of South Carolina. The Company filed a motion to dismiss on April 8, 2019, which was denied by the Court. This case is in discovery.
In December 2019, MiMedx received notice of a complaint filed in July 2018 with the Occupational Safety and Health Administration (“OSHA”) section of the Department of Labor (“DOL”) by Thomas Tierney, a former Regional Sales Director, against MiMedx and the referenced individuals, Tierney v. MiMedx Group, Inc., Parker Petit, William Taylor, Christopher Cashman, Thornton Kuntz, Jr. and Alexandra Haden, DOL No. 4-5070-18-243. Mr. Tierney alleged that he was terminated from MiMedx in retaliation for reporting concerns about revenue recognition practices, compliance issues, and the corporate culture, in violation of the anti-retaliation provisions of the Sarbanes-Oxley Act. The parties settled this matter and OSHA dismissed the complaint on May 20, 2020.
Defamation Claims
On June 4, 2018, Sparrow Fund Management, LP (“Sparrow”) filed a complaint against the Company and Mr. Petit, including claims for defamation and civil conspiracy in the United States District Court for the Southern District of New York (Sparrow Fund Management, L.P. v. MiMedx Group, Inc. et. al.). The complaint seeks monetary damages and injunctive relief and alleges the defendants commenced a campaign to publicly discredit Sparrow by falsely claiming it was a short seller who engaged in illegal and criminal behavior by spreading false information in an attempt to manipulate the price of our Common Stock. On March 31, 2019, a judge granted defendants’ motions to dismiss in full, but allowed Sparrow the ability to file an amended complaint. The Magistrate has recommended Sparrow’s motion for leave to amend be granted in part and denied in part and the Judge adopted the Magistrate’s recommendation. Sparrow filed its amended complaint against MiMedx (Mr. Petit has been dropped from the lawsuit) on April 3, 2020 and the Company filed its answer. This case is in discovery.
On June 17, 2019, the principals of Viceroy Research (“Viceroy”), filed suit in the Circuit Court for the Seventeenth Judicial Circuit in Broward County, Florida (Fraser John Perring et. al. v. MiMedx Group, Inc. et. al.) against the Company and Mr. Petit, alleging defamation and malicious prosecution based on the defendants’ alleged campaign to publicly discredit Viceroy and the

24



lawsuit the Company previously filed against the plaintiffs, but which the Company subsequently dismissed without prejudice. On November 1, 2019, the Court granted Mr. Petit’s motion to dismiss on jurisdictional grounds, denied the Company’s motion to dismiss, and granted plaintiffs leave to file an amended complaint to address the deficiencies in its claims against Mr. Petit, which they did on November 21, 2019. The Company filed its answer on December 20, 2019.
Intellectual Property Litigation
The NuTech Action
On March 2, 2015, the Company filed a patent infringement lawsuit against NuTech Medical, Inc. (“NuTech”) and DCI Donor Services, Inc. (“DCI”) in the United States District Court for the Northern District of Alabama (MiMedx Group, Inc. v. NuTech Medical, Inc. et. al.). The Company has alleged that NuTech and DCI infringed and continue to infringe the Company’s patents through the manufacture, use, sale and/or offering of their tissue graft product. The Company has also asserted that NuTech knowingly and willfully made false and misleading representations about its products to customers and prospective customers. The Company is seeking permanent injunctive relief and unspecified damages. The case was stayed pending the restatement of the Company’s financial statements. Since the Company has completed its restatement, the case has resumed and discovery has recommenced.
The Osiris Action
On February 20, 2019, Osiris Therapeutics, Inc. (“Osiris”) refiled its trade secret and breach of contract action against the Company (which had been dismissed in a different forum) in the United States District Court for the Northern District of Georgia (Osiris Therapeutics, Inc. v. MiMedx Group, Inc.). Osiris has alleged that the Company acquired Stability, a former distributor of Osiris, in order to illegally obtain trade secrets. On February 24, 2020, the Court issued an order granting in part and denying in party MiMedx’s motion to dismiss. The Court dismissed Osiris’s claims for tortious interference, conspiracy to breach contract, unfair competition, and conspiracy to commit unfair competition.  The Court denied MiMedx’s motion to dismiss with respect to the claim for breach of the contract between Osiris and Stability, finding that there is a question as to whether Osiris can maintain such a claim by piercing the corporate veil between MiMedx and its former subsidiary.  If Osiris cannot pierce the corporate veil, the claim against MiMedx fails; if Osiris can pierce the corporate veil, the breach of contract claim must be brought in an arbitration proceeding. MiMedx did not move to dismiss Osiris’s claims for misappropriation of trade secrets and conspiracy to misappropriate trade secrets. MiMedx plans to defend against all remaining claims.
As of March 31, 2020, the Company has accrued approximately $12.8 million related to the legal proceedings discussed above. The Company has paid approximately $9.2 million to settle certain cases noted above.
Other Matters
Under the Florida Business Corporation Act and agreements with its current and former officers and directors, the Company is obligated to indemnify its current and former officers and directors who are made party to a proceeding, including a proceeding brought by or in the right of the corporation, with certain exceptions, and to advance expenses to defend such matters. The Company has already borne substantial costs to satisfy these indemnification and expense advance obligations and expects to continue to do so in the future.
In addition to the matters described above, the Company is a party to a variety of other legal matters that arise in the ordinary course of the Company’s business, none of which is deemed to be individually material at this time. Due to the inherent uncertainty of litigation, there can be no assurance that the resolution of any particular claim or proceeding would not have a material adverse effect on the Company’s business, results of operations, financial position or liquidity.
14.
Product Revenue Detail
MiMedx has two primary distribution channels: (1) direct to customers (healthcare professionals and/or facilities) (“Direct Customers”), and (2) sales through distributors (“Distributors”). For purposes of the required disclosure under ASC 606-10-50-5, the Company groups its customers into these two groups. This grouping by customer types does not constitute a basis for resource allocation but is information intended to provide the reader with ability to better understand how the nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factors applicable to each customer type. These groupings also do not meet the criteria under ASC 280-10-50-1 to qualify as separate operating segments. The Company did not have significant foreign operations or a single external customer from which 10% or more of revenues were derived during the three months ended March 31, 2020 and 2019.

25



Below is a summary of net sales by each customer type (in thousands):
 
Three Months Ended March 31,
 
2020
 
2019
 
 
 
 
Direct Customers
$
59,896

 
$
64,542

Distributors
1,840

 
2,013

Total
$
61,736

 
$
66,555


15.
Subsequent Events
Paycheck Protection Program (PPP) Loan
On April 24, 2020, the Company received a $10.0 million loan under the Paycheck Protection Program (“PPP”). On May 11, 2020 the Company repaid the PPP loan.
BT Loan Agreement Amendment
On April 22, 2020, the Company agreed to terms for an amendment to its BT Loan Agreement with Blue Torch. The amendment provided for an increase in the maximum Total Leverage Ratio (as defined in the BT Loan Agreement), which was a quarterly test, for the remainder of 2020, and also provided for a reduction in the minimum Liquidity (as defined in the BT Loan Agreement) requirement from April 2020 through and including November 2020. Specifically, the maximum Total Leverage Ratio increased from 3.0 to 1 to 5.0 to 1 through December 31, 2020. The minimum Liquidity requirement was reduced from $40 million to $20 million for April and May 2020, and from $30 million to $20 million for June through November 2020. In connection with the amendment, the Company agreed to pay a one-time fee of approximately $0.7 million, added to the principal balance, and a 1 percentage point increase in the interest rate to LIBOR plus 9%.
Sublease
On April 1, 2020 the Company successfully subleased its industrial warehouse space that expires on May 31, 2023. The Company performed an asset recovery test comparing the sum of estimated undiscounted future cash flows attributable to the sublease to its carrying amount. The total undiscounted cash flows for the remaining lease term exceed the carrying amount of the asset, therefore there is no impairment.
Issuance of $100 Million of Series B Convertible Preferred Stock
On July 2, 2020, the Company issued $100 million of Series B Convertible Preferred Stock to an affiliate of EW Healthcare Partners and to certain affiliates of Hayfin Capital Management LLP pursuant to that certain Securities Purchase Agreement, as described above in Note 3, “Liquidity and Capital Resources.”
$75 Million Loan Facility with Hayfin
On July 2, 2020, the Company borrowed an aggregate of $50 million pursuant to the Hayfin Loan Agreement, and obtained an additional committed but undrawn $25 million facility pursuant to the Hayfin Loan Agreement, as described above in Note 3, “Liquidity and Capital Resources.”
Repayment and Termination of BT Loan Agreement
On July 2, 2020, the Company repaid the remaining principal of $72.0 million, accrued interest of $0.1 million, and prepayment penalty of $1.4 million under the BT Loan Agreement with a portion of the proceeds from the Preferred Stock Transaction and the Hayfin Loan Transaction, and terminated the BT Loan Agreement, each as described above in Note 3, “Liquidity and Capital Resources.”




26







27



Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Overview
MiMedx is an industry leader in advanced wound care and an emerging therapeutic biologics company, developing and distributing placental tissue allografts with patent-protected processes for multiple sectors of healthcare. We derive our products from human placental tissues processed using our proprietary processing methodologies, including the PURION® process. We employ aseptic processing techniques in addition to terminal sterilization to produce our allografts. MiMedx provides products in the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic, and dental sectors of healthcare. Our mission is to offer products and tissues to help the body heal itself. All of our products are regulated by the FDA.
MiMedx is the leading supplier of human placental allografts, which are human tissues that are transplanted from one person (a donor) to another person (a recipient). MiMedx has supplied over 1.9 million allografts, through both direct sales and consignment shipments. Our biomaterial platform technologies include AmnioFix®, EpiFix®, EpiCord®, AmnioCord® and AmnioFill®. AmnioFix and EpiFix are our tissue allografts derived from the amnion and chorion layers of the human placental membrane. EpiCord and AmnioCord are tissue allografts derived from umbilical cord tissue. AmnioFill is a placental connective tissue matrix derived from the placental disc and other placental tissue.
Our EpiFix and EpiCord product lines are promoted for external use, such as in advanced wound care applications, while our AmnioFix, AmnioCord and AmnioFill products are positioned for use in surgical applications, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions.
MiMedx has two primary distribution channels: (1) direct to customers (healthcare professionals and/or facilities); and (2) sales through distributors.
Trends in Our Business
Certain areas of our business suffered as a result of the issues identified in the Audit Committee Investigation
The results of the Audit Committee Investigation have caused us to incur significant legal fees, fines, and penalties. Additionally, the Company has incurred significant costs in connection with the associated Restatement. Negative publicity in the marketplace has created challenges for the Company in selling product to customers and retaining talented employees. All of these matters have caused the Company to incur significant costs and have negatively impacted our financial performance.
Demographic shifts are creating opportunities in the wound care space
The advanced wound care category is expected to continue growing due to certain demographic trends, including an aging population, increasing incidence of obesity and diabetes, and the associated higher susceptibility to non-healing chronic wounds. Furthermore, the increasing number of patients requiring advanced treatment represents a significant cost burden on the healthcare system. We expect that these shifts will benefit our business.
As we look for ways to achieve long-term competitive advantages, we plan to continue to invest in research & development
We continue to evaluate these opportunities in alignment with our focus on advanced wound care. We remain focused on advancing our BLA programs and are therefore aligning customer input, industry expertise, and additional resourcing toward seeking FDA approval for micronized dehydrated human amnion/chorion membrane (“dHACM”) for the potential indication to treat musculoskeletal degeneration across multiple indications. In addition, we expect to incur additional costs to achieve compliance with evolving regulatory standards.


28



Important Cautionary Statement
We caution the reader that actual results may differ materially from our expectations. Among the factors that could cause actual results to differ are: variances from our expectations or assumptions; changes in reimbursement policy from public and private insurers and health systems; the loss of a Group Purchasing Organization or Integrated Delivery Network; changes in purchasing behavior by government accounts; the loss of independent sales agents or distributors; the removal of any of our products from the market as a result of regulatory actions; the success of our marketing efforts; the fact that obtaining and maintaining the necessary regulatory approvals for certain of our products will be expensive and time consuming and may impede our ability to fully exploit our technologies; rapid technological change could cause our products to become obsolete and, if we do not enhance our product offerings through our research and development efforts, we may be unable to compete effectively; our ability to transition our manufacturing facilities into compliance with cGMP, advance our IND applications, complete our clinical trials and pursue BLAs for certain of our micronized products; the fact that our business is subject to continuing regulatory compliance by the FDA and other authorities, which is costly, and our failure to comply could result in adverse effects on our business, results of operations and financial condition; the fact that litigation and other matters relating to and arising out of the Investigation, including the accounting review of our previously issued consolidated financial statements and the audits of fiscal years 2018, 2017 and 2016, have been time consuming and expensive, and may result in additional expense; and the fact that our variable rate indebtedness under the Hayfin Term Loan (as defined below) subjects us to interest rate risk, which could result in higher expense in the event of increases in interest rates and adversely affect our business, financial condition, and results of operations.

Expected Impact of COVID-19 Pandemic
On March 11, 2020, the World Health Organization designated the outbreak of a novel strain of coronavirus (“COVID-19”) as a global pandemic. Governments and businesses around the world have taken unprecedented actions to mitigate the spread of COVID-19, including imposing restrictions on movement and travel such as quarantines and shelter-in-place requirements, and restricting or prohibiting outright some or all commercial and business activity, including the manufacture and distribution of certain goods and the provision of nonessential services. As of the end of the first half of 2020, significant uncertainty exists surrounding the efficacy of these measures to mitigate the spread of the virus, in addition to uncertainty surrounding timing and availability of a vaccine. The evolution of the outbreak, combined with these uncertainties, could result in the imposition of similar or greater restrictions for indefinite periods of time.
COVID-19 began to affect our operations during the three months ended March 31, 2020.
Sourcing and Manufacturing
We source the raw materials for our product from donors in hospitals. We have a large, geographically-diverse network of donor hospitals. We experienced interruptions to our access to some hospitals in some geographic areas beginning in the second half of March 2020. However, we have been successful in mitigating this disruption to our supply by adding additional donor hospitals, using third-party providers of donated placentas, and increasing efforts at hospitals that did not impose access limits. Additionally, in anticipation of expected disruptions, we ran manufacturing at levels greater than demand and have been successful in building our inventory of safety stock.
We process donated tissue in a sterile environment. However, the manufacturing space is a confined area where an affected employee might spread the virus to other employees despite the use of personal protective equipment required for this environment. We monitor our employees’ temperatures prior to entering our facilities and to date only two manufacturing employees and one sales representative have tested positive for the virus, each of whom was isolated from our workforce. Additionally, we required our non-manufacturing employees including our executives to work from home from March 13, 2020 until June 1, 2020, and we have continued to allow most employees flexibility in their work arrangements as a result of the pandemic. To date, and due to significant mitigation efforts, COVID-19 has had only a modest impact on our ability to source and manufacture our products.
Sales and Marketing
Our ability to sell our product has been hampered by the pandemic. Our sales force is spread across the country. In many areas, our sales force was excluded from hospitals and the offices of other health care providers. Additionally, many patients stayed away from hospitals and other medical facilities. This had an adverse effect on our revenues beginning late in the first quarter of 2020 and continuing into April. By mid-May, access to hospitals and healthcare providers by our sales force had been mostly restored, and we began to see significant numbers of patients’ return to hospitals and other healthcare providers, including for elective procedures. However, as of early July 2020, additional restrictions have been put in place in some areas of the country that again limit or postpone elective surgical procedures, and in particular, in areas of the country that contribute a larger portion of our sales. Future sales will depend on patients’ willingness to visit healthcare providers for care, and our sales force’s access to healthc

29



are providers. Also, the severity of the COVID-19 pandemic has been uneven across the country, and future waves of the outbreak of COVID-19 may have a greater impact on us than did the first wave depending on where infection rates are highest. We are not able to estimate COVID-19’s future effect on patient behavior and consequently future demand for our products. The COVID-19 pandemic and governmental and societal responses thereto have adversely affected our business, results of operations and financial condition, and the continuation of COVID-19 or the outbreak of other health epidemics could harm our business, results of operations, and financial condition. in the 2019 Form 10-K.
Selling and General Administrative Expenses
In response to these challenges, our management team initiated several actions. Most discretionary expenses such as travel were cancelled. We negotiated additional discounts with vendors. Merit salary increases scheduled for the second quarter of 2020 were deferred until the fourth quarter of 2020. Beginning on April 5, 2020, we reduced employees’ salaries, including those of senior executives, on a sliding scale with larger reductions applied to larger salaries. We intend for these reductions to last up to six months, and estimate that the combination of these efforts has saved the Company approximately $9.0 million through June 30, 2020. This has allowed us to reduce our expense base and reduce cash outlays, although we expect our margins to be temporarily reduced until sales return to normal levels. Nevertheless, at the end of the first quarter of 2020 and continuing into April, we saw a reduction in the amount of cash generated by the business. At May 31, 2020, our cash balance was $27.4 million, net of minimum balance covenants set forth in our Loan Agreement, dated as of June 10, 2019, by and among the Company, the subsidiaries of the Company as guarantors party thereto from time to time, the lenders party thereto from time to time, and Blue Torch Finance LLC (“Blue Torch”), as administrative agent and collateral agent, as amended by that certain First Amendment thereto, dated as of April 22, 2020 (the “BT Loan Agreement”).
Liquidity and Capital Resources
On April 22, 2020, we executed the First Amendment (the “Amendment”) to the BT Loan Agreement with Blue Torch. The Amendment provided for an increase in the maximum Total Leverage Ratio (as defined in the BT Loan Agreement), which is a quarterly test, for the remainder of 2020, and also provided for a reduction in the minimum Liquidity (as defined in the BT Loan Agreement) requirement from April 2020 through and including November 2020. Specifically, the maximum Total Leverage Ratio increased from 3 to 1 to 5 to 1 through December 31, 2020. The minimum Liquidity requirement was reduced from $40.0 million to $20.0 million for April and May 2020, and from $30.0 million to $20.0 million for June through November 2020. In connection with the Amendment, we agreed to pay a one-time fee (the “Amendment Fee”) of approximately $0.7 million, added to the principal balance, and a 1 percentage point increase in the interest rate to LIBOR plus 9%.
In addition, the Amendment loosened restrictions on our ability to borrow additional funds; enabling us to borrow up to $10 million under the Paycheck Protection Program (the “PPP Loan”) offered by the U.S. Small Business Administration under the Coronavirus Aid, Relief, and Economic Security Act. We applied for the PPP Loan prior to obtaining the aforementioned amendment to the BT Loan Agreement, and received the proceeds of the PPP Loan on April 24, 2020.
On May 8, 2020, we received a letter from the U.S. House of Representatives’ Committee on Oversight and Reform’s Select Subcommittee on the Coronavirus Crisis requesting that we return the proceeds of the PPP Loan so that the funds earmarked under the program could be used by smaller companies with more limited access to the capital markets. We repaid the PPP Loan in full on May 11, 2020.
Reserves and Financial Estimates
We do not expect that there be significant changes in judgments in determining the fair value of other assets measured in accordance with U.S. GAAP. As a result of the pandemic, we do not expect to incur any material impairments (e.g., with respect to goodwill, intangible assets, long-lived assets, right of use assets, investment securities), increases in allowances for credit losses, restructuring charges, other expenses, or changes in accounting judgments that have had or are reasonably likely to have a material impact on your financial statements, although we expect our days sales outstanding, post revenue recognition transition discussed in the “Critical Accounting Policies” below, to increase modestly as a result of patient behavior.
The uncertain future impacts of COVID-19 make it difficult for us to forecast future results.     
Financial Reporting Systems and Internal Controls
We have invested in technology to allow our office staff to work remotely. As a result, we do not expect the pandemic to have a material adverse effect on our financial reporting systems, internal controls over financial reporting and disclosure controls and procedures, although we have experienced delays when working with third parties who do not have remote access to our systems or whose procedures require them to review certain physical records.

30



Recent Developments
Appointment of New Officers
On March 19, 2020, we announced that our Board of Directors appointed Peter M. Carlson as Chief Financial Officer of the Company, effective March 18, 2020. He succeeded Edward J. Borkowski, who served as Executive Vice President and Interim Chief Financial Officer from June 6, 2018 through November 15, 2019 and as acting Chief Financial Officer from November 18, 2019 through March 17, 2020.
On May 5, 2020, we announced that we had appointed William L. Phelan as Senior Vice President and Chief Accounting Officer of the Company, effective May 1, 2020.
BT Loan Agreement Amendment
On April 22, 2020, as described above, the BT Loan Agreement was amended to provide for an increase in the maximum Total Leverage Ratio and a reduction in the minimum Liquidity covenant. In connection with the amendment, we agreed to pay a one-time fee of approximately $0.7 million, added to the principal balance, and a 1 percentage point increase in the interest rate to LIBOR plus 9%.
Financing Transactions
On July 2, 2020, the Company issued $100 million of its Series B Convertible Preferred Stock, par value $.001 per share, (the “Series B Preferred Stock”) to an affiliate of EW Healthcare Partners and to certain funds managed by Hayfin Capital Management LLP, pursuant to the Securities Purchase Agreement with Falcon Fund 2 Holding Company, L.P., an affiliate of EW Healthcare Partners, and certain funds managed by Hayfin Capital Management LLP, dated as of June 30, 2020 (the “Securities Purchase Agreement”), for an aggregate purchase price of $100 million (the “Preferred Stock Transaction”). Also on July 2, 2020, the Company borrowed an aggregate of $50 million and obtained an additional committed but undrawn $25 million facility pursuant to the Loan Agreement with, among others, Hayfin Services LLP, an affiliate of Hayfin Capital Management LLP (the “Hayfin Loan Agreement”), which funded on July 2, 2020 (the “Hayfin Loan Transaction”) and that provided the Company with a senior secured term loan in an aggregate amount of $50 million (the “Hayfin Term Loan”) and an additional $25 million delayed draw term loan (the “DD TL”) in the form of a committed but undrawn facility. The Company used a portion of the proceeds of the Preferred Stock Transaction and the Hayfin Loan Transaction to repay the outstanding principal balance of $72.0 million, accrued interest and fees of $0.1 million, and prepayment penalty of $1.4 million under the BT Loan Agreement. The Company also terminated the BT Loan Agreement. For further information regarding the Preferred Stock Transaction, the Hayfin Loan Transaction and the termination of the BT Loan Agreement, see Note 3, “Liquidity and Capital Resources” in this Form 10-Q and Item 9B in the 2019 Form 10-K.
Results of Operations Comparison of the Three Months Ended March 31, 2020, to the Three Months Ended March 31, 2019
 
Three Months Ended March 31,
 
(in thousands)
 
2020
 
2019
 
$ Change
 
% Change
Net Sales
$
61,736

 
$
66,555

 
$
(4,819
)
 
(7.2
)%
Gross profit
51,711

 
59,137

 
(7,426
)
 
(12.6
)%
Selling, general and administrative
46,942

 
50,862

 
(3,920
)
 
(7.7
)%
Investigation, restatement and related
15,592

 
18,107

 
(2,515
)
 
(13.9
)%
Research and development
2,650

 
2,902

 
(252
)
 
(8.7
)%
Amortization of intangible assets
271

 
233

 
38

 
16.3
 %
Impairment of intangible assets

 
446

 
(446
)
 
(100.0
)%
Interest (expense) income, net
(2,387
)
 
211

 
(2,598
)
 
(1,231.3
)%
Other income (expense), net
6

 
(29
)
 
35

 
(120.7
)%
Income tax provision expense
11,304

 
(42
)
 
11,346

 
(27,014.3
)%
Net loss
$
(4,821
)
 
$
(13,273
)
 
$
8,452

 
63.7
 %

31



Net Sales
Net sales for the quarter ended March 31, 2020 were $61.7 million, primarily recognized on an “as-shipped” basis, a 7.2% decrease over the quarter ended March 31, 2019 revenue of $66.6 million, recognized on a “cash-receipts” basis. See Note 2, “Significant Accounting Policies,” for more information on our revenue recognition methodologies. This decrease is due to lower shipment levels in the last half of March 2020, reflecting the impact of the COVID-19 global pandemic. This effect is further discussed below.
Gross Profit Margin
Gross profit margin in the first quarter of 2020 was 84% as compared to 89% in the first quarter of 2019. The gross profit margin decrease reflects the cost of higher quality standards of cGMP and investments in our Biologic License Application (“BLA”) programs in the first quarter of 2020 compared to the first quarter of 2019.
Selling, General and Administrative Expenses
Selling, General and Administrative expenses for the first quarter of 2020 decreased approximately $3.9 million, or 7.7%, to $46.9 million compared to $50.9 million for the first quarter of 2019. The decrease was primarily related to a reduction in legal fees related to normal course of business matters, and a decrease in discretionary expenses as the Company implemented safety and costs-containment measures to mitigate the impact to the business from COVID-19. This was partially offset by an increase in severance expense related to the sales organizational realignment in January 2020.
Investigation, Restatement, and Related Expenses
Investigation, restatement and related expense for the first quarter of 2020 decreased approximately $2.5 million, or 13.9%, to $15.6 million compared to $18.1 million for the first quarter of 2019. The decrease was primarily related to a reduction in investigation and litigation costs, as the Audit Committee Investigation concluded in May 2019.
Research and Development Expenses 
Our research and development expenses decreased approximately $0.3 million, or 8.7%, to $2.7 million in the first quarter of 2020, compared to approximately $2.9 million in the first quarter of 2019. The decrease is primarily due to year-over-year decreases in clinical trial activities as well as decreased patient visit activity brought upon by the COVID-19 pandemic.
Amortization of Intangible Assets
Amortization expense related to intangible assets remained flat for the first quarter of 2020 compared to the first quarter of 2019.
Impairment of Intangible Assets
The impairment of intangible assets of $0.4 million was due to the impairment of certain customer relationship intangible assets in the three months ended March 31, 2019 related to the divestiture of Stability in 2017.
Interest (Expense) Income, Net
Interest (expense) income, net increased approximately $2.6 million or 1,231.3%, to $(2.4) million in the first quarter of 2020, compared to $0.2 million for the first quarter of 2019. This increase was due to the interest on the loan under the BT Loan Agreement (the “BT Term Loan”).
Other Income (Expense), Net
Other income (expense), net remained relatively flat for the first quarter of 2020 compared to the first quarter of 2019.
Income Tax Provision (Expense) Benefit
The effective tax rates for the Company were 70.1% and (0.3)% for the three months ended March 31, 2020 and March 31, 2019, respectively. The change in the effective tax rate was primarily due to the impact of the federal net operating loss carrybacks permitted under the CARES Act resulting in a significant income tax benefit during the first quarter of 2020.

32



Liquidity and Capital Resources
Our business requires capital for its operating activities, including costs associated with the sale of product through direct and indirect sales channels, the conduct of research and development activities, compliance costs, and legal and consulting fees in connection with ongoing litigation and other matters. We generally fund our operating capital requirements through our operating activities, cash reserves and, since June 2019, proceeds from term loans. We expect to use capital in the near and medium term to implement our priorities, including for capital investments, steps to complete achievement of cGMP compliance, advancement of our IND applications, pursuit of BLAs for certain of our micronized products, and settlements of certain legal matters.
As of March 31, 2020, the Company had approximately $53.5 million of cash and cash equivalents. The Company reported total current assets of approximately $115.9 million and total current liabilities of approximately $63.7 million at March 31, 2020, which represents a current ratio of 1.8 as of March 31, 2020.
We have funded our cash requirements, including for our operating activities and for the Investigation and Restatement, through existing cash reserves and from operating activities and the term loans described below. In addition, on July 2, 2020, we issued $100 million of our Series B Preferred Stock to an affiliate of EW Healthcare Partners and to certain funds managed by Hayfin Capital Management LLP pursuant to the Securities Purchase Agreement for an aggregate purchase price of $100,000,000.
The Company is currently paying its obligations in the normal course of business. We believe that, due to the Preferred Stock Transaction and the Hayfin Loan Agreement (which provides for significantly less restrictive financial covenants than the BT Loan Agreement), our anticipated cash from operating activities, existing cash, and cash equivalents will enable us to meet our operational liquidity needs.
We expect to incur additional costs in connection with efforts to enhance our cGMP compliant manufacturing capabilities and toward the completion of the BLA process. This includes development and enhancement of production processes, procedures, tests and assays, and it requires extensive validation work. It can also involve the procurement and installation of new production or lab equipment. These efforts also require human capital, expertise and resources.
We anticipate cash requirements related to the following items within one year from the date of the filing of this Form 10-Q:
lawsuits or potential settlements for which we are not able to estimate a loss;
private securities lawsuits, for which we are currently not able to estimate a loss and for which it is unclear whether we would be indemnified under various insurance policies; and
investments and other expenditures required in order to bring the Company’s facilities into compliance with cGMP.
Following the Preferred Stock Transaction, the Hayfin Loan Transaction, and the repayment and termination of the BT Loan Agreement, as discussed below and in Note 3, “Liquidity and Capital Resources,” we analyzed our ability to address the aforementioned commitments and potential liabilities while remaining compliant with the financial covenants set forth in the Hayfin Loan Agreement for the 12 months extending from the date of the filing of this Form 10-Q. Based on this analysis, and in combination with existing cash on hand, we expect to meet all obligations as they come due without violating the financial covenants set forth by the Hayfin Loan Agreement, as discussed below.
BT Term Loan
On June 10, 2019, we entered into the BT Loan Agreement to borrow funds with a face value of $75.0 million, the full amount of which was borrowed and funded. The proceeds from the BT Term Loan were used (i) for working capital and general corporate purposes and (ii) to pay transaction fees, costs and expenses incurred in connection with the BT Term Loan and the related transactions. On April 22, 2020, the BT Loan Agreement was amended to provide for an increase in the maximum Total Leverage Ratio and a reduction in the minimum Liquidity covenant. In connection with the amendment, the Company agreed to pay a one-time fee of approximately $0.7 million, added to the principal balance, and a 1 percentage point increase in the interest rate to LIBOR plus 9%. See Note 9, “Long-Term Debt,” for more information regarding the terms of the BT Term Loan and the amendment thereto.
Hayfin Term Loan; Preferred Stock Transaction; Termination of BT Term Loan
On July 2, 2020, the Company issued $100 million of Series B Preferred Stock to an affiliate of EW Healthcare Partners and to certain funds managed by Hayfin Capital Management LLP, pursuant to the Securities Purchase Agreement, for an aggregate purchase price of $100 million. Also on July 2, 2020, the Company borrowed an aggregate of $50 million and obtained an additional committed but undrawn $25 million facility pursuant to the Hayfin Loan Agreement. The Company used a portion of the proceeds

33



of the Preferred Stock Transaction and the Hayfin Loan Transaction to repay the outstanding principal balance of $72.0 million, accrued interest and fees of $0.1 million, and prepayment penalty of $1.4 million under the BT Loan Agreement. The Company also terminated the BT Loan Agreement. For further information regarding the Preferred Stock Transaction, the Hayfin Loan Transaction (including certain terms of the Hayfin Loan Agreement) and the termination of the BT Loan Agreement, see Note 3, “Liquidity and Capital Resources.”
Share Repurchases
During the three months ended March 31, 2020, the Company repurchased 205,091 shares surrendered by employees to satisfy tax withholding obligations upon vesting of restricted stock. Other than these, the Company did not repurchase any shares of its common stock during the three months ended March 31, 2020.
The timing and amount of future repurchases, if any, will depend upon the Company’s stock price, economic and market conditions, regulatory requirements, and other corporate considerations. The Company may initiate, suspend or discontinue purchases under the stock repurchase program at any time.
Contingencies
See Note 13 to our Condensed Consolidated Financial Statements in Part I, Item 1 herein.
Contractual Obligations
For the three months ended March 31, 2020 there were no significant changes to our operating lease obligations from those disclosed in the section “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2019 Form 10-K.
Discussion of Cash Flows
Net cash used in operations during the three months ended March 31, 2020 decreased approximately $3.0 million to approximately $12.3 million, compared to $15.3 million from operating activities for the three months ended March 31, 2019, primarily attributable to decreases in selling, general and administrative expenses between periods.
Net cash used in investing activities during the three months ended March 31, 2020 increased to approximately $1.1 million, compared to approximately $0.4 million for 2019. Cash used in investing activities for the three months ended March 31, 2020 included equipment purchases of $1.0 million compared to $0.6 million for the three months ended March 31, 2019.
Net cash used in financing activities during the three months ended March 31, 2020 increased approximately $1.2 million to $2.2 million compared to $1.0 million of cash used during the three months ended March 31, 2019. Cash used in financing activities during the three months ended March 31, 2020 included approximately $0.9 million of BT Term Loan payments and an increase in stock repurchases for tax withholdings of $0.5 million partially offset by proceeds from the exercise of stock options of $0.3 million.
Non-GAAP Financial Measures
In addition to our GAAP results, we provide certain Non-GAAP metrics including Earnings Before Interest, Taxes, Depreciation and Amortization (“EBITDA”) and Adjusted EBITDA. We believe that the presentation of these measures provides important supplemental information to management and investors regarding our performance. These measurements are not a substitute for GAAP measurements, and the manner in which we calculate Adjusted EBITDA may not be identical to the manner in which other companies calculate adjusted EBITDA. We use these Non-GAAP measures as aids in monitoring our on-going financial performance from quarter-to-quarter and year-to-year on a regular basis and for benchmarking against comparable companies.
EBITDA is intended to provide a measure of the Company’s operating performance as it eliminates the effects of financing and capital expenditures. EBITDA consists of GAAP net income (loss) excluding: (i) depreciation, (ii) amortization of intangibles, (iii) interest expense (income) and (iv) income tax provision.
Adjusted EBITDA is intended to provide an enduring, normalized view of EBITDA and our broader business operations that we expect to experience on an ongoing basis by removing items which may be irregular, one-time, or non-recurring from EBITDA; most significantly those expenses related to the Audit Committee Investigation and Restatement. This enables us to identify underlying trends in our business that could otherwise be masked by such items.

34



Adjusted EBITDA consists of GAAP net loss excluding: (i) depreciation, (ii) amortization of intangibles, (iii) interest expense (income), (iv) income tax provision, (v) costs incurred in connection with Audit Committee Investigation and Restatement, (vi) the effect of the change in revenue recognition on net income, (vii) impairment of intangible assets, and (viii) share-based compensation.
A reconciliation of GAAP Net Loss to EBITDA and Adjusted EBITDA appears in the table below (in thousands):
 
Three Months Ended March 31,
 
2020
 
2019
Net loss
$
(4,821
)
 
$
(13,273
)
 
 
 
 
Non-GAAP Adjustments:
 
 
 
Depreciation expense
1,506

 
1,695

Amortization of intangible assets
271

 
233

Interest expense (income), net
2,387

 
(211
)
Income tax provision (benefit) expense
(11,304
)
 
42

EBITDA
(11,961
)
 
(11,514
)
 
 
 
 
Additional Non-GAAP Adjustments:
 
 
 
Costs incurred in connection with Audit Committee Investigation and Restatement
15,592

 
18,107

Effect of change in revenue recognition
(3,866
)
 

Impairment of intangible assets

 
1,258

Share-based compensation
3,349

 
3,014

Adjusted EBITDA
3,114

 
10,865

Critical Accounting Policies
In preparing financial statements, we follow GAAP, which requires us to make certain estimates and apply judgments that affect our financial position and results of operations. We regularly review our accounting policies and financial information disclosures. A summary of significant accounting policies that require the use of estimates and judgments in preparing the financial statements was provided in the 2019 Form 10-K.  During the quarter covered by this report, there were no material changes to the accounting policies and assumptions previously disclosed, except as disclosed in Note 2 to the condensed consolidated financial statements contained herein.
Recent Accounting Pronouncements
For the effect of recent accounting pronouncements, see Note 2 to the condensed consolidated financial statements contained herein.
Off-Balance Sheet Arrangements
The Company has no off-balance sheet arrangements.

35



Item 3. Quantitative and Qualitative Disclosures about Market Risk
Based on our lack of market risk sensitive instruments outstanding at March 31, 2020, we have determined that there was no material market risk exposure to our consolidated financial position, results of operations or cash flows as of such date.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Management maintains a set of disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to management, including our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), to allow for timely decisions regarding required disclosure.
An evaluation of the effectiveness of the design and operation of our disclosure controls and procedures was performed under the supervision and with the participation of our management, including our CEO and CFO. As a result of this evaluation, our CEO and CFO concluded that our disclosure controls and procedures were not effective as of March 31, 2020 because of certain material weaknesses in internal control over financial reporting, as described in Item 9A, “Controls and Procedures” of our 2019 Form 10-K.
Changes in Internal Control over Financial Reporting
Under Exchange Act Rules 13a-15(d) and 15d-15(d), management is required to evaluate, with the participation of our principal executive officer and principal financial officer, any changes in internal control over financial reporting that occurred during each fiscal quarter that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Other than as disclosed under “Remediation Efforts to Address Material Weaknesses in Internal Control over Financial Reporting” below, there were no changes in our internal control over financial reporting during the quarter ended March 31, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Additionally, we have not experienced any material impact to our internal controls over financial reporting from the COVID-19 pandemic despite the fact that most of our employees are working remotely due to the COVID-19 pandemic. We are regularly monitoring and assessing the impact of COVID-19 and the related remote working situation on our internal controls to minimize the impact on the design and operating effectiveness of internal controls.
Remediation Efforts to Address Material Weaknesses in Internal Control Over Financial Reporting
As discussed in Item 9A, "Controls and Procedures" of our 2019 Form 10-K, we identified unremediated material weaknesses related to the Control Environment and Control Activities elements established in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (the "COSO framework" ) as of December 31, 2019. Prior to December 31, 2019, we designed and implemented new controls specific to our information and technology system to remediate identified material weaknesses, specifically, management performed a comprehensive review of permissions and profiles within each information technology (“IT”) application that is significant to the Company's financial reporting objectives, and subsequently reconfigured profiles with appropriate permissions to better align with job responsibilities and enforce segregation of duties. Once user profiles and their associated permissions were reconfigured, management employed procedures to ensure the continued appropriateness of all applicable system and network access. This objective was achieved through the performance of periodic user access reviews and the enhancement of procedures related to the granting and removing of system and network access. Due to the timing of the design and implementation of these controls during the fourth quarter of 2019, however, there was insufficient time to consistently execute against their design as of December 31, 2019. During the first quarter of 2020, we executed the newly designed controls specific to the IT system. We will continue to evaluate the results of our control assessments and testing procedures to determine whether the new controls have been designed appropriately and are operating effectively, and whether the material weakness has been remediated. We expect that our remediation efforts will continue for all identified material weaknesses through 2020 as described in our remediation plan and status in Item 9A, “Controls and Procedures” of our 2019 Form 10-K, with the goal to fully remediate the material weaknesses during 2020.
Inherent Limitation on the Effectiveness of Internal Controls
The effectiveness of any system of internal control over financial reporting is subject to inherent limitations, including the exercise of judgment in designing, implementing, operating, and evaluating the controls and procedures, and the inability to eliminate misconduct completely. Accordingly, any system of internal control over financial reporting can only provide reasonable, not

36



absolute, assurance that its objectives will be met. In addition, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. We intend to continue to monitor and upgrade our internal controls as necessary or appropriate for our business, but we cannot assure that such improvements will be sufficient to provide us with effective internal control over financial reporting in 2020 or future periods.

37



PART II – OTHER INFORMATION

Item 1. Legal Proceedings
For information regarding our material pending legal proceedings, see the disclosure in Note 13, “Contractual Commitments and Contingencies - Litigation and Regulatory Matters” of this Form 10-Q, which is incorporated herein by reference.
Item 1A. Risk Factors
There have been no material changes to the risk factors discussed in Part I, Item 1A., “Risk Factors” of the Company’s 2019 Form 10-K. These factors could materially and adversely affect the Company’s business, financial condition, and results of operations, and should be carefully considered. However, these are not the only risks facing the Company. Additional risks and uncertainties not currently known, or that the Company currently deems to be immaterial, also may adversely affect the Company’s business, financial condition, and results of operations.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
(a) None.
(b) None.
(c) Stock Repurchases:
The following table sets forth information regarding the purchases of the Company’s equity securities made by or on behalf of the Company or any affiliated purchaser (as defined in Exchange Act Rule 10b-18) during the three month period ended March 31, 2020:
 
Total number of
shares purchased
(a)
 
Average price paid
per share
 
Total number of shares purchased under publicly announced plan
 
Approximate dollar value of shares that may yet be purchased under plans or programs
Total amount remaining December 31, 2019
 
 
 
 
 
 
$

 
 
 
 
 
 
 
 
January 1 - January 31, 2020
5,340

 
$
7.56

 

 
$

 
 
 
 
 
 
 
 
February 1 - February 28, 2020
199,193

 
$
7.50

 

 
$

 
 
 
 
 
 
 
 
March 1 - March 31, 2020
558

 
$
6.55

 

 
$

 
 
 
 
 
 
 
 
Total for the quarter
205,091

 
$
7.50

 

 
 
(a) Shares repurchased during the quarter include only shares surrendered by employees to satisfy tax withholding obligations upon vesting of restricted stock.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not applicable.

38



Item 5. Other Information
None.

39



Item 6. Exhibits
Exhibit
Number
 
Description
3.1
 
Articles of Incorporation, together with Articles of Amendment effective each of May 14, 2010; August 8, 2012, November 8, 2012; and May 15, 2015 (incorporated by reference to Exhibit 3.1 to the Registrant’s Form 10-K filed on March 1, 2017).
3.2
 
Articles of Amendment to the Articles of Incorporation effective November 6, 2018 (incorporated by reference to Exhibit 3.1 to the Registrant’s Form 8-A filed on November 7, 2018).
3.3
 
Bylaws of MiMedx Group, Inc., as amended and restated as of October 3, 2018 (incorporated by reference to Exhibit 3.1 to the Registrant’s Form 8-K filed on October 4, 2018).
3.4#
 
10.2*
 
First Amendment, dated as of April 22, 2020, to Loan Agreement, dated June 10, 2019, by and between MiMedx Group, Inc., the other guarantors party thereto, the lenders party thereto and Blue Torch Finance LLC, as administrative agent and collateral agent (incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed April 27, 2020).
31.1 #
 
Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2 #
 
Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1 #
 
Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2 #
 
Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS
 
XBRL Instance Document
101.SCH
 
XBRL Taxonomy Extension Schema Document
101.CAL
 
XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF
 
XBRL Taxonomy Extension Definition Linkbase Document
101.LAB
 
XBRL Taxonomy Extension Label Linkbase Document
101.PRE
 
XBRL Taxonomy Extension Presentation Linkbase Document
 
*
Schedules and exhibits omitted pursuant to Item 601(b)(2) of Regulation S-K. MiMedx agrees to furnish a copy of any omitted schedule or exhibit to the SEC upon request.

 
 
#
Filed herewith



40



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
July 6, 2020
MIMEDX GROUP, INC.
 
 
 
 
By:
/s/ Peter M. Carlson
 
 
Peter M. Carlson
 
 
Chief Financial Officer and Principal Financial Officer


41
EX-3.3 2 a2019ex33articlesofame.htm ARTICLES OF AMENDMENT Exhibit
EXHIBIT 3.3

ARTICLES OF AMENDMENT
TO THE ARTICLES OF INCORPORATION
OF
MIMEDX GROUP, INC.


DESIGNATION OF RIGHTS, PREFERENCES, AND LIMITATIONS OF
SERIES B CONVERTIBLE PREFERRED STOCK
        
FIRST: This Corporation is named MiMedx Group, Inc. (the “Corporation”). The Articles of Incorporation of the Corporation were originally filed in the Office of the Department of State of the State of Florida on February 28, 2008, and amended by the Articles of Merger filed in the Office of the Department of State of the State of Florida on March 31, 2008, the Articles of Amendment filed in the Office of the Department of State of the State of Florida on May 14, 2010, the Articles of Amendment filed in the Office of the Department of State of the State of Florida on August 8, 2012, the Articles of Amendment filed in the Office of the Department of State of the State of Florida on November 8, 2012, the Articles of Amendment filed in the Office of the Department of State of the State of Florida on May 15, 2015, the Articles of Amendment filed in the Office of the Department of State of the State of Florida on November 7, 2018 and the Articles of Merger filed in the Office of the Department of State of the State of Florida on July 25, 2019.

SECOND: Pursuant to the authority of the Board of Directors of the Corporation set forth in the Corporation’s Articles of Incorporation, as amended, and Section 607.0602 of the Florida Business Corporation Act, the Board of Directors of the Corporation, by resolutions duly adopted as of June 28, 2020, has approved the amendment of the Corporation’s Articles of Incorporation to (i) designate a series of preferred stock (“Preferred Stock”) of the Corporation as “Series B Convertible Preferred Stock,” consisting of 100,000 shares of the Corporation’s Preferred Stock and (ii) set the rights, preferences, limitations, and other terms and conditions of the Series B Convertible Preferred Stock. Approval of the shareholders of the Corporation was not required.

THIRD: Article 3 of the Articles of Incorporation of the Corporation is hereby amended to add the following Section 3.4:

“Section 3.4     Series B Convertible Preferred Stock:

1.Designation and Amount. The shares of such series of Preferred Stock shall be designated as “Series B Convertible Preferred Stock” (the “Series B Preferred Stock”). The number of authorized shares constituting the Series B Preferred Stock shall be 100,000. That number from time to time may be increased or decreased (but not below the number of shares of Series B Preferred Stock then outstanding) by further resolution duly adopted by the Board, or any duly authorized committee thereof, and by filing appropriate Articles of Amendment with the Office of the Department of State of the State of Florida. The Corporation shall not have the authority to issue fractional shares of Series B Preferred Stock.

1


2.    Ranking. The Series B Preferred Stock will rank, with respect to dividend rights and rights on the distribution of assets on any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Corporation:
(a)    on a parity basis with each other class or series of Capital Stock of the Corporation authorized on or after the Original Issuance Date, the terms of which expressly provide that such class or series ranks on a parity basis with the Series B Preferred Stock as to dividend rights and rights on the distribution of assets on any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Corporation (such Capital Stock, but for the avoidance of doubt excluding the Series B Preferred Stock, “Parity Stock”);
(b)    junior to each other class or series of Capital Stock of the Corporation authorized on or after the Original Issuance Date, the terms of which expressly provide that such class or series ranks senior to the Series B Preferred Stock as to dividend rights and rights on the distribution of assets on any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Corporation (such Capital Stock, “Senior Stock”); and
(c)    senior to (i) the Series A Junior Participating Preferred Stock and (ii) the Common Stock and each other class or series of Capital Stock of the Corporation authorized on or after the Original Issuance Date, the terms of which do not expressly provide that such class or series ranks on a parity basis with or senior to the Series B Preferred Stock as to dividend rights and rights on the distribution of assets on any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Corporation (such Capital Stock, “Junior Stock”).
3.    Definitions. As used in this Section 3.4 with respect to Series B Preferred Stock:
10% Holder” means, with respect to the EW Investor, that since the Original Issuance Date, the EW Investor and its Affiliates have at all times beneficially owned at least 10% of the total number of outstanding shares of Common Stock (calculated on a Fully-Diluted Basis).
5% Holder” means, with respect to the EW Investor, that since the Original Issuance Date, the EW Investor and its Affiliates have at all times beneficially owned at least 5% of the total number of outstanding shares of Common Stock (calculated on a Fully-Diluted Basis) but the EW Investor and its Affiliates beneficially own less than 10% of the total number of outstanding shares of Common Stock (calculated on a Fully-Diluted Basis).
Acceptable Change of Control Event” has the meaning set forth in Subsection 13(c)(viii).
Accrued Dividend Record Date” has the meaning set forth in Subsection 4(e).

2


Accrued Dividends” means, as of any date, with respect to any share of Series B Preferred Stock, all Dividends that have accrued on such share pursuant to Subsection 4(c), whether or not declared, but that have not, as of such date, been paid.
Accumulated Dividends” means, as of any date, with respect to any share of Series B Preferred Stock, all Dividends that have been accumulated on such share pursuant to Subsection 4(b) but that have not, as of such date, been accrued on such share pursuant to Subsection 4(c) or declared and paid in respect of such share pursuant to Subsection 4(c), Subsection 4(d) or otherwise.
Affected Holder” has the meaning set forth in Subsection 13(d).
Affiliate” means, with respect to any Person, any other Person that, directly or indirectly, Controls or is Controlled by or is under common Control with such Person, and in the case of an investment fund, vehicle or similar entity, any other investment fund, vehicle or similar entity that Controls or is Controlled by or under common Control with such investment fund, vehicle or similar entity. “Affiliated” has a correlative meaning.
Any Person shall be deemed to “beneficially own”, to have “beneficial ownership” of, or to be “beneficially owning” any securities (which securities shall also be deemed “beneficially owned” by such Person) that such Person is deemed to “beneficially own” within the meaning of Rule 13d-3 or 13d-5 under the Exchange Act; provided that any Person shall be deemed to beneficially own any securities that such Person has the right to acquire, whether or not such right is exercisable within sixty (60) days or thereafter (including assuming conversion of all Series B Preferred Stock, if any, owned by such Person to Common Stock).
Board” means the Board of Directors of the Corporation.
Business Day” means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.
Bylaws” means the Amended and Restated Bylaws of the Corporation, as amended as of October 3, 2018, and as may be further amended from time to time.
Capital Stock” means, with respect to any Person, any and all shares of, interests in, rights to purchase, warrants to purchase, options for, participations in or other equivalents of or interests in (however designated) stock issued by such Person.
Change of Control” means the occurrence of one of the following, whether in a single transaction or a series of related transactions:
(a) any “person” or “group” (as such terms are used in Sections 13(d) and 14(d) of the Exchange Act), is or becomes the beneficial owner, directly or indirectly, of a majority of the total voting power of the Voting Stock of the Corporation, other than

3


as a result of a transaction in which (1) the holders of securities that represented 100% of the Voting Stock of the Corporation immediately prior to such transaction are substantially the same as the holders of securities that represent a majority of the Voting Stock of the surviving Person or its Parent Entity immediately following such transaction and (2) the holders of securities that represented 100% of the Voting Stock of the Corporation immediately prior to such transaction own directly or indirectly Voting Stock of the surviving Person or its Parent Entity in substantially the same proportion to each other as immediately prior to such transaction; or
(b) the merger or consolidation of the Corporation with or into another Person or the merger of another Person with or into the Corporation, or the sale, transfer, lease, or exclusive license of all or substantially all the assets of the Corporation (determined on a consolidated basis), whether in a single transaction or a series of related transactions, to another Person, or any recapitalization, reclassification or other transaction in which all or substantially all of the Common Stock is exchanged for or converted into cash, securities or other property, other than (1) in the case of a merger, consolidation, recapitalization, reclassification or other transaction, a transaction pursuant to which the holders of securities that represented 100% of the Voting Stock of the Corporation immediately prior to such transaction own directly or indirectly (in substantially the same proportion to each other as immediately prior to such transaction, other than changes in proportionality as a result of any cash/stock election provided under the terms of the definitive agreement regarding such transaction) at least a majority of the voting power of the Voting Stock of the surviving Person in such merger or consolidation transaction immediately after such transaction, and (2) in the case of a sale, transfer, lease or exclusive license of all or substantially all of the assets of the Corporation, any such sale, transfer or lease made to a Subsidiary of the Corporation or a Person that becomes a Subsidiary of the Corporation.
Change of Control Notice” has the meaning set forth in Subsection 10(c).
Change of Control Redemption Date” has the meaning set forth in Subsection 10(a).
Change of Control Redemption Price” has the meaning set forth in Subsection 10(a).
close of business” means 5:00 p.m. (New York City time).
Common Director” has the meaning set forth in Subsection 14(b).
Common Stock” means the common stock, par value $0.001 per share, of the Corporation.
Competitor” has the meaning set forth in the SPA.
Constituent Person” has the meaning set forth in Subsection 12(a).

4


Control” means, with respect to any Person, the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such Person, whether through the ownership of voting securities or by contract or agency or otherwise. “Controlled” has a correlative meaning.
Conversion Agent” means the Transfer Agent acting in its capacity as conversion agent for the Series B Preferred Stock, and its successors and assigns.
Conversion Date” has the meaning set forth in Subsection 8(a).
Conversion Notice” has the meaning set forth in Subsection 6(c)(i).
Conversion Price” means, for each share of Series B Preferred Stock, $3.85, subject to adjustment in accordance with Subsection 11.
Degressive Issuance” has the meaning set forth in Subsection 11(b).
Director Indemnitors” has the meaning set forth in Subsection 14(e).
Dividend Accrual” has the meaning set forth in Subsection 4(c).
Dividend Payment Date” means March 31, June 30, September 30 and December 31 of each year; provided that if any such Dividend Payment Date is not a Business Day, then the applicable Dividend shall be payable on the next Business Day immediately following such Dividend Payment Date, without any interest.
Dividend Payment Period” means in respect of any share of Series B Preferred Stock the period from and including the Issuance Date of such share to but excluding the next Dividend Payment Date and, subsequently, in each case the period from and including any Dividend Payment Date to but excluding the next Dividend Payment Date.
Dividend Rate” means 4.0% per annum for any Dividend Payment Period ending prior to June 30, 2021, and 6.0% per annum for any Dividend Payment Period thereafter.
Dividend Record Date” has the meaning set forth in Subsection 4(e).
Dividends” has the meaning set forth in Subsection 4(a).
Effective Price” has the following meaning with respect to the issuance or sale of any shares of Common Stock or any Equity-Linked Securities:
(a) in the case of the issuance or sale of shares of Common Stock, the value of the consideration received or receivable by (or at the direction of) the Corporation or any of its Subsidiaries for such shares, expressed as an amount per share of Common Stock; and

5


(b) in the case of the issuance or sale of any Equity-Linked Securities, an amount equal to a fraction whose:
(i) numerator is equal to the sum, without duplication, of (x) the value of the aggregate consideration received or receivable by (or at the direction of) the Corporation or any of its Subsidiaries for the issuance or sale of such Equity-Linked Securities; and (y) the value of the minimum aggregate additional consideration, if any, payable to purchase or otherwise acquire shares of Common Stock pursuant to such Equity-Linked Securities; and
(ii) denominator is equal to the maximum number of shares of Common Stock underlying such Equity-Linked Securities;
provided, however, that:
(w) for purposes of clauses (a) and (b)(i) above, all underwriting commissions, placement agency commissions or similar commissions paid to any broker-dealer by the Corporation or any of its Subsidiaries in connection with such issuance or sale will be added to the aggregate consideration referred to in such clause;
(x) for purposes of clause (b) above, if such minimum aggregate consideration, or such maximum number of shares of Common Stock, is not determinable at the time such Equity-Linked Securities are issued or sold, then (1) the initial consideration payable under such Equity-Linked Securities, or the initial number of shares of Common Stock underlying such Equity-Linked Securities, as applicable, will be used; and (2) at each time thereafter when such amount of consideration or number of shares becomes determinable or is otherwise adjusted (including pursuant to “anti-dilution” or similar provisions), there will be deemed to occur, for purposes of Subsection 11(b) and without affecting any prior adjustments theretofore made to the Conversion Price, an issuance of additional Equity-Linked Securities;
(y) for purposes of clause (b) above, the surrender, extinguishment, maturity or other expiration of any such Equity-Linked Securities will be deemed not to constitute consideration payable to purchase or otherwise acquire shares of Common Stock pursuant to such Equity-Linked Securities; and
(z) the “value” of any such consideration will be the fair value thereof, as of the date such shares or Equity-Linked Securities, as applicable, are issued or sold, determined in good faith by the Board (or, in the case of cash denominated in U.S. dollars, the face amount thereof).
Equity-Linked Securities” means any rights, options, warrants or other securities entitling the holder thereof to purchase or otherwise acquire (whether immediately, during specified times, upon the satisfaction of any conditions, by conversion, exchange, exercise or otherwise) any shares of Common Stock or any rights, options, warrants or other securities

6


exercisable for, convertible into or exchangeable for such rights, options, warrants or other securities.
EW Investor” has the meaning set forth in the SPA.
EW Investor Parties” has the meaning set forth in the SPA.
Exchange Act” means the Securities Exchange Act of 1934, as amended.
Exchange Property” has the meaning set forth in Subsection 12(a).
Excluded Issuance” means (a) the Corporation’s issuance of any securities as full or partial consideration in connection with a merger, acquisition, consolidation or purchase of all or substantially all of the securities or assets of a corporation or other entity; (b) the Corporation’s issuance to directors, officers, employees, consultants, service providers or agents of the Corporation of equity securities, including those issued upon the exercise of stock options, and the vesting and settlement of other awards in each case granted pursuant to any employee share purchase or equity-based incentive plan, program or arrangement of the Corporation in existence as of the Original Issuance Date or that has been approved by either (i) a majority of the independent members of the Board or (ii) the compensation committee of the Board, including inducement grants under Nasdaq Listing Rule 5635(c)(4); (c) the Corporation’s issuance of equity securities in connection with a reclassification, recapitalization, exchange, stock split (including a reverse stock split), combination or readjustment of shares or any stock dividend or stock distribution, or similar transaction; (d) the Corporation’s issuance of securities upon the exercise, exchange or conversion of any securities that are exercisable or exchangeable for, or convertible into, shares of Common Stock and are outstanding as of the Original Issuance Date, provided that such exercise, exchange or conversion is effected pursuant to the terms of such securities as in effect on the Original Issuance Date; (e) the Corporation’s issuance of securities pursuant to any equipment loan or leasing arrangement, real property leasing arrangement or debt financing from a bank or similar financial institution approved by a majority of the disinterested members of the Board and as in effect on the Original Issuance Date; and (f) the Corporation’s issuance of the Series B Preferred Stock and any shares of Common Stock upon conversion of the Series B Preferred Stock. 
Fully-Diluted Basis” means treating for this purpose as outstanding all shares of Common Stock issuable upon exercise, conversion or exchange of all Equity‑Linked Securities (including the Series B Preferred Stock) outstanding as of the relevant date of the calculation.
Governmental Entity” means any federal, state, or local governmental agency, board, commission, department, court or tribunal; or any regulatory agency, bureau, commission, or authority.
Holder” means a Person in whose name the shares of the Series B Preferred Stock are registered, which Person shall be treated by the Corporation, Transfer Agent, Registrar,

7


paying agent and Conversion Agent as the absolute owner of the shares of Series B Preferred Stock for the purpose of making payment and settling conversions and for all other purposes; provided that, to the fullest extent permitted by law, (i) no Person that has received shares of Series B Preferred Stock in violation of the SPA shall be a Holder; (ii) the Transfer Agent, Registrar, paying agent and Conversion Agent, as applicable, shall not, unless directed otherwise by the Corporation, recognize any such Person as a Holder; and (iii) the Person in whose name the shares of the Series B Preferred Stock were registered immediately prior to such transfer shall remain the Holder of such shares.
Independent Financial Advisor” means an accounting, appraisal, investment banking firm or consultant of nationally recognized standing; provided, however, that such firm or consultant is not an Affiliate of the Corporation.
Investor Designee” has the meaning set forth in Subsection 14(a).
Investor Director” has the meaning set forth in Subsection 14(e).
Investor Per Share Purchase Price” means, with respect to any share of Series B Preferred Stock, $1,000 per share.
Issuance Date” means, with respect to any share of Series B Preferred Stock, the date of issuance of such share.
Judgment” has the meaning set forth in the SPA.
Junior Stock” has the meaning set forth in Subsection 2(c).
Liquidation Preference” means, with respect to any share of Series B Preferred Stock, as of any date, $1,000 per share.
Liquidity Event” has the meaning set forth in Subsection 5(a).
Mandatory Conversion” has the meaning set forth in Subsection 7(a).
Mandatory Conversion Date” has the meaning set forth in Subsection 7(a).
Mandatory Conversion Price” means 200% of the Conversion Price (as may be adjusted pursuant to the provisions of Subsection 11). The Mandatory Conversion Price shall initially be $7.70.
Market Disruption Event” means, with respect to any date, the occurrence or existence, during the one-half hour period ending at the scheduled close of trading on such date on the principal U.S. national or regional securities exchange or other market on which the Common Stock is listed for trading or trades, of any material suspension or limitation imposed on trading (by reason of movements in price exceeding limits permitted by the relevant exchange or otherwise) in the Common Stock or in any options contracts or futures contracts relating to the Common Stock.

8


Minimum Price” means $5.25; provided that if the Conversion Price is adjusted pursuant to the provisions of Subsection 11(a), then the Minimum Price shall be proportionately adjusted.
Notice of Mandatory Conversion” has the meaning set forth in Subsection 7(b).
Original Issuance Date” means the date on which the Closing (as defined in the SPA) occurs.
Parent Entity” means, with respect to any Person, any other Person of which such first Person is a direct or indirect wholly owned Subsidiary.
Parity Stock” has the meaning set forth in Subsection 2(a).
Person” means an individual, firm, corporation (including any non-profit corporation), partnership, limited liability company, joint venture, association, trust, Governmental Entity or other entity or organization.
Preferred Director” has the meaning set forth in Subsection 14(a).
Preferred Stock” has the meaning set forth in the recitals above.
A “Qualified Person” means an individual who, (i) qualifies as an “independent director” under applicable rules of the Securities and Exchange Commission, the rules of any stock exchange on which securities of the Corporation are traded and applicable governance policies of the Corporation; (ii) satisfies all other criteria and qualifications for service as a director applicable to all directors of the Corporation; (iii) is not a Representative of a Competitor; (iv) has not been involved in any of the events enumerated under Item 2(d) or (2)(e) of Schedule 13D under the Exchange Act or Item 401(f) of Regulation S-K under the Securities Act; (v) is not subject to any Judgment prohibiting service as a director of any public company; and (vi) is reasonably acceptable to the Board.
Record Date” means, with respect to any dividend, distribution or other transaction or event in which the holders of the Common Stock have the right to receive any cash, securities or other property or in which the Common Stock is exchanged for or converted into any combination of cash, securities or other property, the date fixed for determination of holders of the Common Stock entitled to receive such cash, securities or other property (whether such date is fixed by the Board or by statute, contract or otherwise).
Registrar” means the Transfer Agent acting in its capacity as registrar for the Series B Preferred Stock, and its successors and assigns.
Reorganization Event” has the meaning set forth in Subsection 12(a).
Replacement Designee” has the meaning set forth in Subsection 14(b).
Representative” has the meaning set forth in the SPA.

9


Senior Stock” has the meaning set forth in Subsection 2(b).
Series B Preferred Stock” has the meaning set forth in Subsection 1.
Share Delivery Date” has the meaning set forth in Subsection 8(c)
Shareholder Approval” means such approval as required by the applicable Nasdaq Stock Market Rules by the shareholders of the Corporation with respect to the conversion of all shares of Series B Preferred Stock and the issuance of the shares of Common Stock issuable upon the conversion of the Series B Preferred Stock.
SPA” means that certain Securities Purchase Agreement between the Corporation and the Holders set forth on Schedule 1 thereto, dated as of June 30, 2020, as it may be amended, supplemented or otherwise modified from time to time, with respect to certain terms and conditions concerning, among other things, the rights of and restrictions on the Holders.
Specified Contract Terms” means the covenants, terms and provisions of any indenture, credit agreement or any other agreement, document or instrument evidencing, governing the rights of the holders of or otherwise relating to any indebtedness of the Corporation or any of its Subsidiaries as in effect on the date hereof, or any amendments thereto or refinancings or replacements thereof.
Subsidiary”, means, with respect to any Person, any corporation, partnership, joint venture or other legal entity as to which such Person (either alone or through or together with any other subsidiary), (a) owns, directly or indirectly, more than 50% of the stock or other equity interests, or (b) has the power to elect a majority of the board of directors or similar governing body.
Sunset Date” has the meaning set forth in Subsection 13(c)(vii).
Trading Day” means any day on which trading in the Common Stock generally occurs on the principal U.S. national or regional securities exchange on which the Common Stock is then listed or, if the Common Stock is not then listed on a U.S. national or regional securities exchange, on the principal other market on which the Common Stock is then traded, provided that there is no Market Disruption Event. If the Common Stock is not so listed or traded, then “Trading Day” means a Business Day.
Trading Period” has the meaning set forth in Subsection 7(a).
Transfer Agent” means the Person acting as Transfer Agent, Registrar and paying agent and Conversion Agent for the Series B Preferred Stock, and its successors and assigns. The Transfer Agent initially shall be Issuer Direct Corporation.
Transfer Tax” has the meaning set forth in Subsection 17.

10


Voting Stock” means (i) with respect to the Corporation, the Common Stock, the Series A Junior Participating Preferred Stock, the Series B Preferred Stock (subject to the limitations set forth herein) and any other Capital Stock of the Corporation having the right to vote generally in any election of directors of the Board and (ii) with respect to any other Person, all Capital Stock of such Person having the right to vote generally in any election of directors of the board of directors of such Person or other similar governing body.
VWAP” per share of Common Stock on any Trading Day means the per share volume-weighted average price as displayed under the heading Bloomberg VWAP on Bloomberg (or, if Bloomberg ceases to publish such price, any successor service reasonably chosen by the Corporation) page “USFD <equity> AQR” (or its equivalent successor if such page is not available) in respect of the period from the open of trading on the relevant Trading Day until the close of trading on such Trading Day (or if such volume‑weighted average price is unavailable, the market price of one share of Common Stock on such Trading Day determined, using a volume-weighted average method, by an Independent Financial Advisor retained for such purpose by the Corporation).
Weighted Average Issuance Price” has the meaning set forth in Subsection 11(b).
4.    Dividends.
(a)    Dividends. Holders shall be entitled to receive dividends of the type and in the amount determined as set forth in this Subsection 4 (such dividends, “Dividends”).
(b)    Accumulation of Dividends. Dividends on each share of Series B Preferred Stock shall accumulate (i) on a daily basis from and including the Issuance Date of such share, whether or not declared and whether or not the Corporation has assets legally available to make payment thereof, at a rate equal to the Dividend Rate calculated on the Liquidation Preference plus any Accrued Dividends in respect of such share, and (ii) on the basis of a 365-day year based on actual days elapsed. The amount of Dividends accumulated with respect to any share of Series B Preferred Stock for any Dividend Payment Period shall equal the sum of the daily dividend amounts accumulated in accordance with the first sentence of this Subsection 4(b) with respect to such share during such Dividend Payment Period.
(c)    Payment of Dividend. With respect to any Dividend Payment Date, the Corporation shall, if, as and when authorized by the Board in its sole discretion, and to the extent permitted by applicable law, declare a dividend on each share of Series B Preferred Stock in an amount up to the amount of the Accumulated Dividends in respect of the Dividend Payment Period ending immediately prior to such Dividend Payment Date; provided, however, that if the Corporation does not declare and pay in cash the full amount of such Accumulated Dividends, any portion not so declared and paid in cash shall accrue in respect of each such share (a “Dividend Accrual”). The Corporation shall provide written notice to each Holder of the amount of the

11


Dividend Accrual in respect of such Holder’s shares of Series B Preferred Stock no less than five (5) Business Days prior to such Dividend Payment Date.
(d)    Arrearages. The Corporation shall be entitled to at any time and from time to time, at its option, to declare and pay all or any part of the Accrued Dividends or Accumulated Dividends in cash and, following such payment, such paid Accrued Dividends or Accumulated Dividends, as applicable, shall no longer be deemed Accrued Dividends or Accumulated Dividends hereunder.
(e)    Record Date. The Record Date for payment of Dividends that are declared and paid on any relevant Dividend Payment Date in accordance with Subsection 4(c) will be the close of business on the fifteenth (15th) day of the calendar month which contains the relevant Dividend Payment Date (each, a “Dividend Record Date”), and the Record Date for payment of any Accrued Dividends or Accumulated Dividends in accordance with Subsection 4(d) will be the close of business on the date that is established by the Board, or a duly authorized committee thereof, as such, which will not be more than forty‑five (45) days prior to the date on which such Dividends are paid (each, an “Accrued Dividend Record Date”), in each case whether or not such day is a Business Day.
(f)    Priority of Dividends. So long as any shares of Series B Preferred Stock remain outstanding, unless all Accrued Dividends and Accumulated Dividends on all outstanding shares of Series B Preferred Stock have been declared and paid in cash, or have been or contemporaneously are declared and a sum in cash sufficient for the payment of those dividends has been or is set aside for the benefit of the Holders, the Corporation may not declare any dividend on, or make any distributions relating to, Junior Stock or Parity Stock, or redeem, purchase, acquire (either directly or through any Subsidiary) or make a liquidation payment relating to, any Junior Stock or Parity Stock, other than:
(i)    purchases, redemptions or other acquisitions of shares of Junior Stock in connection with any employment contract, benefit plan or other similar arrangement existing on the date hereof or approved by the Board with or for the benefit of current or former employees, officers, directors or consultants;
(ii)    purchases of Junior Stock in an amount equal to the proceeds received from the substantially contemporaneous sale of other shares of Junior Stock;
(iii)    as a result of an exchange or conversion of any class or series of Parity Stock or Junior Stock for any other class or series of Parity Stock (in the case of Parity Stock) or Junior Stock (in the case of Parity Stock or Junior Stock);
(iv)    purchases of fractional interests in shares of Parity Stock or Junior Stock (A) pursuant to the conversion or exchange provisions of such Parity Stock or Junior Stock or the security being converted or exchanged or (B)

12


in connection with any bona-fide reclassification, recapitalization, exchange, stock split (including a reverse stock split), combination or readjustment of shares or any stock dividend or stock distribution, or similar transaction;
(v)    payment of any dividends in respect of Junior Stock where the dividend is in the form of the same stock or rights to purchase the same stock as that on which the dividend is being paid;
(vi)    rights to purchase Common Stock;
(vii)    dividends or distributions of Common Stock or rights to purchase Common Stock;
(viii)    any dividend in connection with the implementation of a shareholders’ rights or similar plan, or the redemption or repurchase of any rights under any such plan.
Subject to the provisions of this Subsection 4, dividends may be authorized by the Board, or any duly authorized committee thereof, and declared and paid by the Corporation, on any Junior Stock and Parity Stock from time to time; and the Holders will not be entitled to participate in those dividends.
(g)    Conversion Following a Record Date. If the Conversion Date for any shares of Series B Preferred Stock is prior to the close of business on a Dividend Record Date or an Accrued Dividend Record Date, the Holder of such shares will not be entitled to any dividend in respect of such Dividend Record Date or Accrued Dividend Record Date, as applicable, other than through the inclusion of Accrued Dividends and Accumulated Dividends as of the Conversion Date in the calculation under Subsection 6(a) or 7(a), as applicable. If the Conversion Date for any shares of Series B Preferred Stock is after the close of business on a Dividend Record Date or an Accrued Dividend Record Date but prior to the corresponding payment date for such dividend, the Holder of such shares as of such Dividend Record Date or Accrued Dividend Record Date, as applicable, shall be entitled to receive such dividend, notwithstanding the conversion of such shares prior to the applicable Dividend Payment Date; provided that the amount of such dividend shall not be included for the purpose of determining the amount of Accrued Dividends or Accumulated Dividends under Subsection 6(a) or 7(a), as applicable, with respect to such Conversion Date.
5.    Liquidation Rights.
(a)    Liquidation. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Corporation (each a “Liquidity Event”), the Holders shall be entitled, out of assets legally available therefor, before any distribution or payment out of the assets of the Corporation may be made to or set aside for the holders of any Junior Stock, and subject to the rights of the holders of

13


any Senior Stock or Parity Stock and the rights of the Corporation’s existing and future creditors, to receive in full a liquidating distribution in cash and in the amount per share of Series B Preferred Stock equal to the sum of (i) the Liquidation Preference plus (ii) the Accrued Dividends plus (iii) the Accumulated Dividends with respect to such share of Series B Preferred Stock as of the date of such Liquidity Event. Holders shall not be entitled to any further payments in the event of any such Liquidity Event other than what is expressly provided for in this Subsection 5 and will have no right or claim to any of the Corporation’s remaining assets.
(b)    Partial Payment. If in connection with any distribution described in Subsection 5(a) above, the assets of the Corporation or proceeds therefrom are not sufficient to pay in full the aggregate liquidating distributions required to be paid pursuant to Subsection 5(a) to all Holders and the liquidating distributions payable to all holders of any Parity Stock, the amounts distributed to the Holders and to the holders of all such Parity Stock shall be paid pro rata in accordance with the respective aggregate liquidating distributions to which they would otherwise be entitled if all amounts payable thereon were paid in full.
(c)    Merger, Consolidation and Sale of Assets Not Liquidity Event. For purposes of this Subsection 5, each of the following events shall not be deemed a Liquidity Event: (i) the sale, conveyance, exchange or transfer (for cash, shares of stock, securities or other consideration) of all or substantially all of the property and assets of the Corporation, (ii) the merger, consolidation, statutory exchange or any other business combination transaction of the Corporation into or with any other Person, (iii) the merger, consolidation, statutory exchange or any other business combination transaction of any other Person into or with the Corporation, or (iv) a Change of Control.
6.    Right of the Holders to Convert.
(a)    Each Holder shall have the right, at such Holder’s option, subject to the conversion procedures set forth in Subsection 8, the limitations in Subsection 9 and the right of the Corporation to declare and pay all or any part of the Accrued Dividends or Accumulated Dividends at any time under Subsection 4(c), to convert each share of such Holder’s Series B Preferred Stock at any time into (i) the number of shares of Common Stock equal to the quotient of (A) the sum of (x) the Liquidation Preference plus (y) the Accrued Dividends plus (z) the Accumulated Dividends with respect to such share of Series B Preferred Stock as of the applicable Conversion Date divided by (B) the Conversion Price as of the applicable Conversion Date plus (ii) to the extent applicable, cash in lieu of fractional shares in accordance with Subsection 8(e). The right of conversion may be exercised as to all or any portion of such Holder’s Series B Preferred Stock from time to time; provided that, in each case, no right of conversion may be exercised by a Holder in respect of fewer than 1,000 shares of Series B Preferred Stock (unless such conversion relates to all shares of Series B Preferred Stock held by such Holder).

14


(b)    The Corporation shall at all times reserve and keep available out of its authorized and unissued Common Stock, solely for issuance upon the conversion of the Series B Preferred Stock, such number of shares of Common Stock as shall from time to time be issuable upon the conversion of all the shares of Series B Preferred Stock then outstanding, and if at any time the number of authorized but unissued shares of Common Stock shall not be sufficient to effect the conversion of all the then outstanding shares of the Series B Preferred Stock, the Corporation shall take such corporate action as may be necessary to increase its authorized but unissued shares of Common Stock to such number of shares as shall be sufficient for such purposes, including, without limitation, engaging in reasonable best efforts to obtain the requisite stockholder approval of any necessary amendment to the Articles of Incorporation. Any shares of Common Stock issued upon conversion of Series B Preferred Stock shall be duly authorized, validly issued, fully paid and nonassessable. If the Common Stock is then listed on any securities exchange or quoted on any inter-deal quotation system, then the Corporation will cause each such share of Common Stock, when so delivered, to be admitted for listing on such exchange or quotation on such system.
(c)    A Holder must do each of the following in order to convert shares of Series B Preferred Stock pursuant to this Subsection 6:
(i)    (A) complete and manually sign the conversion notice provided by the Conversion Agent (the “Conversion Notice”), and deliver such notice to the Conversion Agent; provided that a Conversion Notice may be conditional on the completion of a Change of Control or other corporate transaction, and (B) provide the Corporation with at least five (5) Business Days’ written notice prior to the delivery of any Conversion Notice to the Conversion Agent;
(ii)    Promptly after delivery of the Conversion Notice deliver to the Conversion Agent the certificate or certificates (if any) representing the shares of Series B Preferred Stock to be converted;
(iii)    if required by the Conversion Agent, furnish appropriate endorsements and transfer documents; and
(iv)    to the extent applicable, pay any stock transfer, documentary, stamp or similar taxes on such conversion not payable by the Corporation pursuant to Subsection 17.
7.    Mandatory Conversion by the Corporation.
(a)    Mandatory Conversion. All of the outstanding shares of Series B Preferred Stock shall automatically be converted into shares of Common Stock (a “Mandatory Conversion”) if, on a given day following the third anniversary of the Original Issuance Date (the “Mandatory Conversion Date”), the VWAP per share of Common

15


Stock is equal to or greater than the Mandatory Conversion Price (i) for at least twenty (20) Trading Days (whether or not consecutive) in any period of thirty (30) consecutive Trading Days (such thirty (30) consecutive Trading Day period, the “Trading Period”) and (ii) as of the close of trading on the Trading Day immediately prior to the Mandatory Conversion Date. In the case of a Mandatory Conversion, each share of Series B Preferred Stock then outstanding shall be converted into (i) the number of shares of Common Stock equal to the quotient of (A) the sum of (x) the Liquidation Preference plus (y) the Accrued Dividends plus (z) the Accumulated Dividends with respect to such share of Series B Preferred Stock as of the Mandatory Conversion Date divided by (B) the Conversion Price of such share in effect as of the Mandatory Conversion Date plus (ii) to the extent applicable, cash in lieu of fractional shares in accordance with Subsection 8(e).
(b)    Notice of Mandatory Conversion. As soon as practicable, and in any event no later than the fifth (5th) Business Day after the Mandatory Conversion Date, the Corporation shall provide a written notice to the Holders that a Mandatory Conversion has occurred (“Notice of Mandatory Conversion”). As soon as practicable, and in any event within five (5) Business Days following the receipt of a Notice of Mandatory Conversion, each Holder must:
(i)    deliver to the Conversion Agent the certificate or certificates (if any) representing the shares of Series B Preferred Stock to be converted;
(ii)    if required by the Conversion Agent, furnish appropriate endorsements and transfer documents; and
(iii)    to the extent applicable, pay any stock transfer, documentary, stamp or similar taxes on such conversion not payable by the Corporation pursuant to Subsection 17.
8.    Conversion Procedures and Effect of Conversion.
(a)    Conversion Date. The “Conversion Date” means (A) with respect to conversion of any shares of Series B Preferred Stock at the option of any Holder under Subsection 6(a), the date on which such Holder complies with the procedures in Subsection 6(c) (including the satisfaction of any conditions to conversion set forth in the Conversion Notice) and (B) with respect to Mandatory Conversion under Subsection 7(a), the Mandatory Conversion Date.
(b)    Effect of Conversion. Effective immediately prior to the close of business on the Conversion Date applicable to any shares of Series B Preferred Stock, Dividends shall no longer accrue or be declared on any such shares of Series B Preferred Stock, and such shares of Series B Preferred Stock shall cease to be outstanding.

16


(c)    Record Holder of Underlying Securities as of Conversion Date. The Person or Persons entitled to receive the Common Stock and, to the extent applicable, cash, securities or other property issuable upon conversion of Series B Preferred Stock on a Conversion Date shall be treated for all purposes as the record holder(s) of such shares of Common Stock and/or cash, securities or other property as of the close of business on such Conversion Date. As promptly as practicable, but no later than five (5) Business Days after the Conversion Date (the “Share Delivery Date”) and subject to compliance by the applicable Holder with the relevant procedures contained in Subsection 6(c) and Subsection 7(b), the Corporation shall issue the number of whole shares of Common Stock issuable upon conversion (and to the extent applicable, deliver payment of cash in lieu of fractional shares in accordance with Subsection 8(e)) and, to the extent applicable, any cash, securities or other property issuable thereon. Such delivery of shares of Common Stock, securities or other property shall be made by book-entry or, at the request of the Holder, through the facilities of the Conversion Agent or in certificated form. Any such certificate or certificates shall be delivered by the Corporation to the appropriate Holder on a book-entry basis, through the facilities of the Conversion Agent, or by mailing certificates evidencing the shares to the Holders, in each case at their respective addresses as set forth in the Conversion Notice (in the case of a conversion pursuant to Subsection 6(a)) or in the records of the Corporation or as set forth in a notice from the Holder to the Conversion Agent, as applicable (in the case of a Mandatory Conversion). In the event that a Holder shall not by written notice designate the name in which shares of Common Stock (and payments of cash in lieu of fractional shares) and, to the extent applicable, cash, securities or other property to be delivered upon conversion of shares of Series B Preferred Stock should be registered or paid, or the manner in which such shares, cash, securities or other property should be delivered, the Corporation shall be entitled to register and deliver such shares, securities or other property, and make such payment, in the name of the Holder and in the manner shown on the records of the Corporation. If the number of shares of Series B Preferred Stock represented by the Series B Preferred Stock certificate(s) submitted for conversion is greater than the number of shares of Series B Preferred Stock being converted, then the Corporation shall, as soon as practicable and in no event later than ten (10) Business Days after receipt of the Series B Preferred Stock certificate(s) and at its own expense, issue and deliver to such Holder a new Series B Preferred Stock certificate representing the number of shares of Series B Preferred Stock not converted.
(d)    Status of Converted Shares. Shares of Series B Preferred Stock converted in accordance with the terms hereof shall be retired promptly after the conversion or acquisition thereof. All such shares shall, upon their retirement, become authorized but unissued shares of Preferred Stock, without designation as to series until such shares are once more designated as part of a particular series by the Board.
(e)    No Charge of Payment. The issuance of shares of Common Stock upon conversion of shares of Series B Preferred Stock shall be made without payment of

17


additional consideration to the Corporation by, or other charge or cost imposed by the Corporation on the holder in respect thereof.
(f)    Fractional Shares. No fractional shares of Common Stock will be delivered to the Holders upon conversion. In lieu of fractional shares otherwise issuable, the Holders will be entitled to receive, at the Corporation’s sole discretion, either (i) an amount in cash equal to the fraction of a share of Common Stock multiplied by the closing price of the Common Stock on the Trading Day immediately preceding the applicable Conversion Date or (ii) one additional whole share of Common Stock.
9.    Limitations on Common Stock Issuable Upon Conversion.
(a)    Beneficial Ownership Limitation. Notwithstanding anything herein to the contrary, no conversion of a share of Series B Preferred Stock pursuant to Subsection 6 or pursuant to Subsection 7 hereof shall be permitted to the extent such conversion would result in a converting Holder, together with its Affiliates and any other Person whose holdings would be aggregated with such Holder for purposes of Section 13(d) of the Exchange Act:
(i)    beneficially owning more than 19.90% of the issued and outstanding Common Stock; or
(ii)    holding more than 19.90% of the votes entitled to be cast at any shareholders meeting,
in each case, unless the Corporation obtains Shareholder Approval to remove the restrictions contained in this Subsection 9(a). In any vote to obtain any Shareholder Approval, the Holders of shares of Series B Preferred Stock shall not be entitled to vote.
(b)    Subject to Subsection 9(c), any attempted conversion (whether by a Holder pursuant to Subsection 6 or by Mandatory Conversion pursuant to Subsection 7) to the extent it would violate this Subsection 9 shall be void ab initio and of no force and effect.
(c)    If any conversion in accordance with Subsection 6 or any Mandatory Conversion pursuant to Subsection 7 would be limited as a result of the application of Subsection 9(a), then (i) in the case of a Conversion Notice pursuant to Subsection 6, the Conversion Notice in respect of such conversion shall be deemed to have been amended automatically and without any action by the Holder thereof so that it applies only to the number of shares of Series B Preferred Stock that are permitted to be converted pursuant to Subsection 9(a) and (ii) in the case of a Mandatory Conversion pursuant to Subsection 7, all shares of Series B Preferred Stock that are permitted to be converted pursuant to Subsection 9(a) shall be so converted in accordance with Subsection 7, and thereafter from time to time, to the extent Series B Preferred Stock are permitted to be converted in accordance with Subsection 9(a), they shall be deemed to have been so automatically converted.

18


10.    Redemption upon Change of Control.
(a)    Corporation’s Rights upon a Change of Control. Subject to the other terms of this Subsection 10, if a Change of Control occurs, the Corporation will have the right to redeem, contingent upon and substantially contemporaneously with the consummation of the Change of Control (the date of such consummation, the “Change of Control Redemption Date”) any or all of the shares of Series B Preferred Stock for cash in an amount equal to the sum of (x) the Liquidation Preference plus (y) the Accrued Dividends plus (z) the Accumulated Dividends for each such share of Series B Preferred Stock redeemed (the “Change of Control Redemption Price”), subject to the right of each Holder to convert its Series B Preferred Stock pursuant to Subsection 6 prior to such redemption.
(b)    Holders’ Rights upon a Change of Control. If and to the extent the Corporation does not exercise its right to redeem any or all of the then-outstanding shares of Series B Preferred Stock under Subsection 10(a), each Holder shall have the option to (i) require the Corporation to redeem any or all of such Holder’s then-outstanding shares of Series B Preferred Stock for cash in an amount equal to (x) the Liquidation Preference plus (y) the Accrued Dividends plus (z) the Accumulated Dividends for each such share of Series B Preferred Stock redeemed, or (ii) convert any or all of such Holder’s then-outstanding shares of Series B Preferred Stock into shares of Common Stock and, if any consideration is payable to the holders of Common Stock upon such Change of Control, receive for each share of Common Stock issued upon such conversion (including payments of cash in lieu of fractional shares) the consideration per share of Common Stock payable upon the Change of Control thereunder, in each case of clauses (i) or (ii) above, as of the Change of Control Redemption Date. If the value of the consideration payable to the holders of Common Stock upon such Change of Control (if any) has changed since the date of a Holder’s election under this Subsection 10(b) then, each Holder may withdraw or amend its election made under this Subsection 10(b) by delivering a written notice of such withdrawal or amendment, as the case may be, to the Corporation at any time before the close of business on the fifth (5th) Business Day immediately prior to the date on which the Corporation anticipates consummating the Change of Control.
(c)    Initial Change of Control Notice. On or before the twentieth (20th) Business Day prior to the date on which the Corporation anticipates consummating a Change of Control (or, if later, promptly after the Corporation discovers that a Change of Control may occur), a written notice (a “Change of Control Notice”) shall be sent by or on behalf of the Corporation to each Holder at its address as it appears in the records of the Corporation. The Change of Control Notice shall include (i) a brief summary of the events causing the Change of Control; (ii) a description of the material terms and conditions of the Change of Control; (iii) the Conversion Price in effect on the date of such Change of Control Notice and a description and quantification of any adjustments to the Conversion Price that may result from such

19


Change of Control (if any); (iv) the date on which the Change of Control is anticipated to be consummated, to the extent that such information does not constitute material non-public information (or, if applicable, the date on which a Schedule TO or other schedule, form or report disclosing a Change of Control was filed); (v) subject to the right of each Holder to convert its Series B Preferred Stock pursuant to Subsection 6 prior to such redemption, whether the Corporation is exercising its right under Subsection 10(a) to redeem any or all of the outstanding shares of Series B Preferred Stock and, if so, the number of shares of Series B Preferred Stock to be redeemed from such Holder, and stating the place or places at which the shares of Series B Preferred Stock called for redemption shall, upon presentation and surrender of the certificates evidencing such shares of Series B Preferred Stock, be redeemed (and other instructions a Holder must follow to receive payment); and (vi) the applicable Change of Control Redemption Price (which may be stated as a formula to the extent the date of such Change of Control is not definitively known). If, or to the extent that, the Corporation is not exercising its rights pursuant to Subsection 10(a), a Holder may exercise its right pursuant to Subsection 10(b) to (y) require the Corporation to redeem all or any portion of the outstanding shares of Series B Preferred Stock owned by such Holder by delivering a written notice to the Corporation stating that such Holder is exercising its right to require the Corporation to redeem all or a portion of its outstanding shares of Series B Preferred Stock and including wire transfer instructions for the payment of the Change of Control Redemption Price or (z) convert any or all of such Holder’s then-outstanding shares of Series B Preferred Stock into shares of Common Stock in accordance with Subsection 6 and if any consideration is payable to the holders of Common Stock upon such Change of Control, receive for each share of Common Stock issued upon such conversion, the consideration per share of Common Stock payable upon the Change of Control thereunder, which notice for redemption or conversion, as the case may be, shall be delivered no later the fifth (5th) Business Day prior to the date on which the Corporation anticipates consummating the Change of Control. In the event that a Holder so exercises it rights pursuant to Subsection 10(b), the Corporation will, as promptly as practicable, deliver to such Holder at its address as it appears in the records of the Corporation written instructions stating the place or places at which the shares of Series B Preferred Stock to be redeemed or converted shall, upon presentation and surrender of the certificates evidencing such shares of Series B Preferred Stock, be redeemed or converted (and other instructions such Holder must follow to receive payment or such other consideration (if any) per share of Common Stock payable upon the Change of Control, as applicable) and the applicable Change of Control Redemption Price (which may be stated as a formula to the extent the date of such Change of Control is not definitively known).
(d)    Delivery upon Change of Control. If either the Corporation or a Holder has exercised its right to redeem, or require redemption of, any outstanding shares of Series B Preferred Stock pursuant to Subsection 10(a) or 10(b), then upon the consummation of a Change of Control and subject to Subsection 10(e) below and subject to such Holder properly surrendering the certificates evidencing the

20


applicable shares of Series B Preferred Stock, the Corporation (or its successor) shall promptly deliver or cause to be delivered to such Holder by wire transfer the applicable Change of Control Redemption Price with respect to each of such Holder’s shares so redeemed.
(e)    Cash Redemption Not Permitted. If the Corporation shall (A) not have sufficient funds legally available to redeem in compliance with applicable law, or (B) will be in violation of Specified Contract Terms if its redeems, all outstanding shares of Series B Preferred Stock otherwise required or sought to be redeemed pursuant to this Subsection 10, the Corporation shall not be entitled to elect to redeem any shares of Series B Preferred Stock pursuant to Subsection 10(a) and, with respect to any shares of Series B Preferred Stock with respect to which Holders of such shares have exercised their rights pursuant to Subsection 10(b), the Corporation shall (i) redeem, pro rata among such electing Holders, a number of shares of Series B Preferred Stock with an aggregate applicable Change of Control Redemption Price equal to the lesser of: (1) the amount legally available therefor and (2) the largest amount that can be used for such redemption not prohibited by the Specified Contract Terms, in each case for the redemption of shares of Series B Preferred Stock, (ii) take all actions, including taking commercially reasonable efforts to seek any consents or approvals required from any third party or Governmental Entity, (as determined by the Board in good faith and consistent with its fiduciary duties) required or permitted under applicable law to permit the redemption or repurchase of the Series B Preferred Stock, including, without limitation, if and to the extent permitted by law, generally accepted accounting principles and the rules and regulations of any stock exchange on which the Common Stock is then traded, through the revaluation of the Corporation’s assets in accordance with applicable law, to make funds legally available under applicable law for such redemption, and (iii) redeem any shares of Series B Preferred Stock with respect to which Holders of such shares have exercised their rights pursuant to Subsection 10(b) not purchased because of the foregoing limitations at the applicable Change of Control Redemption Price as soon as practicable after the Corporation is able to make such redemption out of assets legally available under applicable law for the purchase of such shares of Series B Preferred Stock and without violation of the Specified Contract Terms. The Corporation will not voluntarily consummate any transaction, that would result in a Change of Control unless the Corporation will, on the date of payment, have sufficient funds legally available to fully pay the maximum aggregate Change of Control Redemption Price that would be payable in respect of such Change of Control on all shares of Series B Preferred Stock then outstanding. The inability of the Corporation (or its successor) to make a redemption payment for any reason shall not relieve the Corporation (or its successor) from its obligation to effect any required redemption when, as and if permitted by applicable law and the Specified Contract Terms.
(f)    Effect of Redemption. Effective immediately prior to the close of business on the Change of Control Redemption Date for any shares of Series B Preferred

21


Stock redeemed pursuant to this Subsection 10, Dividends shall, notwithstanding anything else herein to the contrary, no longer accumulate, accrue or be declared on any such shares of Series B Preferred Stock, and such shares of Series B Preferred Stock shall cease to be outstanding.
(g)    Status of Redeemed Shares. Any shares of Series B Preferred Stock redeemed or otherwise acquired by the Corporation in any manner whatsoever shall be retired promptly after the acquisition thereof. All such shares shall, upon their retirement, become authorized but unissued shares of Preferred Stock, without designation as to series until such shares are once more designated as part of a particular series by the Board.
11.    Anti-Dilution Adjustments.
(a)    Stock Dividends, Splits and Combinations. For so long as any shares of Series B Preferred Stock remain outstanding, if the Corporation issues shares of Common Stock as a dividend or distribution on all or substantially all shares of Common Stock, or if the Corporation effects a stock split or a stock combination in respect of the Common Stock (in each case excluding an issuance pursuant to a Reorganization Event, as to which Subsection 12 will apply), then the Conversion Price will be adjusted based on the following formula:
a201910kex33articleso_image1.gif
where:
CP0 =
the Conversion Price in effect immediately before the close of business on the Dividend Record Date, or immediately before the close of business on the effective date of such dividend, distribution, stock split or stock combination, as applicable;
CP1=
the Conversion Price in effect immediately after the close of business on such Dividend Record Date or effective date, as applicable;
OS0 =
the number of shares of Common Stock outstanding (calculated on a Fully-Diluted Basis) immediately before the close of business on such Dividend Record Date or effective date, as applicable, without giving effect to such dividend, distribution, stock split or stock combination; and
OS1 =
the number of shares of Common Stock outstanding (calculated on a Fully-Diluted Basis) immediately after giving effect to such dividend, distribution, stock split or stock combination.
If any dividend, distribution, stock split or stock combination of the type described in this Subsection 11(a) is declared or announced, but not so paid or made, then the

22


Conversion Price will be readjusted, effective as of the date the Board (or its authorized delegate) determines not to pay such dividend or distribution or to effect such stock split or stock combination, to the Conversion Price that would then be in effect had such dividend, distribution, stock split or stock combination not been declared or announced. For the purpose of this Subsection 11, the number of shares of Common Stock outstanding at any time will exclude shares of Common Stock held in the Corporation’s treasury (unless the Corporation pays any dividend or makes any distribution on shares of Common Stock held in its treasury).
(b)    Degressive Issuances. Subject to Subsection 11(c), if, on or after the Original Issuance Date and prior to the second anniversary of the Original Issuance Date, the Corporation issues or otherwise sells any shares of Common Stock, or any Equity-Linked Securities, in each case at an Effective Price per share of Common Stock that is less than the Conversion Price in effect (before giving effect to the adjustment required by this Subsection 11(b)) as of the date of the issuance or sale of such shares or Equity-Linked Securities (such an issuance or sale, a “Degressive Issuance”), then, effective as of the close of business on such date, the Conversion Price will be decreased to an amount equal to the Weighted Average Issuance Price. For these purposes, the “Weighted Average Issuance Price” will be equal to:
a201910kex33articleso_image2.gif
where:
CP =    such Conversion Price;
OS =
the number of shares of Common Stock outstanding immediately before such Degressive Issuance (treating for this purpose as outstanding all shares of Common Stock issuable upon exercise, conversion or exchange of all Equity‑Linked Securities (including the Series B Preferred Stock) outstanding immediately prior to such issue);
EP =
the Effective Price per share of Common Stock in such Degressive Issuance; and
X =
the sum, without duplication, of (x) the total number of shares of Common Stock issued or sold in such Degressive Issuance; and (y) the maximum number of shares of Common Stock underlying such Equity-Linked Securities issued or sold in such Degressive Issuance;
provided, however, that (A) the Conversion Price will not be adjusted pursuant to this Subsection 11(b) to the extent that the Degressive Issuance is an Excluded Issuance; (B) the issuance of shares of Common Stock pursuant to any Equity-Linked Securities will not constitute an additional issuance or sale of shares of Common Stock for purposes of this Subsection 11(b) (it being understood, for the avoidance

23


of doubt, that the issuance or sale of such Equity-Linked Securities, or any re-pricing or amendment thereof, will be subject to this Subsection 11(b)); and (C) in no event will the Conversion Price be increased pursuant to this Subsection 11(b). For purposes of this Subsection 11(b), any re-pricing or amendment of any Equity-Linked Securities (including, for the avoidance of doubt, any Equity-Linked Securities existing as of the Original Issuance Date) will be deemed to be the issuance of additional Equity-Linked Securities, without affecting any prior adjustments theretofore made to the Conversion Price.
(c)    Limitations on Adjustments.
(i)    Adjustment Cap on Degressive Issuances. Notwithstanding anything to the contrary in this Subsection 11, under no circumstances shall adjustments to the Conversion Price pursuant to Subsection 11(b) cause the Conversion Price to be less than $3.47.
(ii)    No Adjustments in Certain Events. The Corporation will not be required to adjust the Conversion Price except pursuant to this Subsection 11. Without limiting the foregoing, the Corporation will not be required to adjust the Conversion Price on account of:
(A)    except as otherwise provided in Subsection 11(b), the sale of shares of Common Stock for a purchase price that is less than the market price per share of Common Stock or less than the Conversion Price;
(B)    the issuance of any shares of Common Stock pursuant to any present or future plan providing for the reinvestment of dividends or interest payable on the Corporation’s securities and the investment of additional optional amounts in shares of Common Stock under any such plan;
(C)    except as otherwise provided in Subsection 11(b), the issuance of any shares of Common Stock or options or rights to purchase shares of Common Stock pursuant to any present or future employee, director or consultant benefit plan or program of, or assumed by, the Corporation or any of its Subsidiaries, including inducement grants under Nasdaq Listing Rule 5635(c)(4);
(D)    except as otherwise provided in Subsection 11(b), the issuance of any shares of Common Stock pursuant to any option, warrant, right, restricted stock unit, performance stock unit or other awards granted under any employee share purchase or equity-based incentive plan, program or arrangement of the Corporation, or convertible or exchangeable security of the Corporation outstanding as of the Original Issuance Date; or
(E)    solely a change in the par value of the Common Stock.

24


(iii)    Adjustment Deferral. If an adjustment to the Conversion Price otherwise required by this Subsection 11 would result in a change of less than one percent (1%) to the Conversion Price, then the Corporation may, at its election, defer such adjustment, except that all such deferred adjustments must be given effect immediately upon the earliest to occur of the following: (A) when all such deferred adjustments would result in a change of at least one percent (1%) to the Conversion Price, (B) the Conversion Date of any share of Series B Preferred Stock and (C) the Change of Control Redemption Date for any Change of Control.
(iv)    Shareholder Rights Plans. If any shares of Common Stock are to be issued upon conversion of any Series B Preferred Stock and, at the time of such conversion, the Corporation has in effect any shareholder rights plan, then the Holders of such Series B Preferred Stock will be entitled to receive, in addition to, and concurrently with the delivery of, the consideration otherwise due upon such conversion, the rights set forth in such shareholder rights plan.
(v)    Notice of Conversion Price Adjustments. Upon the effectiveness of any adjustment to the Conversion Price pursuant to this Subsection 11, the Corporation will, as soon as reasonably practicable and no later than ten (10) Business Days after the date of such effectiveness, send notice to the Holders containing (A) a brief description of the transaction or other event on account of which such adjustment was made, (B) the Conversion Price in effect immediately after such adjustment, and (C) the effective time of such adjustment.
12.    Adjustment for Reorganization Events.
(a)    Reorganization Events. In the event of:
(i)    any reclassification, statutory exchange, merger, consolidation or other similar business combination of the Corporation with or into another Person, in each case, pursuant to which at least a majority of the Common Stock is changed or converted into, or exchanged for, cash, securities or other property of the Corporation or another Person;
(ii)    any sale, transfer, lease, exclusive license, or conveyance to another Person of all or a majority of the property and assets of the Corporation, in each case pursuant to which the Common Stock is converted into cash, securities or other property; or
(iii)    any statutory exchange of securities of the Corporation with another Person (other than in connection with a merger or acquisition) or reclassification, recapitalization or reorganization of the Common Stock into other securities;

25


other than, in each case, any such transaction that constitutes a Change of Control, with respect to which, for the avoidance of doubt, the provisions of Subsection 10 shall apply (each of which is referred to as a “Reorganization Event”), each share of Series B Preferred Stock outstanding immediately prior to such Reorganization Event will, without the consent of the Holders but subject to Subsection 12(d), remain outstanding but shall become convertible into, out of funds legally available therefor, the number, kind and amount of securities, cash and other property (the “Exchange Property”) (without any interest on such Exchange Property and without any right to dividends or distribution on such Exchange Property that have a Record Date that is prior to the applicable Conversion Date) that the Holder of such share of Series B Preferred Stock would have received in such Reorganization Event had such Holder converted its shares of Series B Preferred Stock into the applicable number of shares of Common Stock immediately prior to the effective date of the Reorganization Event using the Conversion Price applicable immediately prior to the effective date of the Reorganization Event and the Liquidation Preference (plus (y) the Accrued Dividends plus (z) the Accumulated Dividends for each such shares of Series B Preferred Stock) applicable at the time of such subsequent conversion (without regard to the provisions of Subsection 9); provided that the foregoing shall not apply if such Holder is a Person with which the Corporation consolidated or into which the Corporation merged or which merged into the Corporation or to which such sale or transfer was made, as the case may be (any such Person, a “Constituent Person”), or an Affiliate of a Constituent Person, to the extent such Reorganization Event provides for different treatment of Common Stock held by such Constituent Persons or such Affiliate thereof. If the kind or amount of securities, cash and other property receivable upon such Reorganization Event is not the same for each share of Common Stock held immediately prior to such Reorganization Event by a Person (other than a Constituent Person or an Affiliate thereof), then for the purpose of this Subsection 12(a), the kind and amount of securities, cash and other property receivable upon conversion following such Reorganization Event will be deemed to be the weighted average of the types and amounts of consideration received by the holders of Common Stock.
(b)    Successive Reorganization Events. The above provisions of this Subsection 12 shall similarly apply to successive Reorganization Events and the provisions of Subsection 11 shall apply to any shares of Capital Stock received by the holders of the Common Stock in any such Reorganization Event.
(c)    Reorganization Event Notice. The Corporation (or any successor) shall, no less than thirty (30) days prior to the anticipated effective date of any Reorganization Event, provide written notice to the Holders of such occurrence of such event and of the kind and amount of the cash, securities or other property that constitutes the Exchange Property. Failure to deliver such notice shall not affect the operation of this Subsection 12.

26


(d)    Reorganization Event Agreements. The Corporation shall not enter into any agreement for a transaction constituting a Reorganization Event unless (i) such agreement provides for or does not interfere with or prevent (as applicable) conversion of the Series B Preferred Stock into the Exchange Property in a manner that is consistent with and gives effect to this Subsection 12 and (ii) to the extent that the Corporation is not the surviving corporation in such Reorganization Event or will be dissolved in connection with such Reorganization Event, proper provision shall be made in the agreements governing such Reorganization Event for the conversion of the Series B Preferred Stock into stock of the Person surviving such Reorganization Event or such other continuing entity in such Reorganization Event.
13.    Voting Rights.
(a)    General. Except as provided in Subsection 13(c) or as otherwise provided in the Florida Business Corporation Act, the Holders shall be entitled to vote as a single class with the holders of the Common Stock and the holders of any other class or series of Capital Stock of the Corporation then entitled to vote with the Common Stock on all matters submitted to a vote of the holders of Common Stock (and, if applicable, holders of any other class or series of Capital Stock of the Corporation). Subject to Subsection 13(b), each Holder shall be entitled in respect of each share of Preferred Stock held by such Holder to a number of votes equal to the number of whole shares of Common Stock into which each share of Series B Preferred Stock is convertible pursuant to Subsection 6, in each case at and calculated as of the Record Date for the determination of shareholders entitled to vote or consent on such matters or, if no such Record Date is established, at and as of the date such vote or consent is taken or any written consent of shareholders is first executed. The Holders shall be entitled to notice of any meeting of holders of Common Stock (or requests for consent) to the same extent that holders of Common Stock are entitled to thereunder.
(b)    Voting Cap. Notwithstanding anything herein to the contrary:
(i)    no Holder (together with its Affiliates) shall be entitled to vote (in respect of such Person’s holdings of Series B Preferred Stock and any Common Stock issued or issuable upon conversion of such Series B Preferred Stock) more than 19.90% of the total Voting Stock of the Corporation (measured as of the time of such vote); and
(ii)    no Holder shall be entitled in respect of each share of Series B Preferred Stock to more than a number of votes equal to (x) $1,000 divided by (y) the Minimum Price.
(c)    Special Voting Rights. For as long as any shares of Series B Preferred Stock remain outstanding, the Corporation shall not take, and shall cause its Subsidiaries not to take, any of the actions described in this Subsection 13(c) without the prior written consent of the Holders of not less than a majority of the then total outstanding shares of Series B Preferred Stock, voting separately as a single class with one vote

27


per share, in person or by proxy, either in writing without a meeting or at an annual or a special meeting of such Holders, and any such action taken without such consent shall be null and void ab initio, and of no force or effect:
(i)    alter, amend or change the rights, preference or privileges of the Series B Preferred Stock;
(ii)    amend or restate any organizational document of the Corporation or its Subsidiaries in a manner that materially, adversely and disproportionately affects the rights, preferences and privileges of the Series B Preferred Stock as compared to Common Stock;
(iii)    authorize or create any class or series of Senior Stock or Parity Stock (or any security convertible or exchangeable into or evidencing the right to purchase, shares of any class or series of Senior Stock or Parity Stock);
(iv)    declare or pay dividends or otherwise make distributions with respect to any shares of Parity Stock or Junior Stock, except dividends or distributions made for purposes as set forth in Subsection 4(f)(i) through Subsection 4(f)(vii);
(v)    repurchase or redeem any issued and outstanding shares of Junior Stock or Parity Stock, other than repurchases or redemptions as contemplated by Subsection 4(f)(i) through Subsection 4(f)(vii);
(vi)    repurchase or redeem any issued and outstanding shares of Series B Preferred Stock, other than repurchases or redemptions of shares of Series B Preferred Stock upon the occurrence of a Change of Control in accordance with Subsection 10 (for the avoidance of doubt, conversions of Preferred Stock shall not constitute repurchases or redemptions);
(vii)    at any time prior to the date that is 30 months after the Original Issuance Date (the “Sunset Date”), (A) sell, transfer or otherwise dispose of any assets (other than sales of inventory in the ordinary course of business), business or operations, for consideration equal to or greater than $25 million or (B) acquire any assets, business or operations, for consideration equal to or greater than $75 million, in each case of clauses (A) or (B) above in any one transaction or series of related transactions;
(viii)    at any time prior to the Sunset Date, merge or consolidate the Corporation with and into any other company unless either (A) the surviving company will have no class of equity securities ranking superior to or on parity with the Series B Preferred Stock in any liquidation, dissolution or wind-up of the Corporation or with respect to dividends, or (B) the Holders will receive in connection with such merger or consolidation, consideration (in the form of cash or publicly traded securities) in respect of each share of

28


Series B Preferred Stock valued (as of the time a definitive agreement in respect of such merger or consolidation is entered into) at or above an amount equal to 200% of the Investor Per Share Purchase Price (any merger or consolidation or other Change of Control in which the Holders will receive consideration meeting the requirements set forth in this clause (B), an “Acceptable Change of Control Event”);
(ix)    at any time prior to the Sunset Date, commence a voluntary case under any applicable bankruptcy, insolvency or other similar law or consent to the entry of an order for relief in an involuntary case under any such law, or effect any general assignment for the benefit of creditors; or
(x)    at any time prior to the Sunset Date, enter into any settlement agreement with respect to the following proceeding: In re MiMedx Group, Inc. Securities Litigation, Case No. 1:18-cv-00830-WMR (N.D. Ga.).
Notwithstanding anything herein to the contrary, no consent or approval of the Holders shall be required for (i) the Corporation to enter into or consummate an Acceptable Change of Control Event or (ii) the authorization or creation of, or the increase in the number of authorized or issued shares of Junior Stock. For the avoidance of doubt, any consent in writing executed by the Holders of at least a majority of the then total outstanding shares of Series B Preferred Stock shall be sufficient to grant any consent required under this Subsection 13(c) for all purposes hereunder and (except as otherwise agreed in writing with a Holder) no notice of such action to the other Holders of Series B Preferred Stock shall be required and no meeting of the Holders of the Series B Preferred Stock shall be required to be convened; provided, that, if the Corporation has not publicly disclosed any action set forth in clauses (i) through (vi) within 10 Business Days of taking such action, then the Corporation shall provide written notice to all Holders of Series B Preferred Stock no less than five (5) Business Days following the taking of such action.
(a)    Consent Rights of the Series B Preferred Holders. For as long as any shares of Series B Preferred Stock remain outstanding, the Corporation shall not amend the provisions of its Articles of Incorporation in a manner that adversely and disproportionately affects the rights, preferences and privileges of any Holder of Series B Preferred Stock (such affected holder, an “Affected Holder”) as compared to any other Holder of Series B Preferred Stock, without the prior written consent of the Affected Holder.
14.    Investor Designees. Notwithstanding anything else to the contrary herein, this Subsection 14 shall be effective only for so long as any shares of Series B Preferred Stock remain outstanding.
(a)    Right to Designate Preferred Directors.

29


(i)    Subject to Subsection 14(b), from and after the Original Issuance Date, so long as the EW Investor is a 10% Holder, the EW Investor shall have the right to designate two (2) Investor Designees to serve as preferred directors (each, a “Preferred Director”). To effect this right, on the Original Issuance Date, the size of the Board shall be increased by two (2) members, and two (2) Qualified Persons designated by the EW Investor (each Qualified Person designated by the EW Investor, an “Investor Designee”) shall be appointed to the Board as Preferred Directors, filling the vacancies created by such increase. The initial Preferred Directors shall be Martin P. Sutter and William A. Hawkins, III, each of whom shall take office effective as of the Original Issuance Date subject to the terms of this Subsection 14. If any Investor Designee is not elected to serve as a Preferred Director, the Board will take all lawful actions to appoint such Investor Designee as a Preferred Director.
(i)    Subject to Subsection 14(b), from and after the Original Issuance Date, so long as the EW Investor is a 5% Holder, the EW Investor shall have the right to designate one (1) Investor Designee to serve as a Preferred Director.
(i)    From and after the Original Issuance Date, if the EW Investor is at any time neither a 5% Holder nor a 10% Holder, the EW Investor shall have no right to designate any person to serve as a Preferred Director.
(i)    Notwithstanding anything to the contrary contained in Article 10 of the Articles of Incorporation, and subject to the other terms and conditions of this Subsection 14, including Subsection 14(b) and Subsection 14(c), each Preferred Director shall continue to hold office until the death, disability, resignation or removal of such Preferred Director and shall not be a member of any class of directors that is elected by the holders of shares of Common Stock. Subject to Subsection 14(b), no Person other than the EW Investor shall have any right to designate, appoint, elect or remove any Preferred Directors, and the EW Investor may remove any Preferred Director at any time with or without cause. Only the EW Investor shall have the right to fill any Preferred Director vacancies resulting from death, disability, resignation, disqualification, removal or other cause; provided, however, that the EW Investor shall not designate anyone other than a Qualified Person to fill any such vacancy and provided further that the EW Investor shall not have any right to fill any vacancy resulting from the acceptance of any resignation pursuant to Subsection 14(c).
(i)    So long as the EW Investor has any right to designate any Preferred Director, in the event of the death, disability, resignation, disqualification or removal of a Preferred Director as a member of the Board (other than pursuant

30


to Subsection 14(c)), the EW Investor may designate a Qualified Person to be a replacement Preferred Director to the Board.
(i)    The size of the Board may be increased or decreased at any time in accordance with the Articles of Incorporation, the Bylaws and applicable law; provided that no such decrease shall limit the rights of the EW Investor to designate Preferred Directors under this Subsection 14.
(a)    Service as Common Directors in Lieu of Service as Preferred Directors. The Board may, by notice to the EW Investor, (i) appoint any Investor Designee (including any Investor Designee who is then serving as a Preferred Director) as a director under Article 10 of the Articles of Incorporation (any such director, a “Common Director”) or (ii) nominate any Investor Designee (including any Investor Designee who is then serving as a Preferred Director) for election to the Board by holders of Common Stock at the Corporation’s next annual meeting of shareholders, provided that (x) no such appointment or nomination of an Investor Designee shall take place if such Investor Designee would be up for election as a Common Director prior to the 2022 annual meeting of shareholders of the Corporation, and (y) if an Investor Designee is appointed or nominated as a Common Director prior to the second anniversary of the Original Issuance Date, then the other Investor Designee may not be so appointed or nominated to be a Common Director prior to the second anniversary of the Original Issuance Date. Any such notice shall indicate the class of Common Director to which such Investor Designee will be appointed or nominated for election. Upon the earlier of the appointment or the election of such Investor Designee (or a Replacement Designee (as defined below)) as a Common Director, and for so long as such Investor Designee (or a Replacement Designee) serves as a Common Director, the EW Investor’s rights to designate an Investor Designee as a Preferred Director under Subsection 14(a) shall be deemed to have been satisfied. For the avoidance of doubt, the total number of Investor Designees that the EW Investor is entitled to have serving on the Board as Preferred Directors, Common Directors or a combination thereof when the EW Investor is a 10% Holder shall be no greater than two (2), and the total number of Investor Designees that the EW Investor is entitled to have serving on the Board as Preferred Directors or Common Directors when the EW Investor is a 5% Holder shall be no greater than one (1). In the event of the death, disability, resignation or removal of an Investor Designee who is serving as a Common Director pursuant to this Subsection 14(b), the EW Investor may designate a Qualified Person to serve as a replacement Investor Designee (any such Person, a “Replacement Designee”).
(a)    Resignation; Removal.
(i)    If, at any time after the Original Issuance Date, two (2) Investor Designees are serving on the Board, whether as Preferred Directors, Common Directors or a combination thereof, and the EW Investor ceases to be a 10% Holder, the EW Investor shall immediately deliver notice to the Board

31


indicating which Investor Designee’s conditional resignation described in Subsection 14(d)(iii) below shall be deemed to have been tendered, and a majority of the then remaining directors (other than the Investor Designees) shall determine whether or not to accept such resignation. If the Board receives no such notice within five (5) Business Days after the EW Investor ceases to be a 10% Holder, the Board (other than the Investor Designees) shall determine which Investor Designee’s conditional resignation described in Subsection 14(d)(iii) below shall be deemed to have been tendered, and a majority of the then remaining directors (other than the Investor Designees) shall determine whether or not to accept such resignation. If the Board determines to accept such resignation, the Investor Designee who tendered his or her resignation shall cease to be an Investor Designee hereunder. If the Board determines not to accept such resignation then, regardless of whether such Investor Designee served as a Preferred Director or a Common Director immediately prior to the time when the EW Investor ceased to be a 10% Holder, such Investor Designee shall, upon the Board’s determination not to accept such Investor Designee’s resignation, serve on the Board as a Common Director in such class as the Board shall determine (if such a determination has not been previously been made by the Board) and not as a Preferred Director.
(i)    If, at any time after the Original Issuance Date, pursuant to Subsection 14(c)(i) only one (1) Investor Designee is serving on the Board as a Preferred Director or a Common Director, and the EW Investor ceases to be a 5% Holder, (a) a majority of the then remaining directors (other than the Investor Designee) shall determine whether or not to accept the conditional resignation of such Investor Designee and (b) the EW Investor shall no longer have any rights under this Subsection 14. If the Board determines to accept such resignation, the Investor Designee who tendered his or her resignation shall cease to be an Investor Designee hereunder. If the Board determines not to accept such resignation then, regardless of whether such Investor Designee served as a Preferred Director or a Common Director immediately prior to the time when the EW Investor ceased to be a 5% Holder, such Investor Designee shall, upon the Board’s determination not to accept such Investor Designee’s resignation, serve on the Board as a Common Director in such class as the Board shall determine (if such a determination has not been previously been made by the Board) and not as a Preferred Director.
(a)    As a condition to any Investor Designee’s appointment to the Board pursuant to this Subsection 14, the EW Investor and such Investor Designee shall provide to the Corporation:
(i)    if requested by the Corporation, the information required from a nominating shareholder or a Proposed Nominee (as defined in Article II, Section 10 of the Bylaws) under Article II, Section 10 of the Bylaws;

32


(i)    an undertaking in writing by the Investor Designee to (A) be subject to, bound by and duly comply with the code of conduct and other policies of the Corporation to the same extent required of other non-executive directors of the Corporation; and (B) recuse himself or herself from any deliberations or discussion of the Board or any committee thereof regarding the Corporation’s relationship with the EW Investor or any of its Affiliates, including in connection with the EW Investor Parties’ purchase or holding of the Series B Preferred Stock; and
(i)    a conditional irrevocable letter of resignation signed by the Investor Designee resigning automatically and without further action, subject to acceptance of such resignation by vote of a majority of the then remaining directors (other than any Investor Designees), upon the occurrence of any of the following events: (A) the EW Investor’s ceasing to be a 10% Holder and notice to such Investor Designee of the effectiveness of such Investor Designee’s resignation pursuant to Subsection 14(c)(i), (B) the EW Investor’s ceasing to be a 5% Holder, (C) such Investor Designee’s failure satisfy the requirements set forth in clause (i), (ii), (iii), (iv) or (v) of the definition of Qualified Person or (D) such Investor Designee’s material breach of any of the Corporation’s Articles of Incorporation or Bylaws, committee charters, corporate governance guidelines, insider trading policies, stock ownership guidelines or similar governance documents.
(a)    Indemnification. Upon election or appointment to the Board, an Investor Designee shall herein be referred to as an “Investor Director”. The Corporation shall indemnify each Investor Director and provide each Investor Director with director and officer insurance to the same extent as it indemnifies and provides such insurance to other non-executive members of the Board, pursuant to the Articles of Incorporation and Bylaws of the Corporation, applicable laws or otherwise. The Corporation hereby acknowledges that an Investor Director may have rights to indemnification and advancement of expenses provided by the EW Investor or its Affiliates (directly or through insurance obtained by any such entity) (collectively, the “Director Indemnitors”). The Corporation hereby agrees and acknowledges that (i) it is the indemnitor of first resort with respect to an Investor Director, (ii) it shall be required to advance the full amount of expenses incurred by such Investor Director, as required by law, the terms of the Articles of Incorporation and Bylaws, an agreement, vote of stockholders or disinterested directors, or otherwise, without regard to any rights such Investor Director may have against the Director Indemnitors and (iii) to the extent permitted by law, it irrevocably waives, relinquishes and releases the Director Indemnitors from any and all claims against the Director Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof. The Corporation further agrees that no advancement or payment by the Director Indemnitors on behalf of the Corporation with respect to any claim for which such Investor Director has sought indemnification from the Corporation shall affect the foregoing and the Director Indemnitors shall have a right of contribution

33


and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of such Investor Director against the Corporation. These rights shall be a contract right.
(a)    Conflicts.
(i)    The Corporation reserves the right to withhold any information and to exclude the Investor Designees from any meeting or portion thereof if access to such information or attendance at such meeting would reasonably be expected to result in a conflict of interest.
(ii)    The EW Investor shall cause the Investor Designees not to participate in, and to recuse themselves from, any Board deliberations and actions relating to the Corporation’s relationship with the EW Investor Parties, including in connection with the EW Investor Parties’ purchase or holding of the Series B Preferred Stock.
(b)    No Assignment or Transfer. The rights of the EW Investor hereunder may not be assigned or transferred whether directly or indirectly.
15.    Transfer Agent, Conversion Agent, Registrar and Paying Agent. The initial duly appointed Transfer Agent, Conversion Agent, Registrar and paying agent for the Series B Preferred Stock shall be Issuer Direct Corporation. The Corporation may, in its sole discretion, appoint any other Person to serve as Transfer Agent, Conversion Agent, Registrar or paying agent for the Series B Preferred Stock and thereafter may remove or replace such other Person at any time. Upon any such appointment or removal, the Corporation shall send written notice thereof by first class mail or email to the Holders.
16.    Replacement Certificates.
(a)    Mutilated, Destroyed, Stolen and Lost Certificates. If physical certificates evidencing the Series B Preferred Stock are issued, the Corporation shall replace any mutilated certificate at the Holder’s expense upon surrender of that certificate to the Transfer Agent. The Corporation shall replace certificates that become destroyed, stolen or lost at the Holder’s expense upon delivery to the Corporation and the Transfer Agent of satisfactory evidence that the certificate has been destroyed, stolen or lost, together with any bond, indemnity or security that may be required by the Transfer Agent and the Corporation.
(b)    Certificates Following Conversion. If physical certificates representing the Series B Preferred Stock are issued, the Corporation shall not be required to issue replacement certificates representing shares of Series B Preferred Stock on or after the Conversion Date applicable to such shares, to the extent that no shares of Series B Preferred Stock represented by such certificates remain outstanding following such Conversion Date. In place of the delivery of a replacement certificate following the applicable Conversion Date, the Transfer Agent, upon receipt of the satisfactory

34


evidence and bond described in clause (a) above, shall deliver the shares of Common Stock issuable upon conversion of such shares of Series B Preferred Stock formerly evidenced by the physical certificate.
1.    Taxes.
(a)    The Corporation may deduct and withhold, or cause to be deducted and withheld, any amounts required to be deducted and withheld under applicable law with respect to the Series B Preferred Stock (and may set off any such amounts required to be deducted and withheld against any Dividends, distributions or other payments on the Series B Preferred Stock).
(b)    The Corporation shall pay any and all documentary, stamp, recording, registration and similar issue or transfer tax (“Transfer Tax”) due on (x) the issuance of the Series B Preferred Stock and (y) the issuance of shares of Common Stock upon conversion of Series B Preferred Stock. However, the Corporation shall not be required to pay any Transfer Tax that may be payable in respect of the issuance or delivery (or any transfer involved in the issuance or delivery) of Series B Preferred Stock or shares of Common Stock issued upon conversion of Series B Preferred Stock to a beneficial owner other than the beneficial owner of the Series B Preferred Stock or shares of Common Stock issued upon conversion of Series B Preferred Stock immediately prior to the event pursuant to which such issuance or delivery is required, and no such issuance or delivery shall be made unless and until the Person requesting such issuance or delivery has paid to the Corporation the amount of any such Transfer Tax or has established to the satisfaction of the Corporation that such Transfer Tax has been paid or is not payable.
2.    Notices. All notices referred to herein shall be in writing and, unless otherwise specified herein, all notices hereunder shall be deemed to have been given upon the earlier of delivery or three (3) Business Days after the mailing thereof, with respect to mailing in the United States and ten (10) Business Days after the mailing thereof, with respect to mailing outside of the United States, in each case if sent by registered or certified mail with postage prepaid, or by private courier service addressed: (i) if to the Corporation, to its office at 1775 West Oak Commons Court, Marietta, GA 30062 (Attention: General Counsel), (ii) if to any Holder, to such Holder at the address of such Holder as listed in the stock record books of the Corporation (which may include the records of the Transfer Agent) or (iii) to such other address as the Corporation or any such Holder, as the case may be, shall have designated by notice similarly given; provided, that notices to the Holders hereunder may be provided by e-mail if and to the extent the Corporation has on file an e-mail address for such Holder.
3.    Waiver. Any provision contained herein and any right of the Holders granted hereunder may be waived as to all shares of Series B Preferred Stock (and the Holders thereof) upon the vote or written consent of the Holders of a majority of the shares of Series B Preferred Stock then outstanding, provided that any waiver of a provision or rights that adversely and disproportionately affects the rights, preferences and privileges of an Affected

35


Holder as compared to any other Holder of Series B Preferred Stock shall require the consent of the Affected Holder.
4.    Severability. If any term of the Series B Preferred Stock set forth herein is invalid, unlawful or incapable of being enforced by reason of any rule of law or public policy, all other terms set forth herein which can be given effect without the invalid, unlawful or unenforceable term will, nevertheless, remain in full force and effect, and no term herein set forth will be deemed dependent upon any other such term unless so expressed herein. Notwithstanding the foregoing in the event of any conflict between the Corporation’s Articles of Incorporation and this Article 3, this Article 3 shall control.”
[Signature Page Follows]



IN WITNESS WHEREOF, the undersigned has executed these Articles of Amendment as of June 30, 2020.



MIMEDX GROUP, INC.



By:      /s/ William F. “Butch” Hulse    
Name: William F. “Butch” Hulse
Title: General Counsel and Secretary







36
EX-31.1 3 a2020331exhibit311.htm EXHIBIT 31.1 Exhibit


Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO RULES 13a-14(A) AND 15d-14(A)
OF THE SECURITIES EXCHANGE ACT OF 1934
 
I, Timothy R. Wright, certify that:
 
1. I have reviewed this Form 10-Q for the quarter ended March 31, 2020, of MiMedx Group, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. 
Date:
July 6, 2020
/s/ Timothy R. Wright
 
 
Timothy R. Wright
 
 
Chief Executive Officer


EX-31.2 4 a2020331exhibit312.htm EXHIBIT 31.2 Exhibit


Exhibit 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO RULES 13a-14(A) AND 15d-14(A)
OF THE SECURITIES EXCHANGE ACT OF 1934
 
I, Peter M. Carlson, certify that:

1. I have reviewed this Form 10-Q for the quarter ended March 31, 2020, of MiMedx Group, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. 
Date:
July 6, 2020
/s/ Peter M. Carlson
 
 
Peter M. Carlson
 
 
Chief Financial Officer


EX-32.1 5 a2020331exhibit321.htm EXHIBIT 32.1 Exhibit


Exhibit 32.1
 
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
The undersigned Timothy R. Wright, the Chief Executive Officer of MiMedx Group, Inc. (the “Company”), has executed this certification in connection with the filing with the Securities and Exchange Commission of the Company’s Quarterly Report on Form 10-Q for the period ending March 31, 2020 (the “Report”). Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned hereby certifies, to his knowledge, that:

(1)
the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date:
July 6, 2020
/s/ Timothy R. Wright
 
 
Timothy R. Wright
 
 
Chief Executive Officer


EX-32.2 6 a2020331exhibit322.htm EXHIBIT 32.2 Exhibit


 Exhibit 32.2
 
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
The undersigned Peter M. Carlson, the Chief Financial Officer of MiMedx Group, Inc. (the “Company”), has executed this certification in connection with the filing with the Securities and Exchange Commission of the Company’s Quarterly Report on Form 10-Q for the period ending March 31, 2020 (the “Report”). Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned hereby certifies, to his knowledge, that:

(1)
the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. 
Date:
July 6, 2020
/s/ Peter M. Carlson
 
 
Peter M. Carlson
 
 
Chief Financial Officer


EX-101.SCH 7 mdxg-20200331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2109100 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - Contractual Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2416401 - Disclosure - Contractual Commitments and Contingencies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 2114100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2414401 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 2408404 - Disclosure - Intangible Assets - Estimated Future Amortization Expense for Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - Intangible Assets - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Intangible Assets - Summary of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 2406404 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2406404 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Leases - Supplemental Balance Sheet Information (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Liquidity and Capital Resources link:presentationLink link:calculationLink link:definitionLink 2402401 - Disclosure - Liquidity and Capital Resources (Details) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Long Term Debt link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - Long Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2410406 - Disclosure - Long Term Debt - Subsequent Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - Long Term Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 2410403 - Disclosure - Long Term Debt - Term Loan Balances (Details) link:presentationLink link:calculationLink link:definitionLink 2410404 - Disclosure - Long Term Debt - Term Loan Interest Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2410405 - Disclosure - Long Term Debt - Term Loan Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Nature of Business link:presentationLink link:calculationLink link:definitionLink 2401401 - Disclosure - Nature of Business (Details) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 2411402 - Disclosure - Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2117100 - Disclosure - Product Revenue Detail link:presentationLink link:calculationLink link:definitionLink 2417402 - Disclosure - Product Revenue Detail (Details) link:presentationLink link:calculationLink link:definitionLink 2317301 - Disclosure - Product Revenue Detail (Tables) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - Property and Equipment - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Property and Equipment - Summary of Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2401404 - Disclosure - Significant Accounting Policies - Assessment of Revenue under ASC 606 (Details) link:presentationLink link:calculationLink link:definitionLink 2401403 - Disclosure - Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2401405 - Disclosure - Significant Accounting Policies - Recently Issued and Adopted Accounting Standards (Details) link:presentationLink link:calculationLink link:definitionLink 2301302 - Disclosure - Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 2118100 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 2418401 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities link:presentationLink link:calculationLink link:definitionLink 2415402 - Disclosure - Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities (Details) link:presentationLink link:calculationLink link:definitionLink 2315301 - Disclosure - Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 mdxg-20200331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 mdxg-20200331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 mdxg-20200331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Commitments and Contingencies Disclosure [Abstract] Contractual Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Earnings Per Share [Abstract] Net Loss Per Share Earnings Per Share [Text Block] Revenue from Contract with Customer [Abstract] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Customer [Axis] Customer [Axis] Customer [Domain] Customer [Domain] Direct Customers Direct Customers [Member] Direct Customers [Member] Distributors Distributors [Member] Distributors [Member] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Number of primary distribution channels Number of Distribution Channels Number of Distribution Channels Net sales Revenue from Contract with Customer, Excluding Assessed Tax Organization, Consolidation and Presentation of Financial Statements [Abstract] Nature of Business Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Leases [Abstract] Supplemental Balance Sheet Information Related to Leases Lease, Cost [Table Text Block] Maturities of Operating Lease Liabilities Lessee, Operating Lease, Liability, Maturity [Table Text Block] Property, Plant and Equipment [Abstract] Property and Equipment Property, Plant and Equipment Disclosure [Text Block] Statement of Financial Position [Abstract] ASSETS Assets [Abstract] Current assets: Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Inventory, net Inventory, Net Prepaid expenses Prepaid Expense, Current Income tax receivable Income Taxes Receivable, Current Other current assets Other Assets, Current Total current assets Assets, Current Property and equipment, net Property, Plant and Equipment, Net Right of use asset Operating Lease, Right-of-Use Asset Goodwill Goodwill Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Other assets Deferred Costs and Other Assets Total assets Assets LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable Accrued compensation Employee-related Liabilities, Current Accrued expenses Accrued Liabilities, Current Current portion of long term debt Long-term Debt, Current Maturities Other current liabilities Other Liabilities, Current Total current liabilities Liabilities, Current Long term debt, net Long-term Debt, Excluding Current Maturities Other liabilities Other Liabilities, Noncurrent Total liabilities Liabilities Commitments and contingencies (Note 13) Commitments and Contingencies Stockholders' equity: Stockholders' Equity Attributable to Parent [Abstract] Preferred stock; $.001 par value; 5,000,000 shares authorized; 0 issued and 0 outstanding at March 31, 2020 and 0 issued and 0 outstanding at December 31, 2019 Preferred Stock, Value, Issued Common stock; $.001 par value; 150,000,000 shares authorized; 112,703,926 issued and 110,540,860 outstanding at March 31, 2020 and 112,703,926 issued and 110,818,649 outstanding at December 31, 2019 Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital Treasury stock at cost; 2,163,066 shares at March 31, 2020 and 1,885,277 shares at December 31, 2019 Treasury Stock, Value Accumulated deficit Retained Earnings (Accumulated Deficit) Total stockholders' equity Stockholders' Equity Attributable to Parent Total liabilities and stockholders' equity Liabilities and Equity Statement of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Net loss Net Income (Loss) Attributable to Parent Adjustments to reconcile net income to net cash from operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Share-based compensation Share-based Payment Arrangement, Noncash Expense Depreciation Depreciation Amortization of intangible assets Amortization of Intangible Assets Amortization of deferred financing costs and debt discount Amortization of Debt Issuance Costs and Discounts Non-cash lease expenses Operating Lease, Right-of-use Asset, Amortization Operating Lease, Right-of-use Asset, Amortization Loss on fixed asset disposal Gain (Loss) on Disposition of Property Plant Equipment Impairment of intangible assets Impairment of Intangible Assets (Excluding Goodwill) Increase (decrease) in cash resulting from changes in: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable Increase (Decrease) in Accounts Receivable Inventory Increase (Decrease) in Inventories Prepaid expenses Increase (Decrease) in Prepaid Expense Income tax receivable Increase (Decrease) in Income Taxes Receivable Other assets Increase (Decrease) in Other Current Assets Accounts payable Increase (Decrease) in Accounts Payable Accrued compensation Increase (Decrease) in Deferred Compensation Accrued expenses Increase (Decrease) in Accrued Liabilities Income taxes Increase (Decrease) in Accrued Taxes Payable Other liabilities Increase (Decrease) in Other Operating Liabilities Cash flows used in operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of equipment Payments to Acquire Machinery and Equipment Principal payments from note receivable Proceeds from Collection of Notes Receivable Patent application costs Payments for Application Costs, Patent Payments for Application Costs, Patent Cash flows used in investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Proceeds from exercise of stock options Proceeds from Stock Options Exercised Stock repurchased for tax withholdings on vesting of restricted stock Payment, Tax Withholding, Share-based Payment Arrangement Repayment of term loan Repayments of Medium-term Notes Cash flows used in financing activities Net Cash Provided by (Used in) Financing Activities Net change in cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash and cash equivalents, beginning of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and cash equivalents, end of period Inventory Disclosure [Abstract] Inventory Schedule of Inventory, Current [Table Text Block] Goodwill and Intangible Assets Disclosure [Abstract] Schedule of Finite And Indefinite-Lived Intangible Assets [Table] Schedule of Finite And Indefinite-Lived Intangible Assets [Table] Schedule of Finite And Indefinite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Licenses Licensing Agreements [Member] Patents & Know How Patents [Member] Customer & Supplier Relationships Customer Relationships [Member] Non-compete agreements Noncompete Agreements [Member] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Tradenames & Trademarks Trademarks and Trade Names [Member] Patents in Process Patents in Process [Member] Patents in Process Schedule of Finite And Indefinite-Lived Intangible Assets [Line Items] Schedule of Finite And Indefinite-Lived Intangible Assets [Line Items] [Line Items] for Schedule of Finite And Indefinite-Lived Intangible Assets [Table] Gross carrying amount, amortized intangible assets Finite-Lived Intangible Assets, Gross Accumulated amortization, amortized intangible assets Finite-Lived Intangible Assets, Accumulated Amortization Net carrying amount, amortized intangible assets Finite-Lived Intangible Assets, Net Carrying amount, unamortized intangible assets Indefinite-lived Intangible Assets (Excluding Goodwill) Total Intangible Assets, Gross (Excluding Goodwill) Net Payables and Accruals [Abstract] Schedule of Accrued Expenses Schedule of Accrued Liabilities [Table Text Block] Subsequent Events [Abstract] Subsequent Events Subsequent Events [Text Block] Summary of Property and Equipment Property, Plant and Equipment [Table Text Block] Estimated Amortization Expense Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] 2020 (excluding the three months ended March 31, 2020) Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year 2021 Finite-Lived Intangible Assets, Amortization Expense, Year Two 2022 Finite-Lived Intangible Assets, Amortization Expense, Year Three 2023 Finite-Lived Intangible Assets, Amortization Expense, Year Four 2024 Finite-Lived Intangible Assets, Amortization Expense, Year Five Thereafter Finite-Lived Intangible Assets, Amortization Expense, after Year Five Debt Disclosure [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Scenario [Axis] Scenario [Axis] Scenario [Domain] Scenario [Domain] Forecast Forecast [Member] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Term Loan Notes Payable, Other Payables [Member] Senior secured term loan Senior Notes [Member] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] BT Loan Agreement Term Loan Agreement [Member] Term Loan Agreement [Member] Hayfin Loan Agreement Term Loan Hayfin Loan Agreement Term Loan [Member] Hayfin Loan Agreement Term Loan [Member] Hayfin Loan Agreement Delayed Draw Term Loan Hayfin Loan Agreement Delayed Draw Term Loan [Member] Hayfin Loan Agreement Delayed Draw Term Loan [Member] Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] LIBOR London Interbank Offered Rate (LIBOR) [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Face value of debt Debt Instrument, Face Amount Basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Minimum liquidity Debt Covenant, Minimum Liquidity Debt Covenant, Minimum Liquidity 2020 (excluding the three months ended March 31, 2020) Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year 2021 Lessee, Operating Lease, Liability, Payments, Due Year Two 2022 Lessee, Operating Lease, Liability, Payments, Due Year Three 2023 Lessee, Operating Lease, Liability, Payments, Due Year Four 2024 Lessee, Operating Lease, Liability, Payments, Due Year Five Thereafter Lessee, Operating Lease, Liability, Payments, Due after Year Five Total lease payments Lessee, Operating Lease, Liability, Payments, Due Less: imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Lease liabilities Operating Lease, Liability Product Revenue Detail Revenue from Contract with Customer [Text Block] Supplemental Cash Flow Elements [Abstract] Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities Cash Flow, Supplemental Disclosures [Text Block] Liquidity and Capital Resources [Abstract] Liquidity and Capital Resources [Abstract] Liquidity and Capital Resources Liquidity and Capital Resources [Text Block] Liquidity and Capital Resources [Text Block] Supplemental disclosure of cash flow and non-cash investing and financing activities [Abstract] Supplemental disclosure of cash flow and non cash investing and financing activities [Abstract] -- None. No documentation exists for this element. -- Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Income taxes paid Income Taxes Paid Current portion Debt, Current [Abstract] Liability component - principal Long-term Debt, Current Maturities, Gross Long-term Debt, Current Maturities, Gross Original issue discount Debt Instrument, Unamortized Discount, Current Deferred financing cost Debt Issuance Costs, Current, Net Liability component - net carrying value Long-term Long-term Debt, Excluding Current Maturities [Abstract] Liability component - principal Long-term Debt, Excluding Current Maturities, Gross Long-term Debt, Excluding Current Maturities, Gross Original issue discount Debt Instrument, Unamortized Discount, Noncurrent Deferred financing cost Debt Issuance Costs, Noncurrent, Net Liability component - net carrying value Right of use asset Short term lease liability Operating Lease, Liability, Current Long term lease liability Operating Lease, Liability, Noncurrent Weighted-average remaining lease term (years) Operating Lease, Weighted Average Remaining Lease Term Weighted-average discount rate Operating Lease, Weighted Average Discount Rate, Percent Interest expense - stated interest rate Interest Expense, Debt, Excluding Amortization Interest expense - amortization of original issue discount and costs Amortization of Debt Discount (Premium) Interest expense - amortization of deferred financing costs Amortization of Debt Issuance Costs Total term loan interest expense Interest Expense, Debt Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock Issued Common Stock [Member] Additional Paid-in Capital Additional Paid-in Capital [Member] Treasury Stock Treasury Stock [Member] Accumulated Deficit Retained Earnings [Member] Statement [Line Items] Statement [Line Items] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Balance (in shares) Shares, Outstanding Balance, beginning of period Share-based compensation expense Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture Exercise of stock options (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Issuance of restricted stock (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Gross Issuance of restricted stock Stock Issued During Period, Value, Restricted Stock Award, Gross Restricted stock shares canceled/forfeited Stock Issued During Period, Value, Restricted Stock Award, Forfeitures Restricted stock shares cancelled/forfeited (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Forfeited Shares repurchased for tax withholding (in shares) Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Shares repurchased for tax withholding Share-based Payment Arrangement, Decrease for Tax Withholding Obligation Balance (in shares) Balance, end of period Intangible Assets Intangible Assets Disclosure [Text Block] Net Sales by Customer Type Revenue from External Customers by Products and Services [Table Text Block] Accounting Policies [Abstract] Significant Accounting Policies Significant Accounting Policies [Text Block] Schedule of Debt Schedule of Debt [Table Text Block] Schedule of Interest Expense Schedule of Interest Expense [Table Text Block] Schedule of Interest Expense [Table Text Block] Future Principal Payments for the Term Loan Schedule of Maturities of Long-term Debt [Table Text Block] Computation of Basic and Diluted Net Income per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Stockholders' equity: Preferred stock par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized (in shares) Common Stock, Shares Authorized Common stock, shares issued (in shares) Common Stock, Shares, Issued Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Treasury stock, shares (in shares) Treasury Stock, Shares Subsequent Event [Table] Subsequent Event [Table] Statistical Measurement [Axis] Statistical Measurement [Axis] Statistical Measurement [Domain] Statistical Measurement [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Hayfin Loan Agreement Hayfin Loan Agreement [Member] Hayfin Loan Agreement [Member] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Series B Convertible Preferred Stock Series B Preferred Stock [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] Total current assets Total current liabilities Stock issued during period Stock Issued During Period, Value, New Issues Proceeds from issuance of convertible preferred stock Proceeds from Issuance of Convertible Preferred Stock Repayment of principal Repayments of Debt Accrued interest paid Interest Paid, Including Capitalized Interest Interest Paid, Including Capitalized Interest Prepayment of premium paid Payment for Debt Extinguishment or Debt Prepayment Cost Floor interest rate (percent) Debt Instrument, Floor Interest Rate Debt Instrument, Floor Interest Rate Basis spread on variable rate, based on total net leverage levels (percent) Debt Instrument, Basis Spread on Variable Rate, Based on Total Net Leverage Levels Debt Instrument, Basis Spread on Variable Rate, Based on Total Net Leverage Levels Upfront commitment fee (percent) Line of Credit Facility, Commitment Fee Percentage Commitment fee on undrawn amounts (percent) Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Total net leverage ratio Total Net Leverage Ratio Total Net Leverage Ratio Cap on cash netting for calculation of Total Net Leverage Debt Covenant, Cap on Cash Netting Debt Covenant, Cap on Cash Netting Income Statement [Abstract] Cost of sales Cost of Goods and Services Sold Gross profit Gross Profit Operating expenses: Operating Expenses [Abstract] Selling, general and administrative Selling, General and Administrative Expense Investigation, restatement and related Investigation, Restatement and Related Investigation, Restatement and Related Research and development Research and Development Expense Impairment of intangible asset Asset Impairment Charges Operating loss Operating Income (Loss) Other income (expense), net Nonoperating Income (Expense) [Abstract] Interest (expense) income, net Interest Income (Expense), Net Other income (expense), net Other Nonoperating Income (Expense) Loss before income tax provision Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Income tax provision benefit (expense) Income Tax Expense (Benefit) Net loss Net loss per common share - basic (in dollars per share) Earnings Per Share, Basic Net loss per common share - diluted (in dollars per share) Earnings Per Share, Diluted Weighted average shares outstanding - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Weighted average shares outstanding - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Number of business segments Number of Operating Segments Federal income tax receivable Income Taxes Receivable Leases Lessee, Operating Leases [Text Block] Assessment of Revenue under ASC 606 Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block] 2020 (excluding the three months ended March 31, 2020) Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year 2021 Long-term Debt, Maturities, Repayments of Principal in Year Two 2022 Long-term Debt, Maturities, Repayments of Principal in Year Three 2023 Long-term Debt, Maturities, Repayments of Principal in Year Four 2024 Long-term Debt, Maturities, Repayments of Principal in Year Five Thereafter Long-term Debt, Maturities, Repayments of Principal after Year Five Total Long Term Debt Long-term Debt Legal costs Accrued Professional Fees Settlement costs Accrued Settlement Costs, Current Accrued Settlement Costs, Current Pricing adjustment settlement with Veterans Affairs Loss Contingency, Accrual, Current Estimated returns Contract with Customer, Refund Liability, Current External commissions Accrued Sales Commission, Current Accrued clinical trials Accrued Clinical Trials, Current Accrued Clinical Trials, Current Other Other Accrued Liabilities, Current Total Income Tax Disclosure [Abstract] Income Tax Contingency [Table] Income Tax Contingency [Table] Income Tax Contingency [Line Items] Income Tax Contingency [Line Items] Effective tax rate Effective Income Tax Rate Reconciliation, Percent Effective income tax rate reconciliation, discrete items Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount Tax benefit recognized with respect to net operating losses Effective Income Tax Rate Reconciliation, Net Operating Loss Carryforward Effective Income Tax Rate Reconciliation, Net Operating Loss Carryforward Inventory Inventory Disclosure [Text Block] Raw materials Inventory, Raw Materials, Gross Work in process Inventory, Work in Process, Gross Finished goods Inventory, Finished Goods, Gross Inventory, gross Inventory, Gross Reserve for obsolescence Inventory Valuation Reserves Inventory, net Concentration Risk [Table] Concentration Risk [Table] Patents Concentration Risk [Line Items] Concentration Risk [Line Items] Amounts Invoiced and Not Collected, After Transition Adjustment Amounts Invoiced and Not Collected, After Transition Adjustment Amounts Invoiced and Not Collected, After Transition Adjustment Typical payment period for customers Typical Payment Period for Customers Typical Payment Period for Customers Deferred Cost of Sales, After Transition Adjustment Deferred Cost of Sales, After Transition Adjustment Deferred Cost of Sales, After Transition Adjustment Deferred cost of sales Contract with Customer, Asset, Net, Current GPO administrative fees as percent of purchase volume Group Purchasing Organization Administrative Fees as Percent of Purchase Volume Group Purchasing Organization Administrative Fees as Percent of Purchase Volume Intangible assets, net of accumulated amortization Finite-Lived Intangible Assets, Period Increase (Decrease) Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Segment Reporting Segment Reporting, Policy [Policy Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Principles of Consolidation Consolidation, Policy [Policy Text Block] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Accounts Receivable and Notes Receivable Receivable [Policy Text Block] Inventories Inventory, Policy [Policy Text Block] Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Leases Lessee, Leases [Policy Text Block] Patent Costs Legal Costs, Policy [Policy Text Block] Treasury Stock Stockholders' Equity, Policy [Policy Text Block] Recently Issued and Adopted Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] Income Taxes Income Tax Disclosure [Text Block] Quarterly installments Debt Instrument, Periodic Payment Original issue discount Debt Instrument, Unamortized Discount Deferred financing costs Debt Issuance Costs, Gross Stated interest rate (percent) Debt Instrument, Interest Rate, Stated Percentage Total leverage ratio Debt Covenant, Total Leverage Ratio Debt Covenant, Total Leverage Ratio Prepayment penalty as percent of prepaid principal Debt Instrument, Prepayment Penalty as Percent of Prepaid Principal, Percent Debt Instrument, Prepayment Penalty as Percent of Prepaid Principal, Percent Fair value of term loan Long-term Debt, Fair Value Loss Contingencies Loss Contingencies [Table] Title of Individual [Axis] Title of Individual [Axis] Title of Individual [Domain] Title of Individual [Domain] Former Chief Financial Officer Chief Financial Officer [Member] Litigation Case [Axis] Litigation Case [Axis] Litigation Case [Domain] Litigation Case [Domain] Shareholder Derivative Suits Shareholder Derivative Suits [Member] Shareholder Derivative Suits [Member] Securities Class Action Securities Class Action [Member] Securities Class Action [Member] Department of Veterans' Affairs Office of the Inspector General's Investigation Department of Veterans' Affairs Office of the Inspector General's Investigation [Member] Department of Veterans' Affairs Office of the Inspector General's Investigation [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Lease expiration period Lessee, Operating Lease, Term of Contract Rent expense Lease, Cost Severance costs Severance Costs Number of shareholder derivative actions Number of Shareholder Derivative Actions Number of Shareholder Derivative Actions Estimated litigation liability Estimated Litigation Liability Number of class actions Number of Class Actions Number of Class Actions Payments for legal settlements Payments for Legal Settlements Number of former VA employees Number of Former VA Employees Number of Former VA Employees Prosecution deferral period Loss Contingency, Prosecution Deferral Period Loss Contingency, Prosecution Deferral Period Number of former VA employees who completed the pretrial diversion program Number of Former VA Employees Who Completed Pretrial Diversion Program Number of Former VA Employees Who Completed Pretrial Diversion Program Cover [Abstract] Document Type Document Quarterly Report Document Quarterly Report Document Period End Date Document Transition Report Document Transition Report Entity File Number Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Shell Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Central Index Key Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Amendment Flag Operating lease cost Operating Lease, Cost Interest on lease obligations Operating Lease Liability, Interest Expense Operating Lease Liability, Interest Expense Cash paid for amounts included in the measurement of operating lease liabilities Operating Lease, Payments, Use Amortization of right of use assets Computation of basic and diluted net loss per share [Abstract] Computation of basic and diluted net loss per share [Abstract] -- None. No documentation exists for this element. -- Net loss Denominator for basic earnings per share - weighted average shares (in shares) Effect of dilutive securities: Stock options, restricted stock, and warrants outstanding (in shares) Weighted Average Number Diluted Shares Outstanding Adjustment Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities (in shares) Loss per common share - basic (in dollars per share) Loss per common share - diluted (in dollars per share) Summary of Antidilutive Securities [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Outstanding Stock Options Share-based Payment Arrangement, Option [Member] Performance Based Awards Performance Shares [Member] Restricted Stock Awards Restricted Stock [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Leasehold improvements Leasehold Improvements [Member] Lab and clean room equipment Equipment [Member] Furniture and office equipment Furniture and Fixtures [Member] Construction in progress Construction in Progress [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Property and equipment, gross Property, Plant and Equipment, Gross Less accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property and equipment, net Amended Term Loan Agreement Amended Term Loan Agreement [Member] Amended Term Loan Agreement [Member] Paycheck Protection Program Loan Paycheck Protection Program Loan [Member] Paycheck Protection Program Loan [Member] Increase in interest rate (percent) Debt Instrument, Interest Rate, Increase (Decrease) Operating lease, impairment loss Operating Lease, Impairment Loss Intangible Assets Activity Summary - Finite Lived Schedule of Finite-Lived Intangible Assets [Table Text Block] Intangible Assets Activity Summary - Indefinite Lived Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Estimated Future Amortization Expense for Intangible Assets Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Long Term Debt Debt Disclosure [Text Block] Accounts Receivable, Net [Roll Forward] Accounts Receivable, Net [Roll Forward] Accounts Receivable, Net [Roll Forward] Amounts Invoiced and Not Collected, beginning Proceeds from Sale and Collection of Receivables Proceeds from Sale and Collection of Receivables Amounts Invoiced and Not Collected, ending Deferred Cost of Sales [Roll Forward] Deferred Cost of Sales [Roll Forward] Deferred Cost of Sales [Roll Forward] Deferred Cost of Sales, beginning Deferred Cost of Sales, Cash Collected Deferred Cost of Sales, Cash Collected Deferred Cost of Sales, Cash Collected Deferred Cost of Sales, ending Amounts Invoiced and Not Collected, Write-off of Deferred Costs for Customer Contracts where Collection is no Longer Reasonable Assured Amounts Invoiced and Not Collected, Write-off of Deferred Costs for Customer Contracts where Collection is no Longer Reasonable Assured Amounts Invoiced and Not Collected, Write-off of Deferred Costs for Customer Contracts where Collection is no Longer Reasonable Assured Accounts Expenses Accounts Payable and Accrued Liabilities Disclosure [Text Block] New Accounting Pronouncements or Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Table] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] ASU No. 2016-02 Accounting Standards Update 2016-02 [Member] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Lease liability Effect on opening retained earnings Cumulative Effect on Retained Earnings, Net of Tax EX-101.PRE 11 mdxg-20200331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 12 a201910kex33articleso_image1.gif begin 644 a201910kex33articleso_image1.gif M1TE&.#EA^0!H /, "4E)3P\/%%146-C8W1T=(6%A924E*.CH[&QL;^_ MO\S,S-G9V>;FYO/S\____RP ^0!H $,(_P ?"!Q(L*#!@P@3*ES(L*'# MAQ C2IQ(L:+%BQ@S:MS(L:-#!@!"%G! D$!( P<%A$10< " 1YCRIQ)LV9$ M!R$!D$2X(&0 A Y,YEQ@LZC1HT@WN@1P@& #E0 $["08DD#!IR&)7GTY$"< MK4G#BAU+MF*"D 6]@BW+MJW;MPP;Y&1P4 $ !0=SYD4+]Z#F9E^D5*9.:?G9X6)QB_?450DN1F"B##1S@ MZ*..BNGG PXDX"B>9'4XX58AU9A0;T%.*BIL"!0PP %)-"G0 TH<("IIZ;_ MNBI!@(YJ:X.UWJKKKKSVZNNO AXPXVTC)60= MQNRU$G7X[$'#2CG:IMB&^]"-VQHTK*1 0063N.PN=&.9:0V[J:L("96> E ) M@&Z[RP*'H[Z,#8OC (1&^R)B_";L),*V4:OPPQ:I19!=,4)L<47"5D7HQ1S' MQ.27 \VX;D$=AC?0C5FN][%P(L.W4D$H=^Q73K,>U)C) S56+F2&UFS0S3]7 MM9%Y "C86(@0-C;R0W8-F>QZ2DO4-++*8F3>L""7N"A$YBT]TY-0XKAQ=08W MU'58>NK)(E0$D,? D],1'5%\IZD$;E)LNPVW07)#_W06O _8_1N6??*II8&> M,H3@@+FVV%A:9;.U5-8/7,TW:09QA[1ZC;.8(D'F57V45T5_2"5!-P;@\WIT MVOI78"!Y31:H"I%K[+0 J"XSNYHB9.C8!'4(_.Z[3FV @0@(K"#1!2A@8,8 M;/Z J41U3OSU!UF/_?9DW\T]]P[,N//WY)=O_OGHIZ_^^J(R@$"DB0.U *0+ MK,Y^B0PL=X !6*?7P+ !,,#^!'8_486/2%TQS,00V"4 *Z GAL/HDXWD*U! M\%:&BE\%R\:9X5VP1%#95T%HUIS1/.V#1>I-Q0PR+>D-9&JE0R&+>L<3$BXD M@S(\$0W'),&&""^')K*<0?^$(CN7Q.\OLCO82)SC0B!^AF@"<-2.@L-#GPCP M $MQS)NT.) +C<^)UV& I0Z0 VF90%C)*,9*\>PWJP1C+<2U @=!D=?R9$J M=*PCKWKC&3[J$5@JP=EQ'OA'7EUHB1<282$7R<@%.0 !67R)K.;(HP 0P(.0 M>60D4:4J2N+(DICD&),JF0[?L 09R#/O,+@W22VC%,('!I(@#!B"Z%S6104PBY$+,LS/2J>PD$:%F MU+EA@PE$:^,3(S*6UC8 M> 3_/'K>!',"P>=<8J(GPU5DGPA-J$)3Z:&Y5;)Y_-GA0\"&'(C6!(KV8USD M&,)- 5GP(1TUBI<(QZ*/-N1&WFN(\QQ"T80"SZ0,0>E$7'4 ))F-I ?KC(FB MIJ*[<"LD&675CE):%)Z"CH($&590 Q=#/PY.IP4QJ(88(+!_E7 H7-N)]HI" M5:===:,)4HQ&6I3X-CT.HK-$&,;QE>: M,*F)%2K).2&460B%CC?)%$O,PEHVTCDV0*6%T"%%^]:C?O3P('WCF\ B2YU& MB68U9&S?28Y#1;<8=4J"70BHQME(ZDCT2K5L"$R;NY[G;C!Z5R$4D]9HG-I2 M-RG=*@CN%*16@K#I9P(CZG?%PAEBI>='//+>5&*[WA/1M[Y::RA^=W7?_6:H ;O_Y]$( #+"#@1#(YTB2P@A?,X 8[N",! 0 [ end GRAPHIC 13 a201910kex33articleso_image2.gif begin 644 a201910kex33articleso_image2.gif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end XML 14 mdxg-2020331x10xq_htm.xml IDEA: XBRL DOCUMENT 0001376339 2020-01-01 2020-03-31 0001376339 2020-06-25 0001376339 2019-12-31 0001376339 2020-03-31 0001376339 2019-01-01 2019-03-31 0001376339 us-gaap:TreasuryStockMember 2019-01-01 2019-03-31 0001376339 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001376339 us-gaap:TreasuryStockMember 2018-12-31 0001376339 us-gaap:CommonStockMember 2019-03-31 0001376339 us-gaap:TreasuryStockMember 2019-03-31 0001376339 us-gaap:RetainedEarningsMember 2019-03-31 0001376339 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001376339 2019-03-31 0001376339 us-gaap:CommonStockMember 2018-12-31 0001376339 us-gaap:RetainedEarningsMember 2018-12-31 0001376339 2018-12-31 0001376339 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001376339 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001376339 us-gaap:TreasuryStockMember 2020-01-01 2020-03-31 0001376339 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001376339 us-gaap:TreasuryStockMember 2019-12-31 0001376339 us-gaap:CommonStockMember 2019-12-31 0001376339 us-gaap:TreasuryStockMember 2020-03-31 0001376339 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001376339 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001376339 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001376339 us-gaap:CommonStockMember 2020-03-31 0001376339 us-gaap:RetainedEarningsMember 2019-12-31 0001376339 us-gaap:RetainedEarningsMember 2020-03-31 0001376339 srt:MaximumMember 2020-01-01 2020-03-31 0001376339 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0001376339 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 2019-01-01 0001376339 srt:MinimumMember 2020-01-01 2020-03-31 0001376339 us-gaap:PatentsMember 2020-01-01 2020-03-31 0001376339 2019-07-01 2019-09-30 0001376339 us-gaap:PatentsMember 2019-01-01 2019-03-31 0001376339 srt:ScenarioForecastMember mdxg:HayfinLoanAgreementMember us-gaap:SeniorNotesMember 2021-01-01 2021-06-30 0001376339 srt:ScenarioForecastMember mdxg:HayfinLoanAgreementMember us-gaap:SeniorNotesMember 2021-07-01 2025-06-29 0001376339 mdxg:HayfinLoanAgreementMember us-gaap:SeniorNotesMember us-gaap:SubsequentEventMember 2020-07-02 2020-07-02 0001376339 srt:ScenarioForecastMember mdxg:HayfinLoanAgreementMember us-gaap:SeniorNotesMember 2020-07-02 2020-12-31 0001376339 mdxg:HayfinLoanAgreementTermLoanMember us-gaap:SeniorNotesMember us-gaap:SubsequentEventMember 2020-07-02 0001376339 mdxg:TermLoanAgreementMember us-gaap:NotesPayableOtherPayablesMember us-gaap:SubsequentEventMember 2020-07-02 2020-07-02 0001376339 srt:MaximumMember mdxg:HayfinLoanAgreementMember us-gaap:SeniorNotesMember us-gaap:SubsequentEventMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-07-02 2020-07-02 0001376339 mdxg:HayfinLoanAgreementMember us-gaap:SeniorNotesMember us-gaap:SubsequentEventMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-07-02 0001376339 mdxg:HayfinLoanAgreementDelayedDrawTermLoanMember us-gaap:NotesPayableOtherPayablesMember us-gaap:SubsequentEventMember 2020-07-02 2020-07-02 0001376339 us-gaap:SeriesBPreferredStockMember us-gaap:SubsequentEventMember 2020-07-02 0001376339 srt:MinimumMember mdxg:HayfinLoanAgreementMember us-gaap:SeniorNotesMember us-gaap:SubsequentEventMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-07-02 2020-07-02 0001376339 mdxg:HayfinLoanAgreementDelayedDrawTermLoanMember us-gaap:NotesPayableOtherPayablesMember us-gaap:SubsequentEventMember 2020-07-02 0001376339 us-gaap:SeriesBPreferredStockMember us-gaap:SubsequentEventMember 2020-07-02 2020-07-02 0001376339 mdxg:HayfinLoanAgreementMember us-gaap:SeniorNotesMember us-gaap:SubsequentEventMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-07-02 2020-07-02 0001376339 us-gaap:EquipmentMember 2020-03-31 0001376339 us-gaap:FurnitureAndFixturesMember 2019-12-31 0001376339 us-gaap:ConstructionInProgressMember 2020-03-31 0001376339 us-gaap:LeaseholdImprovementsMember 2019-12-31 0001376339 us-gaap:EquipmentMember 2019-12-31 0001376339 us-gaap:LeaseholdImprovementsMember 2020-03-31 0001376339 us-gaap:FurnitureAndFixturesMember 2020-03-31 0001376339 us-gaap:ConstructionInProgressMember 2019-12-31 0001376339 us-gaap:CustomerRelationshipsMember 2020-03-31 0001376339 us-gaap:NoncompeteAgreementsMember 2019-12-31 0001376339 us-gaap:NoncompeteAgreementsMember 2020-03-31 0001376339 mdxg:PatentsinProcessMember 2019-12-31 0001376339 us-gaap:TrademarksAndTradeNamesMember 2020-03-31 0001376339 us-gaap:TrademarksAndTradeNamesMember 2019-12-31 0001376339 us-gaap:CustomerRelationshipsMember 2019-12-31 0001376339 us-gaap:PatentsMember 2019-12-31 0001376339 mdxg:PatentsinProcessMember 2020-03-31 0001376339 us-gaap:LicensingAgreementsMember 2019-12-31 0001376339 us-gaap:LicensingAgreementsMember 2020-03-31 0001376339 us-gaap:PatentsMember 2020-03-31 0001376339 srt:ScenarioForecastMember mdxg:TermLoanAgreementMember us-gaap:NotesPayableOtherPayablesMember 2021-01-01 2022-06-20 0001376339 mdxg:TermLoanAgreementMember us-gaap:NotesPayableOtherPayablesMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-01-01 2020-03-31 0001376339 srt:ScenarioForecastMember mdxg:TermLoanAgreementMember us-gaap:NotesPayableOtherPayablesMember 2019-06-10 2020-05-31 0001376339 srt:ScenarioForecastMember mdxg:TermLoanAgreementMember us-gaap:NotesPayableOtherPayablesMember 2020-06-01 2020-12-30 0001376339 mdxg:TermLoanAgreementMember us-gaap:NotesPayableOtherPayablesMember 2020-03-31 0001376339 srt:ScenarioForecastMember mdxg:TermLoanAgreementMember us-gaap:NotesPayableOtherPayablesMember 2020-12-31 0001376339 mdxg:TermLoanAgreementMember us-gaap:NotesPayableOtherPayablesMember 2019-06-10 0001376339 srt:ScenarioForecastMember mdxg:TermLoanAgreementMember us-gaap:NotesPayableOtherPayablesMember 2020-06-11 2021-06-10 0001376339 mdxg:TermLoanAgreementMember us-gaap:NotesPayableOtherPayablesMember 2019-06-10 2019-06-10 0001376339 srt:ScenarioForecastMember mdxg:TermLoanAgreementMember us-gaap:NotesPayableOtherPayablesMember 2019-06-10 2020-06-10 0001376339 mdxg:TermLoanAgreementMember us-gaap:NotesPayableOtherPayablesMember 2020-01-01 2020-03-31 0001376339 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001376339 us-gaap:RestrictedStockMember 2019-01-01 2019-03-31 0001376339 us-gaap:RestrictedStockMember 2020-01-01 2020-03-31 0001376339 us-gaap:PerformanceSharesMember 2019-01-01 2019-03-31 0001376339 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-03-31 0001376339 us-gaap:PerformanceSharesMember 2020-01-01 2020-03-31 0001376339 srt:ScenarioForecastMember 2020-01-01 2020-12-31 0001376339 mdxg:DepartmentofVeteransAffairsOfficeoftheInspectorGeneralsInvestigationMember 2020-01-01 2020-03-31 0001376339 mdxg:DepartmentofVeteransAffairsOfficeoftheInspectorGeneralsInvestigationMember 2019-01-01 2019-01-31 0001376339 srt:MinimumMember 2020-03-31 0001376339 mdxg:SecuritiesClassActionMember 2019-01-16 2019-01-16 0001376339 srt:MaximumMember 2020-03-31 0001376339 mdxg:DepartmentofVeteransAffairsOfficeoftheInspectorGeneralsInvestigationMember 2018-05-01 2018-05-31 0001376339 srt:ChiefFinancialOfficerMember us-gaap:SubsequentEventMember 2020-01-01 2020-06-30 0001376339 mdxg:ShareholderDerivativeSuitsMember 2018-12-06 0001376339 mdxg:DirectCustomersMember 2020-01-01 2020-03-31 0001376339 mdxg:DistributorsMember 2020-01-01 2020-03-31 0001376339 mdxg:DistributorsMember 2019-01-01 2019-03-31 0001376339 mdxg:DirectCustomersMember 2019-01-01 2019-03-31 0001376339 srt:ScenarioForecastMember mdxg:TermLoanAgreementMember us-gaap:NotesPayableOtherPayablesMember 2020-04-01 2020-05-31 0001376339 mdxg:AmendedTermLoanAgreementMember us-gaap:NotesPayableOtherPayablesMember us-gaap:SubsequentEventMember 2020-04-22 0001376339 srt:ScenarioForecastMember mdxg:TermLoanAgreementMember us-gaap:NotesPayableOtherPayablesMember 2020-06-01 2020-11-30 0001376339 mdxg:AmendedTermLoanAgreementMember us-gaap:SubsequentEventMember 2020-04-22 0001376339 us-gaap:SubsequentEventMember 2020-04-01 2020-04-01 0001376339 mdxg:PaycheckProtectionProgramLoanMember 2020-03-27 0001376339 srt:ScenarioForecastMember mdxg:AmendedTermLoanAgreementMember us-gaap:NotesPayableOtherPayablesMember 2020-04-01 2020-05-31 0001376339 mdxg:TermLoanAgreementMember us-gaap:SubsequentEventMember 2020-04-22 0001376339 srt:ScenarioForecastMember mdxg:AmendedTermLoanAgreementMember us-gaap:NotesPayableOtherPayablesMember 2020-06-01 2020-11-30 0001376339 mdxg:AmendedTermLoanAgreementMember us-gaap:NotesPayableOtherPayablesMember us-gaap:SubsequentEventMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-04-22 2020-04-22 mdxg:former_employee iso4217:USD shares pure mdxg:segment iso4217:USD mdxg:lawsuit mdxg:distribution_channel shares false --12-31 Q1 2020 1775 West Oak Commons Ct NE Marietta GA 0001376339 false Accelerated Filer false 0.001 0.001 150000000 150000000 112703926 112703926 110818649 110540860 0.001 0.001 5000000 5000000 0 0 0 0 1885277 2163066 10-Q true 2020-03-31 false 001-35887 MIMEDX GROUP, INC. FL 26-2792552 30062 770 651-9100 No No false 110328875 53525000 69069000 31932000 32327000 9247000 9104000 5239000 6669000 10729000 18000 5216000 6058000 115888000 123245000 11833000 12328000 3158000 3397000 19976000 19976000 7581000 7777000 473000 443000 158909000 167166000 9756000 8710000 17116000 21302000 30661000 32161000 3750000 3750000 2416000 1399000 63699000 67322000 61637000 61906000 3234000 3540000 128570000 132768000 0 0 113000 113000 149765000 147231000 12578000 10806000 -106961000 -102140000 30339000 34398000 158909000 167166000 61736000 66555000 10025000 7418000 51711000 59137000 46942000 50862000 15592000 18107000 2650000 2902000 271000 233000 0 446000 -13744000 -13413000 -2387000 211000 6000 -29000 -16125000 -13231000 -11304000 42000 -4821000 -13273000 -0.04 -0.12 -0.04 -0.12 107538509 106420317 107538509 106420317 112703926 113000 147231000 1885277 -10806000 -102140000 34398000 1915000 1915000 -1214000 170300 1512000 298000 -1746000 242998 1746000 0 -87000 205091 1538000 1451000 -4821000 -4821000 112703926 113000 149765000 2163066 -12578000 -106961000 30339000 112703926 113000 164744000 3605263 -38642000 -76560000 49655000 3014000 3014000 -3025000 251305 3025000 0 -1563000 141381 1563000 0 336674 1044000 1044000 -13273000 -13273000 112703926 113000 166296000 3832013 -38224000 -89833000 38352000 -4821000 -13273000 3349000 3014000 1506000 1695000 271000 233000 668000 0 239000 269000 0 -1000 0 1258000 -395000 0 143000 442000 -1430000 -2053000 10711000 12000 -812000 1612000 1046000 -4173000 -4186000 -7501000 -2845000 3895000 0 0 709000 -665000 -12281000 -15260000 1011000 648000 0 389000 75000 174000 -1086000 -433000 298000 0 1538000 1044000 937000 0 -2177000 -1044000 -15544000 -16737000 69069000 45118000 53525000 28381000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;">Nature of Business</span></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">MiMedx Group, Inc. (together with its subsidiaries except where the context otherwise requires “</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">MiMedx</span><span style="font-family:inherit;font-size:10pt;">,” or the “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Company</span><span style="font-family:inherit;font-size:10pt;">”) is an advanced wound care and emerging therapeutic biologics company, developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. The Company derives its products from human placental tissues processed using proprietary processing methodologies. The Company’s mission is to offer physicians products and tissues to help the body heal itself. MiMedx provides products in the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic and dental sectors of healthcare. All of the Company’s products are regulated by the United States Food and Drug Administration (“</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">FDA</span><span style="font-family:inherit;font-size:10pt;">”). </span></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">MiMedx is the leading supplier of human placental allografts, which are human tissues that are transplanted from one person (a donor) to another person (a recipient). The Company operates in </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> business segment, Regenerative Biomaterials, which includes the design, manufacture, and marketing of products for the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic and dental sectors of healthcare. The Company’s allograft product families include: the dHACM family with AmnioFix® and EpiFix® brands; the Umbilical family with EpiCord® and AmnioCord® brands; and the Placental Collagen family with AmnioFill™ brands. AmnioFix and EpiFix are tissue allografts derived from amnion and chorion layers of human placental membrane; EpiCord and AmnioCord are tissue allografts derived from umbilical cord tissue. AmnioFill is a placental connective tissue matrix, derived from the placental disc and other placental tissue.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s business model is focused primarily on the United States of America but the Company is exploring potential future international expansion opportunities.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Effect of COVID-19 Pandemic</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The COVID-19 pandemic and governmental and societal responses thereto have affected the Company’s business, results of operations and financial condition. The continuation or additional waves of the outbreak of COVID-19 or the outbreak of other health epidemics could harm the Company’s operations and increase the Company’s costs and expenses in numerous ways. The ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change. The Company does not yet know the full extent of delays or impacts on the business, clinical trials, healthcare systems or the global economy as a whole, or how long such effects will endure. The effects of the COVID-19 pandemic or other health epidemics could have an adverse impact on the Company’s business, results of operations and financial condition. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On March 27, 2020, the Coronavirus Aid, Relief and Economic Security Act (the “</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">CARES Act</span><span style="font-family:inherit;font-size:10pt;">”) was signed into law. The CARES Act includes provisions relating to refundable payroll tax credits, deferment of the employer portion of certain payroll taxes, loans and grants to certain business, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. As a result of the CARES Act, the Company expects a federal tax refund of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$11.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> and has recognized an income tax benefit of the same amount.</span></div> The Company operates in <span style="font-family:inherit;font-size:10pt;"><span>one</span></span> business segment, 1 11300000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;">Significant Accounting Policies</span></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Please see Note 3 to the Company’s Consolidated Financial Statements included in the Company’s Form 10-K for the fiscal year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> (the “</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">2019 Form 10-K</span><span style="font-family:inherit;font-size:10pt;">”), filed with the Securities and Exchange Commission (“</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">SEC</span><span style="font-family:inherit;font-size:10pt;">”) on </span><span style="font-family:inherit;font-size:10pt;">July 6, 2020</span><span style="font-family:inherit;font-size:10pt;"> for a description of all significant accounting policies. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Basis of Presentation</span></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">GAAP</span><span style="font-family:inherit;font-size:10pt;">”) from interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.  Changes to GAAP are established by the Financial Accounting Standards Board (“</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">FASB</span><span style="font-family:inherit;font-size:10pt;">”) in the form of Accounting Standards Updates (“</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">ASU</span><span style="font-family:inherit;font-size:10pt;">’’) to the FASB’s Accounting Standards Codification (“</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">ASC</span><span style="font-family:inherit;font-size:10pt;">”).  In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the results of operations for the periods presented have been included.  Operating results for the </span><span style="font-family:inherit;font-size:10pt;">three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, are not necessarily indicative of the results that may be expected for the fiscal year.  The balance sheet at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, has been derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements. </span></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">You should read these condensed consolidated financial statements together with the historical consolidated financial statements of the Company for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, included in the 2019 Form 10-K.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Use of Estimates</span></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The consolidated financial statements have been prepared in accordance with GAAP. Conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported consolidated statements of operations during the reporting period. Actual results could differ from those estimates. Significant estimates include estimated useful lives and potential impairment of property and equipment and intangible assets, estimates for contingent liabilities, management’s assessment of the Company’s ability to continue as a going concern, estimates of fair value of share-based payments and valuation of deferred tax assets.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Principles of Consolidation</span></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The consolidated financial statements include the accounts of MiMedx Group, Inc. and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Cash and Cash Equivalents</span></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents include cash and Federal Deposit Insurance Corporation (“</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">FDIC</span><span style="font-family:inherit;font-size:10pt;">”) insured certificates of deposit held at various banks with an original maturity of three months or less.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounts Receivable</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing receivables. The Company determines the allowance based on factors such as historical collection experience, customers’ current creditworthiness, customer concentrations, age of accounts receivable and general economic conditions that may affect customers’ ability to pay.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Notes Receivable</span></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Notes receivable represent formal payment agreements with customers which generally arise in situations where amounts shipped and billed have aged significantly as well as the promissory note issued by Stability Biologics, LLC (“</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Stability</span><span style="font-family:inherit;font-size:10pt;">”) as part of the divestiture of Stability in 2017. The promissory note from Stability was paid in full in the three months ended September 30, 2019. The Company’s notes receivable are included in other current and long-term assets in the accompanying condensed consolidated balance sheets and were valued taking into consideration cost of the market participant inputs, market conditions, liquidity, operating results and other qualitative factors.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Inventories</span></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories are valued at the lower of cost or net realizable value, using the first-in, first-out (“</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">FIFO</span><span style="font-family:inherit;font-size:10pt;">”) method.  Inventory is tracked through raw material, work-in-process, and finished good stages as the product progresses through various production steps and stocking locations. Labor and overhead costs are absorbed through the various production processes until the work order closes. Historical yields and normal capacities are utilized in the calculation of production overhead rates. Reserves for inventory obsolescence are utilized to account for slow-moving inventory as well as inventory no longer needed due to diminished market demand.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Revenue Recognition</span></div><div style="line-height:120%;padding-bottom:13px;padding-top:17px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company sells its products primarily to individual customers and independent distributors (collectively referred to as “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">customers</span><span style="font-family:inherit;font-size:10pt;">”). During the three months ended March 31, 2019, the Company’s control environment was such that it created uncertainty surrounding all of its customer arrangements, which required consideration related to the proper revenue recognition under the applicable literature. The control environment allowed for the existence of extra-contractual or undocumented terms or arrangements initiated by or agreed to by the Company and former members of Company management at the outset of the transactions (side agreements). Concessions were also agreed to subsequent to the initial sale (e.g. sales above established customer credit limits extended and unusually long payment terms, return or exchange rights, and contingent payment obligations) that called into question the ability to recognize revenue at the time that product was shipped to a customer. The applicable revenue </span></div><div style="line-height:120%;padding-bottom:13px;padding-top:17px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">recognition guidance also changed beginning January 1, 2018, which further impacted the Company’s revenue recognition methodology.</span></div><div style="line-height:120%;padding-bottom:13px;padding-top:17px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result, the Company’s application of the applicable revenue recognition guidance varies for the three months ended March 31, 2020 and 2019. Additionally, the Company changed its pattern of revenue recognition effective October 1, 2019. The application of the relevant revenue recognition guidance and the pattern of revenue recognition are further discussed below for each period presented. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Three Months Ended March 31, 2019</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company follows ASC Topic 606, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (“</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">ASC 606”</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">)</span><span style="font-family:inherit;font-size:10pt;"> which establishes principles for reporting information about the nature, amount, timing and uncertainty of revenue and cash flows arising from the entity’s contracts to provide goods or services to customers. The core principle requires an entity to recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration that it expects to be entitled to receive in exchange for those goods or services recognized as performance obligations are satisfied. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ASC 606 establishes a five-step model for revenue recognition. The first of these steps requires the identification of the contract as described in ASC 606-10-25-1. The specific criteria (the “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Step 1 Criteria</span><span style="font-family:inherit;font-size:10pt;">”) to this determination are as follows:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The parties to the contract have approved the contract (in writing, orally, or in accordance with other customary business practices) and are committed to perform their respective obligations;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The entity can identify each party’s rights regarding the goods or services to be transferred; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The entity can identify the payment terms for the goods or services to be transferred.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The contract has commercial substance.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">It is probable that the entity will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the three months ended March 31, 2019, the Company concluded that the first three of the above criteria were not met upon shipment of product to the customer, the fourth criterion had been met, and the Company acknowledges that there is a degree of uncertainty as to whether the last criterion above had been met. Although the parties to the contract may have approved the contract and purchase orders in writing, the Company concluded that upon shipment of products to the customer there is not sufficient evidence that its customers were committed to perform their obligations defined in the contract due to the existence of extra-contractual or undocumented terms or arrangements (e.g., regarding payment terms, right of return, etc.).</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s inability to fulfill these criteria was due to uncertainties of contractual adjustments with customers created by a combination of an inappropriate tone at the top and extra-contractual arrangements. Consequently, the Company concluded that it did not meet the Step 1 Criteria upon shipment of the product. Subsequent to the shipment of product, uncertainties surrounding contractual adjustment were not resolved until either: (1) the customer returned the product prior to payment; or (2) the Company received payment from the customer. At that point, the Company determined that an accounting contract existed and the performance obligations of the Company to deliver product and the customer to pay for the product were satisfied. The Company determined the transaction price of its contracts to equal the amount of consideration received from customers less the amount expected to be refunded or credited to customers, which is recognized as a refund liability that is updated at the end of each reporting period for changes in circumstances. The refund liability is included within accrued expenses in the consolidated balance sheet.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Transition and the Three Months Ended March 31, 2020</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company continued to assess contracts, new and existing, throughout 2019 to determine if the Step 1 Criteria noted above for the determination of a contract under ASC 606 were met for new contracts at the outset of a sales transaction (i.e., upon shipment of product) or for existing contracts at some point within 2019 when all the terms of the arrangement would have been known. Until the Step 1 Criteria had been met, revenue recognition continued to be deferred consistent with the assessment for the year ended December 31, 2018. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As further discussed above, the primary factors contributing to the determination in prior periods that the Step 1 Criteria had not been met were the inappropriate tone at the top and the existence of pervasive extra-contractual or undocumented terms or arrangements. These prior business practices and the lack of transparency surrounding them created a systemically implied right for customers to demand future, unknown performance by the Company. Although some of the former executives were employed by the Company only through June 2018, the Company determined that based on the impact of the prior tone at the top, the </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">continued internal sales force strategy and the existing customer base’s continued expectations (based on past practice), there would be flexibility with respect to arrangement terms even after delivery of the product so pervasive that all customer arrangements continued to be subject to uncertain modification of terms into 2019. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">After identifying the primary factors contributing to the lack of knowledge regarding its customer contractual terms, the Company began implementing changes in mid-2018 to remediate the pervasive weaknesses in the control environment, followed by gradually implementing measures to empower its compliance, legal, and accounting departments, educating its sales force on appropriate business practices, and communicating its revised terms of sale to customers. The Company assessed its efforts throughout 2019 to determine when, if at any point, the factors contributing to the inability to satisfy the Step 1 Criteria were sufficiently addressed such that the Step 1 Criteria were met at the time of physical delivery to the customer. Determining when these conditions were effectively satisfied was a matter of judgment; however, the Company determined that adequate knowledge of the contractual arrangements with its customers did exist in 2019. Management did note that there is no single determinative change that overcame the pervasive challenges noted above, but rather an accumulation of efforts that taken together, resulted in sufficient knowledge of contractual relationships both internally within the Company and externally with its customers. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To address the tone at the top issues, the Company noted that proper remediation involved not only the removal of members of management that were setting an inappropriate tone but also the establishment of new management throughout the organization that emphasized a commitment to integrity, ethical values and transparency and have that reinforcement for a sustained period of time. The changes made to management positions throughout the organization and the resulting organization behavior changes were assessed to have been sufficiently addressed by mid-2019.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Therefore, beginning October 1, 2019, for all new customer arrangements, the Company determined adequate measures were in place to understand the terms of its contracts with customers. As such, beginning October 1, 2019, the Company concluded that the Step 1 Criteria would be met prior to shipment of product to the customer or implantation of the products on consignment.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the remaining customer arrangements at September 30, 2019 (the “</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Remaining Contracts</span><span style="font-family:inherit;font-size:10pt;">”), the Company concluded that due to the uncertainty that extracontractual arrangement may continue the Step 1 Criteria would not be satisfied until the Company receives payment from the customer. At that point, the Company determined that an accounting contract would exist and the performance obligations of the company to deliver product and the customer to pay for the product would be satisfied. As of March 31, 2020, upon reassessment, the Company concluded that the Step 1 Criteria continued to not be met due to the same circumstances described above. The amount related to these Remaining Contracts at March 31, 2020 was </span><span style="font-family:inherit;font-size:10pt;"><span>$4.5 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.875%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts Invoiced and Not Collected</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred Cost of Sales</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts as of December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,006</span></span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,261</span></span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue recognized related to amounts invoiced and not collected at September 30, 2019:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash collected during the three months ended March 31, 2020 related to the Remaining Contracts</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,495</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(629</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts as of March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,511</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>632</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of the reassessment as of September 30, 2019, the Company also determined that, for approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$10.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> of existing contracts where payment had not been received, it was not probable that substantially all consideration would be collected. For these customer contracts, the Company continued to fail the Step 1 Criteria and, therefore, no revenue was recognized in 2019. Any collections during the three months ended March 31, 2020, as well as any future collections relating to these customer contracts, will be recorded as revenue at the time payment is received.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For all customer transactions concluded to meet the Step 1 Criteria, the Company then assessed the remaining criteria of ASC 606 to determine the proper timing of revenue recognition. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under ASC 606, the Company recognizes revenue following the five-step model: (i) identify the contracts with a customer (the Step 1 Criteria); (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. As noted above, during the third quarter of 2019, the Company determined that they had met the Step 1 Criteria. The Company also determined that the performance obligation was met upon delivery of the product to the customer, or at the time the product is implanted for products on consignment, at which point the Company determined it will collect the consideration it is entitled to in exchange for the product transferred to the customer. As a result, the Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied, generally upon shipment of the product to the customer. The nature of the Company’s contracts gives rise </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">to certain types of variable consideration, including rebates and other discounts. The Company includes estimated amounts of variable consideration in the transaction price to the extent that it is probable there will not be a significant reversal of revenue. Estimates are based on historical or anticipated performance. The Company does have consignment agreements with several customers and distributors which allow the Company to better market its products by moving them closer to the end user. In these cases, the Company determined that it has fulfilled its performance obligation once control of the product has been delivered to the customer, which occurs simultaneously with the product being implanted. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company acts as the principal in all of its customer arrangements and therefore records revenue on a gross basis. Shipping is considered immaterial in the context of the overall customer arrangement, and damages or loss of goods in transit are rare. Therefore, shipping is not deemed a separately recognized performance obligation. The Company maintains a returns policy that allows its customers to return product that is consigned, damaged or non-conforming, ordered in error, or due to a recall. The estimate of the provision for returns is based upon historical experience with actual returns. The Company’s payment terms for customers are typically </span><span style="font-family:inherit;font-size:10pt;"><span>30</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>60</span></span><span style="font-family:inherit;font-size:10pt;"> days from receipt of title of the goods.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Subsequent to the Transition, the Company continued to defer the cost of sales for certain arrangements for which all revenue recognition criteria have not been met. These amounts were recorded within other current assets on the consolidated balance sheet in the amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of March 31, 2020 and December 31, 2019, respectively.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">GPO Fees</span></div><div style="line-height:120%;padding-bottom:13px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company sells to Group Purchasing Organization (“</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">GPO</span><span style="font-family:inherit;font-size:10pt;">”) members who transact directly with the Company at GPO-agreed pricing. GPOs are funded by administrative fees that are paid by the Company. These fees are set as a percentage of the purchase volume, which is typically </span><span style="font-family:inherit;font-size:10pt;"><span>3%</span></span><span style="font-family:inherit;font-size:10pt;"> of sales made to the GPO members. The Company presents the administrative fees paid to GPOs as a reduction of revenues because the benefit received by the Company in exchange for the GPO fees is not sufficiently separable from the GPO member’s purchase of the Company’s products. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Cost of Sales </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of sales includes all costs directly related to bringing the Company’s products to their final selling destination. Amounts include direct and indirect costs to manufacture products including raw materials, personnel costs and direct overhead expenses necessary to convert collected tissues into finished goods, product testing costs, quality assurance costs, facility costs associated with the Company’s manufacturing and warehouse facilities, depreciation, freight charges, costs to operate equipment and other shipping and handling costs for products shipped to customers.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Leases</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effective January 1, 2019, the Company accounts for its leases under ASC 842, “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;">”. The Company determines if an arrangement is, or contains, a lease at inception. Right-of-use assets and the related liabilities result from operating leases were included in Right of use asset, Other current liabilities and Other liabilities, respectively, in the condensed consolidated balance sheets as of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and December 31, 2019.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. The lease term used in the calculation includes options to extend or terminate the lease when the exercise of such options are reasonably certain. The Company uses the estimated incremental borrowing rate in determining the present value of lease payments. Variable components of the lease payments such as fair market value adjustments, utilities, and maintenance costs are expensed as incurred and not included in determining the present value of lease liabilities. As an accounting policy election, the Company excludes short-term leases having initial terms of 12 months or fewer. Lease expense is recognized on a straight-line basis over the lease term. See Note 6, “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;">” for further information regarding lease obligations.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Patent Costs</span></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company incurs certain legal and related costs in connection with patent applications for tissue-based products and processes. The Company capitalizes such costs as patents in progress until a patent is obtained. When a patent is issued, the costs are amortized over the expected life of the patent to the extent that an economic benefit is anticipated from the resulting patent or alternative future use is available to the Company. If a patent is not obtained, costs are expensed. Patents are included in Intangible assets in the condensed consolidated balance sheet. The Company capitalized approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> of patent costs during the first three months of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Treasury Stock</span></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company accounts for the purchase of treasury stock under the cost method. Treasury stock which is reissued for the exercise of option grants and the issuance of restricted stock grants is accounted for on a FIFO basis.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Recently Issued Accounting Standards Adopted by the Company</span></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, FASB issued ASU No. 2016-02, “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</span><span style="font-family:inherit;font-size:10pt;">”, which amended the guidance on accounting for leases. The FASB issued this update to increase transparency and comparability among organizations. This update requires the recognition of lease assets and lease liabilities on the balance sheet and the disclosure of key information about leasing arrangements. The Company adopted the ASU effective January 1, 2019 using the additional (optional) approach, in accordance with ASU 2018-11, “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842): Targeted Improvements</span><span style="font-family:inherit;font-size:10pt;">.” Upon adoption, the Company recorded a right of use asset of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> and a right of use liability of </span><span style="font-family:inherit;font-size:10pt;"><span>$5.2 million</span></span><span style="font-family:inherit;font-size:10pt;">. The right of use asset, in its entirety, is included in Right of use assets, net on the condensed consolidated balance sheet. Right of use liabilities are included in Other current liabilities to the extent that such liabilities are expected to be settled within one year and Other liabilities to the extent that such obligations are due more than one year from the balance sheet date. The difference between the right of use asset and liability relates to rent credits which existed as of January 1, 2019. There was </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> effect on opening retained earnings at adoption.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In adopting the new lease standard, the Company elected the permitted package of practical expedients permitted, which allowed the Company to account for existing leases under their current classification, as well as omit any new costs classified as initial direct costs, under the new standard. See Note 6 for additional information on leases.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2018, the FASB issued ASU No. 2018-02, “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Statement - Reporting Comprehensive Income (Topic 220)</span><span style="font-family:inherit;font-size:10pt;">,” to address certain income tax effects in Accumulated Other Comprehensive Income (“</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">AOCI</span><span style="font-family:inherit;font-size:10pt;">”) resulting from the tax reform enacted in 2017. The amended guidance provides an option to reclassify tax effects within AOCI to retained earnings in the period in which the effect of the tax reform is recorded. The amendments were effective for fiscal years beginning after December 15, 2018, including interim periods. The Company adopted this ASU on January 1, 2019, which did not have any impact on the Company’s results of operations or financial condition as there were no balances in AOCI that are tax effected.</span></div><div style="line-height:120%;padding-bottom:13px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2018, the FASB issued ASU 2018-07, “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation-Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Payment Accounting</span><span style="font-family:inherit;font-size:10pt;">” (“</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">ASU 2018-07</span><span style="font-family:inherit;font-size:10pt;">”), which simplifies the accounting for share-based payments to non-employees by aligning it with the accounting for share-based payments to employees, with certain exceptions. Under the new guidance, the measurement of equity-classified nonemployee awards will be fixed at the grant date. ASU 2018-07 is effective for interim and annual reporting periods beginning after December 15, 2018 and early adoption was permitted. The Company adopted the new standard on January 1, 2019. The adoption of ASU 2018-07 did not have a material impact on the Company’s consolidated financial statements and related disclosures</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU 2016-13, “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="font-family:inherit;font-size:10pt;">,” that introduces a new model for recognizing credit losses on financial instruments based on an estimate of current expected credit losses. This includes accounts receivable, trade receivables, loans, held-to-maturity debt securities, net investments in leases and certain off-balance sheet credit exposures. The guidance also modifies the impairment model for available-for-sale debt securities. The ASU is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2019. The Company adopted this ASU on January 1, 2020 using a modified retrospective transition method which requires a cumulative-effect adjustment to the opening balance of retained earnings to be recognized on the date of adoption with no change to financial results reported in prior periods. The cumulative effect adjustment recorded on January 1, 2020 is not material. The adoption of this ASU did not have a significant impact on the Company’s consolidated financial statements and related disclosures.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All other ASUs issued and not yet effective for the three months ended </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company’s financial position or results of operations.</span></div> <div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Basis of Presentation</span></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">GAAP</span><span style="font-family:inherit;font-size:10pt;">”) from interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.  Changes to GAAP are established by the Financial Accounting Standards Board (“</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">FASB</span><span style="font-family:inherit;font-size:10pt;">”) in the form of Accounting Standards Updates (“</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">ASU</span><span style="font-family:inherit;font-size:10pt;">’’) to the FASB’s Accounting Standards Codification (“</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">ASC</span><span style="font-family:inherit;font-size:10pt;">”).  In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the results of operations for the periods presented have been included.  Operating results for the </span><span style="font-family:inherit;font-size:10pt;">three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, are not necessarily indicative of the results that may be expected for the fiscal year.  The balance sheet at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, has been derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements. </span></div><span style="font-family:inherit;font-size:10pt;">You should read these condensed consolidated financial statements together with the historical consolidated financial statements of the Company for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span>, included in the <div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Use of Estimates</span></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The consolidated financial statements have been prepared in accordance with GAAP. Conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported consolidated statements of operations during the reporting period. Actual results could differ from those estimates. Significant estimates include estimated useful lives and potential impairment of property and equipment and intangible assets, estimates for contingent liabilities, management’s assessment of the Company’s ability to continue as a going concern, estimates of fair value of share-based payments and valuation of deferred tax assets.</span></div> <div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Principles of Consolidation</span></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The consolidated financial statements include the accounts of MiMedx Group, Inc. and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation.</span></div> <div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Cash and Cash Equivalents</span></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents include cash and Federal Deposit Insurance Corporation (“</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">FDIC</span><span style="font-family:inherit;font-size:10pt;">”) insured certificates of deposit held at various banks with an original maturity of three months or less.</span></div> <div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounts Receivable</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing receivables. The Company determines the allowance based on factors such as historical collection experience, customers’ current creditworthiness, customer concentrations, age of accounts receivable and general economic conditions that may affect customers’ ability to pay.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Notes Receivable</span></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Notes receivable represent formal payment agreements with customers which generally arise in situations where amounts shipped and billed have aged significantly as well as the promissory note issued by Stability Biologics, LLC (“</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Stability</span><span style="font-family:inherit;font-size:10pt;">”) as part of the divestiture of Stability in 2017. The promissory note from Stability was paid in full in the three months ended September 30, 2019. The Company’s notes receivable are included in other current and long-term assets in the accompanying condensed consolidated balance sheets and were valued taking into consideration cost of the market participant inputs, market conditions, liquidity, operating results and other qualitative factors.</span></div> <div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Inventories</span></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories are valued at the lower of cost or net realizable value, using the first-in, first-out (“</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">FIFO</span><span style="font-family:inherit;font-size:10pt;">”) method.  Inventory is tracked through raw material, work-in-process, and finished good stages as the product progresses through various production steps and stocking locations. Labor and overhead costs are absorbed through the various production processes until the work order closes. Historical yields and normal capacities are utilized in the calculation of production overhead rates. Reserves for inventory obsolescence are utilized to account for slow-moving inventory as well as inventory no longer needed due to diminished market demand.</span></div> <div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Revenue Recognition</span></div><div style="line-height:120%;padding-bottom:13px;padding-top:17px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company sells its products primarily to individual customers and independent distributors (collectively referred to as “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">customers</span><span style="font-family:inherit;font-size:10pt;">”). During the three months ended March 31, 2019, the Company’s control environment was such that it created uncertainty surrounding all of its customer arrangements, which required consideration related to the proper revenue recognition under the applicable literature. The control environment allowed for the existence of extra-contractual or undocumented terms or arrangements initiated by or agreed to by the Company and former members of Company management at the outset of the transactions (side agreements). Concessions were also agreed to subsequent to the initial sale (e.g. sales above established customer credit limits extended and unusually long payment terms, return or exchange rights, and contingent payment obligations) that called into question the ability to recognize revenue at the time that product was shipped to a customer. The applicable revenue </span></div><div style="line-height:120%;padding-bottom:13px;padding-top:17px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">recognition guidance also changed beginning January 1, 2018, which further impacted the Company’s revenue recognition methodology.</span></div><div style="line-height:120%;padding-bottom:13px;padding-top:17px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result, the Company’s application of the applicable revenue recognition guidance varies for the three months ended March 31, 2020 and 2019. Additionally, the Company changed its pattern of revenue recognition effective October 1, 2019. The application of the relevant revenue recognition guidance and the pattern of revenue recognition are further discussed below for each period presented. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Three Months Ended March 31, 2019</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company follows ASC Topic 606, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (“</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">ASC 606”</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">)</span><span style="font-family:inherit;font-size:10pt;"> which establishes principles for reporting information about the nature, amount, timing and uncertainty of revenue and cash flows arising from the entity’s contracts to provide goods or services to customers. The core principle requires an entity to recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration that it expects to be entitled to receive in exchange for those goods or services recognized as performance obligations are satisfied. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ASC 606 establishes a five-step model for revenue recognition. The first of these steps requires the identification of the contract as described in ASC 606-10-25-1. The specific criteria (the “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Step 1 Criteria</span><span style="font-family:inherit;font-size:10pt;">”) to this determination are as follows:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The parties to the contract have approved the contract (in writing, orally, or in accordance with other customary business practices) and are committed to perform their respective obligations;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The entity can identify each party’s rights regarding the goods or services to be transferred; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The entity can identify the payment terms for the goods or services to be transferred.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The contract has commercial substance.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">It is probable that the entity will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the three months ended March 31, 2019, the Company concluded that the first three of the above criteria were not met upon shipment of product to the customer, the fourth criterion had been met, and the Company acknowledges that there is a degree of uncertainty as to whether the last criterion above had been met. Although the parties to the contract may have approved the contract and purchase orders in writing, the Company concluded that upon shipment of products to the customer there is not sufficient evidence that its customers were committed to perform their obligations defined in the contract due to the existence of extra-contractual or undocumented terms or arrangements (e.g., regarding payment terms, right of return, etc.).</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s inability to fulfill these criteria was due to uncertainties of contractual adjustments with customers created by a combination of an inappropriate tone at the top and extra-contractual arrangements. Consequently, the Company concluded that it did not meet the Step 1 Criteria upon shipment of the product. Subsequent to the shipment of product, uncertainties surrounding contractual adjustment were not resolved until either: (1) the customer returned the product prior to payment; or (2) the Company received payment from the customer. At that point, the Company determined that an accounting contract existed and the performance obligations of the Company to deliver product and the customer to pay for the product were satisfied. The Company determined the transaction price of its contracts to equal the amount of consideration received from customers less the amount expected to be refunded or credited to customers, which is recognized as a refund liability that is updated at the end of each reporting period for changes in circumstances. The refund liability is included within accrued expenses in the consolidated balance sheet.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Transition and the Three Months Ended March 31, 2020</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company continued to assess contracts, new and existing, throughout 2019 to determine if the Step 1 Criteria noted above for the determination of a contract under ASC 606 were met for new contracts at the outset of a sales transaction (i.e., upon shipment of product) or for existing contracts at some point within 2019 when all the terms of the arrangement would have been known. Until the Step 1 Criteria had been met, revenue recognition continued to be deferred consistent with the assessment for the year ended December 31, 2018. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As further discussed above, the primary factors contributing to the determination in prior periods that the Step 1 Criteria had not been met were the inappropriate tone at the top and the existence of pervasive extra-contractual or undocumented terms or arrangements. These prior business practices and the lack of transparency surrounding them created a systemically implied right for customers to demand future, unknown performance by the Company. Although some of the former executives were employed by the Company only through June 2018, the Company determined that based on the impact of the prior tone at the top, the </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">continued internal sales force strategy and the existing customer base’s continued expectations (based on past practice), there would be flexibility with respect to arrangement terms even after delivery of the product so pervasive that all customer arrangements continued to be subject to uncertain modification of terms into 2019. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">After identifying the primary factors contributing to the lack of knowledge regarding its customer contractual terms, the Company began implementing changes in mid-2018 to remediate the pervasive weaknesses in the control environment, followed by gradually implementing measures to empower its compliance, legal, and accounting departments, educating its sales force on appropriate business practices, and communicating its revised terms of sale to customers. The Company assessed its efforts throughout 2019 to determine when, if at any point, the factors contributing to the inability to satisfy the Step 1 Criteria were sufficiently addressed such that the Step 1 Criteria were met at the time of physical delivery to the customer. Determining when these conditions were effectively satisfied was a matter of judgment; however, the Company determined that adequate knowledge of the contractual arrangements with its customers did exist in 2019. Management did note that there is no single determinative change that overcame the pervasive challenges noted above, but rather an accumulation of efforts that taken together, resulted in sufficient knowledge of contractual relationships both internally within the Company and externally with its customers. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To address the tone at the top issues, the Company noted that proper remediation involved not only the removal of members of management that were setting an inappropriate tone but also the establishment of new management throughout the organization that emphasized a commitment to integrity, ethical values and transparency and have that reinforcement for a sustained period of time. The changes made to management positions throughout the organization and the resulting organization behavior changes were assessed to have been sufficiently addressed by mid-2019.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Therefore, beginning October 1, 2019, for all new customer arrangements, the Company determined adequate measures were in place to understand the terms of its contracts with customers. As such, beginning October 1, 2019, the Company concluded that the Step 1 Criteria would be met prior to shipment of product to the customer or implantation of the products on consignment.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the remaining customer arrangements at September 30, 2019 (the “</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Remaining Contracts</span><span style="font-family:inherit;font-size:10pt;">”), the Company concluded that due to the uncertainty that extracontractual arrangement may continue the Step 1 Criteria would not be satisfied until the Company receives payment from the customer. At that point, the Company determined that an accounting contract would exist and the performance obligations of the company to deliver product and the customer to pay for the product would be satisfied. As of March 31, 2020, upon reassessment, the Company concluded that the Step 1 Criteria continued to not be met due to the same circumstances described above. The amount related to these Remaining Contracts at March 31, 2020 was </span><span style="font-family:inherit;font-size:10pt;"><span>$4.5 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.875%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts Invoiced and Not Collected</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred Cost of Sales</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts as of December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,006</span></span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,261</span></span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue recognized related to amounts invoiced and not collected at September 30, 2019:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash collected during the three months ended March 31, 2020 related to the Remaining Contracts</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,495</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(629</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts as of March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,511</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>632</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of the reassessment as of September 30, 2019, the Company also determined that, for approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$10.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> of existing contracts where payment had not been received, it was not probable that substantially all consideration would be collected. For these customer contracts, the Company continued to fail the Step 1 Criteria and, therefore, no revenue was recognized in 2019. Any collections during the three months ended March 31, 2020, as well as any future collections relating to these customer contracts, will be recorded as revenue at the time payment is received.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For all customer transactions concluded to meet the Step 1 Criteria, the Company then assessed the remaining criteria of ASC 606 to determine the proper timing of revenue recognition. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under ASC 606, the Company recognizes revenue following the five-step model: (i) identify the contracts with a customer (the Step 1 Criteria); (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. As noted above, during the third quarter of 2019, the Company determined that they had met the Step 1 Criteria. The Company also determined that the performance obligation was met upon delivery of the product to the customer, or at the time the product is implanted for products on consignment, at which point the Company determined it will collect the consideration it is entitled to in exchange for the product transferred to the customer. As a result, the Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied, generally upon shipment of the product to the customer. The nature of the Company’s contracts gives rise </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">to certain types of variable consideration, including rebates and other discounts. The Company includes estimated amounts of variable consideration in the transaction price to the extent that it is probable there will not be a significant reversal of revenue. Estimates are based on historical or anticipated performance. The Company does have consignment agreements with several customers and distributors which allow the Company to better market its products by moving them closer to the end user. In these cases, the Company determined that it has fulfilled its performance obligation once control of the product has been delivered to the customer, which occurs simultaneously with the product being implanted. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company acts as the principal in all of its customer arrangements and therefore records revenue on a gross basis. Shipping is considered immaterial in the context of the overall customer arrangement, and damages or loss of goods in transit are rare. Therefore, shipping is not deemed a separately recognized performance obligation. The Company maintains a returns policy that allows its customers to return product that is consigned, damaged or non-conforming, ordered in error, or due to a recall. The estimate of the provision for returns is based upon historical experience with actual returns. The Company’s payment terms for customers are typically </span><span style="font-family:inherit;font-size:10pt;"><span>30</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>60</span></span><span style="font-family:inherit;font-size:10pt;"> days from receipt of title of the goods.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Subsequent to the Transition, the Company continued to defer the cost of sales for certain arrangements for which all revenue recognition criteria have not been met. These amounts were recorded within other current assets on the consolidated balance sheet in the amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of March 31, 2020 and December 31, 2019, respectively.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">GPO Fees</span></div><div style="line-height:120%;padding-bottom:13px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company sells to Group Purchasing Organization (“</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">GPO</span><span style="font-family:inherit;font-size:10pt;">”) members who transact directly with the Company at GPO-agreed pricing. GPOs are funded by administrative fees that are paid by the Company. These fees are set as a percentage of the purchase volume, which is typically </span><span style="font-family:inherit;font-size:10pt;"><span>3%</span></span><span style="font-family:inherit;font-size:10pt;"> of sales made to the GPO members. The Company presents the administrative fees paid to GPOs as a reduction of revenues because the benefit received by the Company in exchange for the GPO fees is not sufficiently separable from the GPO member’s purchase of the Company’s products. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Cost of Sales </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of sales includes all costs directly related to bringing the Company’s products to their final selling destination. Amounts include direct and indirect costs to manufacture products including raw materials, personnel costs and direct overhead expenses necessary to convert collected tissues into finished goods, product testing costs, quality assurance costs, facility costs associated with the Company’s manufacturing and warehouse facilities, depreciation, freight charges, costs to operate equipment and other shipping and handling costs for products shipped to customers.</span></div> 4500000 <div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.875%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts Invoiced and Not Collected</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred Cost of Sales</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts as of December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,006</span></span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,261</span></span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue recognized related to amounts invoiced and not collected at September 30, 2019:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash collected during the three months ended March 31, 2020 related to the Remaining Contracts</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,495</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(629</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts as of March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,511</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>632</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 9006000 1261000 4495000 629000 4511000 632000 10300000 P30D P60D 600000 1300000 0.03 <div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Leases</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effective January 1, 2019, the Company accounts for its leases under ASC 842, “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;">”. The Company determines if an arrangement is, or contains, a lease at inception. Right-of-use assets and the related liabilities result from operating leases were included in Right of use asset, Other current liabilities and Other liabilities, respectively, in the condensed consolidated balance sheets as of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and December 31, 2019.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. The lease term used in the calculation includes options to extend or terminate the lease when the exercise of such options are reasonably certain. The Company uses the estimated incremental borrowing rate in determining the present value of lease payments. Variable components of the lease payments such as fair market value adjustments, utilities, and maintenance costs are expensed as incurred and not included in determining the present value of lease liabilities. As an accounting policy election, the Company excludes short-term leases having initial terms of 12 months or fewer. Lease expense is recognized on a straight-line basis over the lease term. See Note 6, “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;">” for further information regarding lease obligations.</span></div> <div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Patent Costs</span></div>The Company incurs certain legal and related costs in connection with patent applications for tissue-based products and processes. The Company capitalizes such costs as patents in progress until a patent is obtained. When a patent is issued, the costs are amortized over the expected life of the patent to the extent that an economic benefit is anticipated from the resulting patent or alternative future use is available to the Company. If a patent is not obtained, costs are expensed. Patents are included in Intangible assets in the condensed consolidated balance sheet. 100000 200000 <div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Treasury Stock</span></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company accounts for the purchase of treasury stock under the cost method. Treasury stock which is reissued for the exercise of option grants and the issuance of restricted stock grants is accounted for on a FIFO basis.</span></div> <div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Recently Issued Accounting Standards Adopted by the Company</span></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, FASB issued ASU No. 2016-02, “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</span><span style="font-family:inherit;font-size:10pt;">”, which amended the guidance on accounting for leases. The FASB issued this update to increase transparency and comparability among organizations. This update requires the recognition of lease assets and lease liabilities on the balance sheet and the disclosure of key information about leasing arrangements. The Company adopted the ASU effective January 1, 2019 using the additional (optional) approach, in accordance with ASU 2018-11, “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842): Targeted Improvements</span><span style="font-family:inherit;font-size:10pt;">.” Upon adoption, the Company recorded a right of use asset of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> and a right of use liability of </span><span style="font-family:inherit;font-size:10pt;"><span>$5.2 million</span></span><span style="font-family:inherit;font-size:10pt;">. The right of use asset, in its entirety, is included in Right of use assets, net on the condensed consolidated balance sheet. Right of use liabilities are included in Other current liabilities to the extent that such liabilities are expected to be settled within one year and Other liabilities to the extent that such obligations are due more than one year from the balance sheet date. The difference between the right of use asset and liability relates to rent credits which existed as of January 1, 2019. There was </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> effect on opening retained earnings at adoption.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In adopting the new lease standard, the Company elected the permitted package of practical expedients permitted, which allowed the Company to account for existing leases under their current classification, as well as omit any new costs classified as initial direct costs, under the new standard. See Note 6 for additional information on leases.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2018, the FASB issued ASU No. 2018-02, “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Statement - Reporting Comprehensive Income (Topic 220)</span><span style="font-family:inherit;font-size:10pt;">,” to address certain income tax effects in Accumulated Other Comprehensive Income (“</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">AOCI</span><span style="font-family:inherit;font-size:10pt;">”) resulting from the tax reform enacted in 2017. The amended guidance provides an option to reclassify tax effects within AOCI to retained earnings in the period in which the effect of the tax reform is recorded. The amendments were effective for fiscal years beginning after December 15, 2018, including interim periods. The Company adopted this ASU on January 1, 2019, which did not have any impact on the Company’s results of operations or financial condition as there were no balances in AOCI that are tax effected.</span></div><div style="line-height:120%;padding-bottom:13px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2018, the FASB issued ASU 2018-07, “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation-Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Payment Accounting</span><span style="font-family:inherit;font-size:10pt;">” (“</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">ASU 2018-07</span><span style="font-family:inherit;font-size:10pt;">”), which simplifies the accounting for share-based payments to non-employees by aligning it with the accounting for share-based payments to employees, with certain exceptions. Under the new guidance, the measurement of equity-classified nonemployee awards will be fixed at the grant date. ASU 2018-07 is effective for interim and annual reporting periods beginning after December 15, 2018 and early adoption was permitted. The Company adopted the new standard on January 1, 2019. The adoption of ASU 2018-07 did not have a material impact on the Company’s consolidated financial statements and related disclosures</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU 2016-13, “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="font-family:inherit;font-size:10pt;">,” that introduces a new model for recognizing credit losses on financial instruments based on an estimate of current expected credit losses. This includes accounts receivable, trade receivables, loans, held-to-maturity debt securities, net investments in leases and certain off-balance sheet credit exposures. The guidance also modifies the impairment model for available-for-sale debt securities. The ASU is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2019. The Company adopted this ASU on January 1, 2020 using a modified retrospective transition method which requires a cumulative-effect adjustment to the opening balance of retained earnings to be recognized on the date of adoption with no change to financial results reported in prior periods. The cumulative effect adjustment recorded on January 1, 2020 is not material. The adoption of this ASU did not have a significant impact on the Company’s consolidated financial statements and related disclosures.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All other ASUs issued and not yet effective for the three months ended </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company’s financial position or results of operations.</span></div> 4300000 5200000 0 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;">Liquidity and Capital Resources</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Net Working Capital</span></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company had approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$53.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> of cash and cash equivalents.  The Company reported total current assets of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$115.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> and current liabilities of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$63.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">.  </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Overall Liquidity and Capital Resources</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s largest cash requirement for the </span><span style="font-family:inherit;font-size:10pt;">three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> was cash for general working capital needs and capital expenditures. The Company funded its cash requirements through its existing cash reserves, and the Term Loan that closed in June 2019. The Company believes that its anticipated cash from operating and financing activities and existing cash and </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">cash equivalents will enable the Company to meet its operational liquidity needs and fund its planned investing activities for the next year from the date these financial statements were available to be issued.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Issuance of $100 Million of Series B Convertible Preferred Stock</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On </span><span style="font-family:inherit;font-size:10pt;">July 2</span><span style="font-family:inherit;font-size:10pt;">, 2020, the Company issued </span><span style="font-family:inherit;font-size:10pt;"><span>$100 million</span></span><span style="font-family:inherit;font-size:10pt;"> of the Company’s Series B Convertible Preferred Stock, par value </span><span style="font-family:inherit;font-size:10pt;"><span>$0.001</span></span><span style="font-family:inherit;font-size:10pt;"> per share (the “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Series B</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Preferred Stock</span><span style="font-family:inherit;font-size:10pt;">”) to an affiliate of EW Healthcare Partners and to certain funds managed by Hayfin Capital Management LLP pursuant to a Securities Purchase Agreement with Falcon Fund 2 Holding Company, L.P., an affiliate of EW Healthcare Partners, and </span><span style="font-family:inherit;font-size:10pt;">certain funds managed by Hayfin Capital Management LLP</span><span style="font-family:inherit;font-size:10pt;">, dated as of </span><span style="font-family:inherit;font-size:10pt;">June 30</span><span style="font-family:inherit;font-size:10pt;">, 2020 (the “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Securities Purchase Agreement</span><span style="font-family:inherit;font-size:10pt;">”), for an aggregate purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$100 million</span></span><span style="font-family:inherit;font-size:10pt;"> (the “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Preferred Stock Transaction</span><span style="font-family:inherit;font-size:10pt;">”). </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">$75 Million Loan Facility with Hayfin</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On June 30, 2020, the Company entered into a Loan Agreement with, among others, Hayfin Services LLP, an affiliate of Hayfin Capital Management LLP (the “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Hayfin Loan Agreement</span><span style="font-family:inherit;font-size:10pt;">”), which funded on July 2, 2020 (the “Hayfin Loan Transaction”) and provided the Company with a senior secured term loan in an aggregate amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$50 million</span></span><span style="font-family:inherit;font-size:10pt;"> (the “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Hayfin</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Term Loan</span><span style="font-family:inherit;font-size:10pt;">”) and an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$25 million</span></span><span style="font-family:inherit;font-size:10pt;"> delayed draw term loan (the “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">DD TL</span><span style="font-family:inherit;font-size:10pt;">”) in the form of a committed but undrawn facility. The Hayfin Term Loan and the DD TL mature on July 2, 2025 (the “Maturity Date”). The Hayfin Term Loan and the DD TL have no fixed amortization (i.e. interest only through the Maturity Date).</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Borrowings under the Hayfin Loan Agreement bear interest at a rate equal to LIBOR (subject to a floor of </span><span style="font-family:inherit;font-size:10pt;"><span>1.5%</span></span><span style="font-family:inherit;font-size:10pt;">) plus a margin of </span><span style="font-family:inherit;font-size:10pt;"><span>6.75%</span></span><span style="font-family:inherit;font-size:10pt;">. The margin will be eligible to step down to </span><span style="font-family:inherit;font-size:10pt;"><span>6.5%</span></span><span style="font-family:inherit;font-size:10pt;"> or </span><span style="font-family:inherit;font-size:10pt;"><span>6.0%</span></span><span style="font-family:inherit;font-size:10pt;"> based on future Total Net Leverage levels, as defined in the Hayfin Loan Agreement. The Company paid an upfront commitment fee of </span><span style="font-family:inherit;font-size:10pt;"><span>2%</span></span><span style="font-family:inherit;font-size:10pt;"> of the aggregate of the Hayfin Term Loan and the DD TL. The DD TL is subject to an additional commitment fee of </span><span style="font-family:inherit;font-size:10pt;"><span>1%</span></span><span style="font-family:inherit;font-size:10pt;"> of the amount undrawn. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Hayfin Loan Agreement also contains certain affirmative covenants that impose certain reporting and/or performance obligations on the Company and its subsidiaries, including (i) Maximum Total Net Leverage of </span><span style="font-family:inherit;font-size:10pt;"><span>5.0</span></span><span style="font-family:inherit;font-size:10pt;">x through December 31, 2020, stepping down to </span><span style="font-family:inherit;font-size:10pt;"><span>4.5</span></span><span style="font-family:inherit;font-size:10pt;">x through June 30, 2021, and to </span><span style="font-family:inherit;font-size:10pt;"><span>4.0</span></span><span style="font-family:inherit;font-size:10pt;">x thereafter until the Maturity Date; (ii) Cap on Cash Netting for the purposes of calculating Total Net Leverage set at </span><span style="font-family:inherit;font-size:10pt;"><span>$10,000,000</span></span><span style="font-family:inherit;font-size:10pt;">; (iii) DD TL Incurrence Covenant of </span><span style="font-family:inherit;font-size:10pt;"><span>3.5</span></span><span style="font-family:inherit;font-size:10pt;">x Total Net leverage, tested prior to any drawings under the DD TL; and (iv) Minimum Liquidity of </span><span style="font-family:inherit;font-size:10pt;"><span>$10,000,000</span></span><span style="font-family:inherit;font-size:10pt;">, an at-all-times covenant tested monthly. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Repayment and Termination of BT Loan Agreement</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On July 2, 2020, the Company repaid the remaining </span><span style="font-family:inherit;font-size:10pt;"><span>$72.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of principal and accrued interest of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> under the loan agreement, dated as of June 10, 2019, by and among the Company, the subsidiaries of the Company as guarantors party thereto from time to time, the lenders party thereto from time to time, and Blue Torch Finance LLC (“</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Blue Torch</span><span style="font-family:inherit;font-size:10pt;">”), as administrative agent and collateral agent, as amended by that certain First Amendment thereto, dated as of April 22, 2020 (the “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">BT Loan Agreement</span><span style="font-family:inherit;font-size:10pt;">”), and terminated the BT Loan Agreement. As a result of the early termination of the BT Loan Agreement, the Company also incurred a prepayment premium of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.4 million</span></span><span style="font-family:inherit;font-size:10pt;">, which it paid with a portion of the proceeds from the Preferred Stock Transaction and the Hayfin Loan Transaction, as described above.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For more information regarding the Preferred Stock Transaction, the Hayfin Loan Transaction, and the repayment of the BT Term Loan (as defined below) refer to Item 9B of the 2019 Form 10-K.</span></div> 53500000 115900000 63700000 100000000 0.001 100000000 50000000 25000000 0.015 0.0675 0.065 0.060 0.02 0.01 5.0 4.5 4.0 10000000 3.5 10000000 72000000.0 100000 1400000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;">Inventory</span></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventory consisted of the following (in thousands):</span></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:64%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>330</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>318</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Work in process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,913</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,299</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,587</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,206</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> Inventory, gross</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,830</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,823</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reserve for obsolescence</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(583</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(719</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> Inventory, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,247</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,104</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventory consisted of the following (in thousands):</span></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:64%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>330</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>318</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Work in process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,913</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,299</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,587</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,206</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> Inventory, gross</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,830</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,823</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reserve for obsolescence</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(583</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(719</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> Inventory, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,247</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,104</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 330000 318000 3913000 4299000 5587000 5206000 9830000 9823000 583000 719000 9247000 9104000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;">Property and Equipment </span></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment consisted of the following (in thousands):</span></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:61%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leasehold improvements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,321</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,321</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lab and clean room equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,128</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,894</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furniture and office equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,405</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,118</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Construction in progress</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,463</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>972</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">   Property and equipment, gross</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,317</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36,305</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less accumulated depreciation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(25,484</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(23,977</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">   Property and equipment, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,833</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,328</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation expense for the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div> <div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment consisted of the following (in thousands):</span></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:61%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leasehold improvements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,321</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,321</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lab and clean room equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,128</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,894</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furniture and office equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,405</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,118</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Construction in progress</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,463</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>972</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">   Property and equipment, gross</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,317</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36,305</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less accumulated depreciation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(25,484</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(23,977</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">   Property and equipment, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,833</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,328</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 5321000 5321000 15128000 14894000 15405000 15118000 1463000 972000 37317000 36305000 25484000 23977000 11833000 12328000 1500000 1700000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;">Leases</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As discussed in Note 2, on January 1, 2019, MiMedx adopted new guidance for the accounting and reporting of leases. The Company has operating leases primarily for corporate offices, vehicles, and certain equipment. Such leases do not require any contingent rental payments, impose any financial restrictions, or contain any residual value guarantees. The Company determines if an arrangement is or contains a lease at inception. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under ASC 842 transition guidance, the Company has not elected the hindsight practical expedient to determine the lease term for existing leases, which permits companies to consider available information prior to the effective date of the new guidance as to the actual or likely exercise of options to extend or terminate the lease. Certain of the Company’s leases include renewal options and escalation clauses; renewal options have not been included in the calculation of the lease liabilities and right of use assets as the Company is not reasonably certain to exercise the options. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lease expense for operating lease payments is recognized on a straight-line basis over the term of the lease. Operating lease assets and liabilities are recognized based on the present value of lease payments over the lease term. Since most of the Company’s leases do not have a readily determinable implicit discount rate, the Company uses its incremental borrowing rate to calculate the present value of lease payments. As a practical expedient, the Company has made an accounting policy election not to separate lease components from non-lease components in the event that the agreement contains both. The Company includes both the lease and non-lease components for purposes of calculating the right-of-use asset and related lease liability.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company does not act as a lessor or have any leases classified as financing leases. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease cost was </span><span style="font-family:inherit;font-size:10pt;"><span>$0.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the three months ended </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and was recorded in Selling, general, and administrative expenses. Interest on lease obligations was </span><span style="font-family:inherit;font-size:10pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the three months ended </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and was recorded in Selling, general, and administrative expenses. Cash paid for amounts included in the measurement of operating lease liabilities was </span><span style="font-family:inherit;font-size:10pt;"><span>$0.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">. The amortization of leased assets was </span><span style="font-family:inherit;font-size:10pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the three months ended </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supplemental balance sheet information related to operating leases is as follows (amounts in thousands, except lease term and discount rate):</span></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:83.984375%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:6%;"/><td style="width:53%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right of use asset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,158</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,397</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short term lease liability</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,195</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,168</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long term lease liability</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,611</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,919</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average remaining lease term (years)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average discount rate</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Maturities of operating leases liabilities are as follows (amounts in thousands):</span></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.34375%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:7%;"/><td style="width:68%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year ended December 31,</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Maturities</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020 (excluding the three months ended March 31, 2020)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,170</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,528</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,552</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>195</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,445</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: imputed interest</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(639</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,806</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 400000 100000 400000 200000 300000 <div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supplemental balance sheet information related to operating leases is as follows (amounts in thousands, except lease term and discount rate):</span></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:83.984375%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:6%;"/><td style="width:53%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right of use asset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,158</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,397</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short term lease liability</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,195</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,168</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long term lease liability</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,611</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,919</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average remaining lease term (years)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average discount rate</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 3158000 3397000 1195000 1168000 2611000 2919000 P2Y9M18D P3Y1M6D 0.115 0.115 <div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Maturities of operating leases liabilities are as follows (amounts in thousands):</span></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.34375%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:7%;"/><td style="width:68%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year ended December 31,</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Maturities</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020 (excluding the three months ended March 31, 2020)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,170</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,528</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,552</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>195</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,445</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: imputed interest</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(639</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,806</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1170000 1528000 1552000 195000 0 0 4445000 639000 3806000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;">Intangible Assets </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets are summarized as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.9921875%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"/></tr><tr><td style="width:30%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross Carrying Amount</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated Amortization</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net Carrying Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross Carrying Amount</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated Amortization</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net Carrying Amount</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortized intangible assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Licenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,414</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,234</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>180</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,414</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,200</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>214</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Patents and know how</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,108</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,232</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,876</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,099</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,070</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,029</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Customer and supplier relationships</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,761</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,485</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,276</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,761</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,417</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,344</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-compete agreements</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>120</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(75</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>120</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(68</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total amortized intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,403</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9,026</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,377</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,394</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8,755</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,639</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Unamortized intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Trade names and trademarks</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,008</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,008</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,008</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,008</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Patents in process</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,196</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,196</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,130</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,130</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total intangible assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,607</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,581</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,532</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,777</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization expense for the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$0.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected future amortization of intangible assets as of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, is as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year ending December 31,</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Estimated</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization </span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expense</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020 (excluding the three months ended March 31, 2020)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>739</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>978</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>955</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>955</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>955</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>795</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,377</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets are summarized as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.9921875%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"/></tr><tr><td style="width:30%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross Carrying Amount</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated Amortization</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net Carrying Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross Carrying Amount</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated Amortization</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net Carrying Amount</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortized intangible assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Licenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,414</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,234</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>180</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,414</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,200</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>214</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Patents and know how</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,108</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,232</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,876</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,099</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,070</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,029</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Customer and supplier relationships</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,761</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,485</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,276</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,761</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,417</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,344</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-compete agreements</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>120</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(75</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>120</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(68</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total amortized intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,403</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9,026</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,377</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,394</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8,755</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,639</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Unamortized intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Trade names and trademarks</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,008</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,008</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,008</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,008</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Patents in process</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,196</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,196</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,130</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,130</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total intangible assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,607</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,581</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,532</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,777</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets are summarized as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.9921875%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"/></tr><tr><td style="width:30%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross Carrying Amount</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated Amortization</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net Carrying Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross Carrying Amount</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated Amortization</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net Carrying Amount</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortized intangible assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Licenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,414</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,234</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>180</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,414</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,200</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>214</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Patents and know how</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,108</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,232</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,876</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,099</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,070</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,029</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Customer and supplier relationships</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,761</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,485</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,276</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,761</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,417</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,344</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-compete agreements</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>120</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(75</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>120</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(68</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total amortized intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,403</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9,026</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,377</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,394</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8,755</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,639</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Unamortized intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Trade names and trademarks</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,008</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,008</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,008</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,008</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Patents in process</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,196</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,196</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,130</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,130</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total intangible assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,607</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,581</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,532</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,777</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1414000 1234000 180000 1414000 1200000 214000 9108000 5232000 3876000 9099000 5070000 4029000 3761000 2485000 1276000 3761000 2417000 1344000 120000 75000 45000 120000 68000 52000 14403000 9026000 5377000 14394000 8755000 5639000 1008000 1008000 1008000 1008000 1196000 1196000 1130000 1130000 16607000 7581000 16532000 7777000 300000 200000 <div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected future amortization of intangible assets as of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, is as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year ending December 31,</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Estimated</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization </span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expense</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020 (excluding the three months ended March 31, 2020)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>739</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>978</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>955</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>955</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>955</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>795</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,377</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 739000 978000 955000 955000 955000 795000 5377000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;">Accrued Expenses</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses include the following (in thousands):</span></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.34375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:55%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Legal costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,302</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,202</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Settlement costs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,931</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,931</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pricing adjustment settlement with Veterans Affairs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,894</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,894</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Estimated returns</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,567</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,581</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">External commissions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,328</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,722</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued clinical trials</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>566</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,076</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,073</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,755</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">    Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,661</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,161</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses include the following (in thousands):</span></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.34375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:55%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Legal costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,302</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,202</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Settlement costs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,931</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,931</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pricing adjustment settlement with Veterans Affairs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,894</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,894</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Estimated returns</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,567</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,581</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">External commissions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,328</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,722</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued clinical trials</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>566</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,076</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,073</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,755</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">    Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,661</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,161</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 13302000 12202000 5931000 5931000 6894000 6894000 1567000 2581000 1328000 1722000 566000 1076000 1073000 1755000 30661000 32161000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;">Long-Term Debt</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On June 10, 2019, the Company entered into the BT Loan Agreement, pursuant to which the full amount was borrowed and funded (the “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">BT Term Loan</span><span style="font-family:inherit;font-size:10pt;">”). The proceeds from the BT Term Loan were used (i) for working capital and general corporate purposes and (ii) to pay transaction fees, costs and expenses incurred in connection with the BT Term Loan and the related transactions. The BT Term Loan would have matured on June 20, 2022 and was repayable in quarterly installments of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.9 million</span></span><span style="font-family:inherit;font-size:10pt;">; the balance was due on June 20, 2022. Blue Torch maintained a first-priority security interest in substantially all the Company’s assets. The BT Term Loan was issued net of the original issue discount of </span><span style="font-family:inherit;font-size:10pt;"><span>$2.3 million</span></span><span style="font-family:inherit;font-size:10pt;">. The Company also incurred </span><span style="font-family:inherit;font-size:10pt;"><span>$6.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> of deferred financing costs. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of March 31, 2020, interest applicable to any borrowings under the BT Term Loan accrued at a rate equal to LIBOR plus a margin of </span><span style="font-family:inherit;font-size:10pt;"><span>8.00%</span></span><span style="font-family:inherit;font-size:10pt;"> per annum. The BT Term Loan had an interest rate equal to </span><span style="font-family:inherit;font-size:10pt;"><span>10.46%</span></span><span style="font-family:inherit;font-size:10pt;"> at the time the BT Loan Agreement was executed and an interest rate as of March 31, 2020 was </span><span style="font-family:inherit;font-size:10pt;"><span>9.95%</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The BT Loan Agreement originally contained financial covenants requiring the Company, on a consolidated basis, to maintain the following: </span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Maximum Total Leverage Ratio, defined as funded debt divided by consolidated adjusted EBITDA, of not more than </span><span style="font-family:inherit;font-size:10pt;"><span>3.0</span></span><span style="font-family:inherit;font-size:10pt;"> to 1.0 as of the last day of the previous four consecutive fiscal quarters. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Minimum Liquidity, defined as unrestricted cash and cash equivalents, of less than </span><span style="font-family:inherit;font-size:10pt;"><span>$40.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of the last business day of each fiscal month following the BT Term Loan closing date through and including the fiscal month ending May 31, 2020. For fiscal months beginning June 30, 2020, the Company was not permitted to have liquidity of less than </span><span style="font-family:inherit;font-size:10pt;"><span>$30.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. Beginning with the fiscal month ending December 31, 2020, if the total leverage ratio is less than </span><span style="font-family:inherit;font-size:10pt;"><span>2.50</span></span><span style="font-family:inherit;font-size:10pt;"> to 1.0 as of the last business day of any fiscal month, the Company’s liquidity was not permitted to be less than </span><span style="font-family:inherit;font-size:10pt;"><span>$20.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The BT Term Loan was amended on April 22, 2020 to, among other things, modify the financial covenants. See Note 15, “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Subsequent Events</span><span style="font-family:inherit;font-size:10pt;">,” of the consolidated financial statements. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The BT Loan Agreement also specified that any prepayment of the loan, voluntary or mandatory, as defined in the BT Loan Agreement, subjected MiMedx to a prepayment penalty as of the date of the prepayment with respect to the BT Term Loan of:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the period from June 10, 2019 through June 10, 2020, an amount equal to </span><span style="font-family:inherit;font-size:10pt;"><span>3%</span></span><span style="font-family:inherit;font-size:10pt;"> of the principal amount of the BT Term Loan prepaid on such date; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the period from June 11, 2020 through June 10, 2021, an amount equal to </span><span style="font-family:inherit;font-size:10pt;"><span>2%</span></span><span style="font-family:inherit;font-size:10pt;"> of the principal amount of the BT Term Loan prepaid on such date.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Principal prepayments after June 10, 2021 were not subject to a prepayment penalty.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The BT Loan Agreement also included events of default customary for facilities of this type, and upon the occurrence of such events of default, subject to customary cure rights, all outstanding loans under the BT Loan Agreement could have been accelerated and/or the lenders’ commitments terminated.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The balances of the BT Term Loan were as follows (amounts in thousands):</span></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.8203125%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"/></tr><tr><td style="width:38%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current portion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current portion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liability component - principal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,750</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68,438</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,750</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69,375</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Original issue discount</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,723</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,890</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred financing cost</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,078</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,579</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liability component - net carrying value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,750</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61,637</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,750</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61,906</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense related to the BT Term Loan, included in Interest income (expense), net in the consolidated statements of operations, was as follows (amounts in thousands):</span></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:82.421875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:27%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense - stated interest rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,840</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense - amortization of original issue discount and costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>167</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense - amortization of deferred financing costs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>491</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total term loan interest expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,498</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The future principal payments for the Company’s BT Term Loan as of March 31, 2020 were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year ending December 31,</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Principal</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020 (excluding the three months ended March 31, 2020)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,088</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66,350</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Long Term Debt</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>72,188</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the fair value of the Company’s BT Term Loan was </span><span style="font-family:inherit;font-size:10pt;"><span>$62.7 million</span></span><span style="font-family:inherit;font-size:10pt;">. This valuation was calculated based on a series of Level 2 and Level 3 inputs by calculating a discount rate based on the credit risk spread of debt instruments of a similar risk character in reference to U.S. Treasury instruments with identical securities, with an incremental risk premium for Company-specific risk factors. The remaining cash flows associated with the BT Term Loan were discounted to </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> with this calculated discount rate to derive the fair value as of that date. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As described above in Note 3, “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Liquidity and Capital Resources</span><span style="font-family:inherit;font-size:10pt;">,” on July 2, 2020, a portion of the proceeds from the Preferred Stock Transaction and the Hayfin Loan Transaction were used to repay the outstanding balance of principal, accrued but unpaid </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">interest, and prepayment premium under the BT Loan Agreement. In connection with the repayment of the BT Term Loan, the Company terminated the BT Loan Agreement.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additionally, on July 2, 2020, the Company borrowed an aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span>$50 million</span></span><span style="font-family:inherit;font-size:10pt;"> pursuant to the Hayfin Loan Agreement, and obtained an additional committed but undrawn </span><span style="font-family:inherit;font-size:10pt;"><span>$25 million</span></span><span style="font-family:inherit;font-size:10pt;"> facility pursuant to the Hayfin Loan Agreement, as described above in Note 3, “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Liquidity and Capital Resources</span><span style="font-family:inherit;font-size:10pt;">.”</span></div> 900000 2300000 6700000 0.0800 0.1046 0.0995 3.0 40000000.0 30000000.0 2.50 20000000.0 0.03 0.02 <div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The balances of the BT Term Loan were as follows (amounts in thousands):</span></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.8203125%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"/></tr><tr><td style="width:38%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current portion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current portion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liability component - principal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,750</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68,438</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,750</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69,375</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Original issue discount</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,723</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,890</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred financing cost</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,078</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,579</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liability component - net carrying value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,750</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61,637</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,750</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61,906</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 3750000 68438000 3750000 69375000 0 1723000 0 1890000 0 5078000 0 5579000 3750000 61637000 3750000 61906000 <div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense related to the BT Term Loan, included in Interest income (expense), net in the consolidated statements of operations, was as follows (amounts in thousands):</span></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:82.421875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:27%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense - stated interest rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,840</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense - amortization of original issue discount and costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>167</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense - amortization of deferred financing costs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>491</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total term loan interest expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,498</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1840000 167000 491000 2498000 <div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The future principal payments for the Company’s BT Term Loan as of March 31, 2020 were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year ending December 31,</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Principal</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020 (excluding the three months ended March 31, 2020)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,088</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66,350</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Long Term Debt</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>72,188</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 2088000 3750000 66350000 0 0 0 72188000 62700000 50000000 25000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Loss Per Share</span></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic net loss per common share is computed using the weighted-average number of common shares outstanding during the period.  Diluted net loss per common share is computed using the weighted-average number of common and dilutive common equivalent shares from stock options, restricted stock and warrants using the treasury stock method. </span></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table sets forth the computation of basic and diluted net income per share (in thousands except share data):</span></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.2890625%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,821</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13,273</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Denominator for basic earnings per share - weighted average shares</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>107,538,509</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>106,420,317</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of dilutive securities: Stock options, restricted stock, and warrants outstanding(a)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,706,804</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>803,487</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>107,538,509</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>106,420,317</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss per common share - basic </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.04</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.12</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss per common share - diluted</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.04</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.12</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(a) Securities outstanding that are included in the computation above, utilizing the treasury stock method are as follows:</span></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.09375%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:73%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding Stock Options</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>919,555</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>609,292</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Performance Based Awards</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,402</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted Stock Awards</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,769,847</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>194,195</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,706,804</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>803,487</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table sets forth the computation of basic and diluted net income per share (in thousands except share data):</span></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.2890625%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,821</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13,273</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Denominator for basic earnings per share - weighted average shares</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>107,538,509</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>106,420,317</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of dilutive securities: Stock options, restricted stock, and warrants outstanding(a)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,706,804</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>803,487</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>107,538,509</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>106,420,317</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss per common share - basic </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.04</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.12</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss per common share - diluted</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.04</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.12</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(a) Securities outstanding that are included in the computation above, utilizing the treasury stock method are as follows:</span></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.09375%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:73%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding Stock Options</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>919,555</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>609,292</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Performance Based Awards</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,402</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted Stock Awards</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,769,847</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>194,195</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,706,804</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>803,487</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> -4821000 -13273000 107538509 106420317 2706804 803487 107538509 106420317 -0.04 -0.12 -0.04 -0.12 Securities outstanding that are included in the computation above, utilizing the treasury stock method are as follows:<div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.09375%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:73%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding Stock Options</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>919,555</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>609,292</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Performance Based Awards</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,402</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted Stock Awards</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,769,847</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>194,195</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,706,804</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>803,487</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 919555 609292 17402 0 1769847 194195 2706804 803487 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;">Income Taxes </span></div><span style="font-family:inherit;font-size:10pt;">The effective tax rates for the Company of </span><span style="font-family:inherit;font-size:10pt;"><span>70.1%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>0.3%</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively includes the impact of discrete items of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$11.4</span></span><span style="font-family:inherit;font-size:10pt;"> million in 2020 and </span><span style="font-family:inherit;font-size:10pt;"><span>$0</span></span><span style="font-family:inherit;font-size:10pt;"> in 2019. As of March 31, 2020, the projected annual effective tax rate for 2020 is </span><span style="font-family:inherit;font-size:10pt;"><span>(0.6)%</span></span><span style="font-family:inherit;font-size:10pt;">. The discrete items recorded for the three months ended March 31, 2020 are primarily related to modifications to the tax rules for carryback of net operating losses as a result of the CARES Act which are expected to result in a federal tax refund of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$11.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> and an income tax benefit of the same amount. </span><span style="font-family:inherit;font-size:10pt;"><span>No</span></span> benefit had been recognized with respect to the net operating losses due to a valuation allowance previously recorded. -0.701 0.003 11400000 0 -0.006 11300000 0 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;">Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selected cash payments, receipts, and noncash activities are as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.4140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,840</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income taxes paid</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selected cash payments, receipts, and noncash activities are as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.4140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,840</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income taxes paid</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1840000 1000 6000 46000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;">Contractual Commitments and Contingencies</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Contractual Commitments</span></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to the leases noted under Note 6 “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;">,” the Company has commitments for meeting space. These leases expire over </span><span style="font-family:inherit;font-size:10pt;"><span>3</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>3.5 years</span></span><span style="font-family:inherit;font-size:10pt;"> following March 31, 2020, and generally contain renewal options. The Company anticipates that most of these leases will be renewed or replaced upon expiration. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Rent expense for the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$0.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.4 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, and is allocated among cost of sales, research and development, and selling, general and administrative expenses.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Separation and Transition Services Agreement of Edward J. Borkowski</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On November 18, 2019, the Company entered into a Separation and Transition Services Agreement (“</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Separation Agreement</span><span style="font-family:inherit;font-size:10pt;">”) with Edward J. Borkowski, under which Mr. Borkowski resigned as Executive Vice President and Interim Chief Financial Officer of the Company, as well as from any and all officer, director or other positions that he held with the Company and its affiliates, effective November 15, 2019. Pursuant to the Separation Agreement, Mr. Borkowski agreed to perform the duties of the Interim Chief Financial Officer with respect to the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 (the “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2018 Form 10-K</span><span style="font-family:inherit;font-size:10pt;">”) and assist with the transition of his duties as described in the Separation Agreement from November 15, 2019 through the earlier of the first business day following the Company’s filing of its 2018 Form 10-K with the SEC or December 31, 2019 (the “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Transition Period</span><span style="font-family:inherit;font-size:10pt;">”). From the end of the Transition Period until March 31, 2020, Mr. Borkowski agreed to provide services as may be requested by the Company with respect to matters related to the 2018 Form 10-K and the 2019 Form 10-K. The Company has paid Mr. Borkowski the full amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of July 6, 2020.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Litigation and Regulatory Matters</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the ordinary course of business, the Company and its subsidiaries are parties to numerous civil claims and lawsuits and subject to regulatory examinations, investigations, and requests for information. Some of these matters involve claims for substantial amounts. The Company’s experience has shown that the damages alleged by plaintiffs or claimants are often overstated, based on unsubstantiated legal theories, unsupported by facts, and/or bear no relation to the ultimate award that a court might grant. Additionally, the outcome of litigation and regulatory matters and the timing of ultimate resolution are inherently difficult to predict. These factors make it difficult for the Company to provide a meaningful estimate of the range of reasonably possible outcomes of claims in the aggregate or by individual claim. However, on a case-by-case basis, reserves are established for those legal claims in which it is probable that a loss will be incurred and the amount of such loss can be reasonably estimated. The Company's financial statements at March 31, 2020 reflect the Company's current best estimate of probable losses associated with these matters, including costs to comply with various settlement agreements, where applicable. The actual costs of resolving these claims may be substantially higher or lower than the amounts reserved. For more information regarding the Company’s legal proceedings, refer to the disclosure under Item 3, “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Legal Proceedings</span><span style="font-family:inherit;font-size:10pt;">” and Note 16, “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Commitments and Contingencies</span><span style="font-family:inherit;font-size:10pt;">” in the Company’s 2019 Form 10-K, which disclosure is incorporated herein by reference.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a description of certain litigation and regulatory matters:</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Shareholder Derivative Suits</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 6, 2018, the United States District Court for the Northern District of Georgia entered an order consolidating </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> shareholder derivative actions (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Evans v. Petit, et al. </span><span style="font-family:inherit;font-size:10pt;">filed September 25, 2018, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Georgalas v. Petit, et al. </span><span style="font-family:inherit;font-size:10pt;">filed September 27, 2018, and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Roloson v. Petit, et al. </span><span style="font-family:inherit;font-size:10pt;">filed October 22, 2018) that had been filed in the Northern District of Georgia. On January 22, 2019, plaintiffs filed a verified consolidated shareholder derivative complaint. The consolidated action sets forth claims of breach of fiduciary duty, corporate waste and unjust enrichment against certain former officers, and certain current and former directors, of the Company: Parker H. Petit, William C. Taylor, Michael J. Senken, John E. Cranston, Alexandra O. Haden, Joseph G. Bleser, J. Terry Dewberry, Charles R. Evans, Larry W. Papasan, Luis A. Aguilar, Bruce L. Hack, Charles E. Koob, Neil S. Yeston and Christopher M. Cashman. The allegations generally involve claims that the defendants breached their fiduciary duties by causing or allowing the Company to misrepresent its financial statements as a result of improper revenue recognition. The Company filed a motion to stay on February 18, 2019, pending the completion of the investigation by the Company’s Special Litigation Committee. The Special Litigation Committee completed its investigation relating to this action and filed an executive summary of its findings with the Court on July 1, 2019. The parties (together with parties from the Hialeah derivative lawsuit, the Nix and Demaio derivative lawsuit, and the Murphy derivative lawsuit, each described below) held a mediation on February 11, 2020. Following continued discussions, on May 1, 2020, the parties notified the Court that plaintiffs and the Company had reached an agreement in principle to settle this consolidated derivative action, which settlement also encompasses all claims asserted in the Hialeah derivative lawsuit, the Nix and Demaio derivative lawsuit, and the Murphy derivative lawsuit. As of the date of the filing of this Form 10-Q, the </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">parties are drafting, and intend to file, a stipulation of settlement and motion seeking preliminary approval of the settlement.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span>On February 10, 2020, Charles Pike filed a shareholder derivative complaint in the United States District Court for the Southern District of Florida (</span><span style="font-style:italic;">Pike v. Petit, et al.</span><span>). The complaint alleges claims for breaches of fiduciary duty against certain former officers, and certain current and former directors, of the Company: Parker H. Petit, William C. Taylor, Michael J. Senken, John E. Cranston, Charles R. Evans, Luis A. Aguilar, Joseph G. Bleser, J. Terry Dewberry, Bruce L. Hack, Charles E. Koob, Larry W. Papasan and Neil S. Yeston. Similar to the prior-filed actions discussed above, the allegations generally involve claims that the defendants breached their fiduciary duties by causing or allowing the Company to misrepresent its financial statements as a result of improper revenue recognition. On May 12, 2020, prior to the Company’s time to respond to the complaint, the plaintiff filed a notice of voluntary dismissal of this action without prejudice.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span>On February 18, 2020, Bruce Cassamajor filed a shareholder derivative complaint in the United States District Court for the Northern District of Florida (C</span><span style="font-style:italic;">assamajor v. Petit, et al.</span><span>). The complaint alleges claims for breaches of fiduciary duty against certain former officers, and certain current and former directors, of the Company: Parker H. Petit, William C. Taylor, Michael J. Senken, John E. Cranston, Charles R. Evans, Luis A. Aguilar, Joseph G. Bleser, J. Terry Dewberry, Bruce L. Hack, Charles E. Koob, Larry W. Papasan and Neil S. Yeston. Similar to the prior-filed actions discussed above, the allegations generally involve claims that the defendants breached their fiduciary duties by causing or allowing the Company to misrepresent its financial statements as a result of improper revenue recognition. On May 22, 2020, prior to service of the complaint, the plaintiff filed a notice of voluntary dismissal of this action without prejudice. On May 26, 2020, the court ordered this case to be dismissed for failure to serve process.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Securities Class Action</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 16, 2019, the United States District Court for the Northern District of Georgia entered an order consolidating </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> purported securities class actions (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">MacPhee v. MiMedx Group, Inc., et al. </span><span style="font-family:inherit;font-size:10pt;">filed February 23, 2018 and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Kline v. MiMedx Group, Inc., et al.</span><span style="font-family:inherit;font-size:10pt;"> filed February 26, 2018). The order also appointed Carpenters Pension Fund of Illinois as lead plaintiff. On May 1, 2019, the lead plaintiff filed a consolidated amended complaint, naming as defendants the Company, Michael J. Senken, Parker H. Petit, William C. Taylor, Christopher M. Cashman and Cherry Bekaert &amp; Holland LLP. The amended complaint (the “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Securities Class Action Complaint</span><span style="font-family:inherit;font-size:10pt;">”) alleged violations of Section 10(b) of the Securities Exchange Act of 1934, as amended (the “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Exchange Act</span><span style="font-family:inherit;font-size:10pt;">”), Rule 10b-5 promulgated thereunder and Section 20(a) of the Exchange Act. It asserted a class period of March 7, 2013 through June 29, 2018. Following the filing of motions to dismiss by the various defendants, the lead plaintiff was granted leave to file an amended complaint. The lead plaintiff filed its amended complaint against the Company, Michael Senken, Pete Petit, William Taylor, and Cherry Bekaert &amp; Holland (Christopher Cashman was dropped as a defendant) on March 30, 2020; defendants filed motions to dismiss on May 29, 2020. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Investigations</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">United States Attorney’s Office for the Southern District of New York (“</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">USAO-SDNY</span><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">”) Investigation</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The USAO-SDNY is conducting an investigation into, among other things, the Company’s recognition of revenue and practices with certain distributors and customers. The USAO-SDNY requested that the Company provide it with copies of all information the Company furnished to the SEC staff and made additional requests for information. The USAO-SDNY conducted interviews of various individuals, including employees and former employees of the Company. In November 2019, former executives Messrs. Petit and Taylor were indicted for securities fraud and conspiracy to commit securities fraud, to make false filings with the SEC, and to influence improperly the conduct of audits relating to alleged misconduct that resulted in inflated revenue figures for fiscal 2015. The Company is cooperating with the USAO-SDNY. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Department of Veterans’ Affairs Office of Inspector General (“</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">VA-OIG</span><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">”) and Civil Division of the Department of Justice (“</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">DOJ-Civil</span><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">”) Subpoenas and/or Investigations</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">VA-OIG has issued subpoenas to the Company seeking, among other things, information concerning the Company’s financial relationships with VA clinicians. DOJ-Civil has requested similar information. The Company has cooperated fully and produced responsive information to VA-OIG and DOJ-Civil. Periodically, VA-OIG has requested additional documents and information regarding payments to individual VA clinicians. Most recently, on June 3, 2020, the Company received a subpoena from the VA-OIG requesting information regarding the Company’s financial relationships and interactions with two healthcare providers at the VA Long Beach Healthcare System. The Company has continued to cooperate and respond to these requests.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As part of its cooperation, the Company provided documents in response to subpoenas concerning its relationship with </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> now former VA employees in South Carolina, who were ultimately indicted in May 2018. Among other things, the indictment referenced speaker fees paid by the Company to the former VA employees and other interactions between now former Company employees and the former VA employees. In January 2019, prosecution was deferred for </span><span style="font-family:inherit;font-size:10pt;"><span>18 months</span></span><span style="font-family:inherit;font-size:10pt;"> to allow the three former VA employees to enter and complete a Pretrial Diversion Program, the completion of which would result in the dismissal of the indictment. As far as the Company is aware, </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> of the former VA employees have completed the program early and the indictment has been dismissed with respect to them. To date, no actions have been taken against the Company with respect to this matter. </span></div><div style="line-height:174%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-style:italic;">United States Attorney’s Office for the Middle District of North Carolina (“</span><span style="font-style:italic;font-weight:bold;">USAO-MDNC</span><span style="font-style:italic;">”) Investigation</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 9, 2020, the USAO-MDNC informed the Company that it is investigating the Company’s financial relationships with two former clinicians at the Durham VA Medical Center. The Company is cooperating with the investigation.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Qui Tam Actions</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span>On January 19, 2017, a former employee of the Company filed a </span><span style="font-style:italic;">qui tam</span><span> False Claims Act complaint in the United States District Court for the District of South Carolina (</span><span style="font-style:italic;">United States of America, ex rel. Jon Vitale v. MiMedx Group, Inc.</span><span>) alleging that the Company’s donations to the patient assistance program, Patient Access Network Foundation, violated the Anti-Kickback Statute and resulted in submission of false claims to the government. The government declined to intervene and the complaint was unsealed on August 10, 2018. The Company filed a motion to dismiss on October 1, 2018. The Company’s motion to dismiss was granted in part and denied in part on May 15, 2019. The case is in discovery.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Former Employee Litigation</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span>On November 19, 2018, the Company’s former Chief Financial Officer filed a complaint in the Superior Court for Cobb County, Georgia (</span><span style="font-style:italic;">Michael J. Senken v. MiMedx Group, Inc.</span><span>) in which he claims that the Company has breached its obligations under the Company’s charter and bylaws to advance to him, and indemnify him for, his legal fees and costs that he incurred in connection with certain Company internal investigations and litigation. The Company filed its answer denying the plaintiff’s claims on April 19, 2019. To date, no deadlines have been established by the court.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span>On January 21, 2019, a former employee filed a complaint in the Fifth Judicial Circuit, Richland County, South Carolina (</span><span style="font-style:italic;">Jon Michael Vitale v. MiMedx Group, Inc. et. al.</span><span>) against the Company alleging retaliation, defamation and unjust enrichment and seeking monetary damages. The former employee claims he was retaliated against after raising concerns related to insurance fraud and later defamed by comments concerning the indictments of three South Carolina VA employees. On February 19, 2019, the case was removed to the U.S. District Court for the District of South Carolina. The Company filed a motion to dismiss on April 8, 2019, which was denied by the Court. This case is in discovery.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span>In December 2019, MiMedx received notice of a complaint filed in July 2018 with the Occupational Safety and Health Administration (“OSHA”) section of the Department of Labor (“DOL”) by Thomas Tierney, a former Regional Sales Director, against MiMedx and the referenced individuals, </span><span style="font-style:italic;">Tierney v. MiMedx Group, Inc., Parker Petit, William Taylor, Christopher Cashman, Thornton Kuntz, Jr. and Alexandra Haden,</span><span> DOL No. 4-5070-18-243. Mr. Tierney alleged that he was terminated from MiMedx in retaliation for reporting concerns about revenue recognition practices, compliance issues, and the corporate culture, in violation of the anti-retaliation provisions of the Sarbanes-Oxley Act. The parties settled this matter and OSHA dismissed the complaint on May 20, 2020.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Defamation Claims</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span>On June 4, 2018, Sparrow Fund Management, LP (“</span><span style="font-style:italic;font-weight:bold;">Sparrow</span><span>”) filed a complaint against the Company and Mr. Petit, including claims for defamation and civil conspiracy in the United States District Court for the Southern District of New York (</span><span style="font-style:italic;">Sparrow Fund Management, L.P. v. MiMedx Group, Inc. et. al.</span><span>). The complaint seeks monetary damages and injunctive relief and alleges the defendants commenced a campaign to publicly discredit Sparrow by falsely claiming it was a short seller who engaged in illegal and criminal behavior by spreading false information in an attempt to manipulate the price of our Common Stock. On March 31, 2019, a judge granted defendants’ motions to dismiss in full, but allowed Sparrow the ability to file an amended complaint. The Magistrate has recommended Sparrow’s motion for leave to amend be granted in part and denied in part and the Judge adopted the Magistrate’s recommendation. Sparrow filed its amended complaint against MiMedx (Mr. Petit has been dropped from the lawsuit) on April 3, 2020 and the Company filed its answer. This case is in discovery.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span>On June 17, 2019, the principals of Viceroy Research (“</span><span style="font-style:italic;font-weight:bold;">Viceroy</span><span>”), filed suit in the Circuit Court for the Seventeenth Judicial Circuit in Broward County, Florida (</span><span style="font-style:italic;">Fraser John Perring et. al. v. MiMedx Group, Inc. et. al.</span><span>) against the Company and Mr. Petit, alleging defamation and malicious prosecution based on the defendants’ alleged campaign to publicly discredit Viceroy and the </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span>lawsuit the Company previously filed against the plaintiffs, but which the Company subsequently dismissed without prejudice. On November 1, 2019, the Court granted Mr. Petit’s motion to dismiss on jurisdictional grounds, denied the Company’s motion to dismiss, and granted plaintiffs leave to file an amended complaint to address the deficiencies in its claims against Mr. Petit, which they did on November 21, 2019. The Company filed its answer on December 20, 2019.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Intellectual Property Litigation</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">The NuTech Action</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span>On March 2, 2015, the Company filed a patent infringement lawsuit against NuTech Medical, Inc. (“</span><span style="font-style:italic;font-weight:bold;">NuTech</span><span>”) and DCI Donor Services, Inc. (“</span><span style="font-style:italic;font-weight:bold;">DCI</span><span>”) in the United States District Court for the Northern District of Alabama (</span><span style="font-style:italic;">MiMedx Group, Inc. v. NuTech Medical, Inc. et. al.</span><span>). The Company has alleged that NuTech and DCI infringed and continue to infringe the Company’s patents through the manufacture, use, sale and/or offering of their tissue graft product. The Company has also asserted that NuTech knowingly and willfully made false and misleading representations about its products to customers and prospective customers. The Company is seeking permanent injunctive relief and unspecified damages. The case was stayed pending the restatement of the Company’s financial statements. Since the Company has completed its restatement, the case has resumed and discovery has recommenced.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">The Osiris Action</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span>On February 20, 2019, Osiris Therapeutics, Inc. (“</span><span style="font-style:italic;font-weight:bold;">Osiris</span><span>”) refiled its trade secret and breach of contract action against the Company (which had been dismissed in a different forum) in the United States District Court for the Northern District of Georgia (</span><span style="font-style:italic;">Osiris Therapeutics, Inc. v. MiMedx Group, Inc.</span><span>). Osiris has alleged that the Company acquired Stability, a former distributor of Osiris, in order to illegally obtain trade secrets. On February 24, 2020, the Court issued an order granting in part and denying in party MiMedx’s motion to dismiss. The Court dismissed Osiris’s claims for tortious interference, conspiracy to breach contract, unfair competition, and conspiracy to commit unfair competition.  The Court denied MiMedx’s motion to dismiss with respect to the claim for breach of the contract between Osiris and Stability, finding that there is a question as to whether Osiris can maintain such a claim by piercing the corporate veil between MiMedx and its former subsidiary.  If Osiris cannot pierce the corporate veil, the claim against MiMedx fails; if Osiris can pierce the corporate veil, the breach of contract claim must be brought in an arbitration proceeding. MiMedx did not move to dismiss Osiris’s claims for misappropriation of trade secrets and conspiracy to misappropriate trade secrets. MiMedx plans to defend against all remaining claims.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of March 31, 2020, the Company has accrued approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$12.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> related to the legal proceedings discussed above. The Company has paid approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$9.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> to settle certain cases noted above.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Other Matters</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the Florida Business Corporation Act and agreements with its current and former officers and directors, the Company is obligated to indemnify its current and former officers and directors who are made party to a proceeding, including a proceeding brought by or in the right of the corporation, with certain exceptions, and to advance expenses to defend such matters. The Company has already borne substantial costs to satisfy these indemnification and expense advance obligations and expects to continue to do so in the future.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to the matters described above, the Company is a party to a variety of other legal matters that arise in the ordinary course of the Company’s business, none of which is deemed to be individually material at this time. Due to the inherent uncertainty of litigation, there can be no assurance that the resolution of any particular claim or proceeding would not have a material adverse effect on the Company’s business, results of operations, financial position or liquidity.</span></div> P3Y P3Y6M 300000 400000 4000000.0 3 2 3 P18M 2 12800000 9200000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;">Product Revenue Detail</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">MiMedx has </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> primary distribution channels: (1) direct to customers (healthcare professionals and/or facilities) (“</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Direct Customers</span><span style="font-family:inherit;font-size:10pt;">”), and (2) sales through distributors (“</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Distributors</span><span style="font-family:inherit;font-size:10pt;">”). For purposes of the required disclosure under ASC 606-10-50-5, the Company groups its customers into these two groups. This grouping by customer types does not constitute a basis for resource allocation but is information intended to provide the reader with ability to better understand how the nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factors applicable to each customer type. These groupings also do not meet the criteria under ASC 280-10-50-1 to qualify as separate operating segments. The Company did not have significant foreign operations or a single external customer from which </span><span style="font-family:inherit;font-size:10pt;">10%</span><span style="font-family:inherit;font-size:10pt;"> or more of revenues were derived during the three months ended March 31, 2020 and 2019.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Below is a summary of net sales by each customer type (in thousands): </span></div><div style="line-height:120%;padding-bottom:13px;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:52.34375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:25%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:25%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Direct Customers</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59,896</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>64,542</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Distributors</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,840</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,013</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61,736</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66,555</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 2 <div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Below is a summary of net sales by each customer type (in thousands): </span></div><div style="line-height:120%;padding-bottom:13px;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:52.34375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:25%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:25%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Direct Customers</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59,896</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>64,542</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Distributors</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,840</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,013</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61,736</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66,555</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 59896000 64542000 1840000 2013000 61736000 66555000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;">Subsequent Events</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Paycheck Protection Program (PPP) Loan</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 24, 2020, the Company received a </span><span style="font-family:inherit;font-size:10pt;"><span>$10.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> loan under the Paycheck Protection Program (“</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">PPP</span><span style="font-family:inherit;font-size:10pt;">”). On May 11, 2020 the Company repaid the PPP loan.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">BT Loan Agreement Amendment</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 22, 2020, the Company agreed to terms for an amendment to its BT Loan Agreement with Blue Torch. The amendment provided for an increase in the maximum Total Leverage Ratio (as defined in the BT Loan Agreement), which was a quarterly test, for the remainder of 2020, and also provided for a reduction in the minimum Liquidity (as defined in the BT Loan Agreement) requirement from April 2020 through and including November 2020. Specifically, the maximum Total Leverage Ratio increased from </span><span style="font-family:inherit;font-size:10pt;"><span>3.0</span></span><span style="font-family:inherit;font-size:10pt;"> to 1 to </span><span style="font-family:inherit;font-size:10pt;"><span>5.0</span></span><span style="font-family:inherit;font-size:10pt;"> to 1 through December 31, 2020. The minimum Liquidity requirement was reduced from </span><span style="font-family:inherit;font-size:10pt;"><span>$40 million</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>$20 million</span></span><span style="font-family:inherit;font-size:10pt;"> for April and May 2020, and from </span><span style="font-family:inherit;font-size:10pt;"><span>$30 million</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>$20 million</span></span><span style="font-family:inherit;font-size:10pt;"> for June through November 2020. In connection with the amendment, the Company agreed to pay a one-time fee of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$0.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, added to the principal balance, and a </span><span style="font-family:inherit;font-size:10pt;"><span>1</span></span><span style="font-family:inherit;font-size:10pt;"> percentage point increase in the interest rate to LIBOR plus </span><span style="font-family:inherit;font-size:10pt;"><span>9%</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Sublease</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 1, 2020 the Company successfully subleased its industrial warehouse space that expires on May 31, 2023. The Company performed an asset recovery test comparing the sum of estimated undiscounted future cash flows attributable to the sublease to its carrying amount. The total undiscounted cash flows for the remaining lease term exceed the carrying amount of the asset, therefore there is </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> impairment.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Issuance of $100 Million of Series B Convertible Preferred Stock</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On </span><span style="font-family:inherit;font-size:10pt;">July 2</span><span style="font-family:inherit;font-size:10pt;">, 2020, the Company issued </span><span style="font-family:inherit;font-size:10pt;"><span>$100 million</span></span><span style="font-family:inherit;font-size:10pt;"> of Series B Convertible Preferred Stock to an affiliate of EW Healthcare Partners and to certain affiliates of Hayfin Capital Management LLP pursuant to that certain Securities Purchase Agreement, as described above in Note 3, “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Liquidity and Capital Resources</span><span style="font-family:inherit;font-size:10pt;">.” </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">$75 Million Loan Facility with Hayfin</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On July 2, 2020, the Company borrowed an aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span>$50 million</span></span><span style="font-family:inherit;font-size:10pt;"> pursuant to the Hayfin Loan Agreement, and obtained an additional committed but undrawn </span><span style="font-family:inherit;font-size:10pt;"><span>$25 million</span></span><span style="font-family:inherit;font-size:10pt;"> facility pursuant to the Hayfin Loan Agreement, as described above in Note 3, “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Liquidity and Capital Resources</span><span style="font-family:inherit;font-size:10pt;">.” </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Repayment and Termination of BT Loan Agreement</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On July 2, 2020, the Company repaid the remaining principal of </span><span style="font-family:inherit;font-size:10pt;"><span>$72.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, accrued interest of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, and prepayment penalty of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> under the BT Loan Agreement with a portion of the proceeds from the Preferred Stock Transaction and the Hayfin Loan Transaction, and terminated the BT Loan Agreement, each as described above in Note 3, “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Liquidity and Capital Resources</span><span style="font-family:inherit;font-size:10pt;">.”</span></div> 10000000.0 3.0 5.0 40000000 20000000 30000000 20000000 700000 0.01 0.09 0 100000000 50000000 25000000 72000000.0 100000 1400000 XML 15 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Cover Page - shares
3 Months Ended
Mar. 31, 2020
Jun. 25, 2020
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2020  
Document Transition Report false  
Entity File Number 001-35887  
Entity Registrant Name MIMEDX GROUP, INC.  
Entity Incorporation, State or Country Code FL  
Entity Tax Identification Number 26-2792552  
Entity Address, Address Line One 1775 West Oak Commons Ct NE  
Entity Address, City or Town Marietta  
Entity Address, State or Province GA  
Entity Address, Postal Zip Code 30062  
City Area Code 770  
Local Phone Number 651-9100  
Entity Current Reporting Status No  
Entity Interactive Data Current No  
Entity Filer Category Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   110,328,875
Entity Central Index Key 0001376339  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2020  
Document Fiscal Period Focus Q1  
Amendment Flag false  
XML 16 R2.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 53,525 $ 69,069
Accounts receivable, net 31,932 32,327
Inventory, net 9,247 9,104
Prepaid expenses 5,239 6,669
Income tax receivable 10,729 18
Other current assets 5,216 6,058
Total current assets 115,888 123,245
Property and equipment, net 11,833 12,328
Right of use asset 3,158 3,397
Goodwill 19,976 19,976
Intangible assets, net 7,581 7,777
Other assets 473 443
Total assets 158,909 167,166
Current liabilities:    
Accounts payable 9,756 8,710
Accrued compensation 17,116 21,302
Accrued expenses 30,661 32,161
Current portion of long term debt 3,750 3,750
Other current liabilities 2,416 1,399
Total current liabilities 63,699 67,322
Long term debt, net 61,637 61,906
Other liabilities 3,234 3,540
Total liabilities 128,570 132,768
Commitments and contingencies (Note 13)
Stockholders' equity:    
Preferred stock; $.001 par value; 5,000,000 shares authorized; 0 issued and 0 outstanding at March 31, 2020 and 0 issued and 0 outstanding at December 31, 2019 0 0
Common stock; $.001 par value; 150,000,000 shares authorized; 112,703,926 issued and 110,540,860 outstanding at March 31, 2020 and 112,703,926 issued and 110,818,649 outstanding at December 31, 2019 113 113
Additional paid-in capital 149,765 147,231
Treasury stock at cost; 2,163,066 shares at March 31, 2020 and 1,885,277 shares at December 31, 2019 (12,578) (10,806)
Accumulated deficit (106,961) (102,140)
Total stockholders' equity 30,339 34,398
Total liabilities and stockholders' equity $ 158,909 $ 167,166
XML 17 R3.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Mar. 31, 2020
Dec. 31, 2019
Stockholders' equity:    
Preferred stock par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized (in shares) 5,000,000 5,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 150,000,000 150,000,000
Common stock, shares issued (in shares) 112,703,926 112,703,926
Common stock, shares outstanding (in shares) 110,540,860 110,818,649
Treasury stock, shares (in shares) 2,163,066 1,885,277
XML 18 R4.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Income Statement [Abstract]    
Net sales $ 61,736 $ 66,555
Cost of sales 10,025 7,418
Gross profit 51,711 59,137
Operating expenses:    
Selling, general and administrative 46,942 50,862
Investigation, restatement and related 15,592 18,107
Research and development 2,650 2,902
Amortization of intangible assets 271 233
Impairment of intangible asset 0 446
Operating loss (13,744) (13,413)
Other income (expense), net    
Interest (expense) income, net (2,387) 211
Other income (expense), net 6 (29)
Loss before income tax provision (16,125) (13,231)
Income tax provision benefit (expense) 11,304 (42)
Net loss $ (4,821) $ (13,273)
Net loss per common share - basic (in dollars per share) $ (0.04) $ (0.12)
Net loss per common share - diluted (in dollars per share) $ (0.04) $ (0.12)
Weighted average shares outstanding - basic (in shares) 107,538,509 106,420,317
Weighted average shares outstanding - diluted (in shares) 107,538,509 106,420,317
XML 19 R5.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
Common Stock Issued
Additional Paid-in Capital
Treasury Stock
Accumulated Deficit
Balance (in shares) at Dec. 31, 2018   112,703,926   3,605,263  
Balance, beginning of period at Dec. 31, 2018 $ 49,655 $ 113 $ 164,744 $ (38,642) $ (76,560)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Share-based compensation expense 3,014   3,014    
Issuance of restricted stock (in shares)       (251,305)  
Issuance of restricted stock 0   (3,025) $ 3,025  
Restricted stock shares canceled/forfeited 0   1,563 $ (1,563)  
Restricted stock shares cancelled/forfeited (in shares)       141,381  
Shares repurchased for tax withholding (in shares)       336,674  
Shares repurchased for tax withholding (1,044)     $ (1,044)  
Net loss (13,273)       (13,273)
Balance (in shares) at Mar. 31, 2019   112,703,926   3,832,013  
Balance, end of period at Mar. 31, 2019 38,352 $ 113 166,296 $ (38,224) (89,833)
Balance (in shares) at Dec. 31, 2019   112,703,926   1,885,277  
Balance, beginning of period at Dec. 31, 2019 34,398 $ 113 147,231 $ (10,806) (102,140)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Share-based compensation expense 1,915   1,915    
Exercise of stock options (in shares)       (170,300)  
Exercise of stock options 298   (1,214) $ 1,512  
Restricted stock shares canceled/forfeited 0   1,746 $ (1,746)  
Restricted stock shares cancelled/forfeited (in shares)       242,998  
Shares repurchased for tax withholding (in shares)       205,091  
Shares repurchased for tax withholding (1,451)   87 $ (1,538)  
Net loss (4,821)       (4,821)
Balance (in shares) at Mar. 31, 2020   112,703,926   2,163,066  
Balance, end of period at Mar. 31, 2020 $ 30,339 $ 113 $ 149,765 $ (12,578) $ (106,961)
XML 20 R6.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Cash flows from operating activities:    
Net loss $ (4,821) $ (13,273)
Adjustments to reconcile net income to net cash from operating activities:    
Share-based compensation 3,349 3,014
Depreciation 1,506 1,695
Amortization of intangible assets 271 233
Amortization of deferred financing costs and debt discount 668 0
Non-cash lease expenses 239 269
Loss on fixed asset disposal 0 1
Impairment of intangible assets 0 1,258
Increase (decrease) in cash resulting from changes in:    
Accounts receivable 395 0
Inventory (143) (442)
Prepaid expenses 1,430 2,053
Income tax receivable (10,711) (12)
Other assets 812 (1,612)
Accounts payable 1,046 (4,173)
Accrued compensation (4,186) (7,501)
Accrued expenses (2,845) 3,895
Income taxes 0 0
Other liabilities 709 (665)
Cash flows used in operating activities (12,281) (15,260)
Cash flows from investing activities:    
Purchases of equipment (1,011) (648)
Principal payments from note receivable 0 389
Patent application costs (75) (174)
Cash flows used in investing activities (1,086) (433)
Cash flows from financing activities:    
Proceeds from exercise of stock options 298 0
Stock repurchased for tax withholdings on vesting of restricted stock (1,538) (1,044)
Repayment of term loan (937) 0
Cash flows used in financing activities (2,177) (1,044)
Net change in cash (15,544) (16,737)
Cash and cash equivalents, beginning of period 69,069 45,118
Cash and cash equivalents, end of period $ 53,525 $ 28,381
XML 21 R7.htm IDEA: XBRL DOCUMENT v3.20.2
Nature of Business
3 Months Ended
Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Nature of Business
Nature of Business
MiMedx Group, Inc. (together with its subsidiaries except where the context otherwise requires “MiMedx,” or the “Company”) is an advanced wound care and emerging therapeutic biologics company, developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. The Company derives its products from human placental tissues processed using proprietary processing methodologies. The Company’s mission is to offer physicians products and tissues to help the body heal itself. MiMedx provides products in the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic and dental sectors of healthcare. All of the Company’s products are regulated by the United States Food and Drug Administration (“FDA”).
MiMedx is the leading supplier of human placental allografts, which are human tissues that are transplanted from one person (a donor) to another person (a recipient). The Company operates in one business segment, Regenerative Biomaterials, which includes the design, manufacture, and marketing of products for the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic and dental sectors of healthcare. The Company’s allograft product families include: the dHACM family with AmnioFix® and EpiFix® brands; the Umbilical family with EpiCord® and AmnioCord® brands; and the Placental Collagen family with AmnioFill™ brands. AmnioFix and EpiFix are tissue allografts derived from amnion and chorion layers of human placental membrane; EpiCord and AmnioCord are tissue allografts derived from umbilical cord tissue. AmnioFill is a placental connective tissue matrix, derived from the placental disc and other placental tissue.
The Company’s business model is focused primarily on the United States of America but the Company is exploring potential future international expansion opportunities.
Effect of COVID-19 Pandemic
The COVID-19 pandemic and governmental and societal responses thereto have affected the Company’s business, results of operations and financial condition. The continuation or additional waves of the outbreak of COVID-19 or the outbreak of other health epidemics could harm the Company’s operations and increase the Company’s costs and expenses in numerous ways. The ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change. The Company does not yet know the full extent of delays or impacts on the business, clinical trials, healthcare systems or the global economy as a whole, or how long such effects will endure. The effects of the COVID-19 pandemic or other health epidemics could have an adverse impact on the Company’s business, results of operations and financial condition.
On March 27, 2020, the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”) was signed into law. The CARES Act includes provisions relating to refundable payroll tax credits, deferment of the employer portion of certain payroll taxes, loans and grants to certain business, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. As a result of the CARES Act, the Company expects a federal tax refund of approximately $11.3 million and has recognized an income tax benefit of the same amount.
XML 22 R8.htm IDEA: XBRL DOCUMENT v3.20.2
Significant Accounting Policies
3 Months Ended
Mar. 31, 2020
Accounting Policies [Abstract]  
Significant Accounting Policies
Significant Accounting Policies
Please see Note 3 to the Company’s Consolidated Financial Statements included in the Company’s Form 10-K for the fiscal year ended December 31, 2019 (the “2019 Form 10-K”), filed with the Securities and Exchange Commission (“SEC”) on July 6, 2020 for a description of all significant accounting policies. 
Basis of Presentation
The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) from interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.  Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of Accounting Standards Updates (“ASU’’) to the FASB’s Accounting Standards Codification (“ASC”).  In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the results of operations for the periods presented have been included.  Operating results for the three months ended March 31, 2020 and 2019, are not necessarily indicative of the results that may be expected for the fiscal year.  The balance sheet at December 31, 2019, has been derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements. 
You should read these condensed consolidated financial statements together with the historical consolidated financial statements of the Company for the year ended December 31, 2019, included in the 2019 Form 10-K.
Use of Estimates
The consolidated financial statements have been prepared in accordance with GAAP. Conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported consolidated statements of operations during the reporting period. Actual results could differ from those estimates. Significant estimates include estimated useful lives and potential impairment of property and equipment and intangible assets, estimates for contingent liabilities, management’s assessment of the Company’s ability to continue as a going concern, estimates of fair value of share-based payments and valuation of deferred tax assets.
Principles of Consolidation
The consolidated financial statements include the accounts of MiMedx Group, Inc. and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation.
Cash and Cash Equivalents
Cash and cash equivalents include cash and Federal Deposit Insurance Corporation (“FDIC”) insured certificates of deposit held at various banks with an original maturity of three months or less.
Accounts Receivable
Accounts receivable represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables.
The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing receivables. The Company determines the allowance based on factors such as historical collection experience, customers’ current creditworthiness, customer concentrations, age of accounts receivable and general economic conditions that may affect customers’ ability to pay.
Notes Receivable
Notes receivable represent formal payment agreements with customers which generally arise in situations where amounts shipped and billed have aged significantly as well as the promissory note issued by Stability Biologics, LLC (“Stability”) as part of the divestiture of Stability in 2017. The promissory note from Stability was paid in full in the three months ended September 30, 2019. The Company’s notes receivable are included in other current and long-term assets in the accompanying condensed consolidated balance sheets and were valued taking into consideration cost of the market participant inputs, market conditions, liquidity, operating results and other qualitative factors.
Inventories
Inventories are valued at the lower of cost or net realizable value, using the first-in, first-out (“FIFO”) method.  Inventory is tracked through raw material, work-in-process, and finished good stages as the product progresses through various production steps and stocking locations. Labor and overhead costs are absorbed through the various production processes until the work order closes. Historical yields and normal capacities are utilized in the calculation of production overhead rates. Reserves for inventory obsolescence are utilized to account for slow-moving inventory as well as inventory no longer needed due to diminished market demand.
Revenue Recognition
The Company sells its products primarily to individual customers and independent distributors (collectively referred to as “customers”). During the three months ended March 31, 2019, the Company’s control environment was such that it created uncertainty surrounding all of its customer arrangements, which required consideration related to the proper revenue recognition under the applicable literature. The control environment allowed for the existence of extra-contractual or undocumented terms or arrangements initiated by or agreed to by the Company and former members of Company management at the outset of the transactions (side agreements). Concessions were also agreed to subsequent to the initial sale (e.g. sales above established customer credit limits extended and unusually long payment terms, return or exchange rights, and contingent payment obligations) that called into question the ability to recognize revenue at the time that product was shipped to a customer. The applicable revenue
recognition guidance also changed beginning January 1, 2018, which further impacted the Company’s revenue recognition methodology.
As a result, the Company’s application of the applicable revenue recognition guidance varies for the three months ended March 31, 2020 and 2019. Additionally, the Company changed its pattern of revenue recognition effective October 1, 2019. The application of the relevant revenue recognition guidance and the pattern of revenue recognition are further discussed below for each period presented.
Three Months Ended March 31, 2019
The Company follows ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”) which establishes principles for reporting information about the nature, amount, timing and uncertainty of revenue and cash flows arising from the entity’s contracts to provide goods or services to customers. The core principle requires an entity to recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration that it expects to be entitled to receive in exchange for those goods or services recognized as performance obligations are satisfied.
ASC 606 establishes a five-step model for revenue recognition. The first of these steps requires the identification of the contract as described in ASC 606-10-25-1. The specific criteria (the “Step 1 Criteria”) to this determination are as follows:
The parties to the contract have approved the contract (in writing, orally, or in accordance with other customary business practices) and are committed to perform their respective obligations;
The entity can identify each party’s rights regarding the goods or services to be transferred; and
The entity can identify the payment terms for the goods or services to be transferred.
The contract has commercial substance.
It is probable that the entity will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.
For the three months ended March 31, 2019, the Company concluded that the first three of the above criteria were not met upon shipment of product to the customer, the fourth criterion had been met, and the Company acknowledges that there is a degree of uncertainty as to whether the last criterion above had been met. Although the parties to the contract may have approved the contract and purchase orders in writing, the Company concluded that upon shipment of products to the customer there is not sufficient evidence that its customers were committed to perform their obligations defined in the contract due to the existence of extra-contractual or undocumented terms or arrangements (e.g., regarding payment terms, right of return, etc.).
The Company’s inability to fulfill these criteria was due to uncertainties of contractual adjustments with customers created by a combination of an inappropriate tone at the top and extra-contractual arrangements. Consequently, the Company concluded that it did not meet the Step 1 Criteria upon shipment of the product. Subsequent to the shipment of product, uncertainties surrounding contractual adjustment were not resolved until either: (1) the customer returned the product prior to payment; or (2) the Company received payment from the customer. At that point, the Company determined that an accounting contract existed and the performance obligations of the Company to deliver product and the customer to pay for the product were satisfied. The Company determined the transaction price of its contracts to equal the amount of consideration received from customers less the amount expected to be refunded or credited to customers, which is recognized as a refund liability that is updated at the end of each reporting period for changes in circumstances. The refund liability is included within accrued expenses in the consolidated balance sheet.
Transition and the Three Months Ended March 31, 2020
The Company continued to assess contracts, new and existing, throughout 2019 to determine if the Step 1 Criteria noted above for the determination of a contract under ASC 606 were met for new contracts at the outset of a sales transaction (i.e., upon shipment of product) or for existing contracts at some point within 2019 when all the terms of the arrangement would have been known. Until the Step 1 Criteria had been met, revenue recognition continued to be deferred consistent with the assessment for the year ended December 31, 2018.
As further discussed above, the primary factors contributing to the determination in prior periods that the Step 1 Criteria had not been met were the inappropriate tone at the top and the existence of pervasive extra-contractual or undocumented terms or arrangements. These prior business practices and the lack of transparency surrounding them created a systemically implied right for customers to demand future, unknown performance by the Company. Although some of the former executives were employed by the Company only through June 2018, the Company determined that based on the impact of the prior tone at the top, the
continued internal sales force strategy and the existing customer base’s continued expectations (based on past practice), there would be flexibility with respect to arrangement terms even after delivery of the product so pervasive that all customer arrangements continued to be subject to uncertain modification of terms into 2019.
After identifying the primary factors contributing to the lack of knowledge regarding its customer contractual terms, the Company began implementing changes in mid-2018 to remediate the pervasive weaknesses in the control environment, followed by gradually implementing measures to empower its compliance, legal, and accounting departments, educating its sales force on appropriate business practices, and communicating its revised terms of sale to customers. The Company assessed its efforts throughout 2019 to determine when, if at any point, the factors contributing to the inability to satisfy the Step 1 Criteria were sufficiently addressed such that the Step 1 Criteria were met at the time of physical delivery to the customer. Determining when these conditions were effectively satisfied was a matter of judgment; however, the Company determined that adequate knowledge of the contractual arrangements with its customers did exist in 2019. Management did note that there is no single determinative change that overcame the pervasive challenges noted above, but rather an accumulation of efforts that taken together, resulted in sufficient knowledge of contractual relationships both internally within the Company and externally with its customers.
To address the tone at the top issues, the Company noted that proper remediation involved not only the removal of members of management that were setting an inappropriate tone but also the establishment of new management throughout the organization that emphasized a commitment to integrity, ethical values and transparency and have that reinforcement for a sustained period of time. The changes made to management positions throughout the organization and the resulting organization behavior changes were assessed to have been sufficiently addressed by mid-2019.
Therefore, beginning October 1, 2019, for all new customer arrangements, the Company determined adequate measures were in place to understand the terms of its contracts with customers. As such, beginning October 1, 2019, the Company concluded that the Step 1 Criteria would be met prior to shipment of product to the customer or implantation of the products on consignment.
For the remaining customer arrangements at September 30, 2019 (the “Remaining Contracts”), the Company concluded that due to the uncertainty that extracontractual arrangement may continue the Step 1 Criteria would not be satisfied until the Company receives payment from the customer. At that point, the Company determined that an accounting contract would exist and the performance obligations of the company to deliver product and the customer to pay for the product would be satisfied. As of March 31, 2020, upon reassessment, the Company concluded that the Step 1 Criteria continued to not be met due to the same circumstances described above. The amount related to these Remaining Contracts at March 31, 2020 was $4.5 million.
 
Amounts Invoiced and Not Collected

Deferred Cost of Sales
Amounts as of December 31, 2019
$
9,006

 
$
1,261

Revenue recognized related to amounts invoiced and not collected at September 30, 2019:
 
 
 
Cash collected during the three months ended March 31, 2020 related to the Remaining Contracts
(4,495
)
 
(629
)
Amounts as of March 31, 2020
$
4,511

 
$
632


As a result of the reassessment as of September 30, 2019, the Company also determined that, for approximately $10.3 million of existing contracts where payment had not been received, it was not probable that substantially all consideration would be collected. For these customer contracts, the Company continued to fail the Step 1 Criteria and, therefore, no revenue was recognized in 2019. Any collections during the three months ended March 31, 2020, as well as any future collections relating to these customer contracts, will be recorded as revenue at the time payment is received.
For all customer transactions concluded to meet the Step 1 Criteria, the Company then assessed the remaining criteria of ASC 606 to determine the proper timing of revenue recognition.
Under ASC 606, the Company recognizes revenue following the five-step model: (i) identify the contracts with a customer (the Step 1 Criteria); (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. As noted above, during the third quarter of 2019, the Company determined that they had met the Step 1 Criteria. The Company also determined that the performance obligation was met upon delivery of the product to the customer, or at the time the product is implanted for products on consignment, at which point the Company determined it will collect the consideration it is entitled to in exchange for the product transferred to the customer. As a result, the Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied, generally upon shipment of the product to the customer. The nature of the Company’s contracts gives rise
to certain types of variable consideration, including rebates and other discounts. The Company includes estimated amounts of variable consideration in the transaction price to the extent that it is probable there will not be a significant reversal of revenue. Estimates are based on historical or anticipated performance. The Company does have consignment agreements with several customers and distributors which allow the Company to better market its products by moving them closer to the end user. In these cases, the Company determined that it has fulfilled its performance obligation once control of the product has been delivered to the customer, which occurs simultaneously with the product being implanted.
The Company acts as the principal in all of its customer arrangements and therefore records revenue on a gross basis. Shipping is considered immaterial in the context of the overall customer arrangement, and damages or loss of goods in transit are rare. Therefore, shipping is not deemed a separately recognized performance obligation. The Company maintains a returns policy that allows its customers to return product that is consigned, damaged or non-conforming, ordered in error, or due to a recall. The estimate of the provision for returns is based upon historical experience with actual returns. The Company’s payment terms for customers are typically 30 to 60 days from receipt of title of the goods.
Subsequent to the Transition, the Company continued to defer the cost of sales for certain arrangements for which all revenue recognition criteria have not been met. These amounts were recorded within other current assets on the consolidated balance sheet in the amount of $0.6 million and $1.3 million as of March 31, 2020 and December 31, 2019, respectively.
GPO Fees
The Company sells to Group Purchasing Organization (“GPO”) members who transact directly with the Company at GPO-agreed pricing. GPOs are funded by administrative fees that are paid by the Company. These fees are set as a percentage of the purchase volume, which is typically 3% of sales made to the GPO members. The Company presents the administrative fees paid to GPOs as a reduction of revenues because the benefit received by the Company in exchange for the GPO fees is not sufficiently separable from the GPO member’s purchase of the Company’s products.
Cost of Sales
Cost of sales includes all costs directly related to bringing the Company’s products to their final selling destination. Amounts include direct and indirect costs to manufacture products including raw materials, personnel costs and direct overhead expenses necessary to convert collected tissues into finished goods, product testing costs, quality assurance costs, facility costs associated with the Company’s manufacturing and warehouse facilities, depreciation, freight charges, costs to operate equipment and other shipping and handling costs for products shipped to customers.
Leases
Effective January 1, 2019, the Company accounts for its leases under ASC 842, “Leases”. The Company determines if an arrangement is, or contains, a lease at inception. Right-of-use assets and the related liabilities result from operating leases were included in Right of use asset, Other current liabilities and Other liabilities, respectively, in the condensed consolidated balance sheets as of March 31, 2020 and December 31, 2019.
Operating lease assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. The lease term used in the calculation includes options to extend or terminate the lease when the exercise of such options are reasonably certain. The Company uses the estimated incremental borrowing rate in determining the present value of lease payments. Variable components of the lease payments such as fair market value adjustments, utilities, and maintenance costs are expensed as incurred and not included in determining the present value of lease liabilities. As an accounting policy election, the Company excludes short-term leases having initial terms of 12 months or fewer. Lease expense is recognized on a straight-line basis over the lease term. See Note 6, “Leases” for further information regarding lease obligations.
Patent Costs
The Company incurs certain legal and related costs in connection with patent applications for tissue-based products and processes. The Company capitalizes such costs as patents in progress until a patent is obtained. When a patent is issued, the costs are amortized over the expected life of the patent to the extent that an economic benefit is anticipated from the resulting patent or alternative future use is available to the Company. If a patent is not obtained, costs are expensed. Patents are included in Intangible assets in the condensed consolidated balance sheet. The Company capitalized approximately $0.1 million and $0.2 million of patent costs during the first three months of 2020 and 2019, respectively.
Treasury Stock
The Company accounts for the purchase of treasury stock under the cost method. Treasury stock which is reissued for the exercise of option grants and the issuance of restricted stock grants is accounted for on a FIFO basis.
Recently Issued Accounting Standards Adopted by the Company
In February 2016, FASB issued ASU No. 2016-02, “Leases (Topic 842)”, which amended the guidance on accounting for leases. The FASB issued this update to increase transparency and comparability among organizations. This update requires the recognition of lease assets and lease liabilities on the balance sheet and the disclosure of key information about leasing arrangements. The Company adopted the ASU effective January 1, 2019 using the additional (optional) approach, in accordance with ASU 2018-11, “Leases (Topic 842): Targeted Improvements.” Upon adoption, the Company recorded a right of use asset of $4.3 million and a right of use liability of $5.2 million. The right of use asset, in its entirety, is included in Right of use assets, net on the condensed consolidated balance sheet. Right of use liabilities are included in Other current liabilities to the extent that such liabilities are expected to be settled within one year and Other liabilities to the extent that such obligations are due more than one year from the balance sheet date. The difference between the right of use asset and liability relates to rent credits which existed as of January 1, 2019. There was no effect on opening retained earnings at adoption.
In adopting the new lease standard, the Company elected the permitted package of practical expedients permitted, which allowed the Company to account for existing leases under their current classification, as well as omit any new costs classified as initial direct costs, under the new standard. See Note 6 for additional information on leases.
In February 2018, the FASB issued ASU No. 2018-02, “Income Statement - Reporting Comprehensive Income (Topic 220),” to address certain income tax effects in Accumulated Other Comprehensive Income (“AOCI”) resulting from the tax reform enacted in 2017. The amended guidance provides an option to reclassify tax effects within AOCI to retained earnings in the period in which the effect of the tax reform is recorded. The amendments were effective for fiscal years beginning after December 15, 2018, including interim periods. The Company adopted this ASU on January 1, 2019, which did not have any impact on the Company’s results of operations or financial condition as there were no balances in AOCI that are tax effected.
In June 2018, the FASB issued ASU 2018-07, “Compensation-Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Payment Accounting” (“ASU 2018-07”), which simplifies the accounting for share-based payments to non-employees by aligning it with the accounting for share-based payments to employees, with certain exceptions. Under the new guidance, the measurement of equity-classified nonemployee awards will be fixed at the grant date. ASU 2018-07 is effective for interim and annual reporting periods beginning after December 15, 2018 and early adoption was permitted. The Company adopted the new standard on January 1, 2019. The adoption of ASU 2018-07 did not have a material impact on the Company’s consolidated financial statements and related disclosures.
In June 2016, the FASB issued ASU 2016-13, “Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,” that introduces a new model for recognizing credit losses on financial instruments based on an estimate of current expected credit losses. This includes accounts receivable, trade receivables, loans, held-to-maturity debt securities, net investments in leases and certain off-balance sheet credit exposures. The guidance also modifies the impairment model for available-for-sale debt securities. The ASU is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2019. The Company adopted this ASU on January 1, 2020 using a modified retrospective transition method which requires a cumulative-effect adjustment to the opening balance of retained earnings to be recognized on the date of adoption with no change to financial results reported in prior periods. The cumulative effect adjustment recorded on January 1, 2020 is not material. The adoption of this ASU did not have a significant impact on the Company’s consolidated financial statements and related disclosures.
All other ASUs issued and not yet effective for the three months ended March 31, 2020, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company’s financial position or results of operations.
XML 23 R9.htm IDEA: XBRL DOCUMENT v3.20.2
Liquidity and Capital Resources
3 Months Ended
Mar. 31, 2020
Liquidity and Capital Resources [Abstract]  
Liquidity and Capital Resources
Liquidity and Capital Resources
Net Working Capital
As of March 31, 2020, the Company had approximately $53.5 million of cash and cash equivalents.  The Company reported total current assets of approximately $115.9 million and current liabilities of approximately $63.7 million as of March 31, 2020.  
Overall Liquidity and Capital Resources
The Company’s largest cash requirement for the three months ended March 31, 2020 was cash for general working capital needs and capital expenditures. The Company funded its cash requirements through its existing cash reserves, and the Term Loan that closed in June 2019. The Company believes that its anticipated cash from operating and financing activities and existing cash and
cash equivalents will enable the Company to meet its operational liquidity needs and fund its planned investing activities for the next year from the date these financial statements were available to be issued.
Issuance of $100 Million of Series B Convertible Preferred Stock
On July 2, 2020, the Company issued $100 million of the Company’s Series B Convertible Preferred Stock, par value $0.001 per share (the “Series B Preferred Stock”) to an affiliate of EW Healthcare Partners and to certain funds managed by Hayfin Capital Management LLP pursuant to a Securities Purchase Agreement with Falcon Fund 2 Holding Company, L.P., an affiliate of EW Healthcare Partners, and certain funds managed by Hayfin Capital Management LLP, dated as of June 30, 2020 (the “Securities Purchase Agreement”), for an aggregate purchase price of $100 million (the “Preferred Stock Transaction”).
$75 Million Loan Facility with Hayfin
On June 30, 2020, the Company entered into a Loan Agreement with, among others, Hayfin Services LLP, an affiliate of Hayfin Capital Management LLP (the “Hayfin Loan Agreement”), which funded on July 2, 2020 (the “Hayfin Loan Transaction”) and provided the Company with a senior secured term loan in an aggregate amount of $50 million (the “Hayfin Term Loan”) and an additional $25 million delayed draw term loan (the “DD TL”) in the form of a committed but undrawn facility. The Hayfin Term Loan and the DD TL mature on July 2, 2025 (the “Maturity Date”). The Hayfin Term Loan and the DD TL have no fixed amortization (i.e. interest only through the Maturity Date).
Borrowings under the Hayfin Loan Agreement bear interest at a rate equal to LIBOR (subject to a floor of 1.5%) plus a margin of 6.75%. The margin will be eligible to step down to 6.5% or 6.0% based on future Total Net Leverage levels, as defined in the Hayfin Loan Agreement. The Company paid an upfront commitment fee of 2% of the aggregate of the Hayfin Term Loan and the DD TL. The DD TL is subject to an additional commitment fee of 1% of the amount undrawn.
The Hayfin Loan Agreement also contains certain affirmative covenants that impose certain reporting and/or performance obligations on the Company and its subsidiaries, including (i) Maximum Total Net Leverage of 5.0x through December 31, 2020, stepping down to 4.5x through June 30, 2021, and to 4.0x thereafter until the Maturity Date; (ii) Cap on Cash Netting for the purposes of calculating Total Net Leverage set at $10,000,000; (iii) DD TL Incurrence Covenant of 3.5x Total Net leverage, tested prior to any drawings under the DD TL; and (iv) Minimum Liquidity of $10,000,000, an at-all-times covenant tested monthly.
Repayment and Termination of BT Loan Agreement
On July 2, 2020, the Company repaid the remaining $72.0 million of principal and accrued interest of $0.1 million under the loan agreement, dated as of June 10, 2019, by and among the Company, the subsidiaries of the Company as guarantors party thereto from time to time, the lenders party thereto from time to time, and Blue Torch Finance LLC (“Blue Torch”), as administrative agent and collateral agent, as amended by that certain First Amendment thereto, dated as of April 22, 2020 (the “BT Loan Agreement”), and terminated the BT Loan Agreement. As a result of the early termination of the BT Loan Agreement, the Company also incurred a prepayment premium of $1.4 million, which it paid with a portion of the proceeds from the Preferred Stock Transaction and the Hayfin Loan Transaction, as described above.
For more information regarding the Preferred Stock Transaction, the Hayfin Loan Transaction, and the repayment of the BT Term Loan (as defined below) refer to Item 9B of the 2019 Form 10-K.
XML 24 R10.htm IDEA: XBRL DOCUMENT v3.20.2
Inventory
3 Months Ended
Mar. 31, 2020
Inventory Disclosure [Abstract]  
Inventory
Inventory
Inventory consisted of the following (in thousands):
 
March 31, 2020
 
December 31, 2019
Raw materials
$
330

 
$
318

Work in process
3,913

 
4,299

Finished goods
5,587

 
5,206

 Inventory, gross
9,830

 
9,823

Reserve for obsolescence
(583
)
 
(719
)
 Inventory, net
$
9,247

 
$
9,104


XML 25 R11.htm IDEA: XBRL DOCUMENT v3.20.2
Property and Equipment
3 Months Ended
Mar. 31, 2020
Property, Plant and Equipment [Abstract]  
Property and Equipment
Property and Equipment 
Property and equipment consisted of the following (in thousands):
 
March 31, 2020
 
December 31, 2019
Leasehold improvements
$
5,321

 
$
5,321

Lab and clean room equipment
15,128

 
14,894

Furniture and office equipment
15,405

 
15,118

Construction in progress
1,463

 
972

   Property and equipment, gross
37,317

 
36,305

Less accumulated depreciation
(25,484
)
 
(23,977
)
   Property and equipment, net
$
11,833

 
$
12,328


Depreciation expense for the three months ended March 31, 2020 and 2019, was approximately $1.5 million and $1.7 million, respectively.
XML 26 R12.htm IDEA: XBRL DOCUMENT v3.20.2
Leases
3 Months Ended
Mar. 31, 2020
Leases [Abstract]  
Leases
Leases
As discussed in Note 2, on January 1, 2019, MiMedx adopted new guidance for the accounting and reporting of leases. The Company has operating leases primarily for corporate offices, vehicles, and certain equipment. Such leases do not require any contingent rental payments, impose any financial restrictions, or contain any residual value guarantees. The Company determines if an arrangement is or contains a lease at inception.
Under ASC 842 transition guidance, the Company has not elected the hindsight practical expedient to determine the lease term for existing leases, which permits companies to consider available information prior to the effective date of the new guidance as to the actual or likely exercise of options to extend or terminate the lease. Certain of the Company’s leases include renewal options and escalation clauses; renewal options have not been included in the calculation of the lease liabilities and right of use assets as the Company is not reasonably certain to exercise the options.
Lease expense for operating lease payments is recognized on a straight-line basis over the term of the lease. Operating lease assets and liabilities are recognized based on the present value of lease payments over the lease term. Since most of the Company’s leases do not have a readily determinable implicit discount rate, the Company uses its incremental borrowing rate to calculate the present value of lease payments. As a practical expedient, the Company has made an accounting policy election not to separate lease components from non-lease components in the event that the agreement contains both. The Company includes both the lease and non-lease components for purposes of calculating the right-of-use asset and related lease liability.
The Company does not act as a lessor or have any leases classified as financing leases.
Operating lease cost was $0.4 million for the three months ended March 31, 2020 and was recorded in Selling, general, and administrative expenses. Interest on lease obligations was $0.1 million for the three months ended March 31, 2019 and was recorded in Selling, general, and administrative expenses. Cash paid for amounts included in the measurement of operating lease liabilities was $0.4 million at March 31, 2020. The amortization of leased assets was $0.2 million and $0.3 million for the three months ended March 31, 2020 and 2019, respectively.
Supplemental balance sheet information related to operating leases is as follows (amounts in thousands, except lease term and discount rate):
 
 
March 31, 2020
 
December 31, 2019
Assets
 
 
 
 
Right of use asset
$
3,158

 
$
3,397

 
 
 
 
 
Liabilities
 
 
 
 
Short term lease liability
$
1,195

 
$
1,168

 
Long term lease liability
$
2,611

 
$
2,919

 
 
 
 
 
Weighted-average remaining lease term (years)
2.8

 
3.1

Weighted-average discount rate
11.5
%
 
11.5
%

Maturities of operating leases liabilities are as follows (amounts in thousands):
Year ended December 31,
Maturities
2020 (excluding the three months ended March 31, 2020)
$
1,170

2021
1,528

2022
1,552

2023
195

2024

Thereafter

Total lease payments
4,445

Less: imputed interest
(639
)
 
$
3,806


XML 27 R13.htm IDEA: XBRL DOCUMENT v3.20.2
Intangible Assets
3 Months Ended
Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets
Intangible Assets
Intangible assets are summarized as follows (in thousands):
 
 
March 31, 2020
 
December 31, 2019
 
 
Gross Carrying Amount
Accumulated Amortization
Net Carrying Amount
 
Gross Carrying Amount
Accumulated Amortization
Net Carrying Amount
Amortized intangible assets
 
 
 
 
 
 
 
 
Licenses
 
$
1,414

$
(1,234
)
$
180

 
$
1,414

$
(1,200
)
$
214

Patents and know how
 
9,108

(5,232
)
3,876

 
9,099

(5,070
)
4,029

Customer and supplier relationships
 
3,761

(2,485
)
1,276

 
3,761

(2,417
)
1,344

Non-compete agreements
 
120

(75
)
45

 
120

(68
)
52

Total amortized intangible assets
 
$
14,403

$
(9,026
)
$
5,377

 
$
14,394

$
(8,755
)
$
5,639

 
 
 
 
 
 
 
 
 
Unamortized intangible assets
 
 
 
 
 
 
 
 
Trade names and trademarks
 
$
1,008

 
$
1,008

 
$
1,008

 
$
1,008

Patents in process
 
1,196

 
1,196

 
1,130

 
1,130

Total intangible assets
 
$
16,607

 
$
7,581

 
$
16,532

 
$
7,777


Amortization expense for the three months ended March 31, 2020 and 2019, was approximately $0.3 million and $0.2 million, respectively.
Expected future amortization of intangible assets as of March 31, 2020, is as follows (in thousands):
Year ending December 31,
Estimated
Amortization
Expense
2020 (excluding the three months ended March 31, 2020)
$
739

2021
978

2022
955

2023
955

2024
955

Thereafter
795

 
$
5,377


XML 28 R14.htm IDEA: XBRL DOCUMENT v3.20.2
Accrued Expenses
3 Months Ended
Mar. 31, 2020
Payables and Accruals [Abstract]  
Accounts Expenses
Accrued Expenses
Accrued expenses include the following (in thousands):
 
March 31, 2020
 
December 31, 2019
Legal costs
$
13,302

 
$
12,202

Settlement costs
5,931

 
5,931

Pricing adjustment settlement with Veterans Affairs
6,894

 
6,894

Estimated returns
1,567

 
2,581

External commissions
1,328

 
1,722

Accrued clinical trials
566

 
1,076

Other
1,073

 
1,755

    Total
$
30,661

 
$
32,161


XML 29 R15.htm IDEA: XBRL DOCUMENT v3.20.2
Long Term Debt
3 Months Ended
Mar. 31, 2020
Debt Disclosure [Abstract]  
Long Term Debt
Long-Term Debt
On June 10, 2019, the Company entered into the BT Loan Agreement, pursuant to which the full amount was borrowed and funded (the “BT Term Loan”). The proceeds from the BT Term Loan were used (i) for working capital and general corporate purposes and (ii) to pay transaction fees, costs and expenses incurred in connection with the BT Term Loan and the related transactions. The BT Term Loan would have matured on June 20, 2022 and was repayable in quarterly installments of $0.9 million; the balance was due on June 20, 2022. Blue Torch maintained a first-priority security interest in substantially all the Company’s assets. The BT Term Loan was issued net of the original issue discount of $2.3 million. The Company also incurred $6.7 million of deferred financing costs.
As of March 31, 2020, interest applicable to any borrowings under the BT Term Loan accrued at a rate equal to LIBOR plus a margin of 8.00% per annum. The BT Term Loan had an interest rate equal to 10.46% at the time the BT Loan Agreement was executed and an interest rate as of March 31, 2020 was 9.95%.
The BT Loan Agreement originally contained financial covenants requiring the Company, on a consolidated basis, to maintain the following:
Maximum Total Leverage Ratio, defined as funded debt divided by consolidated adjusted EBITDA, of not more than 3.0 to 1.0 as of the last day of the previous four consecutive fiscal quarters.
Minimum Liquidity, defined as unrestricted cash and cash equivalents, of less than $40.0 million as of the last business day of each fiscal month following the BT Term Loan closing date through and including the fiscal month ending May 31, 2020. For fiscal months beginning June 30, 2020, the Company was not permitted to have liquidity of less than $30.0 million. Beginning with the fiscal month ending December 31, 2020, if the total leverage ratio is less than 2.50 to 1.0 as of the last business day of any fiscal month, the Company’s liquidity was not permitted to be less than $20.0 million.
The BT Term Loan was amended on April 22, 2020 to, among other things, modify the financial covenants. See Note 15, “Subsequent Events,” of the consolidated financial statements.
The BT Loan Agreement also specified that any prepayment of the loan, voluntary or mandatory, as defined in the BT Loan Agreement, subjected MiMedx to a prepayment penalty as of the date of the prepayment with respect to the BT Term Loan of:
During the period from June 10, 2019 through June 10, 2020, an amount equal to 3% of the principal amount of the BT Term Loan prepaid on such date; and
During the period from June 11, 2020 through June 10, 2021, an amount equal to 2% of the principal amount of the BT Term Loan prepaid on such date.
Principal prepayments after June 10, 2021 were not subject to a prepayment penalty.
The BT Loan Agreement also included events of default customary for facilities of this type, and upon the occurrence of such events of default, subject to customary cure rights, all outstanding loans under the BT Loan Agreement could have been accelerated and/or the lenders’ commitments terminated.
The balances of the BT Term Loan were as follows (amounts in thousands):
 
March 31, 2020
December 31, 2019
 
Current portion
 
Long-term
Current portion
 
Long-term
Liability component - principal
$
3,750

 
$
68,438

$
3,750

 
$
69,375

Original issue discount

 
(1,723
)

 
(1,890
)
Deferred financing cost

 
(5,078
)

 
(5,579
)
Liability component - net carrying value
$
3,750

 
$
61,637

$
3,750

 
$
61,906


Interest expense related to the BT Term Loan, included in Interest income (expense), net in the consolidated statements of operations, was as follows (amounts in thousands):
 
For the Three Months Ended
 
March 31, 2020
Interest expense - stated interest rate
$
1,840

Interest expense - amortization of original issue discount and costs
167

Interest expense - amortization of deferred financing costs
491

Total term loan interest expense
$
2,498


The future principal payments for the Company’s BT Term Loan as of March 31, 2020 were as follows (in thousands):
Year ending December 31,
Principal
2020 (excluding the three months ended March 31, 2020)
$
2,088

2021
3,750

2022
66,350

2023

2024

Thereafter

Total Long Term Debt
$
72,188


As of March 31, 2020, the fair value of the Company’s BT Term Loan was $62.7 million. This valuation was calculated based on a series of Level 2 and Level 3 inputs by calculating a discount rate based on the credit risk spread of debt instruments of a similar risk character in reference to U.S. Treasury instruments with identical securities, with an incremental risk premium for Company-specific risk factors. The remaining cash flows associated with the BT Term Loan were discounted to March 31, 2020 with this calculated discount rate to derive the fair value as of that date.
As described above in Note 3, “Liquidity and Capital Resources,” on July 2, 2020, a portion of the proceeds from the Preferred Stock Transaction and the Hayfin Loan Transaction were used to repay the outstanding balance of principal, accrued but unpaid
interest, and prepayment premium under the BT Loan Agreement. In connection with the repayment of the BT Term Loan, the Company terminated the BT Loan Agreement.
Additionally, on July 2, 2020, the Company borrowed an aggregate of $50 million pursuant to the Hayfin Loan Agreement, and obtained an additional committed but undrawn $25 million facility pursuant to the Hayfin Loan Agreement, as described above in Note 3, “Liquidity and Capital Resources.”
XML 30 R16.htm IDEA: XBRL DOCUMENT v3.20.2
Net Loss Per Share
3 Months Ended
Mar. 31, 2020
Earnings Per Share [Abstract]  
Net Loss Per Share
Net Loss Per Share
Basic net loss per common share is computed using the weighted-average number of common shares outstanding during the period.  Diluted net loss per common share is computed using the weighted-average number of common and dilutive common equivalent shares from stock options, restricted stock and warrants using the treasury stock method. 
The following table sets forth the computation of basic and diluted net income per share (in thousands except share data):
 
Three Months Ended March 31,
 
2020
 
2019
Net loss
$
(4,821
)
 
$
(13,273
)
Denominator for basic earnings per share - weighted average shares
107,538,509

 
106,420,317

Effect of dilutive securities: Stock options, restricted stock, and warrants outstanding(a)
2,706,804

 
803,487

Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities
107,538,509

 
106,420,317

Loss per common share - basic
$
(0.04
)
 
$
(0.12
)
Loss per common share - diluted
$
(0.04
)
 
$
(0.12
)
(a) Securities outstanding that are included in the computation above, utilizing the treasury stock method are as follows:
 
Three Months Ended March 31,
 
2020
 
2019
Outstanding Stock Options
919,555

 
609,292

Performance Based Awards
17,402

 

Restricted Stock Awards
1,769,847

 
194,195

 
2,706,804

 
803,487


XML 31 R17.htm IDEA: XBRL DOCUMENT v3.20.2
Income Taxes
3 Months Ended
Mar. 31, 2020
Income Tax Disclosure [Abstract]  
Income Taxes
Income Taxes 
The effective tax rates for the Company of 70.1% and 0.3% for the three months ended March 31, 2020 and March 31, 2019, respectively includes the impact of discrete items of approximately $11.4 million in 2020 and $0 in 2019. As of March 31, 2020, the projected annual effective tax rate for 2020 is (0.6)%. The discrete items recorded for the three months ended March 31, 2020 are primarily related to modifications to the tax rules for carryback of net operating losses as a result of the CARES Act which are expected to result in a federal tax refund of approximately $11.3 million and an income tax benefit of the same amount. No benefit had been recognized with respect to the net operating losses due to a valuation allowance previously recorded.
XML 32 R18.htm IDEA: XBRL DOCUMENT v3.20.2
Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities
3 Months Ended
Mar. 31, 2020
Supplemental Cash Flow Elements [Abstract]  
Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities
Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities
Selected cash payments, receipts, and noncash activities are as follows (in thousands):
 
Three Months Ended March 31,
 
2020
 
2019
Cash paid for interest
$
1,840

 
$
1

Income taxes paid
6

 
46


XML 33 R19.htm IDEA: XBRL DOCUMENT v3.20.2
Contractual Commitments and Contingencies
3 Months Ended
Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]  
Contractual Commitments and Contingencies
Contractual Commitments and Contingencies
Contractual Commitments
In addition to the leases noted under Note 6 “Leases,” the Company has commitments for meeting space. These leases expire over 3 to 3.5 years following March 31, 2020, and generally contain renewal options. The Company anticipates that most of these leases will be renewed or replaced upon expiration.
Rent expense for the three months ended March 31, 2020 and 2019, was approximately $0.3 million and $0.4 million, respectively, and is allocated among cost of sales, research and development, and selling, general and administrative expenses.
Separation and Transition Services Agreement of Edward J. Borkowski
On November 18, 2019, the Company entered into a Separation and Transition Services Agreement (“Separation Agreement”) with Edward J. Borkowski, under which Mr. Borkowski resigned as Executive Vice President and Interim Chief Financial Officer of the Company, as well as from any and all officer, director or other positions that he held with the Company and its affiliates, effective November 15, 2019. Pursuant to the Separation Agreement, Mr. Borkowski agreed to perform the duties of the Interim Chief Financial Officer with respect to the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 (the “2018 Form 10-K”) and assist with the transition of his duties as described in the Separation Agreement from November 15, 2019 through the earlier of the first business day following the Company’s filing of its 2018 Form 10-K with the SEC or December 31, 2019 (the “Transition Period”). From the end of the Transition Period until March 31, 2020, Mr. Borkowski agreed to provide services as may be requested by the Company with respect to matters related to the 2018 Form 10-K and the 2019 Form 10-K. The Company has paid Mr. Borkowski the full amount of $4.0 million as of July 6, 2020.
Litigation and Regulatory Matters
In the ordinary course of business, the Company and its subsidiaries are parties to numerous civil claims and lawsuits and subject to regulatory examinations, investigations, and requests for information. Some of these matters involve claims for substantial amounts. The Company’s experience has shown that the damages alleged by plaintiffs or claimants are often overstated, based on unsubstantiated legal theories, unsupported by facts, and/or bear no relation to the ultimate award that a court might grant. Additionally, the outcome of litigation and regulatory matters and the timing of ultimate resolution are inherently difficult to predict. These factors make it difficult for the Company to provide a meaningful estimate of the range of reasonably possible outcomes of claims in the aggregate or by individual claim. However, on a case-by-case basis, reserves are established for those legal claims in which it is probable that a loss will be incurred and the amount of such loss can be reasonably estimated. The Company's financial statements at March 31, 2020 reflect the Company's current best estimate of probable losses associated with these matters, including costs to comply with various settlement agreements, where applicable. The actual costs of resolving these claims may be substantially higher or lower than the amounts reserved. For more information regarding the Company’s legal proceedings, refer to the disclosure under Item 3, “Legal Proceedings” and Note 16, “Commitments and Contingencies” in the Company’s 2019 Form 10-K, which disclosure is incorporated herein by reference.
The following is a description of certain litigation and regulatory matters:
Shareholder Derivative Suits
On December 6, 2018, the United States District Court for the Northern District of Georgia entered an order consolidating three shareholder derivative actions (Evans v. Petit, et al. filed September 25, 2018, Georgalas v. Petit, et al. filed September 27, 2018, and Roloson v. Petit, et al. filed October 22, 2018) that had been filed in the Northern District of Georgia. On January 22, 2019, plaintiffs filed a verified consolidated shareholder derivative complaint. The consolidated action sets forth claims of breach of fiduciary duty, corporate waste and unjust enrichment against certain former officers, and certain current and former directors, of the Company: Parker H. Petit, William C. Taylor, Michael J. Senken, John E. Cranston, Alexandra O. Haden, Joseph G. Bleser, J. Terry Dewberry, Charles R. Evans, Larry W. Papasan, Luis A. Aguilar, Bruce L. Hack, Charles E. Koob, Neil S. Yeston and Christopher M. Cashman. The allegations generally involve claims that the defendants breached their fiduciary duties by causing or allowing the Company to misrepresent its financial statements as a result of improper revenue recognition. The Company filed a motion to stay on February 18, 2019, pending the completion of the investigation by the Company’s Special Litigation Committee. The Special Litigation Committee completed its investigation relating to this action and filed an executive summary of its findings with the Court on July 1, 2019. The parties (together with parties from the Hialeah derivative lawsuit, the Nix and Demaio derivative lawsuit, and the Murphy derivative lawsuit, each described below) held a mediation on February 11, 2020. Following continued discussions, on May 1, 2020, the parties notified the Court that plaintiffs and the Company had reached an agreement in principle to settle this consolidated derivative action, which settlement also encompasses all claims asserted in the Hialeah derivative lawsuit, the Nix and Demaio derivative lawsuit, and the Murphy derivative lawsuit. As of the date of the filing of this Form 10-Q, the
parties are drafting, and intend to file, a stipulation of settlement and motion seeking preliminary approval of the settlement.
On February 10, 2020, Charles Pike filed a shareholder derivative complaint in the United States District Court for the Southern District of Florida (Pike v. Petit, et al.). The complaint alleges claims for breaches of fiduciary duty against certain former officers, and certain current and former directors, of the Company: Parker H. Petit, William C. Taylor, Michael J. Senken, John E. Cranston, Charles R. Evans, Luis A. Aguilar, Joseph G. Bleser, J. Terry Dewberry, Bruce L. Hack, Charles E. Koob, Larry W. Papasan and Neil S. Yeston. Similar to the prior-filed actions discussed above, the allegations generally involve claims that the defendants breached their fiduciary duties by causing or allowing the Company to misrepresent its financial statements as a result of improper revenue recognition. On May 12, 2020, prior to the Company’s time to respond to the complaint, the plaintiff filed a notice of voluntary dismissal of this action without prejudice.
On February 18, 2020, Bruce Cassamajor filed a shareholder derivative complaint in the United States District Court for the Northern District of Florida (Cassamajor v. Petit, et al.). The complaint alleges claims for breaches of fiduciary duty against certain former officers, and certain current and former directors, of the Company: Parker H. Petit, William C. Taylor, Michael J. Senken, John E. Cranston, Charles R. Evans, Luis A. Aguilar, Joseph G. Bleser, J. Terry Dewberry, Bruce L. Hack, Charles E. Koob, Larry W. Papasan and Neil S. Yeston. Similar to the prior-filed actions discussed above, the allegations generally involve claims that the defendants breached their fiduciary duties by causing or allowing the Company to misrepresent its financial statements as a result of improper revenue recognition. On May 22, 2020, prior to service of the complaint, the plaintiff filed a notice of voluntary dismissal of this action without prejudice. On May 26, 2020, the court ordered this case to be dismissed for failure to serve process.
Securities Class Action
On January 16, 2019, the United States District Court for the Northern District of Georgia entered an order consolidating two purported securities class actions (MacPhee v. MiMedx Group, Inc., et al. filed February 23, 2018 and Kline v. MiMedx Group, Inc., et al. filed February 26, 2018). The order also appointed Carpenters Pension Fund of Illinois as lead plaintiff. On May 1, 2019, the lead plaintiff filed a consolidated amended complaint, naming as defendants the Company, Michael J. Senken, Parker H. Petit, William C. Taylor, Christopher M. Cashman and Cherry Bekaert & Holland LLP. The amended complaint (the “Securities Class Action Complaint”) alleged violations of Section 10(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), Rule 10b-5 promulgated thereunder and Section 20(a) of the Exchange Act. It asserted a class period of March 7, 2013 through June 29, 2018. Following the filing of motions to dismiss by the various defendants, the lead plaintiff was granted leave to file an amended complaint. The lead plaintiff filed its amended complaint against the Company, Michael Senken, Pete Petit, William Taylor, and Cherry Bekaert & Holland (Christopher Cashman was dropped as a defendant) on March 30, 2020; defendants filed motions to dismiss on May 29, 2020.
Investigations
United States Attorney’s Office for the Southern District of New York (“USAO-SDNY”) Investigation
The USAO-SDNY is conducting an investigation into, among other things, the Company’s recognition of revenue and practices with certain distributors and customers. The USAO-SDNY requested that the Company provide it with copies of all information the Company furnished to the SEC staff and made additional requests for information. The USAO-SDNY conducted interviews of various individuals, including employees and former employees of the Company. In November 2019, former executives Messrs. Petit and Taylor were indicted for securities fraud and conspiracy to commit securities fraud, to make false filings with the SEC, and to influence improperly the conduct of audits relating to alleged misconduct that resulted in inflated revenue figures for fiscal 2015. The Company is cooperating with the USAO-SDNY.
Department of Veterans’ Affairs Office of Inspector General (“VA-OIG”) and Civil Division of the Department of Justice (“DOJ-Civil”) Subpoenas and/or Investigations
VA-OIG has issued subpoenas to the Company seeking, among other things, information concerning the Company’s financial relationships with VA clinicians. DOJ-Civil has requested similar information. The Company has cooperated fully and produced responsive information to VA-OIG and DOJ-Civil. Periodically, VA-OIG has requested additional documents and information regarding payments to individual VA clinicians. Most recently, on June 3, 2020, the Company received a subpoena from the VA-OIG requesting information regarding the Company’s financial relationships and interactions with two healthcare providers at the VA Long Beach Healthcare System. The Company has continued to cooperate and respond to these requests.
As part of its cooperation, the Company provided documents in response to subpoenas concerning its relationship with three now former VA employees in South Carolina, who were ultimately indicted in May 2018. Among other things, the indictment referenced speaker fees paid by the Company to the former VA employees and other interactions between now former Company employees and the former VA employees. In January 2019, prosecution was deferred for 18 months to allow the three former VA employees to enter and complete a Pretrial Diversion Program, the completion of which would result in the dismissal of the indictment. As far as the Company is aware, two of the former VA employees have completed the program early and the indictment has been dismissed with respect to them. To date, no actions have been taken against the Company with respect to this matter.
United States Attorney’s Office for the Middle District of North Carolina (“USAO-MDNC”) Investigation
On January 9, 2020, the USAO-MDNC informed the Company that it is investigating the Company’s financial relationships with two former clinicians at the Durham VA Medical Center. The Company is cooperating with the investigation.
Qui Tam Actions
On January 19, 2017, a former employee of the Company filed a qui tam False Claims Act complaint in the United States District Court for the District of South Carolina (United States of America, ex rel. Jon Vitale v. MiMedx Group, Inc.) alleging that the Company’s donations to the patient assistance program, Patient Access Network Foundation, violated the Anti-Kickback Statute and resulted in submission of false claims to the government. The government declined to intervene and the complaint was unsealed on August 10, 2018. The Company filed a motion to dismiss on October 1, 2018. The Company’s motion to dismiss was granted in part and denied in part on May 15, 2019. The case is in discovery.
Former Employee Litigation
On November 19, 2018, the Company’s former Chief Financial Officer filed a complaint in the Superior Court for Cobb County, Georgia (Michael J. Senken v. MiMedx Group, Inc.) in which he claims that the Company has breached its obligations under the Company’s charter and bylaws to advance to him, and indemnify him for, his legal fees and costs that he incurred in connection with certain Company internal investigations and litigation. The Company filed its answer denying the plaintiff’s claims on April 19, 2019. To date, no deadlines have been established by the court.
On January 21, 2019, a former employee filed a complaint in the Fifth Judicial Circuit, Richland County, South Carolina (Jon Michael Vitale v. MiMedx Group, Inc. et. al.) against the Company alleging retaliation, defamation and unjust enrichment and seeking monetary damages. The former employee claims he was retaliated against after raising concerns related to insurance fraud and later defamed by comments concerning the indictments of three South Carolina VA employees. On February 19, 2019, the case was removed to the U.S. District Court for the District of South Carolina. The Company filed a motion to dismiss on April 8, 2019, which was denied by the Court. This case is in discovery.
In December 2019, MiMedx received notice of a complaint filed in July 2018 with the Occupational Safety and Health Administration (“OSHA”) section of the Department of Labor (“DOL”) by Thomas Tierney, a former Regional Sales Director, against MiMedx and the referenced individuals, Tierney v. MiMedx Group, Inc., Parker Petit, William Taylor, Christopher Cashman, Thornton Kuntz, Jr. and Alexandra Haden, DOL No. 4-5070-18-243. Mr. Tierney alleged that he was terminated from MiMedx in retaliation for reporting concerns about revenue recognition practices, compliance issues, and the corporate culture, in violation of the anti-retaliation provisions of the Sarbanes-Oxley Act. The parties settled this matter and OSHA dismissed the complaint on May 20, 2020.
Defamation Claims
On June 4, 2018, Sparrow Fund Management, LP (“Sparrow”) filed a complaint against the Company and Mr. Petit, including claims for defamation and civil conspiracy in the United States District Court for the Southern District of New York (Sparrow Fund Management, L.P. v. MiMedx Group, Inc. et. al.). The complaint seeks monetary damages and injunctive relief and alleges the defendants commenced a campaign to publicly discredit Sparrow by falsely claiming it was a short seller who engaged in illegal and criminal behavior by spreading false information in an attempt to manipulate the price of our Common Stock. On March 31, 2019, a judge granted defendants’ motions to dismiss in full, but allowed Sparrow the ability to file an amended complaint. The Magistrate has recommended Sparrow’s motion for leave to amend be granted in part and denied in part and the Judge adopted the Magistrate’s recommendation. Sparrow filed its amended complaint against MiMedx (Mr. Petit has been dropped from the lawsuit) on April 3, 2020 and the Company filed its answer. This case is in discovery.
On June 17, 2019, the principals of Viceroy Research (“Viceroy”), filed suit in the Circuit Court for the Seventeenth Judicial Circuit in Broward County, Florida (Fraser John Perring et. al. v. MiMedx Group, Inc. et. al.) against the Company and Mr. Petit, alleging defamation and malicious prosecution based on the defendants’ alleged campaign to publicly discredit Viceroy and the
lawsuit the Company previously filed against the plaintiffs, but which the Company subsequently dismissed without prejudice. On November 1, 2019, the Court granted Mr. Petit’s motion to dismiss on jurisdictional grounds, denied the Company’s motion to dismiss, and granted plaintiffs leave to file an amended complaint to address the deficiencies in its claims against Mr. Petit, which they did on November 21, 2019. The Company filed its answer on December 20, 2019.
Intellectual Property Litigation
The NuTech Action
On March 2, 2015, the Company filed a patent infringement lawsuit against NuTech Medical, Inc. (“NuTech”) and DCI Donor Services, Inc. (“DCI”) in the United States District Court for the Northern District of Alabama (MiMedx Group, Inc. v. NuTech Medical, Inc. et. al.). The Company has alleged that NuTech and DCI infringed and continue to infringe the Company’s patents through the manufacture, use, sale and/or offering of their tissue graft product. The Company has also asserted that NuTech knowingly and willfully made false and misleading representations about its products to customers and prospective customers. The Company is seeking permanent injunctive relief and unspecified damages. The case was stayed pending the restatement of the Company’s financial statements. Since the Company has completed its restatement, the case has resumed and discovery has recommenced.
The Osiris Action
On February 20, 2019, Osiris Therapeutics, Inc. (“Osiris”) refiled its trade secret and breach of contract action against the Company (which had been dismissed in a different forum) in the United States District Court for the Northern District of Georgia (Osiris Therapeutics, Inc. v. MiMedx Group, Inc.). Osiris has alleged that the Company acquired Stability, a former distributor of Osiris, in order to illegally obtain trade secrets. On February 24, 2020, the Court issued an order granting in part and denying in party MiMedx’s motion to dismiss. The Court dismissed Osiris’s claims for tortious interference, conspiracy to breach contract, unfair competition, and conspiracy to commit unfair competition.  The Court denied MiMedx’s motion to dismiss with respect to the claim for breach of the contract between Osiris and Stability, finding that there is a question as to whether Osiris can maintain such a claim by piercing the corporate veil between MiMedx and its former subsidiary.  If Osiris cannot pierce the corporate veil, the claim against MiMedx fails; if Osiris can pierce the corporate veil, the breach of contract claim must be brought in an arbitration proceeding. MiMedx did not move to dismiss Osiris’s claims for misappropriation of trade secrets and conspiracy to misappropriate trade secrets. MiMedx plans to defend against all remaining claims.
As of March 31, 2020, the Company has accrued approximately $12.8 million related to the legal proceedings discussed above. The Company has paid approximately $9.2 million to settle certain cases noted above.
Other Matters
Under the Florida Business Corporation Act and agreements with its current and former officers and directors, the Company is obligated to indemnify its current and former officers and directors who are made party to a proceeding, including a proceeding brought by or in the right of the corporation, with certain exceptions, and to advance expenses to defend such matters. The Company has already borne substantial costs to satisfy these indemnification and expense advance obligations and expects to continue to do so in the future.
In addition to the matters described above, the Company is a party to a variety of other legal matters that arise in the ordinary course of the Company’s business, none of which is deemed to be individually material at this time. Due to the inherent uncertainty of litigation, there can be no assurance that the resolution of any particular claim or proceeding would not have a material adverse effect on the Company’s business, results of operations, financial position or liquidity.
XML 34 R20.htm IDEA: XBRL DOCUMENT v3.20.2
Product Revenue Detail
3 Months Ended
Mar. 31, 2020
Revenue from Contract with Customer [Abstract]  
Product Revenue Detail
Product Revenue Detail
MiMedx has two primary distribution channels: (1) direct to customers (healthcare professionals and/or facilities) (“Direct Customers”), and (2) sales through distributors (“Distributors”). For purposes of the required disclosure under ASC 606-10-50-5, the Company groups its customers into these two groups. This grouping by customer types does not constitute a basis for resource allocation but is information intended to provide the reader with ability to better understand how the nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factors applicable to each customer type. These groupings also do not meet the criteria under ASC 280-10-50-1 to qualify as separate operating segments. The Company did not have significant foreign operations or a single external customer from which 10% or more of revenues were derived during the three months ended March 31, 2020 and 2019.
Below is a summary of net sales by each customer type (in thousands):
 
Three Months Ended March 31,
 
2020
 
2019
 
 
 
 
Direct Customers
$
59,896

 
$
64,542

Distributors
1,840

 
2,013

Total
$
61,736

 
$
66,555


XML 35 R21.htm IDEA: XBRL DOCUMENT v3.20.2
Subsequent Events
3 Months Ended
Mar. 31, 2020
Subsequent Events [Abstract]  
Subsequent Events
Subsequent Events
Paycheck Protection Program (PPP) Loan
On April 24, 2020, the Company received a $10.0 million loan under the Paycheck Protection Program (“PPP”). On May 11, 2020 the Company repaid the PPP loan.
BT Loan Agreement Amendment
On April 22, 2020, the Company agreed to terms for an amendment to its BT Loan Agreement with Blue Torch. The amendment provided for an increase in the maximum Total Leverage Ratio (as defined in the BT Loan Agreement), which was a quarterly test, for the remainder of 2020, and also provided for a reduction in the minimum Liquidity (as defined in the BT Loan Agreement) requirement from April 2020 through and including November 2020. Specifically, the maximum Total Leverage Ratio increased from 3.0 to 1 to 5.0 to 1 through December 31, 2020. The minimum Liquidity requirement was reduced from $40 million to $20 million for April and May 2020, and from $30 million to $20 million for June through November 2020. In connection with the amendment, the Company agreed to pay a one-time fee of approximately $0.7 million, added to the principal balance, and a 1 percentage point increase in the interest rate to LIBOR plus 9%.
Sublease
On April 1, 2020 the Company successfully subleased its industrial warehouse space that expires on May 31, 2023. The Company performed an asset recovery test comparing the sum of estimated undiscounted future cash flows attributable to the sublease to its carrying amount. The total undiscounted cash flows for the remaining lease term exceed the carrying amount of the asset, therefore there is no impairment.
Issuance of $100 Million of Series B Convertible Preferred Stock
On July 2, 2020, the Company issued $100 million of Series B Convertible Preferred Stock to an affiliate of EW Healthcare Partners and to certain affiliates of Hayfin Capital Management LLP pursuant to that certain Securities Purchase Agreement, as described above in Note 3, “Liquidity and Capital Resources.”
$75 Million Loan Facility with Hayfin
On July 2, 2020, the Company borrowed an aggregate of $50 million pursuant to the Hayfin Loan Agreement, and obtained an additional committed but undrawn $25 million facility pursuant to the Hayfin Loan Agreement, as described above in Note 3, “Liquidity and Capital Resources.”
Repayment and Termination of BT Loan Agreement
On July 2, 2020, the Company repaid the remaining principal of $72.0 million, accrued interest of $0.1 million, and prepayment penalty of $1.4 million under the BT Loan Agreement with a portion of the proceeds from the Preferred Stock Transaction and the Hayfin Loan Transaction, and terminated the BT Loan Agreement, each as described above in Note 3, “Liquidity and Capital Resources.”
XML 36 R22.htm IDEA: XBRL DOCUMENT v3.20.2
Significant Accounting Policies (Policies)
3 Months Ended
Mar. 31, 2020
Accounting Policies [Abstract]  
Segment Reporting The Company operates in one business segment,
Basis of Presentation
Basis of Presentation
The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) from interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.  Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of Accounting Standards Updates (“ASU’’) to the FASB’s Accounting Standards Codification (“ASC”).  In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the results of operations for the periods presented have been included.  Operating results for the three months ended March 31, 2020 and 2019, are not necessarily indicative of the results that may be expected for the fiscal year.  The balance sheet at December 31, 2019, has been derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements. 
You should read these condensed consolidated financial statements together with the historical consolidated financial statements of the Company for the year ended December 31, 2019, included in the
Use of Estimates
Use of Estimates
The consolidated financial statements have been prepared in accordance with GAAP. Conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported consolidated statements of operations during the reporting period. Actual results could differ from those estimates. Significant estimates include estimated useful lives and potential impairment of property and equipment and intangible assets, estimates for contingent liabilities, management’s assessment of the Company’s ability to continue as a going concern, estimates of fair value of share-based payments and valuation of deferred tax assets.
Principles of Consolidation
Principles of Consolidation
The consolidated financial statements include the accounts of MiMedx Group, Inc. and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation.
Cash and Cash Equivalents
Cash and Cash Equivalents
Cash and cash equivalents include cash and Federal Deposit Insurance Corporation (“FDIC”) insured certificates of deposit held at various banks with an original maturity of three months or less.
Accounts Receivable and Notes Receivable
Accounts Receivable
Accounts receivable represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables.
The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing receivables. The Company determines the allowance based on factors such as historical collection experience, customers’ current creditworthiness, customer concentrations, age of accounts receivable and general economic conditions that may affect customers’ ability to pay.
Notes Receivable
Notes receivable represent formal payment agreements with customers which generally arise in situations where amounts shipped and billed have aged significantly as well as the promissory note issued by Stability Biologics, LLC (“Stability”) as part of the divestiture of Stability in 2017. The promissory note from Stability was paid in full in the three months ended September 30, 2019. The Company’s notes receivable are included in other current and long-term assets in the accompanying condensed consolidated balance sheets and were valued taking into consideration cost of the market participant inputs, market conditions, liquidity, operating results and other qualitative factors.
Inventories
Inventories
Inventories are valued at the lower of cost or net realizable value, using the first-in, first-out (“FIFO”) method.  Inventory is tracked through raw material, work-in-process, and finished good stages as the product progresses through various production steps and stocking locations. Labor and overhead costs are absorbed through the various production processes until the work order closes. Historical yields and normal capacities are utilized in the calculation of production overhead rates. Reserves for inventory obsolescence are utilized to account for slow-moving inventory as well as inventory no longer needed due to diminished market demand.
Revenue Recognition
Revenue Recognition
The Company sells its products primarily to individual customers and independent distributors (collectively referred to as “customers”). During the three months ended March 31, 2019, the Company’s control environment was such that it created uncertainty surrounding all of its customer arrangements, which required consideration related to the proper revenue recognition under the applicable literature. The control environment allowed for the existence of extra-contractual or undocumented terms or arrangements initiated by or agreed to by the Company and former members of Company management at the outset of the transactions (side agreements). Concessions were also agreed to subsequent to the initial sale (e.g. sales above established customer credit limits extended and unusually long payment terms, return or exchange rights, and contingent payment obligations) that called into question the ability to recognize revenue at the time that product was shipped to a customer. The applicable revenue
recognition guidance also changed beginning January 1, 2018, which further impacted the Company’s revenue recognition methodology.
As a result, the Company’s application of the applicable revenue recognition guidance varies for the three months ended March 31, 2020 and 2019. Additionally, the Company changed its pattern of revenue recognition effective October 1, 2019. The application of the relevant revenue recognition guidance and the pattern of revenue recognition are further discussed below for each period presented.
Three Months Ended March 31, 2019
The Company follows ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”) which establishes principles for reporting information about the nature, amount, timing and uncertainty of revenue and cash flows arising from the entity’s contracts to provide goods or services to customers. The core principle requires an entity to recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration that it expects to be entitled to receive in exchange for those goods or services recognized as performance obligations are satisfied.
ASC 606 establishes a five-step model for revenue recognition. The first of these steps requires the identification of the contract as described in ASC 606-10-25-1. The specific criteria (the “Step 1 Criteria”) to this determination are as follows:
The parties to the contract have approved the contract (in writing, orally, or in accordance with other customary business practices) and are committed to perform their respective obligations;
The entity can identify each party’s rights regarding the goods or services to be transferred; and
The entity can identify the payment terms for the goods or services to be transferred.
The contract has commercial substance.
It is probable that the entity will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.
For the three months ended March 31, 2019, the Company concluded that the first three of the above criteria were not met upon shipment of product to the customer, the fourth criterion had been met, and the Company acknowledges that there is a degree of uncertainty as to whether the last criterion above had been met. Although the parties to the contract may have approved the contract and purchase orders in writing, the Company concluded that upon shipment of products to the customer there is not sufficient evidence that its customers were committed to perform their obligations defined in the contract due to the existence of extra-contractual or undocumented terms or arrangements (e.g., regarding payment terms, right of return, etc.).
The Company’s inability to fulfill these criteria was due to uncertainties of contractual adjustments with customers created by a combination of an inappropriate tone at the top and extra-contractual arrangements. Consequently, the Company concluded that it did not meet the Step 1 Criteria upon shipment of the product. Subsequent to the shipment of product, uncertainties surrounding contractual adjustment were not resolved until either: (1) the customer returned the product prior to payment; or (2) the Company received payment from the customer. At that point, the Company determined that an accounting contract existed and the performance obligations of the Company to deliver product and the customer to pay for the product were satisfied. The Company determined the transaction price of its contracts to equal the amount of consideration received from customers less the amount expected to be refunded or credited to customers, which is recognized as a refund liability that is updated at the end of each reporting period for changes in circumstances. The refund liability is included within accrued expenses in the consolidated balance sheet.
Transition and the Three Months Ended March 31, 2020
The Company continued to assess contracts, new and existing, throughout 2019 to determine if the Step 1 Criteria noted above for the determination of a contract under ASC 606 were met for new contracts at the outset of a sales transaction (i.e., upon shipment of product) or for existing contracts at some point within 2019 when all the terms of the arrangement would have been known. Until the Step 1 Criteria had been met, revenue recognition continued to be deferred consistent with the assessment for the year ended December 31, 2018.
As further discussed above, the primary factors contributing to the determination in prior periods that the Step 1 Criteria had not been met were the inappropriate tone at the top and the existence of pervasive extra-contractual or undocumented terms or arrangements. These prior business practices and the lack of transparency surrounding them created a systemically implied right for customers to demand future, unknown performance by the Company. Although some of the former executives were employed by the Company only through June 2018, the Company determined that based on the impact of the prior tone at the top, the
continued internal sales force strategy and the existing customer base’s continued expectations (based on past practice), there would be flexibility with respect to arrangement terms even after delivery of the product so pervasive that all customer arrangements continued to be subject to uncertain modification of terms into 2019.
After identifying the primary factors contributing to the lack of knowledge regarding its customer contractual terms, the Company began implementing changes in mid-2018 to remediate the pervasive weaknesses in the control environment, followed by gradually implementing measures to empower its compliance, legal, and accounting departments, educating its sales force on appropriate business practices, and communicating its revised terms of sale to customers. The Company assessed its efforts throughout 2019 to determine when, if at any point, the factors contributing to the inability to satisfy the Step 1 Criteria were sufficiently addressed such that the Step 1 Criteria were met at the time of physical delivery to the customer. Determining when these conditions were effectively satisfied was a matter of judgment; however, the Company determined that adequate knowledge of the contractual arrangements with its customers did exist in 2019. Management did note that there is no single determinative change that overcame the pervasive challenges noted above, but rather an accumulation of efforts that taken together, resulted in sufficient knowledge of contractual relationships both internally within the Company and externally with its customers.
To address the tone at the top issues, the Company noted that proper remediation involved not only the removal of members of management that were setting an inappropriate tone but also the establishment of new management throughout the organization that emphasized a commitment to integrity, ethical values and transparency and have that reinforcement for a sustained period of time. The changes made to management positions throughout the organization and the resulting organization behavior changes were assessed to have been sufficiently addressed by mid-2019.
Therefore, beginning October 1, 2019, for all new customer arrangements, the Company determined adequate measures were in place to understand the terms of its contracts with customers. As such, beginning October 1, 2019, the Company concluded that the Step 1 Criteria would be met prior to shipment of product to the customer or implantation of the products on consignment.
For the remaining customer arrangements at September 30, 2019 (the “Remaining Contracts”), the Company concluded that due to the uncertainty that extracontractual arrangement may continue the Step 1 Criteria would not be satisfied until the Company receives payment from the customer. At that point, the Company determined that an accounting contract would exist and the performance obligations of the company to deliver product and the customer to pay for the product would be satisfied. As of March 31, 2020, upon reassessment, the Company concluded that the Step 1 Criteria continued to not be met due to the same circumstances described above. The amount related to these Remaining Contracts at March 31, 2020 was $4.5 million.
 
Amounts Invoiced and Not Collected

Deferred Cost of Sales
Amounts as of December 31, 2019
$
9,006

 
$
1,261

Revenue recognized related to amounts invoiced and not collected at September 30, 2019:
 
 
 
Cash collected during the three months ended March 31, 2020 related to the Remaining Contracts
(4,495
)
 
(629
)
Amounts as of March 31, 2020
$
4,511

 
$
632


As a result of the reassessment as of September 30, 2019, the Company also determined that, for approximately $10.3 million of existing contracts where payment had not been received, it was not probable that substantially all consideration would be collected. For these customer contracts, the Company continued to fail the Step 1 Criteria and, therefore, no revenue was recognized in 2019. Any collections during the three months ended March 31, 2020, as well as any future collections relating to these customer contracts, will be recorded as revenue at the time payment is received.
For all customer transactions concluded to meet the Step 1 Criteria, the Company then assessed the remaining criteria of ASC 606 to determine the proper timing of revenue recognition.
Under ASC 606, the Company recognizes revenue following the five-step model: (i) identify the contracts with a customer (the Step 1 Criteria); (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. As noted above, during the third quarter of 2019, the Company determined that they had met the Step 1 Criteria. The Company also determined that the performance obligation was met upon delivery of the product to the customer, or at the time the product is implanted for products on consignment, at which point the Company determined it will collect the consideration it is entitled to in exchange for the product transferred to the customer. As a result, the Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied, generally upon shipment of the product to the customer. The nature of the Company’s contracts gives rise
to certain types of variable consideration, including rebates and other discounts. The Company includes estimated amounts of variable consideration in the transaction price to the extent that it is probable there will not be a significant reversal of revenue. Estimates are based on historical or anticipated performance. The Company does have consignment agreements with several customers and distributors which allow the Company to better market its products by moving them closer to the end user. In these cases, the Company determined that it has fulfilled its performance obligation once control of the product has been delivered to the customer, which occurs simultaneously with the product being implanted.
The Company acts as the principal in all of its customer arrangements and therefore records revenue on a gross basis. Shipping is considered immaterial in the context of the overall customer arrangement, and damages or loss of goods in transit are rare. Therefore, shipping is not deemed a separately recognized performance obligation. The Company maintains a returns policy that allows its customers to return product that is consigned, damaged or non-conforming, ordered in error, or due to a recall. The estimate of the provision for returns is based upon historical experience with actual returns. The Company’s payment terms for customers are typically 30 to 60 days from receipt of title of the goods.
Subsequent to the Transition, the Company continued to defer the cost of sales for certain arrangements for which all revenue recognition criteria have not been met. These amounts were recorded within other current assets on the consolidated balance sheet in the amount of $0.6 million and $1.3 million as of March 31, 2020 and December 31, 2019, respectively.
GPO Fees
The Company sells to Group Purchasing Organization (“GPO”) members who transact directly with the Company at GPO-agreed pricing. GPOs are funded by administrative fees that are paid by the Company. These fees are set as a percentage of the purchase volume, which is typically 3% of sales made to the GPO members. The Company presents the administrative fees paid to GPOs as a reduction of revenues because the benefit received by the Company in exchange for the GPO fees is not sufficiently separable from the GPO member’s purchase of the Company’s products.
Cost of Sales
Cost of sales includes all costs directly related to bringing the Company’s products to their final selling destination. Amounts include direct and indirect costs to manufacture products including raw materials, personnel costs and direct overhead expenses necessary to convert collected tissues into finished goods, product testing costs, quality assurance costs, facility costs associated with the Company’s manufacturing and warehouse facilities, depreciation, freight charges, costs to operate equipment and other shipping and handling costs for products shipped to customers.
Leases
Leases
Effective January 1, 2019, the Company accounts for its leases under ASC 842, “Leases”. The Company determines if an arrangement is, or contains, a lease at inception. Right-of-use assets and the related liabilities result from operating leases were included in Right of use asset, Other current liabilities and Other liabilities, respectively, in the condensed consolidated balance sheets as of March 31, 2020 and December 31, 2019.
Operating lease assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. The lease term used in the calculation includes options to extend or terminate the lease when the exercise of such options are reasonably certain. The Company uses the estimated incremental borrowing rate in determining the present value of lease payments. Variable components of the lease payments such as fair market value adjustments, utilities, and maintenance costs are expensed as incurred and not included in determining the present value of lease liabilities. As an accounting policy election, the Company excludes short-term leases having initial terms of 12 months or fewer. Lease expense is recognized on a straight-line basis over the lease term. See Note 6, “Leases” for further information regarding lease obligations.
Patent Costs
Patent Costs
The Company incurs certain legal and related costs in connection with patent applications for tissue-based products and processes. The Company capitalizes such costs as patents in progress until a patent is obtained. When a patent is issued, the costs are amortized over the expected life of the patent to the extent that an economic benefit is anticipated from the resulting patent or alternative future use is available to the Company. If a patent is not obtained, costs are expensed. Patents are included in Intangible assets in the condensed consolidated balance sheet.
Treasury Stock
Treasury Stock
The Company accounts for the purchase of treasury stock under the cost method. Treasury stock which is reissued for the exercise of option grants and the issuance of restricted stock grants is accounted for on a FIFO basis.
Recently Issued and Adopted Accounting Standards
Recently Issued Accounting Standards Adopted by the Company
In February 2016, FASB issued ASU No. 2016-02, “Leases (Topic 842)”, which amended the guidance on accounting for leases. The FASB issued this update to increase transparency and comparability among organizations. This update requires the recognition of lease assets and lease liabilities on the balance sheet and the disclosure of key information about leasing arrangements. The Company adopted the ASU effective January 1, 2019 using the additional (optional) approach, in accordance with ASU 2018-11, “Leases (Topic 842): Targeted Improvements.” Upon adoption, the Company recorded a right of use asset of $4.3 million and a right of use liability of $5.2 million. The right of use asset, in its entirety, is included in Right of use assets, net on the condensed consolidated balance sheet. Right of use liabilities are included in Other current liabilities to the extent that such liabilities are expected to be settled within one year and Other liabilities to the extent that such obligations are due more than one year from the balance sheet date. The difference between the right of use asset and liability relates to rent credits which existed as of January 1, 2019. There was no effect on opening retained earnings at adoption.
In adopting the new lease standard, the Company elected the permitted package of practical expedients permitted, which allowed the Company to account for existing leases under their current classification, as well as omit any new costs classified as initial direct costs, under the new standard. See Note 6 for additional information on leases.
In February 2018, the FASB issued ASU No. 2018-02, “Income Statement - Reporting Comprehensive Income (Topic 220),” to address certain income tax effects in Accumulated Other Comprehensive Income (“AOCI”) resulting from the tax reform enacted in 2017. The amended guidance provides an option to reclassify tax effects within AOCI to retained earnings in the period in which the effect of the tax reform is recorded. The amendments were effective for fiscal years beginning after December 15, 2018, including interim periods. The Company adopted this ASU on January 1, 2019, which did not have any impact on the Company’s results of operations or financial condition as there were no balances in AOCI that are tax effected.
In June 2018, the FASB issued ASU 2018-07, “Compensation-Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Payment Accounting” (“ASU 2018-07”), which simplifies the accounting for share-based payments to non-employees by aligning it with the accounting for share-based payments to employees, with certain exceptions. Under the new guidance, the measurement of equity-classified nonemployee awards will be fixed at the grant date. ASU 2018-07 is effective for interim and annual reporting periods beginning after December 15, 2018 and early adoption was permitted. The Company adopted the new standard on January 1, 2019. The adoption of ASU 2018-07 did not have a material impact on the Company’s consolidated financial statements and related disclosures.
In June 2016, the FASB issued ASU 2016-13, “Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,” that introduces a new model for recognizing credit losses on financial instruments based on an estimate of current expected credit losses. This includes accounts receivable, trade receivables, loans, held-to-maturity debt securities, net investments in leases and certain off-balance sheet credit exposures. The guidance also modifies the impairment model for available-for-sale debt securities. The ASU is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2019. The Company adopted this ASU on January 1, 2020 using a modified retrospective transition method which requires a cumulative-effect adjustment to the opening balance of retained earnings to be recognized on the date of adoption with no change to financial results reported in prior periods. The cumulative effect adjustment recorded on January 1, 2020 is not material. The adoption of this ASU did not have a significant impact on the Company’s consolidated financial statements and related disclosures.
All other ASUs issued and not yet effective for the three months ended March 31, 2020, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company’s financial position or results of operations.
XML 37 R23.htm IDEA: XBRL DOCUMENT v3.20.2
Significant Accounting Policies (Tables)
3 Months Ended
Mar. 31, 2020
Accounting Policies [Abstract]  
Assessment of Revenue under ASC 606
 
Amounts Invoiced and Not Collected

Deferred Cost of Sales
Amounts as of December 31, 2019
$
9,006

 
$
1,261

Revenue recognized related to amounts invoiced and not collected at September 30, 2019:
 
 
 
Cash collected during the three months ended March 31, 2020 related to the Remaining Contracts
(4,495
)
 
(629
)
Amounts as of March 31, 2020
$
4,511

 
$
632


XML 38 R24.htm IDEA: XBRL DOCUMENT v3.20.2
Inventory (Tables)
3 Months Ended
Mar. 31, 2020
Inventory Disclosure [Abstract]  
Inventory
Inventory consisted of the following (in thousands):
 
March 31, 2020
 
December 31, 2019
Raw materials
$
330

 
$
318

Work in process
3,913

 
4,299

Finished goods
5,587

 
5,206

 Inventory, gross
9,830

 
9,823

Reserve for obsolescence
(583
)
 
(719
)
 Inventory, net
$
9,247

 
$
9,104


XML 39 R25.htm IDEA: XBRL DOCUMENT v3.20.2
Property and Equipment (Tables)
3 Months Ended
Mar. 31, 2020
Property, Plant and Equipment [Abstract]  
Summary of Property and Equipment
Property and equipment consisted of the following (in thousands):
 
March 31, 2020
 
December 31, 2019
Leasehold improvements
$
5,321

 
$
5,321

Lab and clean room equipment
15,128

 
14,894

Furniture and office equipment
15,405

 
15,118

Construction in progress
1,463

 
972

   Property and equipment, gross
37,317

 
36,305

Less accumulated depreciation
(25,484
)
 
(23,977
)
   Property and equipment, net
$
11,833

 
$
12,328


XML 40 R26.htm IDEA: XBRL DOCUMENT v3.20.2
Leases (Tables)
3 Months Ended
Mar. 31, 2020
Leases [Abstract]  
Supplemental Balance Sheet Information Related to Leases
Supplemental balance sheet information related to operating leases is as follows (amounts in thousands, except lease term and discount rate):
 
 
March 31, 2020
 
December 31, 2019
Assets
 
 
 
 
Right of use asset
$
3,158

 
$
3,397

 
 
 
 
 
Liabilities
 
 
 
 
Short term lease liability
$
1,195

 
$
1,168

 
Long term lease liability
$
2,611

 
$
2,919

 
 
 
 
 
Weighted-average remaining lease term (years)
2.8

 
3.1

Weighted-average discount rate
11.5
%
 
11.5
%

Maturities of Operating Lease Liabilities
Maturities of operating leases liabilities are as follows (amounts in thousands):
Year ended December 31,
Maturities
2020 (excluding the three months ended March 31, 2020)
$
1,170

2021
1,528

2022
1,552

2023
195

2024

Thereafter

Total lease payments
4,445

Less: imputed interest
(639
)
 
$
3,806


XML 41 R27.htm IDEA: XBRL DOCUMENT v3.20.2
Intangible Assets (Tables)
3 Months Ended
Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets Activity Summary - Finite Lived
Intangible assets are summarized as follows (in thousands):
 
 
March 31, 2020
 
December 31, 2019
 
 
Gross Carrying Amount
Accumulated Amortization
Net Carrying Amount
 
Gross Carrying Amount
Accumulated Amortization
Net Carrying Amount
Amortized intangible assets
 
 
 
 
 
 
 
 
Licenses
 
$
1,414

$
(1,234
)
$
180

 
$
1,414

$
(1,200
)
$
214

Patents and know how
 
9,108

(5,232
)
3,876

 
9,099

(5,070
)
4,029

Customer and supplier relationships
 
3,761

(2,485
)
1,276

 
3,761

(2,417
)
1,344

Non-compete agreements
 
120

(75
)
45

 
120

(68
)
52

Total amortized intangible assets
 
$
14,403

$
(9,026
)
$
5,377

 
$
14,394

$
(8,755
)
$
5,639

 
 
 
 
 
 
 
 
 
Unamortized intangible assets
 
 
 
 
 
 
 
 
Trade names and trademarks
 
$
1,008

 
$
1,008

 
$
1,008

 
$
1,008

Patents in process
 
1,196

 
1,196

 
1,130

 
1,130

Total intangible assets
 
$
16,607

 
$
7,581

 
$
16,532

 
$
7,777


Intangible Assets Activity Summary - Indefinite Lived
Intangible assets are summarized as follows (in thousands):
 
 
March 31, 2020
 
December 31, 2019
 
 
Gross Carrying Amount
Accumulated Amortization
Net Carrying Amount
 
Gross Carrying Amount
Accumulated Amortization
Net Carrying Amount
Amortized intangible assets
 
 
 
 
 
 
 
 
Licenses
 
$
1,414

$
(1,234
)
$
180

 
$
1,414

$
(1,200
)
$
214

Patents and know how
 
9,108

(5,232
)
3,876

 
9,099

(5,070
)
4,029

Customer and supplier relationships
 
3,761

(2,485
)
1,276

 
3,761

(2,417
)
1,344

Non-compete agreements
 
120

(75
)
45

 
120

(68
)
52

Total amortized intangible assets
 
$
14,403

$
(9,026
)
$
5,377

 
$
14,394

$
(8,755
)
$
5,639

 
 
 
 
 
 
 
 
 
Unamortized intangible assets
 
 
 
 
 
 
 
 
Trade names and trademarks
 
$
1,008

 
$
1,008

 
$
1,008

 
$
1,008

Patents in process
 
1,196

 
1,196

 
1,130

 
1,130

Total intangible assets
 
$
16,607

 
$
7,581

 
$
16,532

 
$
7,777


Estimated Future Amortization Expense for Intangible Assets
Expected future amortization of intangible assets as of March 31, 2020, is as follows (in thousands):
Year ending December 31,
Estimated
Amortization
Expense
2020 (excluding the three months ended March 31, 2020)
$
739

2021
978

2022
955

2023
955

2024
955

Thereafter
795

 
$
5,377


XML 42 R28.htm IDEA: XBRL DOCUMENT v3.20.2
Accrued Expenses (Tables)
3 Months Ended
Mar. 31, 2020
Payables and Accruals [Abstract]  
Schedule of Accrued Expenses
Accrued expenses include the following (in thousands):
 
March 31, 2020
 
December 31, 2019
Legal costs
$
13,302

 
$
12,202

Settlement costs
5,931

 
5,931

Pricing adjustment settlement with Veterans Affairs
6,894

 
6,894

Estimated returns
1,567

 
2,581

External commissions
1,328

 
1,722

Accrued clinical trials
566

 
1,076

Other
1,073

 
1,755

    Total
$
30,661

 
$
32,161


XML 43 R29.htm IDEA: XBRL DOCUMENT v3.20.2
Long Term Debt (Tables)
3 Months Ended
Mar. 31, 2020
Debt Disclosure [Abstract]  
Schedule of Debt
The balances of the BT Term Loan were as follows (amounts in thousands):
 
March 31, 2020
December 31, 2019
 
Current portion
 
Long-term
Current portion
 
Long-term
Liability component - principal
$
3,750

 
$
68,438

$
3,750

 
$
69,375

Original issue discount

 
(1,723
)

 
(1,890
)
Deferred financing cost

 
(5,078
)

 
(5,579
)
Liability component - net carrying value
$
3,750

 
$
61,637

$
3,750

 
$
61,906


Schedule of Interest Expense
Interest expense related to the BT Term Loan, included in Interest income (expense), net in the consolidated statements of operations, was as follows (amounts in thousands):
 
For the Three Months Ended
 
March 31, 2020
Interest expense - stated interest rate
$
1,840

Interest expense - amortization of original issue discount and costs
167

Interest expense - amortization of deferred financing costs
491

Total term loan interest expense
$
2,498


Future Principal Payments for the Term Loan
The future principal payments for the Company’s BT Term Loan as of March 31, 2020 were as follows (in thousands):
Year ending December 31,
Principal
2020 (excluding the three months ended March 31, 2020)
$
2,088

2021
3,750

2022
66,350

2023

2024

Thereafter

Total Long Term Debt
$
72,188


XML 44 R30.htm IDEA: XBRL DOCUMENT v3.20.2
Net Loss Per Share (Tables)
3 Months Ended
Mar. 31, 2020
Earnings Per Share [Abstract]  
Computation of Basic and Diluted Net Income per Share
The following table sets forth the computation of basic and diluted net income per share (in thousands except share data):
 
Three Months Ended March 31,
 
2020
 
2019
Net loss
$
(4,821
)
 
$
(13,273
)
Denominator for basic earnings per share - weighted average shares
107,538,509

 
106,420,317

Effect of dilutive securities: Stock options, restricted stock, and warrants outstanding(a)
2,706,804

 
803,487

Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities
107,538,509

 
106,420,317

Loss per common share - basic
$
(0.04
)
 
$
(0.12
)
Loss per common share - diluted
$
(0.04
)
 
$
(0.12
)
(a) Securities outstanding that are included in the computation above, utilizing the treasury stock method are as follows:
 
Three Months Ended March 31,
 
2020
 
2019
Outstanding Stock Options
919,555

 
609,292

Performance Based Awards
17,402

 

Restricted Stock Awards
1,769,847

 
194,195

 
2,706,804

 
803,487


Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Securities outstanding that are included in the computation above, utilizing the treasury stock method are as follows:
 
Three Months Ended March 31,
 
2020
 
2019
Outstanding Stock Options
919,555

 
609,292

Performance Based Awards
17,402

 

Restricted Stock Awards
1,769,847

 
194,195

 
2,706,804

 
803,487


XML 45 R31.htm IDEA: XBRL DOCUMENT v3.20.2
Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities (Tables)
3 Months Ended
Mar. 31, 2020
Supplemental Cash Flow Elements [Abstract]  
Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities
Selected cash payments, receipts, and noncash activities are as follows (in thousands):
 
Three Months Ended March 31,
 
2020
 
2019
Cash paid for interest
$
1,840

 
$
1

Income taxes paid
6

 
46


XML 46 R32.htm IDEA: XBRL DOCUMENT v3.20.2
Product Revenue Detail (Tables)
3 Months Ended
Mar. 31, 2020
Revenue from Contract with Customer [Abstract]  
Net Sales by Customer Type
Below is a summary of net sales by each customer type (in thousands):
 
Three Months Ended March 31,
 
2020
 
2019
 
 
 
 
Direct Customers
$
59,896

 
$
64,542

Distributors
1,840

 
2,013

Total
$
61,736

 
$
66,555


XML 47 R33.htm IDEA: XBRL DOCUMENT v3.20.2
Nature of Business (Details)
$ in Millions
3 Months Ended
Mar. 31, 2020
USD ($)
segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Number of business segments | segment 1
Federal income tax receivable | $ $ 11.3
XML 48 R34.htm IDEA: XBRL DOCUMENT v3.20.2
Significant Accounting Policies (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2019
Concentration Risk [Line Items]      
Amounts Invoiced and Not Collected, After Transition Adjustment $ 4,511   $ 9,006
Deferred Cost of Sales, After Transition Adjustment 632   1,261
Deferred cost of sales $ 600   $ 1,300
GPO administrative fees as percent of purchase volume 3.00%    
Minimum      
Concentration Risk [Line Items]      
Typical payment period for customers 30 days    
Maximum      
Concentration Risk [Line Items]      
Typical payment period for customers 60 days    
Patents      
Concentration Risk [Line Items]      
Intangible assets, net of accumulated amortization $ 100 $ 200  
XML 49 R35.htm IDEA: XBRL DOCUMENT v3.20.2
Significant Accounting Policies - Assessment of Revenue under ASC 606 (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2020
Sep. 30, 2019
Accounts Receivable, Net [Roll Forward]    
Amounts Invoiced and Not Collected, beginning $ 9,006  
Proceeds from Sale and Collection of Receivables (4,495)  
Amounts Invoiced and Not Collected, ending 4,511  
Deferred Cost of Sales [Roll Forward]    
Deferred Cost of Sales, beginning 1,261  
Deferred Cost of Sales, Cash Collected (629)  
Deferred Cost of Sales, ending $ 632  
Amounts Invoiced and Not Collected, Write-off of Deferred Costs for Customer Contracts where Collection is no Longer Reasonable Assured   $ 10,300
XML 50 R36.htm IDEA: XBRL DOCUMENT v3.20.2
Significant Accounting Policies - Recently Issued and Adopted Accounting Standards (Details) - USD ($)
$ in Thousands
Jan. 01, 2019
Mar. 31, 2020
Dec. 31, 2019
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Right of use asset   $ 3,158 $ 3,397
Lease liability   $ 3,806  
ASU No. 2016-02      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Right of use asset $ 4,300    
Lease liability 5,200    
Effect on opening retained earnings $ 0    
XML 51 R37.htm IDEA: XBRL DOCUMENT v3.20.2
Liquidity and Capital Resources (Details)
2 Months Ended 3 Months Ended 6 Months Ended 7 Months Ended 12 Months Ended 18 Months Ended 48 Months Ended
Jul. 02, 2020
USD ($)
$ / shares
May 31, 2020
USD ($)
Mar. 31, 2020
USD ($)
$ / shares
Jun. 30, 2021
Dec. 31, 2020
Nov. 30, 2020
USD ($)
Dec. 30, 2020
USD ($)
May 31, 2020
USD ($)
Jun. 20, 2022
USD ($)
Jun. 29, 2025
Dec. 31, 2019
USD ($)
$ / shares
Subsequent Event [Line Items]                      
Cash and cash equivalents     $ 53,525,000               $ 69,069,000
Total current assets     115,888,000               123,245,000
Total current liabilities     $ 63,699,000               $ 67,322,000
Preferred stock par value (in dollars per share) | $ / shares     $ 0.001               $ 0.001
Subsequent Event | Series B Convertible Preferred Stock                      
Subsequent Event [Line Items]                      
Stock issued during period $ 100,000,000                    
Preferred stock par value (in dollars per share) | $ / shares $ 0.001                    
Proceeds from issuance of convertible preferred stock $ 100,000,000                    
BT Loan Agreement | Term Loan | Subsequent Event                      
Subsequent Event [Line Items]                      
Repayment of principal 72,000,000.0                    
Accrued interest paid 100,000                    
Prepayment of premium paid 1,400,000                    
Hayfin Loan Agreement Term Loan | Senior secured term loan | Subsequent Event                      
Subsequent Event [Line Items]                      
Face value of debt 50,000,000                    
Hayfin Loan Agreement Delayed Draw Term Loan | Term Loan | Subsequent Event                      
Subsequent Event [Line Items]                      
Face value of debt $ 25,000,000                    
Commitment fee on undrawn amounts (percent) 1.00%                    
Total net leverage ratio 3.5                    
Hayfin Loan Agreement | Senior secured term loan | Subsequent Event                      
Subsequent Event [Line Items]                      
Upfront commitment fee (percent) 2.00%                    
Cap on cash netting for calculation of Total Net Leverage $ 10,000,000                    
Minimum liquidity $ 10,000,000                    
LIBOR | BT Loan Agreement | Term Loan                      
Subsequent Event [Line Items]                      
Basis spread on variable rate     8.00%                
LIBOR | Hayfin Loan Agreement | Senior secured term loan | Subsequent Event                      
Subsequent Event [Line Items]                      
Floor interest rate (percent) 1.50%                    
Basis spread on variable rate 6.75%                    
Minimum | LIBOR | Hayfin Loan Agreement | Senior secured term loan | Subsequent Event                      
Subsequent Event [Line Items]                      
Basis spread on variable rate, based on total net leverage levels (percent) 6.50%                    
Maximum | LIBOR | Hayfin Loan Agreement | Senior secured term loan | Subsequent Event                      
Subsequent Event [Line Items]                      
Basis spread on variable rate, based on total net leverage levels (percent) 6.00%                    
Forecast | BT Loan Agreement | Term Loan                      
Subsequent Event [Line Items]                      
Minimum liquidity   $ 40,000,000       $ 30,000,000 $ 30,000,000.0 $ 40,000,000.0 $ 20,000,000.0    
Forecast | Hayfin Loan Agreement | Senior secured term loan                      
Subsequent Event [Line Items]                      
Total net leverage ratio       4.5 5.0         4.0  
XML 52 R38.htm IDEA: XBRL DOCUMENT v3.20.2
Inventory (Details) - USD ($)
$ in Thousands
Mar. 31, 2020
Dec. 31, 2019
Inventory Disclosure [Abstract]    
Raw materials $ 330 $ 318
Work in process 3,913 4,299
Finished goods 5,587 5,206
Inventory, gross 9,830 9,823
Reserve for obsolescence (583) (719)
Inventory, net $ 9,247 $ 9,104
XML 53 R39.htm IDEA: XBRL DOCUMENT v3.20.2
Property and Equipment - Summary of Property and Equipment (Details) - USD ($)
$ in Thousands
Mar. 31, 2020
Dec. 31, 2019
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 37,317 $ 36,305
Less accumulated depreciation (25,484) (23,977)
Property and equipment, net 11,833 12,328
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 5,321 5,321
Lab and clean room equipment    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 15,128 14,894
Furniture and office equipment    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 15,405 15,118
Construction in progress    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 1,463 $ 972
XML 54 R40.htm IDEA: XBRL DOCUMENT v3.20.2
Property and Equipment - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Property, Plant and Equipment [Abstract]    
Depreciation $ 1,506 $ 1,695
XML 55 R41.htm IDEA: XBRL DOCUMENT v3.20.2
Leases - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Leases [Abstract]    
Operating lease cost $ 400  
Interest on lease obligations 100  
Cash paid for amounts included in the measurement of operating lease liabilities 400  
Amortization of right of use assets $ 239 $ 269
XML 56 R42.htm IDEA: XBRL DOCUMENT v3.20.2
Leases - Supplemental Balance Sheet Information (Details) - USD ($)
$ in Thousands
Mar. 31, 2020
Dec. 31, 2019
Leases [Abstract]    
Right of use asset $ 3,158 $ 3,397
Short term lease liability 1,195 1,168
Long term lease liability $ 2,611 $ 2,919
Weighted-average remaining lease term (years) 2 years 9 months 18 days 3 years 1 month 6 days
Weighted-average discount rate 11.50% 11.50%
XML 57 R43.htm IDEA: XBRL DOCUMENT v3.20.2
Leases - Maturities of Operating Lease Liabilities (Details)
$ in Thousands
Mar. 31, 2020
USD ($)
Leases [Abstract]  
2020 (excluding the three months ended March 31, 2020) $ 1,170
2021 1,528
2022 1,552
2023 195
2024 0
Thereafter 0
Total lease payments 4,445
Less: imputed interest (639)
Lease liabilities $ 3,806
XML 58 R44.htm IDEA: XBRL DOCUMENT v3.20.2
Intangible Assets - Summary of Intangible Assets (Details) - USD ($)
$ in Thousands
Mar. 31, 2020
Dec. 31, 2019
Schedule of Finite And Indefinite-Lived Intangible Assets [Line Items]    
Gross carrying amount, amortized intangible assets $ 14,403 $ 14,394
Accumulated amortization, amortized intangible assets (9,026) (8,755)
Net carrying amount, amortized intangible assets 5,377 5,639
Total 16,607 16,532
Net 7,581 7,777
Tradenames & Trademarks    
Schedule of Finite And Indefinite-Lived Intangible Assets [Line Items]    
Carrying amount, unamortized intangible assets 1,008 1,008
Patents in Process    
Schedule of Finite And Indefinite-Lived Intangible Assets [Line Items]    
Carrying amount, unamortized intangible assets 1,196 1,130
Licenses    
Schedule of Finite And Indefinite-Lived Intangible Assets [Line Items]    
Gross carrying amount, amortized intangible assets 1,414 1,414
Accumulated amortization, amortized intangible assets (1,234) (1,200)
Net carrying amount, amortized intangible assets 180 214
Patents & Know How    
Schedule of Finite And Indefinite-Lived Intangible Assets [Line Items]    
Gross carrying amount, amortized intangible assets 9,108 9,099
Accumulated amortization, amortized intangible assets (5,232) (5,070)
Net carrying amount, amortized intangible assets 3,876 4,029
Customer & Supplier Relationships    
Schedule of Finite And Indefinite-Lived Intangible Assets [Line Items]    
Gross carrying amount, amortized intangible assets 3,761 3,761
Accumulated amortization, amortized intangible assets (2,485) (2,417)
Net carrying amount, amortized intangible assets 1,276 1,344
Non-compete agreements    
Schedule of Finite And Indefinite-Lived Intangible Assets [Line Items]    
Gross carrying amount, amortized intangible assets 120 120
Accumulated amortization, amortized intangible assets (75) (68)
Net carrying amount, amortized intangible assets $ 45 $ 52
XML 59 R45.htm IDEA: XBRL DOCUMENT v3.20.2
Intangible Assets - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]    
Amortization of intangible assets $ 271 $ 233
XML 60 R46.htm IDEA: XBRL DOCUMENT v3.20.2
Intangible Assets - Estimated Future Amortization Expense for Intangible Assets (Details) - USD ($)
$ in Thousands
Mar. 31, 2020
Dec. 31, 2019
Estimated Amortization Expense    
2020 (excluding the three months ended March 31, 2020) $ 739  
2021 978  
2022 955  
2023 955  
2024 955  
Thereafter 795  
Net carrying amount, amortized intangible assets $ 5,377 $ 5,639
XML 61 R47.htm IDEA: XBRL DOCUMENT v3.20.2
Accrued Expenses (Details) - USD ($)
$ in Thousands
Mar. 31, 2020
Dec. 31, 2019
Payables and Accruals [Abstract]    
Legal costs $ 13,302 $ 12,202
Settlement costs 5,931 5,931
Pricing adjustment settlement with Veterans Affairs 6,894 6,894
Estimated returns 1,567 2,581
External commissions 1,328 1,722
Accrued clinical trials 566 1,076
Other 1,073 1,755
Total $ 30,661 $ 32,161
XML 62 R48.htm IDEA: XBRL DOCUMENT v3.20.2
Long Term Debt (Details) - Term Loan - BT Loan Agreement
2 Months Ended 3 Months Ended 6 Months Ended 7 Months Ended 12 Months Ended 18 Months Ended
Jun. 10, 2019
USD ($)
May 31, 2020
USD ($)
Mar. 31, 2020
USD ($)
Nov. 30, 2020
USD ($)
Dec. 30, 2020
USD ($)
Jun. 10, 2021
Jun. 10, 2020
May 31, 2020
USD ($)
Jun. 20, 2022
USD ($)
Dec. 31, 2020
Debt Instrument [Line Items]                    
Quarterly installments $ 900,000                  
Original issue discount 2,300,000                  
Deferred financing costs $ 6,700,000                  
Stated interest rate (percent) 10.46%   9.95%              
Total leverage ratio 3.0                  
Fair value of term loan     $ 62,700,000              
LIBOR                    
Debt Instrument [Line Items]                    
Basis spread on variable rate     8.00%              
Forecast                    
Debt Instrument [Line Items]                    
Total leverage ratio                   2.50
Minimum liquidity   $ 40,000,000   $ 30,000,000 $ 30,000,000.0     $ 40,000,000.0 $ 20,000,000.0  
Prepayment penalty as percent of prepaid principal           2.00% 3.00%      
XML 63 R49.htm IDEA: XBRL DOCUMENT v3.20.2
Long Term Debt - Term Loan Balances (Details) - USD ($)
$ in Thousands
Mar. 31, 2020
Dec. 31, 2019
Current portion    
Liability component - principal $ 3,750 $ 3,750
Original issue discount 0 0
Deferred financing cost 0 0
Liability component - net carrying value 3,750 3,750
Long-term    
Liability component - principal 68,438 69,375
Original issue discount (1,723) (1,890)
Deferred financing cost (5,078) (5,579)
Liability component - net carrying value $ 61,637 $ 61,906
XML 64 R50.htm IDEA: XBRL DOCUMENT v3.20.2
Long Term Debt - Term Loan Interest Expense (Details) - Term Loan - BT Loan Agreement
$ in Thousands
3 Months Ended
Mar. 31, 2020
USD ($)
Debt Instrument [Line Items]  
Interest expense - stated interest rate $ 1,840
Interest expense - amortization of original issue discount and costs 167
Interest expense - amortization of deferred financing costs 491
Total term loan interest expense $ 2,498
XML 65 R51.htm IDEA: XBRL DOCUMENT v3.20.2
Long Term Debt - Term Loan Maturity (Details)
$ in Thousands
Mar. 31, 2020
USD ($)
Debt Disclosure [Abstract]  
2020 (excluding the three months ended March 31, 2020) $ 2,088
2021 3,750
2022 66,350
2023 0
2024 0
Thereafter 0
Total Long Term Debt $ 72,188
XML 66 R52.htm IDEA: XBRL DOCUMENT v3.20.2
Long Term Debt - Subsequent Activity (Details) - USD ($)
2 Months Ended 3 Months Ended 6 Months Ended 7 Months Ended 12 Months Ended 18 Months Ended
May 31, 2020
Mar. 31, 2020
Nov. 30, 2020
Dec. 30, 2020
May 31, 2020
Jun. 20, 2022
Jul. 02, 2020
Term Loan | BT Loan Agreement | LIBOR              
Debt Instrument [Line Items]              
Basis spread on variable rate   8.00%          
Subsequent Event | Term Loan | Hayfin Loan Agreement Delayed Draw Term Loan              
Debt Instrument [Line Items]              
Face value of debt             $ 25,000,000
Subsequent Event | Senior secured term loan | Hayfin Loan Agreement Term Loan              
Debt Instrument [Line Items]              
Face value of debt             $ 50,000,000
Forecast | Term Loan | BT Loan Agreement              
Debt Instrument [Line Items]              
Minimum liquidity $ 40,000,000   $ 30,000,000 $ 30,000,000.0 $ 40,000,000.0 $ 20,000,000.0  
XML 67 R53.htm IDEA: XBRL DOCUMENT v3.20.2
Net Loss Per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Computation of basic and diluted net loss per share [Abstract]    
Net loss $ (4,821) $ (13,273)
Denominator for basic earnings per share - weighted average shares (in shares) 107,538,509 106,420,317
Effect of dilutive securities: Stock options, restricted stock, and warrants outstanding (in shares) 2,706,804 803,487
Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities (in shares) 107,538,509 106,420,317
Loss per common share - basic (in dollars per share) $ (0.04) $ (0.12)
Loss per common share - diluted (in dollars per share) $ (0.04) $ (0.12)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 2,706,804 803,487
Outstanding Stock Options    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 919,555 609,292
Performance Based Awards    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 17,402 0
Restricted Stock Awards    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 1,769,847 194,195
XML 68 R54.htm IDEA: XBRL DOCUMENT v3.20.2
Income Taxes (Details) - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2020
Income Tax Contingency [Line Items]      
Effective tax rate (70.10%) 0.30%  
Effective income tax rate reconciliation, discrete items $ 0 $ 11,400,000  
Federal income tax receivable 11,300,000    
Tax benefit recognized with respect to net operating losses $ 0    
Forecast      
Income Tax Contingency [Line Items]      
Effective tax rate     (0.60%)
XML 69 R55.htm IDEA: XBRL DOCUMENT v3.20.2
Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Supplemental disclosure of cash flow and non-cash investing and financing activities [Abstract]    
Cash paid for interest $ 1,840 $ 1
Income taxes paid $ 6 $ 46
XML 70 R56.htm IDEA: XBRL DOCUMENT v3.20.2
Contractual Commitments and Contingencies - Narrative (Details)
$ in Millions
1 Months Ended 3 Months Ended 6 Months Ended
Jan. 16, 2019
lawsuit
Jan. 31, 2019
May 31, 2018
former_employee
Mar. 31, 2020
USD ($)
former_employee
Mar. 31, 2019
USD ($)
Jun. 30, 2020
USD ($)
Dec. 06, 2018
lawsuit
Loss Contingencies [Line Items]              
Rent expense       $ 0.3 $ 0.4    
Estimated litigation liability       12.8      
Payments for legal settlements       $ 9.2      
Shareholder Derivative Suits              
Loss Contingencies [Line Items]              
Number of shareholder derivative actions | lawsuit             3
Securities Class Action              
Loss Contingencies [Line Items]              
Number of class actions | lawsuit 2            
Department of Veterans' Affairs Office of the Inspector General's Investigation              
Loss Contingencies [Line Items]              
Number of former VA employees | former_employee     3        
Prosecution deferral period   18 months          
Number of former VA employees who completed the pretrial diversion program | former_employee       2      
Minimum              
Loss Contingencies [Line Items]              
Lease expiration period       3 years      
Maximum              
Loss Contingencies [Line Items]              
Lease expiration period       3 years 6 months      
Subsequent Event | Former Chief Financial Officer              
Loss Contingencies [Line Items]              
Severance costs           $ 4.0  
XML 71 R57.htm IDEA: XBRL DOCUMENT v3.20.2
Product Revenue Detail (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2020
USD ($)
distribution_channel
Mar. 31, 2019
USD ($)
Disaggregation of Revenue [Line Items]    
Number of primary distribution channels | distribution_channel 2  
Net sales $ 61,736 $ 66,555
Direct Customers    
Disaggregation of Revenue [Line Items]    
Net sales 59,896 64,542
Distributors    
Disaggregation of Revenue [Line Items]    
Net sales $ 1,840 $ 2,013
XML 72 R58.htm IDEA: XBRL DOCUMENT v3.20.2
Subsequent Events (Details)
2 Months Ended 3 Months Ended 6 Months Ended 7 Months Ended 12 Months Ended 18 Months Ended
Jul. 02, 2020
USD ($)
Apr. 22, 2020
USD ($)
Apr. 01, 2020
USD ($)
May 31, 2020
USD ($)
Mar. 31, 2020
Nov. 30, 2020
USD ($)
Dec. 30, 2020
USD ($)
May 31, 2020
USD ($)
Jun. 20, 2022
USD ($)
Dec. 31, 2020
Mar. 27, 2020
USD ($)
Jun. 10, 2019
USD ($)
Subsequent Event                        
Subsequent Event [Line Items]                        
Operating lease, impairment loss     $ 0                  
BT Loan Agreement | Subsequent Event                        
Subsequent Event [Line Items]                        
Total leverage ratio   3.0                    
Amended Term Loan Agreement | Subsequent Event                        
Subsequent Event [Line Items]                        
Total leverage ratio   5.0                    
Paycheck Protection Program Loan                        
Subsequent Event [Line Items]                        
Face value of debt                     $ 10,000,000.0  
Term Loan | BT Loan Agreement                        
Subsequent Event [Line Items]                        
Total leverage ratio                       3.0
Deferred financing costs                       $ 6,700,000
Term Loan | BT Loan Agreement | Subsequent Event                        
Subsequent Event [Line Items]                        
Repayment of principal $ 72,000,000.0                      
Accrued interest paid 100,000                      
Prepayment of premium paid 1,400,000                      
Term Loan | Amended Term Loan Agreement | Subsequent Event                        
Subsequent Event [Line Items]                        
Deferred financing costs   $ 700,000                    
Term Loan | Hayfin Loan Agreement Delayed Draw Term Loan | Subsequent Event                        
Subsequent Event [Line Items]                        
Face value of debt 25,000,000                      
Senior secured term loan | Hayfin Loan Agreement Term Loan | Subsequent Event                        
Subsequent Event [Line Items]                        
Face value of debt 50,000,000                      
Forecast | Term Loan | BT Loan Agreement                        
Subsequent Event [Line Items]                        
Total leverage ratio                   2.50    
Minimum liquidity       $ 40,000,000   $ 30,000,000 $ 30,000,000.0 $ 40,000,000.0 $ 20,000,000.0      
Forecast | Term Loan | Amended Term Loan Agreement                        
Subsequent Event [Line Items]                        
Minimum liquidity       $ 20,000,000   $ 20,000,000            
LIBOR | Term Loan | BT Loan Agreement                        
Subsequent Event [Line Items]                        
Basis spread on variable rate         8.00%              
LIBOR | Term Loan | Amended Term Loan Agreement | Subsequent Event                        
Subsequent Event [Line Items]                        
Increase in interest rate (percent)   1.00%                    
Basis spread on variable rate   9.00%                    
Series B Convertible Preferred Stock | Subsequent Event                        
Subsequent Event [Line Items]                        
Stock issued during period $ 100,000,000                      
EXCEL 73 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 74 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 75 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 76 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 110 343 1 false 38 0 false 8 false false R1.htm 0001000 - Document - Cover Page Sheet http://mimedx.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://mimedx.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 1001501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://mimedx.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://mimedx.com/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Sheet http://mimedx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statements 5 false false R6.htm 1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 2101100 - Disclosure - Nature of Business Sheet http://mimedx.com/role/NatureOfBusiness Nature of Business Notes 7 false false R8.htm 2101100 - Disclosure - Significant Accounting Policies Sheet http://mimedx.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 8 false false R9.htm 2102100 - Disclosure - Liquidity and Capital Resources Sheet http://mimedx.com/role/LiquidityAndCapitalResources Liquidity and Capital Resources Notes 9 false false R10.htm 2103100 - Disclosure - Inventory Sheet http://mimedx.com/role/Inventory Inventory Notes 10 false false R11.htm 2104100 - Disclosure - Property and Equipment Sheet http://mimedx.com/role/PropertyAndEquipment Property and Equipment Notes 11 false false R12.htm 2106100 - Disclosure - Leases Sheet http://mimedx.com/role/Leases Leases Notes 12 false false R13.htm 2108100 - Disclosure - Intangible Assets Sheet http://mimedx.com/role/IntangibleAssets Intangible Assets Notes 13 false false R14.htm 2109100 - Disclosure - Accrued Expenses Sheet http://mimedx.com/role/AccruedExpenses Accrued Expenses Notes 14 false false R15.htm 2110100 - Disclosure - Long Term Debt Sheet http://mimedx.com/role/LongTermDebt Long Term Debt Notes 15 false false R16.htm 2111100 - Disclosure - Net Loss Per Share Sheet http://mimedx.com/role/NetLossPerShare Net Loss Per Share Notes 16 false false R17.htm 2114100 - Disclosure - Income Taxes Sheet http://mimedx.com/role/IncomeTaxes Income Taxes Notes 17 false false R18.htm 2115100 - Disclosure - Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities Sheet http://mimedx.com/role/SupplementalDisclosureOfCashFlowAndNonCashInvestingAndFinancingActivities Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities Notes 18 false false R19.htm 2116100 - Disclosure - Contractual Commitments and Contingencies Sheet http://mimedx.com/role/ContractualCommitmentsAndContingencies Contractual Commitments and Contingencies Notes 19 false false R20.htm 2117100 - Disclosure - Product Revenue Detail Sheet http://mimedx.com/role/ProductRevenueDetail Product Revenue Detail Notes 20 false false R21.htm 2118100 - Disclosure - Subsequent Events Sheet http://mimedx.com/role/SubsequentEvents Subsequent Events Notes 21 false false R22.htm 2201201 - Disclosure - Significant Accounting Policies (Policies) Sheet http://mimedx.com/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://mimedx.com/role/SignificantAccountingPolicies 22 false false R23.htm 2301302 - Disclosure - Significant Accounting Policies (Tables) Sheet http://mimedx.com/role/SignificantAccountingPoliciesTables Significant Accounting Policies (Tables) Tables http://mimedx.com/role/SignificantAccountingPolicies 23 false false R24.htm 2303301 - Disclosure - Inventory (Tables) Sheet http://mimedx.com/role/InventoryTables Inventory (Tables) Tables http://mimedx.com/role/Inventory 24 false false R25.htm 2304301 - Disclosure - Property and Equipment (Tables) Sheet http://mimedx.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Tables http://mimedx.com/role/PropertyAndEquipment 25 false false R26.htm 2306301 - Disclosure - Leases (Tables) Sheet http://mimedx.com/role/LeasesTables Leases (Tables) Tables http://mimedx.com/role/Leases 26 false false R27.htm 2308301 - Disclosure - Intangible Assets (Tables) Sheet http://mimedx.com/role/IntangibleAssetsTables Intangible Assets (Tables) Tables http://mimedx.com/role/IntangibleAssets 27 false false R28.htm 2309301 - Disclosure - Accrued Expenses (Tables) Sheet http://mimedx.com/role/AccruedExpensesTables Accrued Expenses (Tables) Tables http://mimedx.com/role/AccruedExpenses 28 false false R29.htm 2310301 - Disclosure - Long Term Debt (Tables) Sheet http://mimedx.com/role/LongTermDebtTables Long Term Debt (Tables) Tables http://mimedx.com/role/LongTermDebt 29 false false R30.htm 2311301 - Disclosure - Net Loss Per Share (Tables) Sheet http://mimedx.com/role/NetLossPerShareTables Net Loss Per Share (Tables) Tables http://mimedx.com/role/NetLossPerShare 30 false false R31.htm 2315301 - Disclosure - Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities (Tables) Sheet http://mimedx.com/role/SupplementalDisclosureOfCashFlowAndNonCashInvestingAndFinancingActivitiesTables Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities (Tables) Tables http://mimedx.com/role/SupplementalDisclosureOfCashFlowAndNonCashInvestingAndFinancingActivities 31 false false R32.htm 2317301 - Disclosure - Product Revenue Detail (Tables) Sheet http://mimedx.com/role/ProductRevenueDetailTables Product Revenue Detail (Tables) Tables http://mimedx.com/role/ProductRevenueDetail 32 false false R33.htm 2401401 - Disclosure - Nature of Business (Details) Sheet http://mimedx.com/role/NatureOfBusinessDetails Nature of Business (Details) Details http://mimedx.com/role/NatureOfBusiness 33 false false R34.htm 2401403 - Disclosure - Significant Accounting Policies (Details) Sheet http://mimedx.com/role/SignificantAccountingPoliciesDetails Significant Accounting Policies (Details) Details http://mimedx.com/role/SignificantAccountingPoliciesTables 34 false false R35.htm 2401404 - Disclosure - Significant Accounting Policies - Assessment of Revenue under ASC 606 (Details) Sheet http://mimedx.com/role/SignificantAccountingPoliciesAssessmentOfRevenueUnderAsc606Details Significant Accounting Policies - Assessment of Revenue under ASC 606 (Details) Details 35 false false R36.htm 2401405 - Disclosure - Significant Accounting Policies - Recently Issued and Adopted Accounting Standards (Details) Sheet http://mimedx.com/role/SignificantAccountingPoliciesRecentlyIssuedAndAdoptedAccountingStandardsDetails Significant Accounting Policies - Recently Issued and Adopted Accounting Standards (Details) Details 36 false false R37.htm 2402401 - Disclosure - Liquidity and Capital Resources (Details) Sheet http://mimedx.com/role/LiquidityAndCapitalResourcesDetails Liquidity and Capital Resources (Details) Details http://mimedx.com/role/LiquidityAndCapitalResources 37 false false R38.htm 2403402 - Disclosure - Inventory (Details) Sheet http://mimedx.com/role/InventoryDetails Inventory (Details) Details http://mimedx.com/role/InventoryTables 38 false false R39.htm 2404402 - Disclosure - Property and Equipment - Summary of Property and Equipment (Details) Sheet http://mimedx.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails Property and Equipment - Summary of Property and Equipment (Details) Details 39 false false R40.htm 2404403 - Disclosure - Property and Equipment - Narrative (Details) Sheet http://mimedx.com/role/PropertyAndEquipmentNarrativeDetails Property and Equipment - Narrative (Details) Details 40 false false R41.htm 2406402 - Disclosure - Leases - Narrative (Details) Sheet http://mimedx.com/role/LeasesNarrativeDetails Leases - Narrative (Details) Details 41 false false R42.htm 2406403 - Disclosure - Leases - Supplemental Balance Sheet Information (Details) Sheet http://mimedx.com/role/LeasesSupplementalBalanceSheetInformationDetails Leases - Supplemental Balance Sheet Information (Details) Details 42 false false R43.htm 2406404 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details) Sheet http://mimedx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails Leases - Maturities of Operating Lease Liabilities (Details) Details 43 false false R44.htm 2408402 - Disclosure - Intangible Assets - Summary of Intangible Assets (Details) Sheet http://mimedx.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetails Intangible Assets - Summary of Intangible Assets (Details) Details 44 false false R45.htm 2408403 - Disclosure - Intangible Assets - Narrative (Details) Sheet http://mimedx.com/role/IntangibleAssetsNarrativeDetails Intangible Assets - Narrative (Details) Details 45 false false R46.htm 2408404 - Disclosure - Intangible Assets - Estimated Future Amortization Expense for Intangible Assets (Details) Sheet http://mimedx.com/role/IntangibleAssetsEstimatedFutureAmortizationExpenseForIntangibleAssetsDetails Intangible Assets - Estimated Future Amortization Expense for Intangible Assets (Details) Details 46 false false R47.htm 2409402 - Disclosure - Accrued Expenses (Details) Sheet http://mimedx.com/role/AccruedExpensesDetails Accrued Expenses (Details) Details http://mimedx.com/role/AccruedExpensesTables 47 false false R48.htm 2410402 - Disclosure - Long Term Debt (Details) Sheet http://mimedx.com/role/LongTermDebtDetails Long Term Debt (Details) Details http://mimedx.com/role/LongTermDebtTables 48 false false R49.htm 2410403 - Disclosure - Long Term Debt - Term Loan Balances (Details) Sheet http://mimedx.com/role/LongTermDebtTermLoanBalancesDetails Long Term Debt - Term Loan Balances (Details) Details 49 false false R50.htm 2410404 - Disclosure - Long Term Debt - Term Loan Interest Expense (Details) Sheet http://mimedx.com/role/LongTermDebtTermLoanInterestExpenseDetails Long Term Debt - Term Loan Interest Expense (Details) Details 50 false false R51.htm 2410405 - Disclosure - Long Term Debt - Term Loan Maturity (Details) Sheet http://mimedx.com/role/LongTermDebtTermLoanMaturityDetails Long Term Debt - Term Loan Maturity (Details) Details 51 false false R52.htm 2410406 - Disclosure - Long Term Debt - Subsequent Activity (Details) Sheet http://mimedx.com/role/LongTermDebtSubsequentActivityDetails Long Term Debt - Subsequent Activity (Details) Details 52 false false R53.htm 2411402 - Disclosure - Net Loss Per Share (Details) Sheet http://mimedx.com/role/NetLossPerShareDetails Net Loss Per Share (Details) Details http://mimedx.com/role/NetLossPerShareTables 53 false false R54.htm 2414401 - Disclosure - Income Taxes (Details) Sheet http://mimedx.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://mimedx.com/role/IncomeTaxes 54 false false R55.htm 2415402 - Disclosure - Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities (Details) Sheet http://mimedx.com/role/SupplementalDisclosureOfCashFlowAndNonCashInvestingAndFinancingActivitiesDetails Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities (Details) Details http://mimedx.com/role/SupplementalDisclosureOfCashFlowAndNonCashInvestingAndFinancingActivitiesTables 55 false false R56.htm 2416401 - Disclosure - Contractual Commitments and Contingencies - Narrative (Details) Sheet http://mimedx.com/role/ContractualCommitmentsAndContingenciesNarrativeDetails Contractual Commitments and Contingencies - Narrative (Details) Details 56 false false R57.htm 2417402 - Disclosure - Product Revenue Detail (Details) Sheet http://mimedx.com/role/ProductRevenueDetailDetails Product Revenue Detail (Details) Details http://mimedx.com/role/ProductRevenueDetailTables 57 false false R58.htm 2418401 - Disclosure - Subsequent Events (Details) Sheet http://mimedx.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://mimedx.com/role/SubsequentEvents 58 false false All Reports Book All Reports mdxg-2020331x10xq.htm a2019ex33articlesofame.htm a2020331exhibit311.htm a2020331exhibit312.htm a2020331exhibit321.htm a2020331exhibit322.htm mdxg-20200331.xsd mdxg-20200331_cal.xml mdxg-20200331_def.xml mdxg-20200331_lab.xml mdxg-20200331_pre.xml http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/srt/2019-01-31 http://fasb.org/us-gaap/2019-01-31 true true JSON 79 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "mdxg-2020331x10xq.htm": { "axisCustom": 0, "axisStandard": 16, "contextCount": 110, "dts": { "calculationLink": { "local": [ "mdxg-20200331_cal.xml" ] }, "definitionLink": { "local": [ "mdxg-20200331_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "mdxg-2020331x10xq.htm" ] }, "labelLink": { "local": [ "mdxg-20200331_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "mdxg-20200331_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "mdxg-20200331.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 406, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2019-01-31": 18, "http://xbrl.sec.gov/dei/2019-01-31": 11, "total": 29 }, "keyCustom": 31, "keyStandard": 312, "memberCustom": 12, "memberStandard": 26, "nsprefix": "mdxg", "nsuri": "http://mimedx.com/20200331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Cover Page", "role": "http://mimedx.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103100 - Disclosure - Inventory", "role": "http://mimedx.com/role/Inventory", "shortName": "Inventory", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104100 - Disclosure - Property and Equipment", "role": "http://mimedx.com/role/PropertyAndEquipment", "shortName": "Property and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106100 - Disclosure - Leases", "role": "http://mimedx.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108100 - Disclosure - Intangible Assets", "role": "http://mimedx.com/role/IntangibleAssets", "shortName": "Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2109100 - Disclosure - Accrued Expenses", "role": "http://mimedx.com/role/AccruedExpenses", "shortName": "Accrued Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110100 - Disclosure - Long Term Debt", "role": "http://mimedx.com/role/LongTermDebt", "shortName": "Long Term Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111100 - Disclosure - Net Loss Per Share", "role": "http://mimedx.com/role/NetLossPerShare", "shortName": "Net Loss Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114100 - Disclosure - Income Taxes", "role": "http://mimedx.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2115100 - Disclosure - Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities", "role": "http://mimedx.com/role/SupplementalDisclosureOfCashFlowAndNonCashInvestingAndFinancingActivities", "shortName": "Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116100 - Disclosure - Contractual Commitments and Contingencies", "role": "http://mimedx.com/role/ContractualCommitmentsAndContingencies", "shortName": "Contractual Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "role": "http://mimedx.com/role/CondensedConsolidatedBalanceSheets", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FI2020Q1", "decimals": "-3", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2117100 - Disclosure - Product Revenue Detail", "role": "http://mimedx.com/role/ProductRevenueDetail", "shortName": "Product Revenue Detail", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2118100 - Disclosure - Subsequent Events", "role": "http://mimedx.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2201201 - Disclosure - Significant Accounting Policies (Policies)", "role": "http://mimedx.com/role/SignificantAccountingPoliciesPolicies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2301302 - Disclosure - Significant Accounting Policies (Tables)", "role": "http://mimedx.com/role/SignificantAccountingPoliciesTables", "shortName": "Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2303301 - Disclosure - Inventory (Tables)", "role": "http://mimedx.com/role/InventoryTables", "shortName": "Inventory (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2304301 - Disclosure - Property and Equipment (Tables)", "role": "http://mimedx.com/role/PropertyAndEquipmentTables", "shortName": "Property and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2306301 - Disclosure - Leases (Tables)", "role": "http://mimedx.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2308301 - Disclosure - Intangible Assets (Tables)", "role": "http://mimedx.com/role/IntangibleAssetsTables", "shortName": "Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309301 - Disclosure - Accrued Expenses (Tables)", "role": "http://mimedx.com/role/AccruedExpensesTables", "shortName": "Accrued Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2310301 - Disclosure - Long Term Debt (Tables)", "role": "http://mimedx.com/role/LongTermDebtTables", "shortName": "Long Term Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1001501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://mimedx.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2311301 - Disclosure - Net Loss Per Share (Tables)", "role": "http://mimedx.com/role/NetLossPerShareTables", "shortName": "Net Loss Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2315301 - Disclosure - Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities (Tables)", "role": "http://mimedx.com/role/SupplementalDisclosureOfCashFlowAndNonCashInvestingAndFinancingActivitiesTables", "shortName": "Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2317301 - Disclosure - Product Revenue Detail (Tables)", "role": "http://mimedx.com/role/ProductRevenueDetailTables", "shortName": "Product Revenue Detail (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401401 - Disclosure - Nature of Business (Details)", "role": "http://mimedx.com/role/NatureOfBusinessDetails", "shortName": "Nature of Business (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "mdxg:AmountsInvoicedandNotCollectedAfterTransitionAdjustment", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401403 - Disclosure - Significant Accounting Policies (Details)", "role": "http://mimedx.com/role/SignificantAccountingPoliciesDetails", "shortName": "Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FI2020Q1", "decimals": "-5", "lang": null, "name": "us-gaap:ContractWithCustomerAssetNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "mdxg:AmountsInvoicedandNotCollectedAfterTransitionAdjustment", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401404 - Disclosure - Significant Accounting Policies - Assessment of Revenue under ASC 606 (Details)", "role": "http://mimedx.com/role/SignificantAccountingPoliciesAssessmentOfRevenueUnderAsc606Details", "shortName": "Significant Accounting Policies - Assessment of Revenue under ASC 606 (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "lang": null, "name": "us-gaap:ProceedsFromSaleAndCollectionOfReceivables", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401405 - Disclosure - Significant Accounting Policies - Recently Issued and Adopted Accounting Standards (Details)", "role": "http://mimedx.com/role/SignificantAccountingPoliciesRecentlyIssuedAndAdoptedAccountingStandardsDetails", "shortName": "Significant Accounting Policies - Recently Issued and Adopted Accounting Standards (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member", "decimals": "-5", "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402401 - Disclosure - Liquidity and Capital Resources (Details)", "role": "http://mimedx.com/role/LiquidityAndCapitalResourcesDetails", "shortName": "Liquidity and Capital Resources (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "I2020Q3Jul2_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember", "decimals": "INF", "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403402 - Disclosure - Inventory (Details)", "role": "http://mimedx.com/role/InventoryDetails", "shortName": "Inventory (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404402 - Disclosure - Property and Equipment - Summary of Property and Equipment (Details)", "role": "http://mimedx.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails", "shortName": "Property and Equipment - Summary of Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "role": "http://mimedx.com/role/CondensedConsolidatedStatementsOfOperations", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404403 - Disclosure - Property and Equipment - Narrative (Details)", "role": "http://mimedx.com/role/PropertyAndEquipmentNarrativeDetails", "shortName": "Property and Equipment - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R41": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - Leases - Narrative (Details)", "role": "http://mimedx.com/role/LeasesNarrativeDetails", "shortName": "Leases - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406403 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)", "role": "http://mimedx.com/role/LeasesSupplementalBalanceSheetInformationDetails", "shortName": "Leases - Supplemental Balance Sheet Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FI2020Q1", "decimals": "-3", "lang": null, "name": "us-gaap:OperatingLeaseLiabilityCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406404 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details)", "role": "http://mimedx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails", "shortName": "Leases - Maturities of Operating Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408402 - Disclosure - Intangible Assets - Summary of Intangible Assets (Details)", "role": "http://mimedx.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetails", "shortName": "Intangible Assets - Summary of Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408403 - Disclosure - Intangible Assets - Narrative (Details)", "role": "http://mimedx.com/role/IntangibleAssetsNarrativeDetails", "shortName": "Intangible Assets - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R46": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408404 - Disclosure - Intangible Assets - Estimated Future Amortization Expense for Intangible Assets (Details)", "role": "http://mimedx.com/role/IntangibleAssetsEstimatedFutureAmortizationExpenseForIntangibleAssetsDetails", "shortName": "Intangible Assets - Estimated Future Amortization Expense for Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409402 - Disclosure - Accrued Expenses (Details)", "role": "http://mimedx.com/role/AccruedExpensesDetails", "shortName": "Accrued Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "D2019Q2Jun10_us-gaap_DebtInstrumentAxis_mdxg_TermLoanAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableOtherPayablesMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentPeriodicPayment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410402 - Disclosure - Long Term Debt (Details)", "role": "http://mimedx.com/role/LongTermDebtDetails", "shortName": "Long Term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "D2019Q2Jun10_us-gaap_DebtInstrumentAxis_mdxg_TermLoanAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableOtherPayablesMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentPeriodicPayment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "mdxg:LongtermDebtCurrentMaturitiesGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410403 - Disclosure - Long Term Debt - Term Loan Balances (Details)", "role": "http://mimedx.com/role/LongTermDebtTermLoanBalancesDetails", "shortName": "Long Term Debt - Term Loan Balances (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "mdxg:LongtermDebtCurrentMaturitiesGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "role": "http://mimedx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "mdxg:ScheduleofInterestExpenseTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD_us-gaap_DebtInstrumentAxis_mdxg_TermLoanAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableOtherPayablesMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410404 - Disclosure - Long Term Debt - Term Loan Interest Expense (Details)", "role": "http://mimedx.com/role/LongTermDebtTermLoanInterestExpenseDetails", "shortName": "Long Term Debt - Term Loan Interest Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "mdxg:ScheduleofInterestExpenseTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD_us-gaap_DebtInstrumentAxis_mdxg_TermLoanAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableOtherPayablesMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410405 - Disclosure - Long Term Debt - Term Loan Maturity (Details)", "role": "http://mimedx.com/role/LongTermDebtTermLoanMaturityDetails", "shortName": "Long Term Debt - Term Loan Maturity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD_us-gaap_DebtInstrumentAxis_mdxg_TermLoanAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableOtherPayablesMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentBasisSpreadOnVariableRate1", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410406 - Disclosure - Long Term Debt - Subsequent Activity (Details)", "role": "http://mimedx.com/role/LongTermDebtSubsequentActivityDetails", "shortName": "Long Term Debt - Subsequent Activity (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R53": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411402 - Disclosure - Net Loss Per Share (Details)", "role": "http://mimedx.com/role/NetLossPerShareDetails", "shortName": "Net Loss Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": "0", "lang": null, "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414401 - Disclosure - Income Taxes (Details)", "role": "http://mimedx.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InterestPaidNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415402 - Disclosure - Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities (Details)", "role": "http://mimedx.com/role/SupplementalDisclosureOfCashFlowAndNonCashInvestingAndFinancingActivitiesDetails", "shortName": "Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InterestPaidNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416401 - Disclosure - Contractual Commitments and Contingencies - Narrative (Details)", "role": "http://mimedx.com/role/ContractualCommitmentsAndContingenciesNarrativeDetails", "shortName": "Contractual Commitments and Contingencies - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FI2020Q1", "decimals": "INF", "first": true, "lang": null, "name": "mdxg:NumberofDistributionChannels", "reportCount": 1, "unique": true, "unitRef": "distribution_channel", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417402 - Disclosure - Product Revenue Detail (Details)", "role": "http://mimedx.com/role/ProductRevenueDetailDetails", "shortName": "Product Revenue Detail (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FI2020Q1", "decimals": "INF", "first": true, "lang": null, "name": "mdxg:NumberofDistributionChannels", "reportCount": 1, "unique": true, "unitRef": "distribution_channel", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "D2020Q2Apr1_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseImpairmentLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418401 - Disclosure - Subsequent Events (Details)", "role": "http://mimedx.com/role/SubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "D2020Q2Apr1_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseImpairmentLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101100 - Disclosure - Nature of Business", "role": "http://mimedx.com/role/NatureOfBusiness", "shortName": "Nature of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101100 - Disclosure - Significant Accounting Policies", "role": "http://mimedx.com/role/SignificantAccountingPolicies", "shortName": "Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "mdxg:LiquidityandCapitalResourcesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2102100 - Disclosure - Liquidity and Capital Resources", "role": "http://mimedx.com/role/LiquidityAndCapitalResources", "shortName": "Liquidity and Capital Resources", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mdxg-2020331x10xq.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "mdxg:LiquidityandCapitalResourcesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 38, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://mimedx.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://mimedx.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://mimedx.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://mimedx.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://mimedx.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://mimedx.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r281" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://mimedx.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r282" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://mimedx.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://mimedx.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://mimedx.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://mimedx.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://mimedx.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://mimedx.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r283" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://mimedx.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://mimedx.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://mimedx.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r283" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://mimedx.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://mimedx.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r283" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://mimedx.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://mimedx.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r284" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://mimedx.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r283" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://mimedx.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r283" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://mimedx.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r283" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://mimedx.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r283" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://mimedx.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://mimedx.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "mdxg_AccountsReceivableNetRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Accounts Receivable, Net [Roll Forward]", "label": "Accounts Receivable, Net [Roll Forward]", "terseLabel": "Accounts Receivable, Net [Roll Forward]" } } }, "localname": "AccountsReceivableNetRollForward", "nsuri": "http://mimedx.com/20200331", "presentation": [ "http://mimedx.com/role/SignificantAccountingPoliciesAssessmentOfRevenueUnderAsc606Details" ], "xbrltype": "stringItemType" }, "mdxg_AccruedClinicalTrialsCurrent": { "auth_ref": [], "calculation": { "http://mimedx.com/role/AccruedExpensesDetails": { "order": 6.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued Clinical Trials, Current", "label": "Accrued Clinical Trials, Current", "terseLabel": "Accrued clinical trials" } } }, "localname": "AccruedClinicalTrialsCurrent", "nsuri": "http://mimedx.com/20200331", "presentation": [ "http://mimedx.com/role/AccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "mdxg_AccruedSettlementCostsCurrent": { "auth_ref": [], "calculation": { "http://mimedx.com/role/AccruedExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued Settlement Costs, Current", "label": "Accrued Settlement Costs, Current", "terseLabel": "Settlement costs" } } }, "localname": "AccruedSettlementCostsCurrent", "nsuri": "http://mimedx.com/20200331", "presentation": [ "http://mimedx.com/role/AccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "mdxg_AmendedTermLoanAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Amended Term Loan Agreement [Member]", "label": "Amended Term Loan Agreement [Member]", "terseLabel": "Amended Term Loan Agreement" } } }, "localname": "AmendedTermLoanAgreementMember", "nsuri": "http://mimedx.com/20200331", "presentation": [ "http://mimedx.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "mdxg_AmountsInvoicedandNotCollectedAfterTransitionAdjustment": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amounts Invoiced and Not Collected, After Transition Adjustment", "label": "Amounts Invoiced and Not Collected, After Transition Adjustment", "periodEndLabel": "Amounts Invoiced and Not Collected, ending", "periodStartLabel": "Amounts Invoiced and Not Collected, beginning", "terseLabel": "Amounts Invoiced and Not Collected, After Transition Adjustment" } } }, "localname": "AmountsInvoicedandNotCollectedAfterTransitionAdjustment", "nsuri": "http://mimedx.com/20200331", "presentation": [ "http://mimedx.com/role/SignificantAccountingPoliciesAssessmentOfRevenueUnderAsc606Details", "http://mimedx.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "mdxg_AmountsInvoicedandNotCollectedWriteoffofDeferredCostsforCustomerContractswhereCollectionisnoLongerReasonableAssured": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amounts Invoiced and Not Collected, Write-off of Deferred Costs for Customer Contracts where Collection is no Longer Reasonable Assured", "label": "Amounts Invoiced and Not Collected, Write-off of Deferred Costs for Customer Contracts where Collection is no Longer Reasonable Assured", "terseLabel": "Amounts Invoiced and Not Collected, Write-off of Deferred Costs for Customer Contracts where Collection is no Longer Reasonable Assured" } } }, "localname": "AmountsInvoicedandNotCollectedWriteoffofDeferredCostsforCustomerContractswhereCollectionisnoLongerReasonableAssured", "nsuri": "http://mimedx.com/20200331", "presentation": [ "http://mimedx.com/role/SignificantAccountingPoliciesAssessmentOfRevenueUnderAsc606Details" ], "xbrltype": "monetaryItemType" }, "mdxg_ComputationOfBasicAndDilutedNetLossPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Computation of basic and diluted net loss per share [Abstract]", "terseLabel": "Computation of basic and diluted net loss per share [Abstract]" } } }, "localname": "ComputationOfBasicAndDilutedNetLossPerShareAbstract", "nsuri": "http://mimedx.com/20200331", "presentation": [ "http://mimedx.com/role/NetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "mdxg_DebtCovenantCaponCashNetting": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Debt Covenant, Cap on Cash Netting", "label": "Debt Covenant, Cap on Cash Netting", "terseLabel": "Cap on cash netting for calculation of Total Net Leverage" } } }, "localname": "DebtCovenantCaponCashNetting", "nsuri": "http://mimedx.com/20200331", "presentation": [ "http://mimedx.com/role/LiquidityAndCapitalResourcesDetails" ], "xbrltype": "monetaryItemType" }, "mdxg_DebtCovenantMinimumLiquidity": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Debt Covenant, Minimum Liquidity", "label": "Debt Covenant, Minimum Liquidity", "terseLabel": "Minimum liquidity" } } }, "localname": "DebtCovenantMinimumLiquidity", "nsuri": "http://mimedx.com/20200331", "presentation": [ "http://mimedx.com/role/LiquidityAndCapitalResourcesDetails", "http://mimedx.com/role/LongTermDebtDetails", "http://mimedx.com/role/LongTermDebtSubsequentActivityDetails", "http://mimedx.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "mdxg_DebtCovenantTotalLeverageRatio": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Covenant, Total Leverage Ratio", "label": "Debt Covenant, Total Leverage Ratio", "terseLabel": "Total leverage ratio" } } }, "localname": "DebtCovenantTotalLeverageRatio", "nsuri": "http://mimedx.com/20200331", "presentation": [ "http://mimedx.com/role/LongTermDebtDetails", "http://mimedx.com/role/SubsequentEventsDetails" ], "xbrltype": "pureItemType" }, "mdxg_DebtInstrumentBasisSpreadonVariableRateBasedonTotalNetLeverageLevels": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Basis Spread on Variable Rate, Based on Total Net Leverage Levels", "label": "Debt Instrument, Basis Spread on Variable Rate, Based on Total Net Leverage Levels", "terseLabel": "Basis spread on variable rate, based on total net leverage levels (percent)" } } }, "localname": "DebtInstrumentBasisSpreadonVariableRateBasedonTotalNetLeverageLevels", "nsuri": "http://mimedx.com/20200331", "presentation": [ "http://mimedx.com/role/LiquidityAndCapitalResourcesDetails" ], "xbrltype": "percentItemType" }, "mdxg_DebtInstrumentFloorInterestRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Floor Interest Rate", "label": "Debt Instrument, Floor Interest Rate", "terseLabel": "Floor interest rate (percent)" } } }, "localname": "DebtInstrumentFloorInterestRate", "nsuri": "http://mimedx.com/20200331", "presentation": [ "http://mimedx.com/role/LiquidityAndCapitalResourcesDetails" ], "xbrltype": "percentItemType" }, "mdxg_DebtInstrumentPrepaymentPenaltyasPercentofPrepaidPrincipalPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Prepayment Penalty as Percent of Prepaid Principal, Percent", "label": "Debt Instrument, Prepayment Penalty as Percent of Prepaid Principal, Percent", "terseLabel": "Prepayment penalty as percent of prepaid principal" } } }, "localname": "DebtInstrumentPrepaymentPenaltyasPercentofPrepaidPrincipalPercent", "nsuri": "http://mimedx.com/20200331", "presentation": [ "http://mimedx.com/role/LongTermDebtDetails" ], "xbrltype": "percentItemType" }, "mdxg_DeferredCostofSalesAfterTransitionAdjustment": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Deferred Cost of Sales, After Transition Adjustment", "label": "Deferred Cost of Sales, After Transition Adjustment", "periodEndLabel": "Deferred Cost of Sales, ending", "periodStartLabel": "Deferred Cost of Sales, beginning", "terseLabel": "Deferred Cost of Sales, After Transition Adjustment" } } }, "localname": "DeferredCostofSalesAfterTransitionAdjustment", "nsuri": "http://mimedx.com/20200331", "presentation": [ "http://mimedx.com/role/SignificantAccountingPoliciesAssessmentOfRevenueUnderAsc606Details", "http://mimedx.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "mdxg_DeferredCostofSalesCashCollected": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Deferred Cost of Sales, Cash Collected", "label": "Deferred Cost of Sales, Cash Collected", "negatedTerseLabel": "Deferred Cost of Sales, Cash Collected" } } }, "localname": "DeferredCostofSalesCashCollected", "nsuri": "http://mimedx.com/20200331", "presentation": [ "http://mimedx.com/role/SignificantAccountingPoliciesAssessmentOfRevenueUnderAsc606Details" ], "xbrltype": "monetaryItemType" }, "mdxg_DeferredCostofSalesRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Deferred Cost of Sales [Roll Forward]", "label": "Deferred Cost of Sales [Roll Forward]", "terseLabel": "Deferred Cost of Sales [Roll Forward]" } } }, "localname": "DeferredCostofSalesRollForward", "nsuri": "http://mimedx.com/20200331", "presentation": [ "http://mimedx.com/role/SignificantAccountingPoliciesAssessmentOfRevenueUnderAsc606Details" ], "xbrltype": "stringItemType" }, "mdxg_DepartmentofVeteransAffairsOfficeoftheInspectorGeneralsInvestigationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Department of Veterans' Affairs Office of the Inspector General's Investigation [Member]", "label": "Department of Veterans' Affairs Office of the Inspector General's Investigation [Member]", "terseLabel": "Department of Veterans' Affairs Office of the Inspector General's Investigation" } } }, "localname": "DepartmentofVeteransAffairsOfficeoftheInspectorGeneralsInvestigationMember", "nsuri": "http://mimedx.com/20200331", "presentation": [ "http://mimedx.com/role/ContractualCommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mdxg_DirectCustomersMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Direct Customers [Member]", "label": "Direct Customers [Member]", "terseLabel": "Direct Customers" } } }, "localname": "DirectCustomersMember", "nsuri": "http://mimedx.com/20200331", "presentation": [ "http://mimedx.com/role/ProductRevenueDetailDetails" ], "xbrltype": "domainItemType" }, "mdxg_DistributorsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Distributors [Member]", "label": "Distributors [Member]", "terseLabel": "Distributors" } } }, "localname": "DistributorsMember", "nsuri": "http://mimedx.com/20200331", "presentation": [ "http://mimedx.com/role/ProductRevenueDetailDetails" ], "xbrltype": "domainItemType" }, "mdxg_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryforward": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Net Operating Loss Carryforward", "label": "Effective Income Tax Rate Reconciliation, Net Operating Loss Carryforward", "terseLabel": "Tax benefit recognized with respect to net operating losses" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryforward", "nsuri": "http://mimedx.com/20200331", "presentation": [ "http://mimedx.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "mdxg_GroupPurchasingOrganizationAdministrativeFeesasPercentofPurchaseVolume": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Group Purchasing Organization Administrative Fees as Percent of Purchase Volume", "label": "Group Purchasing Organization Administrative Fees as Percent of Purchase Volume", "terseLabel": "GPO administrative fees as percent of purchase volume" } } }, "localname": "GroupPurchasingOrganizationAdministrativeFeesasPercentofPurchaseVolume", "nsuri": "http://mimedx.com/20200331", "presentation": [ "http://mimedx.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "percentItemType" }, "mdxg_HayfinLoanAgreementDelayedDrawTermLoanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Hayfin Loan Agreement Delayed Draw Term Loan [Member]", "label": "Hayfin Loan Agreement Delayed Draw Term Loan [Member]", "terseLabel": "Hayfin Loan Agreement Delayed Draw Term Loan" } } }, "localname": "HayfinLoanAgreementDelayedDrawTermLoanMember", "nsuri": "http://mimedx.com/20200331", "presentation": [ "http://mimedx.com/role/LiquidityAndCapitalResourcesDetails", "http://mimedx.com/role/LongTermDebtSubsequentActivityDetails", "http://mimedx.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "mdxg_HayfinLoanAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Hayfin Loan Agreement [Member]", "label": "Hayfin Loan Agreement [Member]", "terseLabel": "Hayfin Loan Agreement" } } }, "localname": "HayfinLoanAgreementMember", "nsuri": "http://mimedx.com/20200331", "presentation": [ "http://mimedx.com/role/LiquidityAndCapitalResourcesDetails" ], "xbrltype": "domainItemType" }, "mdxg_HayfinLoanAgreementTermLoanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Hayfin Loan Agreement Term Loan [Member]", "label": "Hayfin Loan Agreement Term Loan [Member]", "terseLabel": "Hayfin Loan Agreement Term Loan" } } }, "localname": "HayfinLoanAgreementTermLoanMember", "nsuri": "http://mimedx.com/20200331", "presentation": [ "http://mimedx.com/role/LiquidityAndCapitalResourcesDetails", "http://mimedx.com/role/LongTermDebtSubsequentActivityDetails", "http://mimedx.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "mdxg_InterestPaidIncludingCapitalizedInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Interest Paid, Including Capitalized Interest", "label": "Interest Paid, Including Capitalized Interest", "terseLabel": "Accrued interest paid" } } }, "localname": "InterestPaidIncludingCapitalizedInterest", "nsuri": "http://mimedx.com/20200331", "presentation": [ "http://mimedx.com/role/LiquidityAndCapitalResourcesDetails", "http://mimedx.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "mdxg_InvestigationRestatementandRelated": { "auth_ref": [], "calculation": { "http://mimedx.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Investigation, Restatement and Related", "label": "Investigation, Restatement and Related", "terseLabel": "Investigation, restatement and related" } } }, "localname": "InvestigationRestatementandRelated", "nsuri": "http://mimedx.com/20200331", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "mdxg_LiquidityandCapitalResourcesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Liquidity and Capital Resources [Abstract]", "label": "Liquidity and Capital Resources [Abstract]" } } }, "localname": "LiquidityandCapitalResourcesAbstract", "nsuri": "http://mimedx.com/20200331", "xbrltype": "stringItemType" }, "mdxg_LiquidityandCapitalResourcesTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Liquidity and Capital Resources [Text Block]", "label": "Liquidity and Capital Resources [Text Block]", "terseLabel": "Liquidity and Capital Resources" } } }, "localname": "LiquidityandCapitalResourcesTextBlock", "nsuri": "http://mimedx.com/20200331", "presentation": [ "http://mimedx.com/role/LiquidityAndCapitalResources" ], "xbrltype": "textBlockItemType" }, "mdxg_LongtermDebtCurrentMaturitiesGross": { "auth_ref": [], "calculation": { "http://mimedx.com/role/LongTermDebtTermLoanBalancesDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebtCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Long-term Debt, Current Maturities, Gross", "label": "Long-term Debt, Current Maturities, Gross", "terseLabel": "Liability component - principal" } } }, "localname": "LongtermDebtCurrentMaturitiesGross", "nsuri": "http://mimedx.com/20200331", "presentation": [ "http://mimedx.com/role/LongTermDebtTermLoanBalancesDetails" ], "xbrltype": "monetaryItemType" }, "mdxg_LongtermDebtExcludingCurrentMaturitiesGross": { "auth_ref": [], "calculation": { "http://mimedx.com/role/LongTermDebtTermLoanBalancesDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Long-term Debt, Excluding Current Maturities, Gross", "label": "Long-term Debt, Excluding Current Maturities, Gross", "terseLabel": "Liability component - principal" } } }, "localname": "LongtermDebtExcludingCurrentMaturitiesGross", "nsuri": "http://mimedx.com/20200331", "presentation": [ "http://mimedx.com/role/LongTermDebtTermLoanBalancesDetails" ], "xbrltype": "monetaryItemType" }, "mdxg_LossContingencyProsecutionDeferralPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Loss Contingency, Prosecution Deferral Period", "label": "Loss Contingency, Prosecution Deferral Period", "terseLabel": "Prosecution deferral period" } } }, "localname": "LossContingencyProsecutionDeferralPeriod", "nsuri": "http://mimedx.com/20200331", "presentation": [ "http://mimedx.com/role/ContractualCommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "mdxg_NumberofClassActions": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Class Actions", "label": "Number of Class Actions", "terseLabel": "Number of class actions" } } }, "localname": "NumberofClassActions", "nsuri": "http://mimedx.com/20200331", "presentation": [ "http://mimedx.com/role/ContractualCommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "mdxg_NumberofDistributionChannels": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Distribution Channels", "label": "Number of Distribution Channels", "terseLabel": "Number of primary distribution channels" } } }, "localname": "NumberofDistributionChannels", "nsuri": "http://mimedx.com/20200331", "presentation": [ "http://mimedx.com/role/ProductRevenueDetailDetails" ], "xbrltype": "integerItemType" }, "mdxg_NumberofFormerVAEmployees": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Former VA Employees", "label": "Number of Former VA Employees", "terseLabel": "Number of former VA employees" } } }, "localname": "NumberofFormerVAEmployees", "nsuri": "http://mimedx.com/20200331", "presentation": [ "http://mimedx.com/role/ContractualCommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "mdxg_NumberofFormerVAEmployeesWhoCompletedPretrialDiversionProgram": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Former VA Employees Who Completed Pretrial Diversion Program", "label": "Number of Former VA Employees Who Completed Pretrial Diversion Program", "terseLabel": "Number of former VA employees who completed the pretrial diversion program" } } }, "localname": "NumberofFormerVAEmployeesWhoCompletedPretrialDiversionProgram", "nsuri": "http://mimedx.com/20200331", "presentation": [ "http://mimedx.com/role/ContractualCommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "mdxg_NumberofShareholderDerivativeActions": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Shareholder Derivative Actions", "label": "Number of Shareholder Derivative Actions", "terseLabel": "Number of shareholder derivative actions" } } }, "localname": "NumberofShareholderDerivativeActions", "nsuri": "http://mimedx.com/20200331", "presentation": [ "http://mimedx.com/role/ContractualCommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "mdxg_OperatingLeaseLiabilityInterestExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Operating Lease Liability, Interest Expense", "label": "Operating Lease Liability, Interest Expense", "terseLabel": "Interest on lease obligations" } } }, "localname": "OperatingLeaseLiabilityInterestExpense", "nsuri": "http://mimedx.com/20200331", "presentation": [ "http://mimedx.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mdxg_OperatingLeaseRightofuseAssetAmortization": { "auth_ref": [], "calculation": { "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Operating Lease, Right-of-use Asset, Amortization", "label": "Operating Lease, Right-of-use Asset, Amortization", "terseLabel": "Amortization of right of use assets", "verboseLabel": "Non-cash lease expenses" } } }, "localname": "OperatingLeaseRightofuseAssetAmortization", "nsuri": "http://mimedx.com/20200331", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://mimedx.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mdxg_PatentsinProcessMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Patents in Process", "label": "Patents in Process [Member]", "terseLabel": "Patents in Process" } } }, "localname": "PatentsinProcessMember", "nsuri": "http://mimedx.com/20200331", "presentation": [ "http://mimedx.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "mdxg_PaycheckProtectionProgramLoanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Paycheck Protection Program Loan [Member]", "label": "Paycheck Protection Program Loan [Member]", "terseLabel": "Paycheck Protection Program Loan" } } }, "localname": "PaycheckProtectionProgramLoanMember", "nsuri": "http://mimedx.com/20200331", "presentation": [ "http://mimedx.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "mdxg_PaymentsforApplicationCostsPatent": { "auth_ref": [], "calculation": { "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Payments for Application Costs, Patent", "label": "Payments for Application Costs, Patent", "negatedTerseLabel": "Patent application costs" } } }, "localname": "PaymentsforApplicationCostsPatent", "nsuri": "http://mimedx.com/20200331", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mdxg_ScheduleofFiniteAndIndefiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Line Items] for Schedule of Finite And Indefinite-Lived Intangible Assets [Table]", "label": "Schedule of Finite And Indefinite-Lived Intangible Assets [Line Items]", "terseLabel": "Schedule of Finite And Indefinite-Lived Intangible Assets [Line Items]" } } }, "localname": "ScheduleofFiniteAndIndefiniteLivedIntangibleAssetsLineItems", "nsuri": "http://mimedx.com/20200331", "presentation": [ "http://mimedx.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "mdxg_ScheduleofFiniteAndIndefiniteLivedIntangibleAssetsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of Finite And Indefinite-Lived Intangible Assets [Table]", "label": "Schedule of Finite And Indefinite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite And Indefinite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleofFiniteAndIndefiniteLivedIntangibleAssetsTable", "nsuri": "http://mimedx.com/20200331", "presentation": [ "http://mimedx.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "mdxg_ScheduleofInterestExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of Interest Expense [Table Text Block]", "label": "Schedule of Interest Expense [Table Text Block]", "terseLabel": "Schedule of Interest Expense" } } }, "localname": "ScheduleofInterestExpenseTableTextBlock", "nsuri": "http://mimedx.com/20200331", "presentation": [ "http://mimedx.com/role/LongTermDebtTables" ], "xbrltype": "textBlockItemType" }, "mdxg_SecuritiesClassActionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Securities Class Action [Member]", "label": "Securities Class Action [Member]", "terseLabel": "Securities Class Action" } } }, "localname": "SecuritiesClassActionMember", "nsuri": "http://mimedx.com/20200331", "presentation": [ "http://mimedx.com/role/ContractualCommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mdxg_ShareholderDerivativeSuitsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Shareholder Derivative Suits [Member]", "label": "Shareholder Derivative Suits [Member]", "terseLabel": "Shareholder Derivative Suits" } } }, "localname": "ShareholderDerivativeSuitsMember", "nsuri": "http://mimedx.com/20200331", "presentation": [ "http://mimedx.com/role/ContractualCommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mdxg_SupplementalDisclosureOfCashFlowAndNonCashInvestingAndFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Supplemental disclosure of cash flow and non cash investing and financing activities [Abstract]", "terseLabel": "Supplemental disclosure of cash flow and non-cash investing and financing activities [Abstract]" } } }, "localname": "SupplementalDisclosureOfCashFlowAndNonCashInvestingAndFinancingActivitiesAbstract", "nsuri": "http://mimedx.com/20200331", "presentation": [ "http://mimedx.com/role/SupplementalDisclosureOfCashFlowAndNonCashInvestingAndFinancingActivitiesDetails" ], "xbrltype": "stringItemType" }, "mdxg_TermLoanAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Term Loan Agreement [Member]", "label": "Term Loan Agreement [Member]", "terseLabel": "BT Loan Agreement" } } }, "localname": "TermLoanAgreementMember", "nsuri": "http://mimedx.com/20200331", "presentation": [ "http://mimedx.com/role/LiquidityAndCapitalResourcesDetails", "http://mimedx.com/role/LongTermDebtDetails", "http://mimedx.com/role/LongTermDebtSubsequentActivityDetails", "http://mimedx.com/role/LongTermDebtTermLoanInterestExpenseDetails", "http://mimedx.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "mdxg_TotalNetLeverageRatio": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Total Net Leverage Ratio", "label": "Total Net Leverage Ratio", "terseLabel": "Total net leverage ratio" } } }, "localname": "TotalNetLeverageRatio", "nsuri": "http://mimedx.com/20200331", "presentation": [ "http://mimedx.com/role/LiquidityAndCapitalResourcesDetails" ], "xbrltype": "pureItemType" }, "mdxg_TypicalPaymentPeriodforCustomers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Typical Payment Period for Customers", "label": "Typical Payment Period for Customers", "terseLabel": "Typical payment period for customers" } } }, "localname": "TypicalPaymentPeriodforCustomers", "nsuri": "http://mimedx.com/20200331", "presentation": [ "http://mimedx.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "durationItemType" }, "srt_ChiefFinancialOfficerMember": { "auth_ref": [ "r130" ], "lang": { "en-US": { "role": { "label": "Chief Financial Officer [Member]", "terseLabel": "Former Chief Financial Officer" } } }, "localname": "ChiefFinancialOfficerMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://mimedx.com/role/ContractualCommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://mimedx.com/role/ContractualCommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://mimedx.com/role/ContractualCommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r129", "r200", "r203", "r279" ], "lang": { "en-US": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://mimedx.com/role/ProductRevenueDetailDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://mimedx.com/role/ContractualCommitmentsAndContingenciesNarrativeDetails", "http://mimedx.com/role/LiquidityAndCapitalResourcesDetails", "http://mimedx.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://mimedx.com/role/ContractualCommitmentsAndContingenciesNarrativeDetails", "http://mimedx.com/role/LiquidityAndCapitalResourcesDetails", "http://mimedx.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://mimedx.com/role/ProductRevenueDetailDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://mimedx.com/role/ContractualCommitmentsAndContingenciesNarrativeDetails", "http://mimedx.com/role/LiquidityAndCapitalResourcesDetails", "http://mimedx.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://mimedx.com/role/ContractualCommitmentsAndContingenciesNarrativeDetails", "http://mimedx.com/role/LiquidityAndCapitalResourcesDetails", "http://mimedx.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://mimedx.com/role/IncomeTaxesDetails", "http://mimedx.com/role/LiquidityAndCapitalResourcesDetails", "http://mimedx.com/role/LongTermDebtDetails", "http://mimedx.com/role/LongTermDebtSubsequentActivityDetails", "http://mimedx.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Scenario [Domain]", "terseLabel": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://mimedx.com/role/IncomeTaxesDetails", "http://mimedx.com/role/LiquidityAndCapitalResourcesDetails", "http://mimedx.com/role/LongTermDebtDetails", "http://mimedx.com/role/LongTermDebtSubsequentActivityDetails", "http://mimedx.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r173", "r252" ], "lang": { "en-US": { "role": { "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://mimedx.com/role/IncomeTaxesDetails", "http://mimedx.com/role/LiquidityAndCapitalResourcesDetails", "http://mimedx.com/role/LongTermDebtDetails", "http://mimedx.com/role/LongTermDebtSubsequentActivityDetails", "http://mimedx.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r130", "r250" ], "lang": { "en-US": { "role": { "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://mimedx.com/role/ContractualCommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Title of Individual [Domain]", "terseLabel": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://mimedx.com/role/ContractualCommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r235" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update 2016-02 [Member]", "terseLabel": "ASU No. 2016-02" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/SignificantAccountingPoliciesRecentlyIssuedAndAdoptedAccountingStandardsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r36" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accounts Expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/AccruedExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrentAndNoncurrent": { "auth_ref": [ "r260", "r275" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r3", "r22", "r131", "r132", "r201" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r39" ], "calculation": { "http://mimedx.com/role/AccruedExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://mimedx.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Total" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/AccruedExpensesDetails", "http://mimedx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent": { "auth_ref": [ "r260", "r275" ], "calculation": { "http://mimedx.com/role/AccruedExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received.", "label": "Accrued Professional Fees", "terseLabel": "Legal costs" } } }, "localname": "AccruedProfessionalFeesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/AccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedSalesCommissionCurrent": { "auth_ref": [ "r9", "r10", "r39" ], "calculation": { "http://mimedx.com/role/AccruedExpensesDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Sales Commission, Current", "terseLabel": "External commissions" } } }, "localname": "AccruedSalesCommissionCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/AccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r34", "r165" ], "calculation": { "http://mimedx.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r23" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r97" ], "lang": { "en-US": { "role": { "documentation": "Information by new accounting pronouncement.", "label": "Adjustments for New Accounting Pronouncements [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/SignificantAccountingPoliciesRecentlyIssuedAndAdoptedAccountingStandardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation", "negatedTerseLabel": "Shares repurchased for tax withholding" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash from operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r63", "r80", "r231" ], "calculation": { "http://mimedx.com/role/LongTermDebtTermLoanInterestExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of Debt Discount (Premium)", "terseLabel": "Interest expense - amortization of original issue discount and costs" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LongTermDebtTermLoanInterestExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r59", "r80", "r233" ], "calculation": { "http://mimedx.com/role/LongTermDebtTermLoanInterestExpenseDetails": { "order": 3.0, "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Interest expense - amortization of deferred financing costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LongTermDebtTermLoanInterestExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r80", "r233" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Amortization of deferred financing costs and debt discount" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r80", "r148", "r155" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://mimedx.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://mimedx.com/role/CondensedConsolidatedStatementsOfOperations", "http://mimedx.com/role/IntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r107" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/NetLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r107" ], "lang": { "en-US": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/NetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/NetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r107" ], "lang": { "en-US": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/NetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r80", "r162" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 6.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "Asset Impairment Charges", "terseLabel": "Impairment of intangible asset" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r127", "r255", "r269" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r7", "r54" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "terseLabel": "Total current assets", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedBalanceSheets", "http://mimedx.com/role/LiquidityAndCapitalResourcesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r1", "r32", "r82" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedBalanceSheets", "http://mimedx.com/role/LiquidityAndCapitalResourcesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r13", "r83", "r88" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r74", "r82", "r85" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents, end of period", "periodStartLabel": "Cash and cash equivalents, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r74", "r230" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net change in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowSupplementalDisclosuresTextBlock": { "auth_ref": [ "r86" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Cash Flow, Supplemental Disclosures [Text Block]", "terseLabel": "Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities" } } }, "localname": "CashFlowSupplementalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/SupplementalDisclosureOfCashFlowAndNonCashInvestingAndFinancingActivities" ], "xbrltype": "textBlockItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LiquidityAndCapitalResourcesDetails", "http://mimedx.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r44", "r172", "r261", "r274" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 13)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r171", "r180" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Contractual Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/ContractualCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock Issued" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r21" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r21" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r21" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r21", "r189" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r21" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock; $.001 par value; 150,000,000 shares authorized; 112,703,926 issued and 110,540,860 outstanding at March 31, 2020 and 112,703,926 issued and 110,818,649 outstanding at December 31, 2019" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r119", "r120", "r121", "r122", "r228", "r229" ], "lang": { "en-US": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r88", "r224", "r225", "r226" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction in progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetNetCurrent": { "auth_ref": [ "r197", "r198", "r201" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.", "label": "Contract with Customer, Asset, Net, Current", "terseLabel": "Deferred cost of sales" } } }, "localname": "ContractWithCustomerAssetNetCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerRefundLiabilityCurrent": { "auth_ref": [ "r202" ], "calculation": { "http://mimedx.com/role/AccruedExpensesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as current.", "label": "Contract with Customer, Refund Liability, Current", "terseLabel": "Estimated returns" } } }, "localname": "ContractWithCustomerRefundLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/AccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r61" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1": { "auth_ref": [ "r100" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the cumulative effect on retained earnings net of related income tax effect.", "label": "Cumulative Effect on Retained Earnings, Net of Tax", "terseLabel": "Effect on opening retained earnings" } } }, "localname": "CumulativeEffectOnRetainedEarningsNetOfTax1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/SignificantAccountingPoliciesRecentlyIssuedAndAdoptedAccountingStandardsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r221" ], "lang": { "en-US": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer & Supplier Relationships" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt, Current [Abstract]", "terseLabel": "Current portion" } } }, "localname": "DebtCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LongTermDebtTermLoanBalancesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r187" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Long Term Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LongTermDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r16", "r17", "r18", "r256", "r257", "r268" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LiquidityAndCapitalResourcesDetails", "http://mimedx.com/role/LongTermDebtDetails", "http://mimedx.com/role/LongTermDebtSubsequentActivityDetails", "http://mimedx.com/role/LongTermDebtTermLoanInterestExpenseDetails", "http://mimedx.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Basis spread on variable rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LiquidityAndCapitalResourcesDetails", "http://mimedx.com/role/LongTermDebtDetails", "http://mimedx.com/role/LongTermDebtSubsequentActivityDetails", "http://mimedx.com/role/SubsequentEventsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r232", "r234" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Face value of debt" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LiquidityAndCapitalResourcesDetails", "http://mimedx.com/role/LongTermDebtDetails", "http://mimedx.com/role/LongTermDebtSubsequentActivityDetails", "http://mimedx.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateIncreaseDecrease": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Incremental percentage increase (decrease) in the stated rate on a debt instrument.", "label": "Debt Instrument, Interest Rate, Increase (Decrease)", "terseLabel": "Increase in interest rate (percent)" } } }, "localname": "DebtInstrumentInterestRateIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/SubsequentEventsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r41" ], "lang": { "en-US": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Stated interest rate (percent)" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LongTermDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LongTermDebtDetails", "http://mimedx.com/role/LongTermDebtSubsequentActivityDetails", "http://mimedx.com/role/LongTermDebtTermLoanInterestExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r42" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LiquidityAndCapitalResourcesDetails", "http://mimedx.com/role/LongTermDebtDetails", "http://mimedx.com/role/LongTermDebtSubsequentActivityDetails", "http://mimedx.com/role/LongTermDebtTermLoanInterestExpenseDetails", "http://mimedx.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPeriodicPayment": { "auth_ref": [ "r42", "r265" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the required periodic payments including both interest and principal payments.", "label": "Debt Instrument, Periodic Payment", "terseLabel": "Quarterly installments" } } }, "localname": "DebtInstrumentPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r42", "r91", "r190", "r191", "r192", "r193", "r231", "r232", "r234", "r266" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LongTermDebtDetails", "http://mimedx.com/role/LongTermDebtSubsequentActivityDetails", "http://mimedx.com/role/LongTermDebtTermLoanInterestExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r231", "r234" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "terseLabel": "Original issue discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountCurrent": { "auth_ref": [ "r231", "r234" ], "calculation": { "http://mimedx.com/role/LongTermDebtTermLoanBalancesDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebtCurrent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.", "label": "Debt Instrument, Unamortized Discount, Current", "negatedTerseLabel": "Original issue discount" } } }, "localname": "DebtInstrumentUnamortizedDiscountCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LongTermDebtTermLoanBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent": { "auth_ref": [ "r231", "r234" ], "calculation": { "http://mimedx.com/role/LongTermDebtTermLoanBalancesDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of debt discount to be amortized after one year or the normal operating cycle, if longer.", "label": "Debt Instrument, Unamortized Discount, Noncurrent", "negatedTerseLabel": "Original issue discount" } } }, "localname": "DebtInstrumentUnamortizedDiscountNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LongTermDebtTermLoanBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCostsAndOtherAssets": { "auth_ref": [], "calculation": { "http://mimedx.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred cost assets and assets classified as other.", "label": "Deferred Costs and Other Assets", "terseLabel": "Other assets" } } }, "localname": "DeferredCostsAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsCurrentNet": { "auth_ref": [ "r53", "r233" ], "calculation": { "http://mimedx.com/role/LongTermDebtTermLoanBalancesDetails": { "order": 3.0, "parentTag": "us-gaap_LongTermDebtCurrent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Current, Net", "negatedTerseLabel": "Deferred financing cost" } } }, "localname": "DeferredFinanceCostsCurrentNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LongTermDebtTermLoanBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsGross": { "auth_ref": [ "r233" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Gross", "terseLabel": "Deferred financing costs" } } }, "localname": "DeferredFinanceCostsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LongTermDebtDetails", "http://mimedx.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNoncurrentNet": { "auth_ref": [ "r35", "r233" ], "calculation": { "http://mimedx.com/role/LongTermDebtTermLoanBalancesDetails": { "order": 3.0, "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Noncurrent, Net", "negatedTerseLabel": "Deferred financing cost" } } }, "localname": "DeferredFinanceCostsNoncurrentNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LongTermDebtTermLoanBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r80", "r163" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://mimedx.com/role/PropertyAndEquipmentNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/ProductRevenueDetailDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/ProductRevenueDetailDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r58", "r98", "r103", "r104", "r105", "r106", "r109", "r263", "r278" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per common share - basic (in dollars per share)", "verboseLabel": "Loss per common share - basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfOperations", "http://mimedx.com/role/NetLossPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r58", "r98", "r103", "r104", "r105", "r106", "r109", "r263", "r278" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per common share - diluted (in dollars per share)", "verboseLabel": "Loss per common share - diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfOperations", "http://mimedx.com/role/NetLossPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r110" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "verboseLabel": "Net Loss Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/NetLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r93", "r211", "r212" ], "lang": { "en-US": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r39" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r208" ], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "verboseLabel": "Outstanding Stock Options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/NetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Lab and clean room equipment" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r189" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r154" ], "calculation": { "http://mimedx.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Accumulated amortization, amortized intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "calculation": { "http://mimedx.com/role/IntangibleAssetsEstimatedFutureAmortizationExpenseForIntangibleAssetsDetails": { "order": 6.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/IntangibleAssetsEstimatedFutureAmortizationExpenseForIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://mimedx.com/role/IntangibleAssetsEstimatedFutureAmortizationExpenseForIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year", "terseLabel": "2020 (excluding the three months ended March 31, 2020)" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/IntangibleAssetsEstimatedFutureAmortizationExpenseForIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r156" ], "calculation": { "http://mimedx.com/role/IntangibleAssetsEstimatedFutureAmortizationExpenseForIntangibleAssetsDetails": { "order": 5.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/IntangibleAssetsEstimatedFutureAmortizationExpenseForIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r156" ], "calculation": { "http://mimedx.com/role/IntangibleAssetsEstimatedFutureAmortizationExpenseForIntangibleAssetsDetails": { "order": 4.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/IntangibleAssetsEstimatedFutureAmortizationExpenseForIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r156" ], "calculation": { "http://mimedx.com/role/IntangibleAssetsEstimatedFutureAmortizationExpenseForIntangibleAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three", "terseLabel": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/IntangibleAssetsEstimatedFutureAmortizationExpenseForIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r156" ], "calculation": { "http://mimedx.com/role/IntangibleAssetsEstimatedFutureAmortizationExpenseForIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two", "terseLabel": "2021" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/IntangibleAssetsEstimatedFutureAmortizationExpenseForIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r149", "r151", "r154", "r158", "r254" ], "lang": { "en-US": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetails", "http://mimedx.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]", "terseLabel": "Estimated Amortization Expense" } } }, "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/IntangibleAssetsEstimatedFutureAmortizationExpenseForIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r154", "r254" ], "calculation": { "http://mimedx.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross carrying amount, amortized intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r149", "r153" ], "lang": { "en-US": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetails", "http://mimedx.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r154" ], "calculation": { "http://mimedx.com/role/IntangibleAssetsEstimatedFutureAmortizationExpenseForIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://mimedx.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Net carrying amount, amortized intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/IntangibleAssetsEstimatedFutureAmortizationExpenseForIntangibleAssetsDetails", "http://mimedx.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Period Increase (Decrease)", "terseLabel": "Intangible assets, net of accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and office equipment" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r80" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "negatedTerseLabel": "Loss on fixed asset disposal" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r145", "r146" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r60" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r80", "r159" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.", "label": "Impairment of Intangible Assets (Excluding Goodwill)", "terseLabel": "Impairment of intangible assets" } } }, "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r92" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before income tax provision" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxContingencyLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Tax Contingency [Line Items]", "terseLabel": "Income Tax Contingency [Line Items]" } } }, "localname": "IncomeTaxContingencyLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxContingencyTable": { "auth_ref": [ "r213", "r214", "r215", "r216" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.", "label": "Income Tax Contingency [Table]", "terseLabel": "Income Tax Contingency [Table]" } } }, "localname": "IncomeTaxContingencyTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r218" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "verboseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r90", "r126", "r217" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedTerseLabel": "Income tax provision benefit (expense)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReceivable": { "auth_ref": [ "r31", "r267" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of income taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Also called income tax refund receivable.", "label": "Income Taxes Receivable", "terseLabel": "Federal income tax receivable" } } }, "localname": "IncomeTaxReceivable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/IncomeTaxesDetails", "http://mimedx.com/role/NatureOfBusinessDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationOtherReconcilingItems": { "auth_ref": [ "r211", "r212" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount", "terseLabel": "Effective income tax rate reconciliation, discrete items" } } }, "localname": "IncomeTaxReconciliationOtherReconcilingItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r76", "r84" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "terseLabel": "Income taxes paid" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/SupplementalDisclosureOfCashFlowAndNonCashInvestingAndFinancingActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesReceivable": { "auth_ref": [ "r47", "r259", "r276" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.", "label": "Income Taxes Receivable, Current", "terseLabel": "Income tax receivable" } } }, "localname": "IncomeTaxesReceivable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r79" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r79" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r79" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedTaxesPayable": { "auth_ref": [ "r79" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period of all taxes owed but not paid, including income, property and other taxes.", "label": "Increase (Decrease) in Accrued Taxes Payable", "terseLabel": "Income taxes" } } }, "localname": "IncreaseDecreaseInAccruedTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredCompensation": { "auth_ref": [ "r79" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future.", "label": "Increase (Decrease) in Deferred Compensation", "terseLabel": "Accrued compensation" } } }, "localname": "IncreaseDecreaseInDeferredCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": { "auth_ref": [ "r79" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.", "label": "Increase (Decrease) in Income Taxes Receivable", "negatedTerseLabel": "Income tax receivable" } } }, "localname": "IncreaseDecreaseInIncomeTaxesReceivable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r79" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedTerseLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Increase (decrease) in cash resulting from changes in:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [ "r79" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "Increase (Decrease) in Other Current Assets", "negatedLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r79" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Liabilities", "terseLabel": "Other liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r79" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedTerseLabel": "Prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r150", "r157" ], "lang": { "en-US": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r157" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Carrying amount, unamortized intangible assets" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r150", "r157" ], "lang": { "en-US": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r161" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "verboseLabel": "Intangible Assets" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/IntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "auth_ref": [], "calculation": { "http://mimedx.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.", "label": "Intangible Assets, Gross (Excluding Goodwill)", "totalLabel": "Total" } } }, "localname": "IntangibleAssetsGrossExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r147", "r152" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://mimedx.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net", "totalLabel": "Net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedBalanceSheets", "http://mimedx.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r63", "r186" ], "calculation": { "http://mimedx.com/role/LongTermDebtTermLoanInterestExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt", "totalLabel": "Total term loan interest expense" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LongTermDebtTermLoanInterestExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebtExcludingAmortization": { "auth_ref": [ "r65" ], "calculation": { "http://mimedx.com/role/LongTermDebtTermLoanInterestExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.", "label": "Interest Expense, Debt, Excluding Amortization", "terseLabel": "Interest expense - stated interest rate" } } }, "localname": "InterestExpenseDebtExcludingAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LongTermDebtTermLoanInterestExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r264" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest Income (Expense), Net", "terseLabel": "Interest (expense) income, net" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r73", "r75", "r84" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/SupplementalDisclosureOfCashFlowAndNonCashInvestingAndFinancingActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r143" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "verboseLabel": "Inventory" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/Inventory" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r48" ], "calculation": { "http://mimedx.com/role/InventoryDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryGross": { "auth_ref": [ "r51" ], "calculation": { "http://mimedx.com/role/InventoryDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Inventory, Gross", "totalLabel": "Inventory, gross" } } }, "localname": "InventoryGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r2", "r51", "r139" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://mimedx.com/role/InventoryDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventory, net", "totalLabel": "Inventory, net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedBalanceSheets", "http://mimedx.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r12", "r52", "r88", "r113", "r140", "r141" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r50" ], "calculation": { "http://mimedx.com/role/InventoryDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Raw Materials, Gross", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r51", "r95", "r139", "r142" ], "calculation": { "http://mimedx.com/role/InventoryDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "Inventory Valuation Reserves", "negatedLabel": "Reserve for obsolescence" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r49" ], "calculation": { "http://mimedx.com/role/InventoryDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Inventory, Work in Process, Gross", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r246", "r248" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "terseLabel": "Rent expense" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/ContractualCommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r246" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Supplemental Balance Sheet Information Related to Leases" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r164" ], "lang": { "en-US": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_LegalCostsPolicyTextBlock": { "auth_ref": [ "r87", "r88", "r179" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.", "label": "Legal Costs, Policy [Policy Text Block]", "terseLabel": "Patent Costs" } } }, "localname": "LegalCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r240" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r247" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Maturities of Operating Lease Liabilities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r247" ], "calculation": { "http://mimedx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://mimedx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r247" ], "calculation": { "http://mimedx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r247" ], "calculation": { "http://mimedx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r247" ], "calculation": { "http://mimedx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r247" ], "calculation": { "http://mimedx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r247" ], "calculation": { "http://mimedx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "terseLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r247" ], "calculation": { "http://mimedx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year", "terseLabel": "2020 (excluding the three months ended March 31, 2020)" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r247" ], "calculation": { "http://mimedx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc2": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less: imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r241" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Lease expiration period" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/ContractualCommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r249" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r38" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r27", "r258", "r272" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedBalanceSheets", "http://mimedx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r40" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "terseLabel": "Total current liabilities", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedBalanceSheets", "http://mimedx.com/role/LiquidityAndCapitalResourcesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "verboseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LicensingAgreementsMember": { "auth_ref": [ "r222" ], "lang": { "en-US": { "role": { "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).", "label": "Licensing Agreements [Member]", "terseLabel": "Licenses" } } }, "localname": "LicensingAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.", "label": "Line of Credit Facility, Commitment Fee Percentage", "terseLabel": "Upfront commitment fee (percent)" } } }, "localname": "LineOfCreditFacilityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LiquidityAndCapitalResourcesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.", "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "terseLabel": "Commitment fee on undrawn amounts (percent)" } } }, "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LiquidityAndCapitalResourcesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LitigationReserve": { "auth_ref": [ "r44", "r172" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.", "label": "Estimated Litigation Liability", "terseLabel": "Estimated litigation liability" } } }, "localname": "LitigationReserve", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/ContractualCommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "LIBOR" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LiquidityAndCapitalResourcesDetails", "http://mimedx.com/role/LongTermDebtDetails", "http://mimedx.com/role/LongTermDebtSubsequentActivityDetails", "http://mimedx.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r18", "r185", "r257", "r270" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "terseLabel": "Total Long Term Debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LongTermDebtTermLoanMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r37" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://mimedx.com/role/LongTermDebtTermLoanBalancesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "terseLabel": "Current portion of long term debt", "totalLabel": "Liability component - net carrying value" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedBalanceSheets", "http://mimedx.com/role/LongTermDebtTermLoanBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.", "label": "Long-term Debt, Fair Value", "terseLabel": "Fair value of term loan" } } }, "localname": "LongTermDebtFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": { "auth_ref": [ "r94", "r183" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LongTermDebtTermLoanMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "auth_ref": [ "r94", "r183" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Five", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LongTermDebtTermLoanMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r94", "r183" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Four", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LongTermDebtTermLoanMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r94", "r183" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Three", "terseLabel": "2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LongTermDebtTermLoanMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r94", "r183" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Two", "terseLabel": "2021" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LongTermDebtTermLoanMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "auth_ref": [ "r94" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year", "terseLabel": "2020 (excluding the three months ended March 31, 2020)" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LongTermDebtTermLoanMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r42" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://mimedx.com/role/LongTermDebtTermLoanBalancesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Long term debt, net", "totalLabel": "Liability component - net carrying value" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedBalanceSheets", "http://mimedx.com/role/LongTermDebtTermLoanBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Long-term Debt, Excluding Current Maturities [Abstract]", "terseLabel": "Long-term" } } }, "localname": "LongTermDebtNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LongTermDebtTermLoanBalancesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r42" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LiquidityAndCapitalResourcesDetails", "http://mimedx.com/role/LongTermDebtDetails", "http://mimedx.com/role/LongTermDebtSubsequentActivityDetails", "http://mimedx.com/role/LongTermDebtTermLoanInterestExpenseDetails", "http://mimedx.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r42", "r184" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LiquidityAndCapitalResourcesDetails", "http://mimedx.com/role/LongTermDebtDetails", "http://mimedx.com/role/LongTermDebtSubsequentActivityDetails", "http://mimedx.com/role/LongTermDebtTermLoanInterestExpenseDetails", "http://mimedx.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/ContractualCommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r181", "r182" ], "lang": { "en-US": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/ContractualCommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyAccrualCarryingValueCurrent": { "auth_ref": [ "r172" ], "calculation": { "http://mimedx.com/role/AccruedExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of loss contingency liability expected to be resolved within one year or the normal operating cycle, if longer.", "label": "Loss Contingency, Accrual, Current", "terseLabel": "Pricing adjustment settlement with Veterans Affairs" } } }, "localname": "LossContingencyAccrualCarryingValueCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/AccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r74" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Cash flows used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r74" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Cash flows used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r74", "r78", "r81" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Cash flows used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r55", "r56", "r57", "r81", "r108", "r262", "r277" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://mimedx.com/role/CondensedConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://mimedx.com/role/NetLossPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://mimedx.com/role/CondensedConsolidatedStatementsOfOperations", "http://mimedx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity", "http://mimedx.com/role/NetLossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/SignificantAccountingPoliciesRecentlyIssuedAndAdoptedAccountingStandardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r97", "r99" ], "lang": { "en-US": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Table]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/SignificantAccountingPoliciesRecentlyIssuedAndAdoptedAccountingStandardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued and Adopted Accounting Standards" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncompeteAgreementsMember": { "auth_ref": [ "r220" ], "lang": { "en-US": { "role": { "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party.", "label": "Noncompete Agreements [Member]", "verboseLabel": "Non-compete agreements" } } }, "localname": "NoncompeteAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense), net" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_NotesPayableOtherPayablesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A written promise to pay a note to a third party.", "label": "Notes Payable, Other Payables [Member]", "terseLabel": "Term Loan" } } }, "localname": "NotesPayableOtherPayablesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LiquidityAndCapitalResourcesDetails", "http://mimedx.com/role/LongTermDebtDetails", "http://mimedx.com/role/LongTermDebtSubsequentActivityDetails", "http://mimedx.com/role/LongTermDebtTermLoanInterestExpenseDetails", "http://mimedx.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of business segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/NatureOfBusinessDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://mimedx.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r242", "r248" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseImpairmentLoss": { "auth_ref": [ "r236" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of loss from impairment of right-of-use asset from operating lease.", "label": "Operating Lease, Impairment Loss", "terseLabel": "Operating lease, impairment loss" } } }, "localname": "OperatingLeaseImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r238" ], "calculation": { "http://mimedx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc2": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Lease liability", "verboseLabel": "Lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails", "http://mimedx.com/role/SignificantAccountingPoliciesRecentlyIssuedAndAdoptedAccountingStandardsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r238" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Short term lease liability" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r238" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Long term lease liability" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePaymentsUse": { "auth_ref": [ "r239", "r243" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments, Use", "terseLabel": "Cash paid for amounts included in the measurement of operating lease liabilities" } } }, "localname": "OperatingLeasePaymentsUse", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r237" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right of use asset", "verboseLabel": "Right of use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedBalanceSheets", "http://mimedx.com/role/LeasesSupplementalBalanceSheetInformationDetails", "http://mimedx.com/role/SignificantAccountingPoliciesRecentlyIssuedAndAdoptedAccountingStandardsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r245", "r248" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r244", "r248" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term (years)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r0", "r227" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Nature of Business" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/NatureOfBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r9", "r10", "r11", "r39" ], "calculation": { "http://mimedx.com/role/AccruedExpensesDetails": { "order": 7.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/AccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r53" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r8", "r9", "r39" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r43" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r64" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income (expense), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PatentsMember": { "auth_ref": [ "r223" ], "lang": { "en-US": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Patents [Member]", "netLabel": "Patents & Know How", "verboseLabel": "Patents" } } }, "localname": "PatentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetails", "http://mimedx.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsForLegalSettlements": { "auth_ref": [ "r77" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.", "label": "Payments for Legal Settlements", "terseLabel": "Payments for legal settlements" } } }, "localname": "PaymentsForLegalSettlements", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/ContractualCommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtExtinguishmentCosts": { "auth_ref": [ "r72" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.", "label": "Payment for Debt Extinguishment or Debt Prepayment Cost", "terseLabel": "Prepayment of premium paid" } } }, "localname": "PaymentsOfDebtExtinguishmentCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LiquidityAndCapitalResourcesDetails", "http://mimedx.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r70" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-based Payment Arrangement", "negatedTerseLabel": "Stock repurchased for tax withholdings on vesting of restricted stock" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMachineryAndEquipment": { "auth_ref": [ "r68" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for acquisition of machinery and equipment.", "label": "Payments to Acquire Machinery and Equipment", "negatedTerseLabel": "Purchases of equipment" } } }, "localname": "PaymentsToAcquireMachineryAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "Performance Based Awards" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/NetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r20" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://mimedx.com/role/LiquidityAndCapitalResourcesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r20" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r20" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r20" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r20" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock; $.001 par value; 5,000,000 shares authorized; 0 issued and 0 outstanding at March 31, 2020 and 0 issued and 0 outstanding at December 31, 2019" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r4", "r6", "r144" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromCollectionOfNotesReceivable": { "auth_ref": [ "r66" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation.", "label": "Proceeds from Collection of Notes Receivable", "terseLabel": "Principal payments from note receivable" } } }, "localname": "ProceedsFromCollectionOfNotesReceivable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": { "auth_ref": [ "r69" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.", "label": "Proceeds from Issuance of Convertible Preferred Stock", "terseLabel": "Proceeds from issuance of convertible preferred stock" } } }, "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LiquidityAndCapitalResourcesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndCollectionOfReceivables": { "auth_ref": [ "r67" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the proceeds from sale and collection of receivables during the period.", "label": "Proceeds from Sale and Collection of Receivables", "negatedTerseLabel": "Proceeds from Sale and Collection of Receivables" } } }, "localname": "ProceedsFromSaleAndCollectionOfReceivables", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/SignificantAccountingPoliciesAssessmentOfRevenueUnderAsc606Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r69", "r209" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r34", "r166" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r167" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/PropertyAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r33", "r164" ], "calculation": { "http://mimedx.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r14", "r15", "r166", "r273" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://mimedx.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedBalanceSheets", "http://mimedx.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r14", "r166" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Summary of Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/PropertyAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r14", "r164" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property, Plant and Equipment, Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReceivablesPolicyTextBlock": { "auth_ref": [ "r88", "r133", "r135", "r136", "r137" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.", "label": "Receivable [Policy Text Block]", "terseLabel": "Accounts Receivable and Notes Receivable" } } }, "localname": "ReceivablesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r71" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayments of Debt", "terseLabel": "Repayment of principal" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LiquidityAndCapitalResourcesDetails", "http://mimedx.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfMediumTermNotes": { "auth_ref": [ "r71" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to pay off borrowing used to receive debt funding on a regular basis with maturities ranging from 5-10 years.", "label": "Repayments of Medium-term Notes", "negatedTerseLabel": "Repayment of term loan" } } }, "localname": "RepaymentsOfMediumTermNotes", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r210", "r280" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r107" ], "lang": { "en-US": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock Awards" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/NetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r24", "r194", "r271" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "verboseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r199", "r200" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Net sales" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfOperations", "http://mimedx.com/role/ProductRevenueDetailDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r89", "r204" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r204" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Product Revenue Detail" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/ProductRevenueDetail" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accrued Expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/AccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r107" ], "lang": { "en-US": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Summary of Antidilutive Securities [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/NetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r107" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/NetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "terseLabel": "Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities" } } }, "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/SupplementalDisclosureOfCashFlowAndNonCashInvestingAndFinancingActivitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Schedule of Debt" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LongTermDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r108" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Computation of Basic and Diluted Net Income per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/NetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": { "auth_ref": [ "r128" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table Text Block]", "terseLabel": "Net Sales by Customer Type" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/ProductRevenueDetailTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r149", "r153" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Intangible Assets Activity Summary - Finite Lived" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r157", "r160" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.", "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Intangible Assets Activity Summary - Indefinite Lived" } } }, "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r12", "r28", "r29", "r30" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Inventory" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/InventoryTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r183" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.", "label": "Schedule of Maturities of Long-term Debt [Table Text Block]", "terseLabel": "Future Principal Payments for the Term Loan" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LongTermDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r97", "r99", "r111", "r112", "r114" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.", "label": "Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]", "terseLabel": "Assessment of Revenue under ASC 606" } } }, "localname": "ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r34", "r166" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r153" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Estimated Future Amortization Expense for Intangible Assets" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r88" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment Reporting" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r62", "r138" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeniorNotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.", "label": "Senior Notes [Member]", "terseLabel": "Senior secured term loan" } } }, "localname": "SeniorNotesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LiquidityAndCapitalResourcesDetails", "http://mimedx.com/role/LongTermDebtSubsequentActivityDetails", "http://mimedx.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series B Preferred Stock [Member]", "terseLabel": "Series B Convertible Preferred Stock" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LiquidityAndCapitalResourcesDetails", "http://mimedx.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeveranceCosts1": { "auth_ref": [ "r80", "r168", "r169", "r170" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.", "label": "Severance Costs", "terseLabel": "Severance costs" } } }, "localname": "SeveranceCosts1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/ContractualCommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r79" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "terseLabel": "Shares repurchased for tax withholding (in shares)" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r96" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r19", "r20", "r21", "r189" ], "lang": { "en-US": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LiquidityAndCapitalResourcesDetails", "http://mimedx.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r46", "r189" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": { "auth_ref": [ "r20", "r21", "r189", "r194" ], "lang": { "en-US": { "role": { "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited", "terseLabel": "Restricted stock shares cancelled/forfeited (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r189", "r194" ], "lang": { "en-US": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "negatedLabel": "Issuance of restricted stock (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r20", "r21", "r189", "r194", "r206" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Exercise of stock options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r20", "r21", "r189", "r194" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Stock issued during period" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LiquidityAndCapitalResourcesDetails", "http://mimedx.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures": { "auth_ref": [ "r20", "r21", "r189", "r194" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Value of stock related to Restricted Stock Awards forfeited during the period.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Forfeitures", "negatedTerseLabel": "Restricted stock shares canceled/forfeited" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "auth_ref": [ "r20", "r21", "r189", "r194" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "terseLabel": "Issuance of restricted stock" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r20", "r21", "r194", "r205", "r207" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Share-based compensation expense" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r46", "r189", "r194" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r21", "r25", "r26", "r134" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance, end of period", "periodStartLabel": "Balance, beginning of period", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedBalanceSheets", "http://mimedx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity:", "verboseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedBalanceSheets", "http://mimedx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityPolicyTextBlock": { "auth_ref": [ "r87", "r88", "r188" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.", "label": "Stockholders' Equity, Policy [Policy Text Block]", "terseLabel": "Treasury Stock" } } }, "localname": "StockholdersEquityPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LiquidityAndCapitalResourcesDetails", "http://mimedx.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/ContractualCommitmentsAndContingenciesNarrativeDetails", "http://mimedx.com/role/LiquidityAndCapitalResourcesDetails", "http://mimedx.com/role/LongTermDebtSubsequentActivityDetails", "http://mimedx.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r251" ], "lang": { "en-US": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LiquidityAndCapitalResourcesDetails", "http://mimedx.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r251" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/ContractualCommitmentsAndContingenciesNarrativeDetails", "http://mimedx.com/role/LiquidityAndCapitalResourcesDetails", "http://mimedx.com/role/LongTermDebtSubsequentActivityDetails", "http://mimedx.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r251" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/ContractualCommitmentsAndContingenciesNarrativeDetails", "http://mimedx.com/role/LiquidityAndCapitalResourcesDetails", "http://mimedx.com/role/LongTermDebtSubsequentActivityDetails", "http://mimedx.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r253" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Elements [Abstract]" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_TrademarksAndTradeNamesMember": { "auth_ref": [ "r219" ], "lang": { "en-US": { "role": { "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trademarks and Trade Names [Member]", "verboseLabel": "Tradenames & Trademarks" } } }, "localname": "TrademarksAndTradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r45", "r195" ], "lang": { "en-US": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r45", "r195" ], "lang": { "en-US": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "terseLabel": "Treasury stock, shares (in shares)" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r45", "r195", "r196" ], "calculation": { "http://mimedx.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedTerseLabel": "Treasury stock at cost; 2,163,066 shares at March 31, 2020 and 1,885,277 shares at December 31, 2019" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Type of Adoption [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/SignificantAccountingPoliciesRecentlyIssuedAndAdoptedAccountingStandardsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r115", "r116", "r117", "r118", "r123", "r124", "r125" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LiquidityAndCapitalResourcesDetails", "http://mimedx.com/role/LongTermDebtDetails", "http://mimedx.com/role/LongTermDebtSubsequentActivityDetails", "http://mimedx.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/LiquidityAndCapitalResourcesDetails", "http://mimedx.com/role/LongTermDebtDetails", "http://mimedx.com/role/LongTermDebtSubsequentActivityDetails", "http://mimedx.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r106" ], "calculation": { "http://mimedx.com/role/NetLossPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number Diluted Shares Outstanding Adjustment", "terseLabel": "Effect of dilutive securities: Stock options, restricted stock, and warrants outstanding (in shares)" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/NetLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r102", "r106" ], "calculation": { "http://mimedx.com/role/NetLossPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average shares outstanding - diluted (in shares)", "totalLabel": "Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfOperations", "http://mimedx.com/role/NetLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r101", "r106" ], "calculation": { "http://mimedx.com/role/NetLossPerShareDetails": { "order": 3.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average shares outstanding - basic (in shares)", "verboseLabel": "Denominator for basic earnings per share - weighted average shares (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://mimedx.com/role/CondensedConsolidatedStatementsOfOperations", "http://mimedx.com/role/NetLossPerShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765" }, "r110": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e725-108305" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e765-108305" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.10-01.(b)(6))", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4647-111522" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5033-111524" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r143": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b),(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r161": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r167": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r171": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14615-108349" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14394-108349" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14453-108349" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14472-108349" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=27011672&loc=d3e149975-122751" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12021-110248" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12053-110248" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870" }, "r187": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21459-112644" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130533-203044" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130611-203046-203046" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r204": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117331294&loc=d3e36027-109320" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r218": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5263-128473" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5263-128473" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5333-128473" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5419-128473" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-02)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-03)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828" }, "r227": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=119364159&loc=SL77916155-209984" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888369&loc=SL77918431-209957" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971" }, "r249": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r253": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.5(c))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r281": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r282": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r283": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r284": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6787-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "8", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6904-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586" }, "r86": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "230", "URI": "http://asc.fasb.org/topic&trid=2134446" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04.(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690" }, "r96": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" } }, "version": "2.1" } ZIP 80 0001376339-20-000047-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001376339-20-000047-xbrl.zip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�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